JP6727224B2 - 新生物疾患および/または感染性疾患の治療にとって有用な二環式テトラヒドロチアゼピン誘導体 - Google Patents
新生物疾患および/または感染性疾患の治療にとって有用な二環式テトラヒドロチアゼピン誘導体 Download PDFInfo
- Publication number
- JP6727224B2 JP6727224B2 JP2017546189A JP2017546189A JP6727224B2 JP 6727224 B2 JP6727224 B2 JP 6727224B2 JP 2017546189 A JP2017546189 A JP 2017546189A JP 2017546189 A JP2017546189 A JP 2017546189A JP 6727224 B2 JP6727224 B2 JP 6727224B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- tetrahydro
- amino
- benzothiazepine
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Bicyclic tetrahydrothiazepine derivatives Chemical class 0.000 title claims description 143
- 230000001613 neoplastic effect Effects 0.000 title claims description 38
- 208000035473 Communicable disease Diseases 0.000 title claims description 34
- 238000011282 treatment Methods 0.000 title claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 387
- 150000001875 compounds Chemical class 0.000 claims description 365
- KYGZWDWABVFSJF-UHFFFAOYSA-N thiopyrano[2,3-b]azepine-7-carboxamide Chemical compound S1C=CC=C2C1=NC=C(C=C2)C(=O)N KYGZWDWABVFSJF-UHFFFAOYSA-N 0.000 claims description 197
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 191
- 238000000034 method Methods 0.000 claims description 180
- 125000000217 alkyl group Chemical group 0.000 claims description 92
- 206010028980 Neoplasm Diseases 0.000 claims description 91
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 73
- 210000002865 immune cell Anatomy 0.000 claims description 72
- 210000004027 cell Anatomy 0.000 claims description 61
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 52
- 239000008194 pharmaceutical composition Substances 0.000 claims description 49
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 45
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 41
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 41
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 38
- 229910052736 halogen Inorganic materials 0.000 claims description 38
- 150000002367 halogens Chemical class 0.000 claims description 36
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 32
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 23
- 125000003342 alkenyl group Chemical group 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 125000000304 alkynyl group Chemical group 0.000 claims description 19
- 229920006395 saturated elastomer Polymers 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 10
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 9
- 239000000021 stimulant Substances 0.000 claims description 9
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 7
- 125000004512 1,2,3-thiadiazol-4-yl group Chemical group S1N=NC(=C1)* 0.000 claims description 4
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 claims description 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 4
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 229940049964 oleate Drugs 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 230000035899 viability Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 125000000062 cyclohexylmethoxy group Chemical group [H]C([H])(O*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
- PPCUXGGVGHMCJQ-INIZCTEOSA-N (3R)-3-amino-4-oxo-N-(4,4,4-trifluorobutyl)-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(N(C1=O)CC1=CC=C(C=C1)OC(F)(F)F)C=C(C=C2)C(=O)NCCCC(F)(F)F PPCUXGGVGHMCJQ-INIZCTEOSA-N 0.000 claims description 2
- VKKXEJPXXNYIAG-SFHVURJKSA-N (3R)-3-amino-4-oxo-N-pyridin-3-yl-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(N(C1=O)CC1=CC=C(C=C1)OC(F)(F)F)C=C(C=C2)C(=O)NC=1C=NC=CC=1 VKKXEJPXXNYIAG-SFHVURJKSA-N 0.000 claims description 2
- DVLRABYBCVQGIA-INIZCTEOSA-N (3R)-3-amino-5-[(3,4-dichlorophenyl)methyl]-1,1,4-trioxo-N-propan-2-yl-2,3-dihydro-1lambda6,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CS(C2=C(N(C1=O)CC1=CC(=C(C=C1)Cl)Cl)C=C(C=C2)C(=O)NC(C)C)(=O)=O DVLRABYBCVQGIA-INIZCTEOSA-N 0.000 claims description 2
- SRFRAKRGXQLBPG-IBGZPJMESA-N (3R)-3-amino-5-[(4-chloro-2-fluorophenyl)methyl]-8-fluoro-N-(oxan-4-ylmethyl)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C(=O)NCC3CCOCC3)C(F)=C2)N(CC2=C(F)C=C(Cl)C=C2)C1=O SRFRAKRGXQLBPG-IBGZPJMESA-N 0.000 claims description 2
- OYEGFRGNOIDQTP-IBGZPJMESA-N (3R)-3-amino-5-[(4-chloro-3-fluorophenyl)methyl]-8-fluoro-N-(oxan-4-ylmethyl)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C(=O)NCC3CCOCC3)C(F)=C2)N(CC2=CC(F)=C(Cl)C=C2)C1=O OYEGFRGNOIDQTP-IBGZPJMESA-N 0.000 claims description 2
- MHKPPCVFIFKPMI-INIZCTEOSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-1,1,4-trioxo-N-propan-2-yl-2,3-dihydro-1lambda6,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CS(C2=C(N(C1=O)CC1=CC=C(C=C1)Cl)C=C(C=C2)C(=O)NC(C)C)(=O)=O MHKPPCVFIFKPMI-INIZCTEOSA-N 0.000 claims description 2
- SCTBEMJGTUEUAQ-INIZCTEOSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-4-oxo-N-(4,4,4-trifluorobutyl)-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C=C2)C(=O)NCCCC(F)(F)F)N(CC2=CC=C(Cl)C=C2)C1=O SCTBEMJGTUEUAQ-INIZCTEOSA-N 0.000 claims description 2
- CHMYDCITGPUIIL-INIZCTEOSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-4-oxo-N-propan-2-yl-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CC(C)NC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1 CHMYDCITGPUIIL-INIZCTEOSA-N 0.000 claims description 2
- FUMGLHAFKGCWDQ-INIZCTEOSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-8-fluoro-4-oxo-N-(4,4,4-trifluorobutyl)-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C(=O)NCCCC(F)(F)F)C(F)=C2)N(CC2=CC=C(Cl)C=C2)C1=O FUMGLHAFKGCWDQ-INIZCTEOSA-N 0.000 claims description 2
- HVPGYKJOHZWMIE-INIZCTEOSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-8-fluoro-4-oxo-N-propoxy-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CCCONC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1F HVPGYKJOHZWMIE-INIZCTEOSA-N 0.000 claims description 2
- KPNKFTONEOKIGM-KRWDZBQOSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-8-fluoro-N'-(2-methylpropyl)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carbohydrazide Chemical compound CC(C)CNNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1F KPNKFTONEOKIGM-KRWDZBQOSA-N 0.000 claims description 2
- OKGZASNEISXQGY-IBGZPJMESA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-8-fluoro-N'-(4-fluorophenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carbohydrazide Chemical compound N[C@H]1CSC2=C(C=C(C(=O)NNC3=CC=C(F)C=C3)C(F)=C2)N(CC2=CC=C(Cl)C=C2)C1=O OKGZASNEISXQGY-IBGZPJMESA-N 0.000 claims description 2
- IZHYYXROIKYTGH-INIZCTEOSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-8-fluoro-N-(2-hydroxy-2-methylpropyl)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CC(C)(O)CNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1F IZHYYXROIKYTGH-INIZCTEOSA-N 0.000 claims description 2
- VPEPWXOWQWZGPX-KRWDZBQOSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-8-fluoro-N-(2-methylpropoxy)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CC(C)CONC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1F VPEPWXOWQWZGPX-KRWDZBQOSA-N 0.000 claims description 2
- OPXMMALSTIIELK-IBGZPJMESA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-8-fluoro-N-(oxan-4-ylmethyl)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C(=O)NCC3CCOCC3)C(F)=C2)N(CC2=CC=C(Cl)C=C2)C1=O OPXMMALSTIIELK-IBGZPJMESA-N 0.000 claims description 2
- WRTRQACJCWHRLI-FQEVSTJZSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-8-fluoro-N-[(4-fluorophenyl)methyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C(=O)NCC3=CC=C(F)C=C3)C(F)=C2)N(CC2=CC=C(Cl)C=C2)C1=O WRTRQACJCWHRLI-FQEVSTJZSA-N 0.000 claims description 2
- ZQVNNULZXXJKBE-NRFANRHFSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-8-fluoro-N-[(4-methoxyphenyl)methyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound COC1=CC=C(CNC(=O)C2=CC3=C(SC[C@H](N)C(=O)N3CC3=CC=C(Cl)C=C3)C=C2F)C=C1 ZQVNNULZXXJKBE-NRFANRHFSA-N 0.000 claims description 2
- GLKSFKLTGOULRV-KRWDZBQOSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N'-(2-methylpropyl)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carbohydrazide Chemical compound CC(C)CNNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1 GLKSFKLTGOULRV-KRWDZBQOSA-N 0.000 claims description 2
- PADLLDHRLYAJKJ-INIZCTEOSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-(2-hydroxy-2-methylpropyl)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CC(C)(O)CNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1 PADLLDHRLYAJKJ-INIZCTEOSA-N 0.000 claims description 2
- NJWBSTRDOHIPJP-INIZCTEOSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-(2-methoxyethyl)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound COCCNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1 NJWBSTRDOHIPJP-INIZCTEOSA-N 0.000 claims description 2
- LNYKKWCYZFPENR-KRWDZBQOSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-(2-methylpropoxy)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CC(C)CONC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1 LNYKKWCYZFPENR-KRWDZBQOSA-N 0.000 claims description 2
- QHYYNBABMCTAQQ-INIZCTEOSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-(3,3-difluorocyclobutyl)-1,1,4-trioxo-2,3-dihydro-1lambda6,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CS(C2=C(N(C1=O)CC1=CC=C(C=C1)Cl)C=C(C=C2)C(=O)NC1CC(C1)(F)F)(=O)=O QHYYNBABMCTAQQ-INIZCTEOSA-N 0.000 claims description 2
- SZCWDLFYFWDMDO-INIZCTEOSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-(3,3-difluorocyclobutyl)-8-fluoro-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C(=O)NC3CC(F)(F)C3)C(F)=C2)N(CC2=CC=C(Cl)C=C2)C1=O SZCWDLFYFWDMDO-INIZCTEOSA-N 0.000 claims description 2
- RVHSWYXPQXPTBK-IBYPIGCZSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-(3-methylbutan-2-yl)-1,1,4-trioxo-2,3-dihydro-1lambda6,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CS(C2=C(N(C1=O)CC1=CC=C(C=C1)Cl)C=C(C=C2)C(=O)NC(C)C(C)C)(=O)=O RVHSWYXPQXPTBK-IBYPIGCZSA-N 0.000 claims description 2
- JODZQFRCEPSEKQ-IBYPIGCZSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-(3-methylbutan-2-yl)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CC(C)C(C)NC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1 JODZQFRCEPSEKQ-IBYPIGCZSA-N 0.000 claims description 2
- HDJFHKUEGPGQNN-SFHVURJKSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-(4,4-difluorocyclohexyl)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C=C2)C(=O)NC2CCC(F)(F)CC2)N(CC2=CC=C(Cl)C=C2)C1=O HDJFHKUEGPGQNN-SFHVURJKSA-N 0.000 claims description 2
- PZNQSLCZIYBSPH-KRWDZBQOSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-(cyclopropylmethyl)-8-fluoro-1,1,4-trioxo-2,3-dihydro-1lambda6,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CS(C2=C(N(C1=O)CC1=CC=C(C=C1)Cl)C=C(C(=C2)F)C(=O)NCC1CC1)(=O)=O PZNQSLCZIYBSPH-KRWDZBQOSA-N 0.000 claims description 2
- BOZCYFGNHCFEFQ-CVMIBEPCSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-(oxan-3-ylmethyl)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C=C2)C(=O)NCC2CCCOC2)N(CC2=CC=C(Cl)C=C2)C1=O BOZCYFGNHCFEFQ-CVMIBEPCSA-N 0.000 claims description 2
- GFKNSRPOJSVCHK-IBGZPJMESA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-(oxan-4-ylmethyl)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C=C2)C(=O)NCC2CCOCC2)N(CC2=CC=C(Cl)C=C2)C1=O GFKNSRPOJSVCHK-IBGZPJMESA-N 0.000 claims description 2
- LVCMHEXMPGZUHZ-VFNWGFHPSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-[(1R)-1-(4-fluorophenyl)ethyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound C[C@@H](NC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1)C1=CC=C(F)C=C1 LVCMHEXMPGZUHZ-VFNWGFHPSA-N 0.000 claims description 2
- IJDBWPRTYQUEBX-ZHRRBRCNSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-[(1R)-1-(4-methoxyphenyl)ethyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound COC1=CC=C(C=C1)[C@@H](C)NC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1 IJDBWPRTYQUEBX-ZHRRBRCNSA-N 0.000 claims description 2
- LVCMHEXMPGZUHZ-BTYIYWSLSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-[(1S)-1-(4-fluorophenyl)ethyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound C[C@H](NC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1)C1=CC=C(F)C=C1 LVCMHEXMPGZUHZ-BTYIYWSLSA-N 0.000 claims description 2
- IJDBWPRTYQUEBX-AOMKIAJQSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-[(1S)-1-(4-methoxyphenyl)ethyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound COC1=CC=C(C=C1)[C@H](C)NC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1 IJDBWPRTYQUEBX-AOMKIAJQSA-N 0.000 claims description 2
- ZZNMQERDZJBKDK-FQEVSTJZSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-[(4-fluorophenyl)methyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C=C2)C(=O)NCC2=CC=C(F)C=C2)N(CC2=CC=C(Cl)C=C2)C1=O ZZNMQERDZJBKDK-FQEVSTJZSA-N 0.000 claims description 2
- QEZYFYRYQDLXEP-NRFANRHFSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-[(4-methoxyphenyl)methyl]-1,1,4-trioxo-2,3-dihydro-1lambda6,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CS(C2=C(N(C1=O)CC1=CC=C(C=C1)Cl)C=C(C=C2)C(=O)NCC1=CC=C(C=C1)OC)(=O)=O QEZYFYRYQDLXEP-NRFANRHFSA-N 0.000 claims description 2
- LVCMHEXMPGZUHZ-FXMQYSIJSA-N (3R)-3-amino-5-[(4-chlorophenyl)methyl]-N-[1-(4-fluorophenyl)ethyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CC(NC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1)C1=CC=C(F)C=C1 LVCMHEXMPGZUHZ-FXMQYSIJSA-N 0.000 claims description 2
- DFQMZJZYCYPSIT-IBGZPJMESA-N (3R)-3-amino-5-[(4-fluorophenyl)methyl]-N-(oxan-4-ylmethyl)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C=C2)C(=O)NCC2CCOCC2)N(CC2=CC=C(F)C=C2)C1=O DFQMZJZYCYPSIT-IBGZPJMESA-N 0.000 claims description 2
- MMNKKADCQRXVED-IBGZPJMESA-N (3R)-3-amino-5-[(4-tert-butylphenyl)methyl]-4-oxo-N-propan-2-yl-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CC(C)NC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(C=C2)C(C)(C)C)C=C1 MMNKKADCQRXVED-IBGZPJMESA-N 0.000 claims description 2
- JMFBNEVDZPQMCQ-KRWDZBQOSA-N (3R)-3-amino-5-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)methyl]-8-fluoro-N-[(4-fluorophenyl)methyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C(=O)NCC3=CC=C(F)C=C3)C(F)=C2)N(CC2=NN=C(S2)C2CC2)C1=O JMFBNEVDZPQMCQ-KRWDZBQOSA-N 0.000 claims description 2
- RLQVUDRMASTUPA-NRFANRHFSA-N (3R)-3-amino-5-[[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methyl]-N-(oxan-4-ylmethyl)-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(N(C1=O)CC1=CC=C(C=C1)C1=NOC(=N1)C)C=C(C=C2)C(=O)NCC1CCOCC1 RLQVUDRMASTUPA-NRFANRHFSA-N 0.000 claims description 2
- SQQBZKIDZVIWIP-INIZCTEOSA-N (3R)-3-amino-5-benzyl-8-fluoro-1,1,4-trioxo-N-(4,4,4-trifluorobutyl)-2,3-dihydro-1lambda6,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CS(C2=C(N(C1=O)CC1=CC=CC=C1)C=C(C(=C2)F)C(=O)NCCCC(F)(F)F)(=O)=O SQQBZKIDZVIWIP-INIZCTEOSA-N 0.000 claims description 2
- NJUTUOHNYHFNKF-INIZCTEOSA-N (3R)-3-amino-8-fluoro-4-oxo-N-propan-2-yl-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CC(C)NC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(OC(F)(F)F)C=C2)C=C1F NJUTUOHNYHFNKF-INIZCTEOSA-N 0.000 claims description 2
- BUEPKAIIDMRFDL-SFHVURJKSA-N (3R)-3-amino-8-fluoro-N-(oxan-4-yl)-4-oxo-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C(=O)NC3CCOCC3)C(F)=C2)N(CC2=CC=C(OC(F)(F)F)C=C2)C1=O BUEPKAIIDMRFDL-SFHVURJKSA-N 0.000 claims description 2
- QQHPVOSFTFJWBG-INIZCTEOSA-N (3R)-3-amino-N'-butanoyl-5-[(4-chlorophenyl)methyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carbohydrazide Chemical compound CCCC(=O)NNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1 QQHPVOSFTFJWBG-INIZCTEOSA-N 0.000 claims description 2
- MAMFKLJDZWEWDG-IBGZPJMESA-N (3R)-3-amino-N-(4,4-difluorocyclohexyl)-5-[(4-methoxyphenyl)methyl]-1,1,4-trioxo-2,3-dihydro-1lambda6,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CS(C2=C(N(C1=O)CC1=CC=C(C=C1)OC)C=C(C=C2)C(=O)NC1CCC(CC1)(F)F)(=O)=O MAMFKLJDZWEWDG-IBGZPJMESA-N 0.000 claims description 2
- GJJUEZGTUNNLQN-KRWDZBQOSA-N (3R)-3-amino-N-(5-tert-butyl-1,2-oxazol-3-yl)-5-[(4-chlorophenyl)methyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CC(C)(C)C1=CC(NC(=O)C2=CC3=C(SC[C@H](N)C(=O)N3CC3=CC=C(Cl)C=C3)C=C2)=NO1 GJJUEZGTUNNLQN-KRWDZBQOSA-N 0.000 claims description 2
- NLFIJJLBVWZPAO-SFHVURJKSA-N (3R)-3-amino-N-(oxan-4-yl)-4-oxo-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C=C2)C(=O)NC2CCOCC2)N(CC2=CC=C(OC(F)(F)F)C=C2)C1=O NLFIJJLBVWZPAO-SFHVURJKSA-N 0.000 claims description 2
- AUZLQLJTGKZUSU-IBGZPJMESA-N (3R)-3-amino-N-(oxan-4-ylmethyl)-4-oxo-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C=C2)C(=O)NCC2CCOCC2)N(CC2=CC=C(OC(F)(F)F)C=C2)C1=O AUZLQLJTGKZUSU-IBGZPJMESA-N 0.000 claims description 2
- BAFYTSXOXGVWDH-NRFANRHFSA-N (3R)-3-amino-N-[(4-fluorophenyl)methyl]-4-oxo-5-[[4-(thiadiazol-4-yl)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(N(C1=O)CC1=CC=C(C=C1)C=1N=NSC=1)C=C(C=C2)C(=O)NCC1=CC=C(C=C1)F BAFYTSXOXGVWDH-NRFANRHFSA-N 0.000 claims description 2
- MCSWTUAEWXTFKE-FQEVSTJZSA-N (3R)-3-amino-N-[(4-fluorophenyl)methyl]-4-oxo-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(N(C1=O)CC1=CC=C(C=C1)OC(F)(F)F)C=C(C=C2)C(=O)NCC1=CC=C(C=C1)F MCSWTUAEWXTFKE-FQEVSTJZSA-N 0.000 claims description 2
- WWSDNQRUILZOOC-NRFANRHFSA-N (3R)-3-amino-N-[(4-methoxyphenyl)methyl]-4-oxo-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound COC1=CC=C(CNC(=O)C2=CC3=C(SC[C@H](N)C(=O)N3CC3=CC=C(OC(F)(F)F)C=C3)C=C2)C=C1 WWSDNQRUILZOOC-NRFANRHFSA-N 0.000 claims description 2
- CPMUKMLSBPOPEK-IBGZPJMESA-N (3R)-3-amino-N-[3-(2,2-dimethylpropanoylamino)propyl]-4-oxo-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CC(C)(C)C(=O)NCCCNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(OC(F)(F)F)C=C2)C=C1 CPMUKMLSBPOPEK-IBGZPJMESA-N 0.000 claims description 2
- DUPHZZHUMWUWEI-FQEVSTJZSA-N (3R)-3-amino-N-benzyl-4-oxo-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C=C2)C(=O)NCC2=CC=CC=C2)N(CC2=CC=C(OC(F)(F)F)C=C2)C1=O DUPHZZHUMWUWEI-FQEVSTJZSA-N 0.000 claims description 2
- YAJNWTRKJMMBDY-NRFANRHFSA-N (3R)-3-amino-N-benzyl-5-[(4-chlorophenyl)methyl]-8-(dimethylamino)-1,1,4-trioxo-2,3-dihydro-1lambda6,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CS(C2=C(N(C1=O)CC1=CC=C(C=C1)Cl)C=C(C(=C2)N(C)C)C(=O)NCC1=CC=CC=C1)(=O)=O YAJNWTRKJMMBDY-NRFANRHFSA-N 0.000 claims description 2
- MMSYLVBJRVUULV-FQEVSTJZSA-N (3R)-3-amino-N-benzyl-8-fluoro-4-oxo-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C(=O)NCC3=CC=CC=C3)C(F)=C2)N(CC2=CC=C(OC(F)(F)F)C=C2)C1=O MMSYLVBJRVUULV-FQEVSTJZSA-N 0.000 claims description 2
- YABXXAGESHAJBP-FQEVSTJZSA-N (3R)-3-amino-N-benzyl-8-fluoro-5-[(4-fluorophenyl)methyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C(=O)NCC3=CC=CC=C3)C(F)=C2)N(CC2=CC=C(F)C=C2)C1=O YABXXAGESHAJBP-FQEVSTJZSA-N 0.000 claims description 2
- QIFDYJWOZRSZCR-KRWDZBQOSA-N (3R)-3-amino-N-but-3-enyl-5-[(4-chlorophenyl)methyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(C=C(C=C2)C(=O)NCCC=C)N(CC2=CC=C(Cl)C=C2)C1=O QIFDYJWOZRSZCR-KRWDZBQOSA-N 0.000 claims description 2
- CLBPTPLMXOWAQQ-HNNXBMFYSA-N (3R)-3-amino-N-butyl-1-[(4-chlorophenyl)methyl]-2,5,5-trioxo-3,4-dihydropyrido[3,4-b][1,4]thiazepine-8-carboxamide Chemical compound N[C@@H]1C(N(C2=C(S(C1)(=O)=O)C=NC(=C2)C(=O)NCCCC)CC1=CC=C(C=C1)Cl)=O CLBPTPLMXOWAQQ-HNNXBMFYSA-N 0.000 claims description 2
- MSNCLRDDINFCLQ-KRWDZBQOSA-N (3R)-3-amino-N-butyl-4-oxo-5-[[3-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CCCCNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC(OC(F)(F)F)=CC=C2)C=C1 MSNCLRDDINFCLQ-KRWDZBQOSA-N 0.000 claims description 2
- HYOYXXPEBGXNHO-IBGZPJMESA-N (3R)-3-amino-N-butyl-4-oxo-5-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CSC2=C(N(C1=O)CC1=CC=C(C=C1)N1N=CN=C1)C=C(C=C2)C(=O)NCCCC HYOYXXPEBGXNHO-IBGZPJMESA-N 0.000 claims description 2
- ZQGOKFLFWWHLCU-KRWDZBQOSA-N (3R)-3-amino-N-butyl-4-oxo-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CCCCNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(OC(F)(F)F)C=C2)C=C1 ZQGOKFLFWWHLCU-KRWDZBQOSA-N 0.000 claims description 2
- OBGQHRSUMSKSPZ-KRWDZBQOSA-N (3R)-3-amino-N-butyl-5-[(4-carbamoylphenyl)methyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CCCCNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(C=C2)C(N)=O)C=C1 OBGQHRSUMSKSPZ-KRWDZBQOSA-N 0.000 claims description 2
- KXXDJMFMUKHKDK-KRWDZBQOSA-N (3R)-3-amino-N-butyl-5-[(4-chloro-2-fluorophenyl)methyl]-8-fluoro-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CCCCNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=C(F)C=C(Cl)C=C2)C=C1F KXXDJMFMUKHKDK-KRWDZBQOSA-N 0.000 claims description 2
- JLVWKUNGZWJCBO-KRWDZBQOSA-N (3R)-3-amino-N-butyl-5-[(4-chloro-3-fluorophenyl)methyl]-8-fluoro-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CCCCNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC(F)=C(Cl)C=C2)C=C1F JLVWKUNGZWJCBO-KRWDZBQOSA-N 0.000 claims description 2
- VKGFPMGSSXFILM-KRWDZBQOSA-N (3R)-3-amino-N-butyl-5-[(4-chlorophenyl)methyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CCCCNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1 VKGFPMGSSXFILM-KRWDZBQOSA-N 0.000 claims description 2
- MVVASNLBZOYHMR-KRWDZBQOSA-N (3R)-3-amino-N-butyl-5-[(4-chlorophenyl)methyl]-8-fluoro-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CCCCNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(Cl)C=C2)C=C1F MVVASNLBZOYHMR-KRWDZBQOSA-N 0.000 claims description 2
- SYQTUSNEFHSHDP-SFHVURJKSA-N (3R)-3-amino-N-butyl-5-[(4-cyanophenyl)methyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CCCCNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(C=C2)C#N)C=C1 SYQTUSNEFHSHDP-SFHVURJKSA-N 0.000 claims description 2
- CJCRMSFXHYKQGI-NRFANRHFSA-N (3R)-3-amino-N-butyl-5-[(4-morpholin-4-ylphenyl)methyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CCCCNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(C=C2)N2CCOCC2)C=C1 CJCRMSFXHYKQGI-NRFANRHFSA-N 0.000 claims description 2
- ANPVTSRRHIYJHL-FQEVSTJZSA-N (3R)-3-amino-N-butyl-5-[(4-tert-butylphenyl)methyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CCCCNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(C=C2)C(C)(C)C)C=C1 ANPVTSRRHIYJHL-FQEVSTJZSA-N 0.000 claims description 2
- IGMAZUHIVNVVEK-IBGZPJMESA-N (3R)-3-amino-N-butyl-8-fluoro-4-oxo-5-(quinolin-2-ylmethyl)-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CCCCNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=NC3=CC=CC=C3C=C2)C=C1F IGMAZUHIVNVVEK-IBGZPJMESA-N 0.000 claims description 2
- VXXUXOXAXWJUHS-KRWDZBQOSA-N (3R)-3-amino-N-butyl-8-fluoro-4-oxo-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CCCCNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(OC(F)(F)F)C=C2)C=C1F VXXUXOXAXWJUHS-KRWDZBQOSA-N 0.000 claims description 2
- NFPXYFRFKQIZFF-KRWDZBQOSA-N (3R)-3-amino-N-butyl-8-fluoro-5-[(4-fluorophenyl)methyl]-4-oxo-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CCCCNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(F)C=C2)C=C1F NFPXYFRFKQIZFF-KRWDZBQOSA-N 0.000 claims description 2
- KPHLVLKFJWKEEV-HNNXBMFYSA-N (3R)-3-amino-N-ethyl-4-oxo-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CCNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(OC(F)(F)F)C=C2)C=C1 KPHLVLKFJWKEEV-HNNXBMFYSA-N 0.000 claims description 2
- NSGMEXQAGJVQEW-AWEZNQCLSA-N (3R)-3-amino-N-methyl-4-oxo-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CNC(=O)C1=CC2=C(SC[C@H](N)C(=O)N2CC2=CC=C(OC(F)(F)F)C=C2)C=C1 NSGMEXQAGJVQEW-AWEZNQCLSA-N 0.000 claims description 2
- QHOYTZYKKRYZGI-INIZCTEOSA-N (3R)-3-amino-N-tert-butyl-5-[(4-chlorophenyl)methyl]-8-fluoro-1,1,4-trioxo-2,3-dihydro-1lambda6,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1CS(C2=C(N(C1=O)CC1=CC=C(C=C1)Cl)C=C(C(=C2)F)C(=O)NC(C)(C)C)(=O)=O QHOYTZYKKRYZGI-INIZCTEOSA-N 0.000 claims description 2
- CJGHSBOQKLNCEU-MHZLTWQESA-N (3R)-N-[[4-(5-acetamidopentoxy)phenyl]methyl]-3-amino-4-oxo-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound CC(=O)NCCCCCOC1=CC=C(CNC(=O)C2=CC3=C(SC[C@H](N)C(=O)N3CC3=CC=C(OC(F)(F)F)C=C3)C=C2)C=C1 CJGHSBOQKLNCEU-MHZLTWQESA-N 0.000 claims description 2
- XWASMLCDSBPKES-UHFFFAOYSA-N 2,1-benzothiazepine-7-carboxamide Chemical compound N=1SC=CC=C2C=1C=CC(=C2)C(=O)N XWASMLCDSBPKES-UHFFFAOYSA-N 0.000 claims description 2
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- PYVGTWPJEBRZOD-LJAQVGFWSA-N tert-butyl N-[5-[[(3R)-5-[(4-chlorophenyl)methyl]-8-fluoro-7-[(4-methoxyphenyl)methylcarbamoyl]-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl]amino]pentyl]carbamate Chemical compound COC1=CC=C(CNC(=O)C2=CC3=C(SC[C@H](NCCCCCNC(=O)OC(C)(C)C)C(=O)N3CC3=CC=C(Cl)C=C3)C=C2F)C=C1 PYVGTWPJEBRZOD-LJAQVGFWSA-N 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- LNXGOTVDWRQAPN-UHFFFAOYSA-N 1,5-benzothiazepine-7-carboxamide Chemical compound S1C=CC=NC2=C1C=CC(=C2)C(=O)N LNXGOTVDWRQAPN-UHFFFAOYSA-N 0.000 claims 1
- 239000000543 intermediate Substances 0.000 description 226
- 230000015572 biosynthetic process Effects 0.000 description 165
- 238000003786 synthesis reaction Methods 0.000 description 165
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 152
- 238000005160 1H NMR spectroscopy Methods 0.000 description 143
- 239000007787 solid Substances 0.000 description 143
- 238000005481 NMR spectroscopy Methods 0.000 description 140
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 138
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 79
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 73
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 72
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 72
- 230000002829 reductive effect Effects 0.000 description 57
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 56
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 55
- 239000011541 reaction mixture Substances 0.000 description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 48
- 210000001744 T-lymphocyte Anatomy 0.000 description 45
- 239000000427 antigen Substances 0.000 description 45
- 108091007433 antigens Proteins 0.000 description 44
- 102000036639 antigens Human genes 0.000 description 44
- 102000004127 Cytokines Human genes 0.000 description 40
- 108090000695 Cytokines Proteins 0.000 description 40
- 238000006243 chemical reaction Methods 0.000 description 36
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000000203 mixture Substances 0.000 description 33
- 239000000243 solution Substances 0.000 description 33
- 239000003643 water by type Substances 0.000 description 31
- 235000019439 ethyl acetate Nutrition 0.000 description 28
- 208000015181 infectious disease Diseases 0.000 description 27
- 108010074328 Interferon-gamma Proteins 0.000 description 26
- 108010002350 Interleukin-2 Proteins 0.000 description 26
- 102000000588 Interleukin-2 Human genes 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- 102100037850 Interferon gamma Human genes 0.000 description 24
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 21
- 230000028993 immune response Effects 0.000 description 21
- 210000000822 natural killer cell Anatomy 0.000 description 21
- 210000003719 b-lymphocyte Anatomy 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 230000001965 increasing effect Effects 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 239000012267 brine Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 239000011734 sodium Substances 0.000 description 19
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 125000001424 substituent group Chemical group 0.000 description 18
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 17
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 17
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 17
- 235000019253 formic acid Nutrition 0.000 description 17
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- HMTYPJSMEVCHTE-UHFFFAOYSA-N Cl.S1N=CC=CC2=C1C=CC(=C2)C(=O)N Chemical compound Cl.S1N=CC=CC2=C1C=CC(=C2)C(=O)N HMTYPJSMEVCHTE-UHFFFAOYSA-N 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 239000000556 agonist Substances 0.000 description 16
- 208000036142 Viral infection Diseases 0.000 description 15
- 229910052799 carbon Inorganic materials 0.000 description 15
- 210000004443 dendritic cell Anatomy 0.000 description 15
- 239000003480 eluent Substances 0.000 description 15
- 239000012071 phase Substances 0.000 description 15
- 230000009385 viral infection Effects 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 208000035269 cancer or benign tumor Diseases 0.000 description 14
- 238000004440 column chromatography Methods 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 102100032937 CD40 ligand Human genes 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 230000002441 reversible effect Effects 0.000 description 12
- 108010029697 CD40 Ligand Proteins 0.000 description 11
- 210000000987 immune system Anatomy 0.000 description 11
- 230000002458 infectious effect Effects 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 238000001819 mass spectrum Methods 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 238000005070 sampling Methods 0.000 description 11
- 238000002211 ultraviolet spectrum Methods 0.000 description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 10
- 210000000612 antigen-presenting cell Anatomy 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 230000001900 immune effect Effects 0.000 description 10
- 125000006413 ring segment Chemical group 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 229910052742 iron Inorganic materials 0.000 description 9
- 201000001441 melanoma Diseases 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 8
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 8
- 208000017667 Chronic Disease Diseases 0.000 description 8
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- DTRBIIDYMYVRNE-UHFFFAOYSA-N 1h-azepine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC=CN1 DTRBIIDYMYVRNE-UHFFFAOYSA-N 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- VPYWSRKVRAEDHI-UHFFFAOYSA-N methyl 1h-azepine-2-carboxylate Chemical compound COC(=O)C1=CC=CC=CN1 VPYWSRKVRAEDHI-UHFFFAOYSA-N 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- MILBZZSCXOQEMO-UHFFFAOYSA-N 1H-azepine-2-carboxamide hydrochloride Chemical compound Cl.N1C=CC=CC=C1C(=O)N MILBZZSCXOQEMO-UHFFFAOYSA-N 0.000 description 6
- CVHPEJPFLXVPNO-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1,5-benzothiazepine-7-carboxylic acid Chemical compound S1CCCNC2=CC(C(=O)O)=CC=C21 CVHPEJPFLXVPNO-UHFFFAOYSA-N 0.000 description 6
- 101150013553 CD40 gene Proteins 0.000 description 6
- 239000007821 HATU Substances 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000012678 infectious agent Substances 0.000 description 6
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 210000005170 neoplastic cell Anatomy 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 229920002873 Polyethylenimine Polymers 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 150000001408 amides Chemical group 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000003181 biological factor Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- MYZVQHKSETXXFX-UHFFFAOYSA-N methyl 2,3,4,5-tetrahydro-1,5-benzothiazepine-7-carboxylate Chemical compound S1CCCNC2=CC(C(=O)OC)=CC=C21 MYZVQHKSETXXFX-UHFFFAOYSA-N 0.000 description 5
- 210000000066 myeloid cell Anatomy 0.000 description 5
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 4
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 4
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 4
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
- XSDHTJIYUCIHHO-UHFFFAOYSA-N OC(=O)c1ccc2SN=CC=Cc2c1 Chemical compound OC(=O)c1ccc2SN=CC=Cc2c1 XSDHTJIYUCIHHO-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 4
- 239000001099 ammonium carbonate Substances 0.000 description 4
- 230000000118 anti-neoplastic effect Effects 0.000 description 4
- 230000005809 anti-tumor immunity Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
- 229940034982 antineoplastic agent Drugs 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
- 239000003124 biologic agent Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- ALMTXVIDLFAFMC-UHFFFAOYSA-N methyl 1,2-benzothiazepine-7-carboxylate Chemical compound S1N=CC=CC2=C1C=CC(=C2)C(=O)OC ALMTXVIDLFAFMC-UHFFFAOYSA-N 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 238000007910 systemic administration Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- ATVFTGTXIUDKIZ-YFKPBYRVSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-sulfanylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CS)C(O)=O ATVFTGTXIUDKIZ-YFKPBYRVSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 229940123205 CD28 agonist Drugs 0.000 description 3
- 229940122738 CD3 agonist Drugs 0.000 description 3
- TZBUOQMUESOZCF-UHFFFAOYSA-N Cl.S1CCCNC2=C1C=CC(=C2)C(=O)N Chemical compound Cl.S1CCCNC2=C1C=CC(=C2)C(=O)N TZBUOQMUESOZCF-UHFFFAOYSA-N 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 208000000527 Germinoma Diseases 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 210000005006 adaptive immune system Anatomy 0.000 description 3
- 238000011467 adoptive cell therapy Methods 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 229960000640 dactinomycin Drugs 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 201000003115 germ cell cancer Diseases 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 229940117681 interleukin-12 Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229960001428 mercaptopurine Drugs 0.000 description 3
- QSRRZKPKHJHIRB-UHFFFAOYSA-N methyl 4-[(2,5-dichloro-4-methylthiophen-3-yl)sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=C(Cl)SC(Cl)=C1C QSRRZKPKHJHIRB-UHFFFAOYSA-N 0.000 description 3
- JHVNNAKBEQYMGY-UHFFFAOYSA-N methyl thiazepine-7-carboxylate Chemical compound COC(=O)C1=CC=CC=NS1 JHVNNAKBEQYMGY-UHFFFAOYSA-N 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 238000012805 post-processing Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 150000003536 tetrazoles Chemical class 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 150000003852 triazoles Chemical class 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- JTDGKQNNPKXKII-ZETCQYMHSA-N (1s)-1-(4-methoxyphenyl)ethanamine Chemical compound COC1=CC=C([C@H](C)N)C=C1 JTDGKQNNPKXKII-ZETCQYMHSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 2
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 2
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 2
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- XSLBWZNMWUEVMS-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1,5-benzothiazepine Chemical class S1CCCNC2=CC=CC=C21 XSLBWZNMWUEVMS-UHFFFAOYSA-N 0.000 description 2
- MTVOSXTZNVKGIF-UHFFFAOYSA-N 2,3-dimethoxy-12-methyl-13h-[1,3]benzodioxolo[5,6-c]phenanthridine Chemical compound C1=C2C(N(C)CC=3C=C(C(=CC=33)OC)OC)=C3C=CC2=CC2=C1OCO2 MTVOSXTZNVKGIF-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- HNXQXTQTPAJEJL-UHFFFAOYSA-N 2-aminopteridin-4-ol Chemical compound C1=CN=C2NC(N)=NC(=O)C2=N1 HNXQXTQTPAJEJL-UHFFFAOYSA-N 0.000 description 2
- KKWJCGCIAHLFNE-UHFFFAOYSA-N 22R-hydroxylanosterol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(C(O)CC=C(C)C)C)CCC21C KKWJCGCIAHLFNE-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 241000238876 Acari Species 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 102400000068 Angiostatin Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WIRJRCGWVMBCRU-INIZCTEOSA-N C(C)(C)(C)OC(=O)N[C@H]1CSC2=C(N(C1=O)CC1=CC=C(C=C1)Cl)C=CC=C2 Chemical compound C(C)(C)(C)OC(=O)N[C@H]1CSC2=C(N(C1=O)CC1=CC=C(C=C1)Cl)C=CC=C2 WIRJRCGWVMBCRU-INIZCTEOSA-N 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 239000005973 Carvone Substances 0.000 description 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- NTURVSFTOYPGON-UHFFFAOYSA-N Dihydroquinazoline Chemical compound C1=CC=C2C=NCNC2=C1 NTURVSFTOYPGON-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
- CSYGXJQNODZRQO-UHFFFAOYSA-N Inotodiol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CC(O)C12C)C4(C)CCC(O)C(C)(C)C4CC3 CSYGXJQNODZRQO-UHFFFAOYSA-N 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- ANFSXHKDCKWWDB-UHFFFAOYSA-N Justicidin A Chemical compound C1=C2OCOC2=CC(C=2C=3C(=O)OCC=3C(OC)=C3C=C(C(=CC3=2)OC)OC)=C1 ANFSXHKDCKWWDB-UHFFFAOYSA-N 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108090000778 Platelet factor 4 Proteins 0.000 description 2
- 102000004211 Platelet factor 4 Human genes 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- YWPZRBHJQJIRKI-UHFFFAOYSA-N S1C=CC=NC2=C1C=CC(=C2)C(=O)OC Chemical compound S1C=CC=NC2=C1C=CC(=C2)C(=O)OC YWPZRBHJQJIRKI-UHFFFAOYSA-N 0.000 description 2
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 description 2
- 201000010208 Seminoma Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 102000002938 Thrombospondin Human genes 0.000 description 2
- 108060008245 Thrombospondin Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002223 anti-pathogen Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- ZEKAIRFOYPDZNC-UHFFFAOYSA-N aristolactam-aii Chemical compound O=C1NC2=CC3=CC=CC=C3C3=C2C1=CC(O)=C3OC ZEKAIRFOYPDZNC-UHFFFAOYSA-N 0.000 description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- MXMZCLLIUQEKSN-UHFFFAOYSA-N benzimidazoline Chemical compound C1=CC=C2NCNC2=C1 MXMZCLLIUQEKSN-UHFFFAOYSA-N 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- QZPQTZZNNJUOLS-UHFFFAOYSA-N beta-lapachone Chemical compound C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000002786 image-guided radiation therapy Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- KKWJCGCIAHLFNE-KFPHZHIMSA-N inotodiol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H]([C@H](O)CC=C(C)C)C)CC[C@]21C KKWJCGCIAHLFNE-KFPHZHIMSA-N 0.000 description 2
- 238000002721 intensity-modulated radiation therapy Methods 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- RTDRYYULUYRTAN-UHFFFAOYSA-N justicidin B Natural products C1=C2OCOC2=CC(C=2C=3C(=O)OCC=3C=C3C=C(C(=CC3=2)OC)OC)=C1 RTDRYYULUYRTAN-UHFFFAOYSA-N 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- KLMBOVOUTOBMLS-UHFFFAOYSA-N methyl 2,4-difluoro-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=C(F)C=C1F KLMBOVOUTOBMLS-UHFFFAOYSA-N 0.000 description 2
- CNJJSTPBUHAEFH-UHFFFAOYSA-N methyl 4-fluoro-3-nitrobenzoate Chemical compound COC(=O)C1=CC=C(F)C([N+]([O-])=O)=C1 CNJJSTPBUHAEFH-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- RNYZJZKPGHQTJR-UHFFFAOYSA-N protoanemonin Chemical compound C=C1OC(=O)C=C1 RNYZJZKPGHQTJR-UHFFFAOYSA-N 0.000 description 2
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000002719 stereotactic radiosurgery Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 2
- FEIPLLTUQFBQPL-UHFFFAOYSA-N thiazepine-7-carboxylic acid Chemical compound OC(=O)C1=CC=CC=NS1 FEIPLLTUQFBQPL-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- LUBKKVGXMXTXOZ-QGZVFWFLSA-N (+)-geodin Chemical compound COC(=O)C1=CC(=O)C=C(OC)[C@@]11C(=O)C(C(O)=C(Cl)C(C)=C2Cl)=C2O1 LUBKKVGXMXTXOZ-QGZVFWFLSA-N 0.000 description 1
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- LGSDYQBPJKYJCT-UHFFFAOYSA-N (-)-Akagerine Natural products OC1CC(C(C=O)=CC)CC2N(C)CCC3=C2N1C1=CC=CC=C31 LGSDYQBPJKYJCT-UHFFFAOYSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- RWNHLTKFBKYDOJ-UHFFFAOYSA-N (-)-arjunolic acid Natural products C1C(O)C(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C RWNHLTKFBKYDOJ-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- WSSNWLHFBOKGGL-HSHFZTNMSA-N (1R)-2,2-difluorocyclopropan-1-amine hydrochloride Chemical compound Cl.N[C@@H]1CC1(F)F WSSNWLHFBOKGGL-HSHFZTNMSA-N 0.000 description 1
- SNDRSTHMYNFFEJ-NSHDSACASA-N (2R)-3-(2-amino-4-methoxycarbonylphenyl)sulfanyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound NC1=C(C=CC(=C1)C(=O)OC)SC[C@@H](C(=O)O)NC(=O)OC(C)(C)C SNDRSTHMYNFFEJ-NSHDSACASA-N 0.000 description 1
- QPIMUGHDKZTGBH-NSHDSACASA-N (2R)-3-(2-amino-5-chloro-4-methoxycarbonylphenyl)sulfanyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound NC1=C(C=C(C(=C1)C(=O)OC)Cl)SC[C@@H](C(=O)O)NC(=O)OC(C)(C)C QPIMUGHDKZTGBH-NSHDSACASA-N 0.000 description 1
- QZFCCJMWKKRDCM-NSHDSACASA-N (2R)-3-(2-amino-5-fluoro-4-methoxycarbonylphenyl)sulfanyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound NC1=C(C=C(C(=C1)C(=O)OC)F)SC[C@@H](C(=O)O)NC(=O)OC(C)(C)C QZFCCJMWKKRDCM-NSHDSACASA-N 0.000 description 1
- VNHFTQJKYHSJRM-JTQLQIEISA-N (2R)-3-(4-methoxycarbonyl-2-nitrophenyl)sulfanyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound C(C)(C)(C)OC(=O)N[C@H](C(=O)O)CSC1=C(C=C(C=C1)C(=O)OC)[N+](=O)[O-] VNHFTQJKYHSJRM-JTQLQIEISA-N 0.000 description 1
- BNQDSFKPPZJNSH-JTQLQIEISA-N (2R)-3-(5-chloro-4-methoxycarbonyl-2-nitrophenyl)sulfanyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound C(C)(C)(C)OC(=O)N[C@H](C(=O)O)CSC1=C(C=C(C(=C1)Cl)C(=O)OC)[N+](=O)[O-] BNQDSFKPPZJNSH-JTQLQIEISA-N 0.000 description 1
- UNNVEEWDIZBWDR-JTQLQIEISA-N (2R)-3-(5-fluoro-4-methoxycarbonyl-2-nitrophenyl)sulfanyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound C(C)(C)(C)OC(=O)N[C@H](C(=O)O)CSC1=C(C=C(C(=C1)F)C(=O)OC)[N+](=O)[O-] UNNVEEWDIZBWDR-JTQLQIEISA-N 0.000 description 1
- AIXTWHKXZWGYTI-RITPCOANSA-N (2R,3R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-sulfanylbutanoic acid Chemical compound C(C)(C)(C)OC(=O)N[C@H](C(=O)O)[C@@H](C)S AIXTWHKXZWGYTI-RITPCOANSA-N 0.000 description 1
- WUILLHNIFRQUJH-RNCFNFMXSA-N (2R,3R)-3-(2-amino-4-methoxycarbonylphenyl)sulfanyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound NC1=C(C=CC(=C1)C(=O)OC)S[C@@H]([C@@H](C(=O)O)NC(=O)OC(C)(C)C)C WUILLHNIFRQUJH-RNCFNFMXSA-N 0.000 description 1
- YQDOLVQYJUDVDR-OQPBUACISA-N (2R,3R)-3-(2-amino-5-fluoro-4-methoxycarbonylphenyl)sulfanyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound NC1=C(C=C(C(=C1)C(=O)OC)F)S[C@@H]([C@@H](C(=O)O)NC(=O)OC(C)(C)C)C YQDOLVQYJUDVDR-OQPBUACISA-N 0.000 description 1
- GUYSZGHQJHYSQY-RNCFNFMXSA-N (2R,3R)-3-(4-methoxycarbonyl-2-nitrophenyl)sulfanyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound C(C)(C)(C)OC(=O)N[C@H](C(=O)O)[C@@H](C)SC1=C(C=C(C=C1)C(=O)OC)[N+](=O)[O-] GUYSZGHQJHYSQY-RNCFNFMXSA-N 0.000 description 1
- CGZPZODDIIPQRD-OQPBUACISA-N (2R,3R)-3-(5-fluoro-4-methoxycarbonyl-2-nitrophenyl)sulfanyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound C(C)(C)(C)OC(=O)N[C@H](C(=O)O)[C@@H](C)SC1=C(C=C(C(=C1)F)C(=O)OC)[N+](=O)[O-] CGZPZODDIIPQRD-OQPBUACISA-N 0.000 description 1
- PISANEONGDRAOY-SVRRBLITSA-N (2R,3R)-3-acetylsulfanyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound C(C)(=O)S[C@@H]([C@@H](C(=O)O)NC(=O)OC(C)(C)C)C PISANEONGDRAOY-SVRRBLITSA-N 0.000 description 1
- AEJWYTQUJWGWHF-YJYMSZOUSA-N (2R,3R)-3-amino-5-[(4-chlorophenyl)methyl]-2-methyl-4-oxo-N-(4,4,4-trifluorobutyl)-2,3-dihydro-1,5-benzothiazepine-7-carboxamide Chemical compound N[C@H]1[C@H](SC2=C(N(C1=O)CC1=CC=C(C=C1)Cl)C=C(C=C2)C(=O)NCCCC(F)(F)F)C AEJWYTQUJWGWHF-YJYMSZOUSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- LLHOYOCAAURYRL-WDSKDSINSA-N (2s,3s)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound C[C@H](O)[C@@H](C(O)=O)NC(=O)OC(C)(C)C LLHOYOCAAURYRL-WDSKDSINSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- BGGIZHKHJBQRTI-VTYGAKHASA-N (3s,5s,8r,9s,10s,13r,14s,17r)-5,14-dihydroxy-3-[(2r,3r,4s,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy-13-methyl-17-(5-oxo-2h-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-10-carbaldehyde Chemical compound O1[C@H](C)[C@@H](O)[C@H](OC)[C@@H](OC)[C@@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)CC[C@@H]3[C@@]2(C=O)CC1 BGGIZHKHJBQRTI-VTYGAKHASA-N 0.000 description 1
- RWNHLTKFBKYDOJ-WLVUEYHVSA-N (4aS,6aR,6aS,6bR,8aR,9S,10R,11R,12aR,14bS)-10,11-dihydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C1[C@@H](O)[C@H](O)[C@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C RWNHLTKFBKYDOJ-WLVUEYHVSA-N 0.000 description 1
- ZMSNKXDPESNSSS-SZZHBACVSA-N (4r,4as,6as,6as,6br,8ar,11s,12as,14as,14bs)-8a,11-bis(hydroxymethyl)-4,4a,6a,6b,11,14a-hexamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@@](C)(CO)CC[C@]1(CO)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CCC(=O)[C@@H]1C ZMSNKXDPESNSSS-SZZHBACVSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YXHVCZZLWZYHSA-UHFFFAOYSA-N (Z)-6-[8-pentadecenyl]salicylic acid Natural products CCCCCCC=CCCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-UHFFFAOYSA-N 0.000 description 1
- GQGRDYWMOPRROR-ZIFKCHSBSA-N (e)-7-[(1r,2r,3s,5s)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid Chemical compound O([C@H]1C[C@@H]([C@@H]([C@H]1CC\C=C\CCC(O)=O)N1CCCCC1)O)CC(C=C1)=CC=C1C1=CC=CC=C1 GQGRDYWMOPRROR-ZIFKCHSBSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Chemical group 0.000 description 1
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 1
- POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- UUZJJNBYJDFQHL-UHFFFAOYSA-N 1,2,3-triazolidine Chemical compound C1CNNN1 UUZJJNBYJDFQHL-UHFFFAOYSA-N 0.000 description 1
- IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 description 1
- JVANDLOBMHTTNX-UHFFFAOYSA-N 1h-azepine-2-carboxamide Chemical compound NC(=O)C1=CC=CC=CN1 JVANDLOBMHTTNX-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- WSSNWLHFBOKGGL-UHFFFAOYSA-N 2,2-difluorocyclopropan-1-amine;hydrochloride Chemical compound Cl.NC1CC1(F)F WSSNWLHFBOKGGL-UHFFFAOYSA-N 0.000 description 1
- QLDAACVSUMUMOR-UHFFFAOYSA-M 2,3-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride Chemical compound [Cl-].C1=C2C3=[N+](C)C=C4C=C(OC)C(OC)=CC4=C3C=CC2=CC2=C1OCO2 QLDAACVSUMUMOR-UHFFFAOYSA-M 0.000 description 1
- MDFSGDMPHMKKGB-UHFFFAOYSA-N 2,4-difluoro-5-nitrobenzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=C(F)C=C1F MDFSGDMPHMKKGB-UHFFFAOYSA-N 0.000 description 1
- KIMWNWBXVWTJDT-UHFFFAOYSA-N 2,9-diazaspiro[4.5]decan-1-one Chemical compound O=C1NCCC11CNCCC1 KIMWNWBXVWTJDT-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- SOLIIYNRSAWTSQ-UHFFFAOYSA-N 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-n-pyridin-4-ylacetamide Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2C(C(=O)C(=O)NC=2C=CN=CC=2)=C1 SOLIIYNRSAWTSQ-UHFFFAOYSA-N 0.000 description 1
- SYZKAFCPWNFONG-UHFFFAOYSA-N 2-chloro-4-fluoro-5-nitrobenzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=C(F)C=C1Cl SYZKAFCPWNFONG-UHFFFAOYSA-N 0.000 description 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
- SUSDYISRJSLTST-UHFFFAOYSA-N 2-oxaspiro[3.3]heptane Chemical compound C1CCC21COC2 SUSDYISRJSLTST-UHFFFAOYSA-N 0.000 description 1
- IYPUVUXCGMVHJB-UHFFFAOYSA-N 2-oxo-4,5-dihydro-3H-1,5-benzothiazepine-7-carboxylic acid Chemical compound O=C1SC2=C(NCC1)C=C(C=C2)C(=O)O IYPUVUXCGMVHJB-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- KTYZKXFERQUCPX-XGKXUXTPSA-N 3,7,11,15(17)-cembratetraene-16,2:19,6-diolide Chemical compound C([C@@H]1C(=C)C(=O)O[C@H]1/C=C(C)/C1)CC(/C)=C/CCC2=C[C@@H]1OC2=O KTYZKXFERQUCPX-XGKXUXTPSA-N 0.000 description 1
- LKDJYZBKCVSODK-UHFFFAOYSA-N 3,8-diazabicyclo[3.2.1]octane Chemical compound C1NCC2CCC1N2 LKDJYZBKCVSODK-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 description 1
- DMQUTHYDANVWJS-UHFFFAOYSA-N 3h-1,5-benzothiazepin-2-one Chemical compound S1C(=O)CC=NC2=CC=CC=C21 DMQUTHYDANVWJS-UHFFFAOYSA-N 0.000 description 1
- LAXWLCVPJLBABV-UHFFFAOYSA-N 4,4,4-trifluorobutan-1-amine Chemical compound NCCCC(F)(F)F LAXWLCVPJLBABV-UHFFFAOYSA-N 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- GUUULVAMQJLDSY-UHFFFAOYSA-N 4,5-dihydro-1,2-thiazole Chemical compound C1CC=NS1 GUUULVAMQJLDSY-UHFFFAOYSA-N 0.000 description 1
- WEDKTMOIKOKBSH-UHFFFAOYSA-N 4,5-dihydrothiadiazole Chemical compound C1CN=NS1 WEDKTMOIKOKBSH-UHFFFAOYSA-N 0.000 description 1
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 1
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- YSFGBPCBPNVLOK-UHFFFAOYSA-N 6-hydroxy-2-methylhex-2-enamide Chemical compound NC(=O)C(C)=CCCCO YSFGBPCBPNVLOK-UHFFFAOYSA-N 0.000 description 1
- NDCWHEDPSFRTDA-FJMWQILYSA-N 6-hydroxypaclitaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)[C@H](O)[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 NDCWHEDPSFRTDA-FJMWQILYSA-N 0.000 description 1
- BDHMQGDCUCSDHX-UHFFFAOYSA-N 6-oxa-2-azaspiro[3.4]octane Chemical compound C1NCC11COCC1 BDHMQGDCUCSDHX-UHFFFAOYSA-N 0.000 description 1
- BGHWDQSKCIBAAL-UHFFFAOYSA-N 6h-1-benzazepine-7-carboxylic acid Chemical compound N1=CC=CC=C2CC(C(=O)O)=CC=C21 BGHWDQSKCIBAAL-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical compound C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010068873 Adenosquamous cell carcinoma Diseases 0.000 description 1
- ZGCSNRKSJLVANE-UHFFFAOYSA-N Aglycone-Rebeccamycin Natural products N1C2=C3NC4=C(Cl)C=CC=C4C3=C(C(=O)NC3=O)C3=C2C2=C1C(Cl)=CC=C2 ZGCSNRKSJLVANE-UHFFFAOYSA-N 0.000 description 1
- LGSDYQBPJKYJCT-CCKFTAQKSA-N Akagerin Natural products CC=C(C=O)[C@H]1C[C@H](O)n2c3[C@H](C1)N(C)CCc3c4ccccc24 LGSDYQBPJKYJCT-CCKFTAQKSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- JLUQTCXCAFSSLD-NXEZZACHSA-N Anemonin Chemical compound C1=CC(=O)O[C@]11[C@@]2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-NXEZZACHSA-N 0.000 description 1
- JLUQTCXCAFSSLD-UHFFFAOYSA-N Anemonin Natural products C1=CC(=O)OC11C2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-UHFFFAOYSA-N 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 208000017925 Askin tumor Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 229930190007 Baccatin Natural products 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001302512 Banna virus Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- BMRNQSAXDJQXEL-ALGYPFNYSA-N Bryophyllin A Natural products O=C[C@@]12[C@H]3[C@H](O)C[C@]4(C)[C@H](C5=COC(=O)C=C5)CC[C@]4(O)[C@@H]3CC[C@]31O[C@]1(C)O[C@@H]2C[C@H](O1)C3 BMRNQSAXDJQXEL-ALGYPFNYSA-N 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- CGVFRZMQURRQIE-UHFFFAOYSA-N COC1=CC=C(CN(C(CC=2SC=CC=2)=O)C2=CC(=C(C(=C2)OC)OC)OC)C=C1 Chemical compound COC1=CC=C(CN(C(CC=2SC=CC=2)=O)C2=CC(=C(C(=C2)OC)OC)OC)C=C1 CGVFRZMQURRQIE-UHFFFAOYSA-N 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 1
- 102100029968 Calreticulin Human genes 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 102400000730 Canstatin Human genes 0.000 description 1
- 101800000626 Canstatin Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 102100031186 Chromogranin-A Human genes 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 102100024484 Codanin-1 Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Chemical group 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 239000004265 EU approved glazing agent Substances 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- SIJZIXKTIMECTM-DKWTVANSSA-N FC1(C(C1)C(=O)O)F.FC1([C@@H](C1)C(=O)O)F Chemical compound FC1(C(C1)C(=O)O)F.FC1([C@@H](C1)C(=O)O)F SIJZIXKTIMECTM-DKWTVANSSA-N 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- 229940123414 Folate antagonist Drugs 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- YXHVCZZLWZYHSA-FPLPWBNLSA-N Ginkgoic acid Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-FPLPWBNLSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 241000190708 Guanarito mammarenavirus Species 0.000 description 1
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000893570 Hendra henipavirus Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000980888 Homo sapiens Codanin-1 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241001479210 Human astrovirus Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000046923 Human bocavirus Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 241000342334 Human metapneumovirus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 101150101999 IL6 gene Proteins 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- SFVVQRJOGUKCEG-CQROYNQRSA-N Indicine Natural products C1C[C@H](O)[C@H]2C(COC(=O)[C@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-CQROYNQRSA-N 0.000 description 1
- OONXNTUZEDPBLV-UHFFFAOYSA-N Indicine+ Natural products C1CC2(C)C3CCC4(C)C(C(O)C)CCC4(O)C3CC=C2CC1OC1CC(O)C(O)C(C)O1 OONXNTUZEDPBLV-UHFFFAOYSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 241000712890 Junin mammarenavirus Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010023347 Keratoacanthoma Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- BSBUOIJYJTWEHV-UHFFFAOYSA-N Leukamenin A Natural products C12CCC(C3O)C(=C)C(=O)C23C(O)CC2C1(C)CC(O)C(OC(=O)C)C2(C)C BSBUOIJYJTWEHV-UHFFFAOYSA-N 0.000 description 1
- ZUYCXZKSCBNOSX-UHFFFAOYSA-N Leukamenin B Natural products C12CCC(C3O)C(=C)C(=O)C23C(O)CC2C1(C)CC(OC(=O)C)C(OC(C)=O)C2(C)C ZUYCXZKSCBNOSX-UHFFFAOYSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 241000712898 Machupo mammarenavirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- LLMFFOXSSQHNFR-UHFFFAOYSA-N Marchantin A Chemical compound O1C2=C(O)C=CC=C2CCC(C=C2)=CC=C2OC(C=2)=C(O)C(O)=CC=2CCC2=CC=CC1=C2 LLMFFOXSSQHNFR-UHFFFAOYSA-N 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 1
- 101710200814 Melanotropin alpha Proteins 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 229940121849 Mitotic inhibitor Drugs 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000686934 Mus musculus Prolactin-7D1 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 101100168274 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-3 gene Proteins 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
- CERNCEWWFARVAM-UHFFFAOYSA-N O=C1SC2=C(NCC1)C=C(C=C2)C(=O)OC Chemical compound O=C1SC2=C(NCC1)C=C(C=C2)C(=O)OC CERNCEWWFARVAM-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010073338 Optic glioma Diseases 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 102100040557 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 208000025618 Paget disease of nipple Diseases 0.000 description 1
- VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 description 1
- VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 229940122985 Peptide agonist Drugs 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- 206010073144 Peripheral primitive neuroectodermal tumour of soft tissue Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 102100039419 Plasminogen activator inhibitor 2 Human genes 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 229920001363 Polidocanol Polymers 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- QEHOIJJIZXRMAN-UHFFFAOYSA-N Rebeccamycin Natural products OC1C(O)C(OC)C(CO)OC1N1C2=C3NC4=C(Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 QEHOIJJIZXRMAN-UHFFFAOYSA-N 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 102400001051 Restin Human genes 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- CWBKBISTQYYNTK-UHFFFAOYSA-N S1C=CC=NC2=C1C=CC(=C2)C(=O)O Chemical compound S1C=CC=NC2=C1C=CC(=C2)C(=O)O CWBKBISTQYYNTK-UHFFFAOYSA-N 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 108010005173 SERPIN-B5 Proteins 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 description 1
- 241000192617 Sabia mammarenavirus Species 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102100030333 Serpin B5 Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 241000258242 Siphonaptera Species 0.000 description 1
- 208000009574 Skin Appendage Carcinoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 241000520373 Sphacelia Species 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- PHLJPJICTIGOKC-XKYMZAEISA-N Strychnopentamine Chemical compound CN1CCC[C@@H]1C1=C(O)C=CC2=C1NC1=C2CCN2[C@H]1C[C@H](C[C@H]1C3=C(C4=CC=CC=C4N3)CCN1C)[C@@H](C=C)C2 PHLJPJICTIGOKC-XKYMZAEISA-N 0.000 description 1
- PHLJPJICTIGOKC-UHFFFAOYSA-N Strychnopentamine Natural products CN1CCCC1C1=C(O)C=CC2=C1NC1=C2CCN2C1CC(CC1C3=C(C4=CC=CC=C4N3)CCN1C)C(C=C)C2 PHLJPJICTIGOKC-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 1
- 229910010413 TiO 2 Inorganic materials 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 229930187911 Tubeimoside Natural products 0.000 description 1
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- BGGIZHKHJBQRTI-UHFFFAOYSA-N UNPD92725 Natural products O1C(C)C(O)C(OC)C(OC)C1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CCC3C2(C=O)CC1 BGGIZHKHJBQRTI-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 108010048673 Vitronectin Receptors Proteins 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- KYBLAIAGFNCVHL-VKWWBDAGSA-N Zeorin Natural products OC(C)(C)[C@@H]1[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@@H]([C@@H](O)C4)C(C)(C)CCC5)CC3)CC2)CC1 KYBLAIAGFNCVHL-VKWWBDAGSA-N 0.000 description 1
- FWXLVXABZRYLST-XUOZYSPWSA-N [(3r,4r,4ar,5s,6r,6ar,6as,6br,8ar,10s,12ar,14bs)-5,6,10-trihydroxy-4a-(hydroxymethyl)-2,2,6a,6b,9,9,12a-heptamethyl-4-[(z)-2-methylbut-2-enoyl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicen-3-yl] (e)-2-methylbut-2-enoate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)[C@@H](O)[C@@H](O)[C@@]5(CO)[C@@H](OC(=O)C(\C)=C/C)[C@H](OC(=O)C(/C)=C/C)C(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C FWXLVXABZRYLST-XUOZYSPWSA-N 0.000 description 1
- DNAWGBOKUFFVMB-PZIGJSDBSA-N [(7r,8r)-7-hydroxy-4-oxido-5,6,7,8-tetrahydro-3h-pyrrolizin-4-ium-1-yl]methyl (2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@](O)([C@H](C)O)C(C)C)=CC[N+]21[O-] DNAWGBOKUFFVMB-PZIGJSDBSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- KYBLAIAGFNCVHL-UHFFFAOYSA-N alpha-zeroin Natural products C12CCC3C4(C)CCCC(C)(C)C4C(O)CC3(C)C1(C)CCC1C2(C)CCC1C(C)(O)C KYBLAIAGFNCVHL-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 208000030317 anaplastic cancer Diseases 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000000964 angiostatic effect Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229960003982 apatinib Drugs 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- ZKXBFLQGGFVSGB-UHFFFAOYSA-N aristolactam AII Natural products COc1ccc2C(=O)Nc3cc4ccc(O)cc4c1c23 ZKXBFLQGGFVSGB-UHFFFAOYSA-N 0.000 description 1
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 1
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229930192649 bafilomycin Natural products 0.000 description 1
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 150000007657 benzothiazepines Chemical class 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000004555 blood preservation Methods 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- BMRNQSAXDJQXEL-BGJAGFQLSA-N bryophyllin a Chemical compound C=1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5([C@H]6C[C@H]7C[C@@]5(O[C@](C)(O7)O6)CC4)C=O)[C@H](O)C[C@@]32C)C=CC(=O)OC=1 BMRNQSAXDJQXEL-BGJAGFQLSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- SDORWYKFHHNDIQ-UHFFFAOYSA-N carbamoyl 2-phenoxyacetate Chemical compound NC(=O)OC(=O)COC1=CC=CC=C1 SDORWYKFHHNDIQ-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960002328 chloroquine phosphate Drugs 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229940032122 claris Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 description 1
- DJZCTUVALDDONK-HQMSUKCRSA-N concanamycin A Chemical compound O1C(=O)\C(OC)=C\C(\C)=C\[C@@H](C)[C@@H](O)[C@@H](CC)[C@@H](O)[C@H](C)C\C(C)=C\C=C\[C@H](OC)[C@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](\C=C\C)[C@@H](C)[C@H](O[C@@H]2O[C@H](C)[C@@H](OC(N)=O)[C@H](O)C2)C1 DJZCTUVALDDONK-HQMSUKCRSA-N 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 239000000430 cytokine receptor antagonist Substances 0.000 description 1
- 108010038764 cytoplasmic linker protein 170 Proteins 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- JRHMMVBOTXEHGJ-UHFFFAOYSA-N daphnoretin Chemical compound C1=CC(=O)OC2=CC(OC3=CC=4C=C(C(=CC=4OC3=O)O)OC)=CC=C21 JRHMMVBOTXEHGJ-UHFFFAOYSA-N 0.000 description 1
- UJRSXAFBORHKBS-UHFFFAOYSA-N daphnoretin Natural products COC1=CC2C=C(Oc3ccc4C=CC(=O)Oc4c3)C(=O)OC2C=C1O UJRSXAFBORHKBS-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- NMPPLGMVCCNRTJ-UHFFFAOYSA-N echinatine Natural products C1CC(O)C2C(COC(=O)C(O)(C(C)O)C(C)C)CCN21 NMPPLGMVCCNRTJ-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 150000002085 enols Chemical group 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 229960005416 estradiol cypionate Drugs 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229940012414 factor viia Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 229960000628 fidaxomicin Drugs 0.000 description 1
- ZVGNESXIJDCBKN-UUEYKCAUSA-N fidaxomicin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC\1=C/C=C/C[C@H](O)/C(C)=C/[C@@H]([C@H](/C(C)=C/C(/C)=C/C[C@H](OC/1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-UUEYKCAUSA-N 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
- 229950010152 halofuginone Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- SFVVQRJOGUKCEG-XTWPYSKKSA-N indicine Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@](O)([C@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-XTWPYSKKSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 229940124524 integrase inhibitor Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- SFVVQRJOGUKCEG-UHFFFAOYSA-N isoechinatine Natural products C1CC(O)C2C(COC(=O)C(O)(C(C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-UHFFFAOYSA-N 0.000 description 1
- BBEFSDNXXNECSY-UHFFFAOYSA-N isojusticidin B Natural products C1=C2OCOC2=CC(C2=C3C(=O)OCC3=CC3=CC=C(C(=C32)OC)OC)=C1 BBEFSDNXXNECSY-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- PQFYSRLXICNMSR-UHFFFAOYSA-N justicidine B Natural products COc1ccc(cc1OC)c2c3OCC(=O)c3cc4cc5OCOc5cc24 PQFYSRLXICNMSR-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 230000008949 local secretion Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- ZBJWWKFMHOAPNS-UHFFFAOYSA-N loretin Chemical compound C1=CN=C2C(O)=C(I)C=C(S(O)(=O)=O)C2=C1 ZBJWWKFMHOAPNS-UHFFFAOYSA-N 0.000 description 1
- 229950010248 loretin Drugs 0.000 description 1
- WLHQHAUOOXYABV-UHFFFAOYSA-N lornoxicam Chemical compound OC=1C=2SC(Cl)=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 WLHQHAUOOXYABV-UHFFFAOYSA-N 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000009014 mansonin Substances 0.000 description 1
- SCWKUSONPRYOHV-UHFFFAOYSA-N marchantin A Natural products Oc1cccc2CCc3ccc(Oc4cc(CCc5ccccc5Oc12)cc(O)c4O)cc3 SCWKUSONPRYOHV-UHFFFAOYSA-N 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000000638 mature B-cell neoplasm Diseases 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- ZMSNKXDPESNSSS-UHFFFAOYSA-N maytenfoliol Natural products CC12CCC3(C)C4CC(C)(CO)CCC4(CO)CCC3(C)C2CCC2(C)C1CCC(=O)C2C ZMSNKXDPESNSSS-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- QYNJXPHOFVQUIS-NSHDSACASA-N methyl (3R)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxo-3,5-dihydro-2H-1,5-benzothiazepine-7-carboxylate Chemical compound COC(=O)C1=CC2=C(SC[C@H](NC(=O)OC(C)(C)C)C(=O)N2)C=C1 QYNJXPHOFVQUIS-NSHDSACASA-N 0.000 description 1
- ZTOKLXGDTUVKJO-UHFFFAOYSA-N methyl 6h-1-benzazepine-7-carboxylate Chemical compound N1=CC=CC=C2CC(C(=O)OC)=CC=C21 ZTOKLXGDTUVKJO-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960002757 midecamycin Drugs 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 201000004058 mixed glioma Diseases 0.000 description 1
- 229960005285 mofebutazone Drugs 0.000 description 1
- REOJLIXKJWXUGB-UHFFFAOYSA-N mofebutazone Chemical compound O=C1C(CCCC)C(=O)NN1C1=CC=CC=C1 REOJLIXKJWXUGB-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 201000003731 mucosal melanoma Diseases 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000012177 negative regulation of immune response Effects 0.000 description 1
- 208000010915 neoplasm of mature B-cells Diseases 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 229940127264 non-peptide agonist Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 229960004036 nonivamide Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940042404 nucleoside and nucleotide reverse transcriptase inhibitor Drugs 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- 208000008511 optic nerve glioma Diseases 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- KTYZKXFERQUCPX-KURKYZTESA-N ovatodiolide Natural products CC1=CCCC2=C[C@@H](CC(C)=C[C@@H]3OC(=O)C(=C)[C@H]3CC1)OC2=O KTYZKXFERQUCPX-KURKYZTESA-N 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- GSKDBLIBBOYOFU-UHFFFAOYSA-N oxadiazol-5-amine Chemical compound NC1=CN=NO1 GSKDBLIBBOYOFU-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- VREZDOWOLGNDPW-UHFFFAOYSA-N pancratistatine Natural products C1=C2C3C(O)C(O)C(O)C(O)C3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000002820 pancreatoblastoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229960002226 polidocanol Drugs 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 description 1
- 229960000214 pralatrexate Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000002661 proton therapy Methods 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 229960005567 rebeccamycin Drugs 0.000 description 1
- INSACQSBHKIWNS-QZQSLCQPSA-N rebeccamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](OC)[C@@H](CO)O[C@H]1N1C2=C3N=C4[C](Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 INSACQSBHKIWNS-QZQSLCQPSA-N 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- VKNAGQVZXQTVMW-UHFFFAOYSA-N retrochinensinaphthol methyl ether Natural products C1=C(OC)C(OC)=CC=C1C(C1=C2)=C(OCC3=O)C3=C(OC)C1=CC1=C2OCO1 VKNAGQVZXQTVMW-UHFFFAOYSA-N 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229940116736 romycin Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- LFBIHCZSRPAPHS-UHFFFAOYSA-N rutamontine Natural products COc1cc2OC(=O)C(=Cc2cc1O)Oc3ccc4C=CC(=O)Oc4c3 LFBIHCZSRPAPHS-UHFFFAOYSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229960003021 samarium (153sm) lexidronam Drugs 0.000 description 1
- JSTADIGKFYFAIY-GJNDDOAHSA-F samarium-153(3+);n,n,n',n'-tetrakis(phosphonatomethyl)ethane-1,2-diamine Chemical compound [153Sm+3].[O-]P([O-])(=O)CN(CP([O-])([O-])=O)CCN(CP([O-])([O-])=O)CP([O-])([O-])=O JSTADIGKFYFAIY-GJNDDOAHSA-F 0.000 description 1
- 229940084560 sanguinarine Drugs 0.000 description 1
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 201000007321 sebaceous carcinoma Diseases 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 229950003647 semaxanib Drugs 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 239000003620 semiochemical Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229960001315 sodium aurothiomalate Drugs 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000028647 spindle cell neoplasm Diseases 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000002720 stereotactic body radiation therapy Methods 0.000 description 1
- 238000009199 stereotactic radiation therapy Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 description 1
- 229940006509 strontium-89 Drugs 0.000 description 1
- ODJLBQGVINUMMR-HZXDTFASSA-N strophanthidin Chemical compound C1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@@]5(O)CC4)C=O)CC[C@@]32C)=CC(=O)OC1 ODJLBQGVINUMMR-HZXDTFASSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- IHCDKJZZFOUARO-UHFFFAOYSA-M sulfacetamide sodium Chemical compound O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1 IHCDKJZZFOUARO-UHFFFAOYSA-M 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 208000030457 superficial spreading melanoma Diseases 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 description 1
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 description 1
- 229960004907 tacalcitol Drugs 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- ZITVZMOAHYMMJY-WDSKDSINSA-N tert-butyl n-[(2s,3s)-2-methyl-4-oxooxetan-3-yl]carbamate Chemical compound C[C@@H]1OC(=O)[C@H]1NC(=O)OC(C)(C)C ZITVZMOAHYMMJY-WDSKDSINSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 description 1
- ZYXWYDDFNXBTFO-UHFFFAOYSA-N tetrazolidine Chemical compound C1NNNN1 ZYXWYDDFNXBTFO-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical compound C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- BCTZHJNGSIMPQB-UHFFFAOYSA-N thiopyrano[2,3-b]azepine-7-carboxylic acid Chemical compound S1C=CC=C2C1=NC=C(C=C2)C(=O)O BCTZHJNGSIMPQB-UHFFFAOYSA-N 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960000363 trapidil Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical compound BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 229960005041 troleandomycin Drugs 0.000 description 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229950007952 vapiprost Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 108010060757 vasostatin Proteins 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- KYBLAIAGFNCVHL-PMVHANJISA-N zeorin Chemical compound C([C@]1(C)[C@H]2CC[C@H]34)CCC(C)(C)[C@@H]1[C@@H](O)C[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@@H]1C(C)(O)C KYBLAIAGFNCVHL-PMVHANJISA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
X1は、S;S(O);またはS(O)2であり;
X2は、N;またはC(R4)であり;
R1は、H;またはメチルであり;
R2は、フェニル;3〜7員ヘテロシクリル;または7〜11員ヘテロビシクリルであり、ここで、R2は、場合により、1つまたはそれ以上の同一であるかまたは異なっているR5で置換されており;
R5は、ハロゲン;CN;C(O)OR6;OR6;C(O)R6;C(O)N(R6R6a);S(O)2N(R6R6a);S(O)N(R6R6a);S(O)2R6;S(O)R6;N(R6)S(O)2N(R6aR6b);SR6;N(R6R6a);OC(O)R6;N(R6)C(O)R6a;N(R6)S(O)2R6a;N(R6)S(O)R6a;N(R6)C(O)OR6a;N(R6)C(O)N(R6aR6b);OC(O)N(R6R6a);環が少なくとも部分飽和である場合、オキソ(=O);T1;C1-6アルキル;C2-6アルケニル;またはC2-6アルキニルであり、ここで、C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているハロゲンで置換されており;
R6、R6a、R6bは、独立して、H;C1-6アルキル、C2-6アルケニル;およびC2-6アルキニルからなる群から選択され、ここで、C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているハロゲンで置換されており;
T1は、フェニル;C3-7シクロアルキル;または3〜7員ヘテロシクリルであり、ここで、T1は、場合により、1つまたはそれ以上の同一であるかまたは異なっているR7で置換されており;
R8、R8a、R8bは、独立して、H;C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルからなる群から選択され、ここで、C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているハロゲンで置換されており;
R3は、R3a;OR3a;NHR3a;またはNHC(O)R3aであり;
R3aは、T2;C1-12アルキル;C2-12アルケニル;またはC2-12アルキニルであり、ここで、C1-12アルキル;C2-12アルケニル;およびC2-12アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているR9で置換されており;
R9は、ハロゲン;CN;C(O)OR10;OR10;C(O)R10;C(O)N(R10R10a);S(O)2N(R10R10a);S(O)N(R10R10a);S(O)2R10;S(O)R10;N(R10)S(O)2N(R10aR10b);SR10;N(R10R10a);OC(O)R10;N(R10)C(O)R10a;N(R10)S(O)2R10a;N(R10)S(O)R10a;N(R10)C(O)N(R10aR10b);N(R10)C(O)OR10a;OC(O)N(R10R10a);T2;C1-12アルキル;C2-12アルケニル;またはC2-12アルキニルであり、ここで、C1-12アルキル;C2-12アルケニル;およびC2-12アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているR11で置換されており;
R10、R10a、R10bは、独立して、H;T2;C1-12アルキル;C2-12アルケニル;およびC2-12アルキニルからなる群から選択され、ここで、C1-12アルキル;C2-12アルケニル;およびC2-12アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているR11で置換されており;
T2は、フェニル;C3-7シクロアルキル;3〜7員ヘテロシクリル;または7〜11員ヘテロビシクリルであり、ここで、T2は、場合により、1つまたはそれ以上の同一であるかまたは異なっているR12で置換されており;
R13、R13a、R13bは、独立して、H;C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルからなる群から選択され、ここで、C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているR14で置換されており;
R11、R14は、独立して、ハロゲン;CN;C(O)OR15;OR15;C(O)R15;C(O)N(R15R15a);S(O)2N(R15R15a);S(O)N(R15R15a);S(O)2R15;S(O)R15;N(R15)S(O)2N(R15aR15b);SR15;N(R15R15a);OC(O)R15;N(R15)C(O)R15a;N(R15)S(O)2R15a;N(R15)S(O)R15a;N(R15)C(O)OR15a;N(R15)C(O)N(R15aR15b);OC(O)N(R15R15a);およびT3からなる群から選択され;
R15、R15a、R15bは、独立して、H;T3;C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルからなる群から選択され、ここで、C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているハロゲンで置換されており;
T3は、フェニル;C3-7シクロアルキル;または3〜7員ヘテロシクリルであり、ここで、T3は、場合により、1つまたはそれ以上の同一であるかまたは異なっているR16で置換されており;
R17、R17a、R17bは、独立して、H;C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルからなる群から選択され、ここで、C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているハロゲンで置換されており;
R4は、H;F;Cl;またはN(CH3)2であり;
R18は、H;C1-6アルキル;C2-6アルケニル;またはC2-6アルキニルであり;ここで、C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているR19で置換されており;
R19は、ハロゲン;CN;C(O)OR20;OR20;C(O)R20;C(O)N(R20R20a);S(O)2N(R20R20a);S(O)N(R20R20a);S(O)2R20;S(O)R20;N(R20)S(O)2N(R20aR20b);SR20;N(R20R20a);NO2;OC(O)R20;N(R20)C(O)R20a;N(R20)SO2R20a;N(R20)S(O)R20a;N(R20)C(O)N(R20aR20b);N(R20)C(O)OR20a;またはOC(O)N(R20R20a)であり;
R20、R20a、R20bは、独立して、H;およびC1-6アルキルからなる群から選択され、ここで、C1-6アルキルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているハロゲンで置換されている)。
R2は、フェニル;3−クロロフェニル;4−フルオロフェニル;4−メトキシフェニル;3,5−ジメチル−1,2−オキサゾール−4−イル;2−クロロチオフェン−5−イル;ピリジン−4−イル;1,3−ベンゾジオキソール−5−イル;5−フェニル−1,2,4−オキサジアゾール−3−イル;3−(4−tertブチルフェニル)−1,2,4−オキサジアゾール−5−イル;ビフェン−4−イル;または3,4,5−トリメトキシフェニルであり;
R3は、n−ブチル;2−ヒドロキシ−1−ヒドロキシカルボニル−エチル;2−ヒドロキシカルボニルエチル;フェニル;またはベンジルである);
または
R3は、n−ブチル;2−ヒドロキシ−1−ヒドロキシカルボニル−エチル;2−ヒドロキシカルボニルエチル;フェニル;またはベンジルである)。
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(2,2−ジフルオロシクロプロピル)−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−5−[(4−tert−ブチルフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−tert−ブチルフェニル)メチル]−4−オキソ−N−(プロパン−2−イル)−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−8−フルオロ−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ベンジル−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−[(4−メトキシフェニル)メチル]−4−オキソ−5−{[4−(トリフルオロメトキシ)−フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(オキサン−4−イル)−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−4−オキソ−5−{[3−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−5−[(4−クロロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;(3R)−3−アミノ−N−{[4−(モルホリン−4−イル)フェニル]メチル}−4−オキソ−5−{[4−(トリフルオロメトキシ)−フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
N−(3−{[(3R)−3−アミノ−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−イル]ホルムアミド}プロピル)−2,2−ジメチルプロパンアミド;
(3R)−3−アミノ−8−フルオロ−N−(オキサン−4−イル)−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−フルオロ−4−オキソ−N−(プロパン−2−イル)−5−{[4−(トリフルオロメトキシ)フェニル]−メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ベンジル−8−フルオロ−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−メチル−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−エチル−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−({4−[(5−アセトアミドペンチル)オキシ]フェニル}メチル)−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(2−メトキシエチル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−5−[(4−シアノフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−4−オキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(オキサン−4−イルメチル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(5−tert−ブチル−1,2−オキサゾール−3−イル)−5−[(4−クロロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(4−フルオロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1R)−1−(4−メトキシフェニル)エチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(オキサン−3−イルメチル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−4−オキソ−N−(4,4,4−トリフルオロブチル)−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(オキサン−4−イルメチル)−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−[(4−フルオロフェニル)メチル]−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]−メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−[(4−フルオロフェニル)メチル]−4−オキソ−5−{[4−(1,2,3−チアジアゾール−4−イル)フェニル]−メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(4,4−ジフルオロシクロヘキシル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[1−(4−フルオロフェニル)エチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1S)−1−(4−メトキシフェニル)エチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−4−オキソ−N−(4,4,4−トリフルオロブチル)−5−{[6−(トリフルオロメチル)ピリジン−3−イル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1R)−1−(4−フルオロフェニル)エチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−[(4−フルオロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−4−オキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−5−[(4−クロロフェニル)メチル]−8−フルオロ−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(オキサン−4−イルメチル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−[(4−メトキシフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−{[4−(5−メチル−1,2,4−オキサジアゾール−3−イル)フェニル]メチル}−N−(オキサン−4−イルメチル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−フルオロフェニル)メチル]−N−(オキサン−4−イルメチル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−4−オキソ−5−{[4−(1H−1,2,4−トリアゾール−1−イル)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−5−[(4−カルバモイルフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(2−ヒドロキシ−2−メチルプロピル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(2−ヒドロキシ−2−メチルプロピル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(2R,3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−2−メチル−4−オキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N’−(4−フルオロフェニル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボヒドラジド;
(3R)−3−アミノ−N’−ブタノイル−5−[(4−クロロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボヒドラジド;
(3R)−3−アミノ−N−ブチル−5−[(4−クロロ−2−フルオロフェニル)メチル]−8−フルオロ−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロ−2−フルオロフェニル)メチル]−8−フルオロ−N−(オキサン−4−イルメチル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロ−3−フルオロフェニル)メチル]−8−フルオロ−N−(オキサン−4−イルメチル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−5−[(4−クロロ−3−フルオロフェニル)メチル]−8−フルオロ−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−4−オキソ−N−プロポキシ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(2−メチルプロポキシ)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−4−オキソ−N−(プロパン−2−イル)−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(2−メチルプロポキシ)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(3−メチルブタン−2−イル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(ブタ−3−エン−1−イル)−5−[(4−クロロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N’−(2−メチルプロピル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボヒドラジド;
(3R)−3−アミノ−N−ブチル−5−[(4−クロロフェニル)メチル]−1,4−ジオキソ−2,3,4,5−テトラヒドロ−1λ4,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−1,1,4−トリオキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−[(4−フルオロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−(4,4,4−トリフルオロ−ブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(オキサン−4−イルメチル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−フルオロ−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−5−{[4−(トリフルオロメトキシ)−フェニル]メチル}−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−フルオロ−1,1,4−トリオキソ−N−フェノキシ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(2−メチルプロポキシ)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−フェノキシ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−(プロパン−2−イル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−({4−[(5−アセトアミドペンチル)オキシ]フェニル}−メチル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−N−(プロパン−2−イル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(2−メチルプロポキシ)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−N−プロポキシ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(3−メチルブタン−2−イル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−シクロプロピル−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−シクロブチル−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロ−2−フルオロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−(プロパン−2−イル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(3,4−ジクロロフェニル)メチル]−1,1,4−トリオキソ−N−(プロパン−2−イル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロ−3−フルオロフェニル)メチル]−1,1,4−トリオキソ−N−(プロパン−2−イル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(シクロヘキシルオキシ)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(シクロヘキシルメトキシ)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−(2,2,2−トリフルオロ−エチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−(3,3,3−トリフルオロ−プロピル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−[(2S)−1,1,1−トリフルオロプロパン−2−イル]−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−tert−ブチル−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(tert−ブトキシ)−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−[(1S,2R)−2−フェニルシクロプロピル]−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(1−メチルシクロプロピル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(1−メチルシクロブチル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(2,2−ジメチルシクロプロピル)−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(3,3−ジフルオロシクロブチル)−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ベンジル−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−ヘプチル−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(3,3−ジフルオロシクロペンチル)−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1R)−2,2−ジフルオロシクロプロピル]−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(2R,3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(2,2−ジフルオロシクロプロピル)−2−メチル−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−ヘキサデシル−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(シクロプロピルメチル)−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(2R,3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−2−メチル−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−8−フルオロ−4−オキソ−5−(キノリン−2−イルメチル)−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(5−シクロプロピル−1,3,4−チアジアゾール−2−イル)メチル]−8−フルオロ−N−[(4−フルオロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;(3R)−3−アミノ−N−ブチル−5−[(4−クロロフェニル)メチル]−8−(ジメチルアミノ)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
tert−ブチルN−(5−{[(3R)−5−[(4−クロロフェニル)メチル]−8−フルオロ−7−{[(4−メトキシフェニル)メチル]カルバモイル}−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−3−イル]アミノ}ペンチル)カルバメート;および
(3R)−3−アミノ−N−ブチル−1−[(4−クロロフェニル)メチル]−2,5,5−トリオキソ−1H,2H,3H,4H−5λ6−ピリド[3,4−b][1,4]チアゼピン−8−カルボキサミド
(3R)−3−アミノ−N−ベンジル−5−[(4−クロロフェニル)メチル]−8−(ジメチルアミノ)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(2,2−ジフルオロシクロプロピル)−8−フルオロ−5−{[4−メトキシ−3−(トリフルオロメチル)フェニル]メチル}−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(2R,3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−2−メチル−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−{[4−(5−メチル−1,2,4−オキサジアゾール−3−イル)フェニル]メチル}−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(2−メトキシエチル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(2,2−ジフルオロシクロプロピル)−5−{[4−(5−メチル−1,2,4−オキサジアゾール−3−イル)フェニル]メチル}−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(1S,3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−4−オキソ−7−[(4,4,4−トリフルオロブチル)カルバモイル]−2,3,4,5−テトラヒドロ−1H−1,5−ベンゾチアゼピン−1−イウム−1−オレート;
(1R,3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−4−オキソ−7−[(4,4,4−トリフルオロブチル)カルバモイル]−2,3,4,5−テトラヒドロ−1H−1,5−ベンゾチアゼピン−1−イウム−1−オレート;
(3R)−3−アミノ−5−[(4−シアノフェニル)メチル]−N−(2,2−ジフル
オロシクロプロピル)−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−シアノフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−[2−(トリフルオロメチル)シクロプロピル]−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(3,3−ジフルオロシクロブチル)−8−フルオロ−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−フルオロ−5−[(4−フルオロフェニル)メチル]−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(2,2−ジフルオロシクロプロピル)−8−フルオロ−5−[(4−フルオロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−8−フルオロ−5−[(4−フルオロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ベンジル−8−フルオロ−5−[(4−フルオロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−8−フルオロ−5−[(4−フルオロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ベンジル−8−フルオロ−5−[(4−フルオロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−[2−(オキサン−4−イル)エチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−ベンジル−8−フルオロ−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−フルオロ−5−[(4−フルオロフェニル)メチル]−N−[(オキサン−4−イル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(3,3−ジフルオロシクロブチル)−8−フルオロ−5−[(4−フルオロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−フルオロ−5−[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−フルオロ−5−[(4−メトキシフェニル)メチル]−N−[(オキサン−4−イル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(2,2−ジフルオロシクロプロピル)−8−フルオロ−5−[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(オキサン−4−イル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(3,3−ジフルオロシクロブチル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1S)−3,3−ジフルオロシクロペンチル]−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1R,2S)−2−フルオロシクロプロピル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(3,3−ジフルオロシクロブチル)−5−[(2−フルオロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(3,3−ジフルオロシクロブチル)−5−[(3−メトキシフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N,5−ビス[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−ベンジル−N−[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(4,4−ジフルオロシクロヘキシル)−5−[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−N−(3,3,3−トリフルオロプロピル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−N−[(3R)−オキソラン−3−イル]−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−N−[(オキソラン−3−イル)メチル]−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1R)−2,2−ジフルオロシクロプロピル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−シクロプロピルフェニル)メチル]−N−[(1R)−2,2−ジフルオロシクロプロピル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−[(1R)−2,2−ジフルオロシクロプロピル]−5−{[4−(ジフルオロメトキシ)フェニル]メチル}−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−[(1R)−2,2−ジフルオロシクロプロピル]−5−[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−クロロ−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−{[4−(ジフルオロメトキシ)フェニル]メチル}−N−[(オキサン−4−イル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(4−フルオロオキサン−4−イル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1R)−1−(オキサン−4−イル)エチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−ベンジル−N−[(1R)−2,2−ジフルオロシクロプロピル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(6−メチルピリジン−3−イル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1R)−3,3−ジフルオロシクロペンチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−シアノフェニル)メチル]−8−フルオロ−N−[(4−フルオロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(3,3−ジフルオロシクロブチル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−[2−(2−メトキシエトキシ)エチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(ブタ−3−イン−1−イル)−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−クロロ−5−[(4−クロロフェニル)メチル]−N−[(1R)−2,2−ジフルオロシクロプロピル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[2−(モルホリン−4−イル)エチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(6−メトキシピリジン−3−イル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−{[4−(プロパ−2−イン−1−イルオキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−[(1R)−2,2−ジフルオロシクロプロピル]−1,1,4−トリオキソ−5−{[4−(トリフルオロメチル)フェニル]メチル}−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−ブロモフェニル)メチル]−N−(2,2−ジフルオロシクロプロピル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−{2−オキサスピロ[3.3]ヘプタン−6−イル}−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;および
(3R)−5−[(4−クロロフェニル)メチル]−3−(エチルアミノ)−8−フルオロ−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド
DNAおよびRNA断片、プラスミノーゲン活性化因子阻害剤1、プラスミノーゲン活性化因子阻害剤2、アンチセンスオリゴヌクレオチド、VEGF阻害剤、IGF−1、例えばセファドロキシル、セファゾリン、セファクロル、セフォキシチン、ゲンタマイシン、ペニシリン、ジクロキサシリン、オキサシリンのような抗生物質の群由来の活性剤、スルホンアミド、メトロニダゾール、抗血栓薬、アルガトロバン、アスピリン、アブシキシマブ、合成抗トロンビン、ビバリルジン、クマジン、エノキサパリン、GpIIb/IIIa血小板膜受容体、第Xa因子阻害剤に対する抗体、ヘパリン、ヒルジン、r−ヒルジン、PPACK、プロタミン、プロウロキナーゼ、ストレプトキナーゼ、ワルファリン、ウロキナーゼ、血管拡張剤、ジピリダモール、トラピジル、ニトロプルシド、PDGFアンタゴニスト、トリアゾロピリミジン、セラミン、ACE阻害剤、カプトプリル、シラザプリル、リシノプリル、エナラプリル、ロサルタン、チオプロテアーゼ阻害剤、プロスタシクリン、バピプロスト、インターフェロンα、βおよびγ、ヒスタミンアンタゴニスト、セロトニン遮断薬、アポトーシス阻害剤、アポトーシス調節剤、NF−kBまたはBcl−xLアンチセンスオリゴヌクレオチド、ハロフジノン、ニフェジピン、トコフェロール、モルシドミン、茶ポリフェノール、エピカテキンガレート、エピガロカテキンガレート、ボスウェル酸およびその誘導体、レフルノミド、アナキンラ、エタネルセプト、スルファサラジン、テトラサイクリン、トリアムシノロン、プロカインイミド、レチノイン酸、キニジン、ジソピラミド、フレカイニド、プロパフェノン、ソタロール、アミオダロン、天然および合成で得られたステロイド、例えばブリオフィリンA、イノトジオール、マキロシドA、マンソニン、ストレブロシド、ヒドロコルチゾン、ベタメタゾン、デキサメタゾン、フェノプロフェン、イブプロフェン、インドメタシン、ナプロキセン、フェニルブタゾン、アシクロビル、ガンシクロビル、ジドブジン、抗真菌剤、クロトリマゾール、フルシトシン、グリセオフルビン、ケトコナゾール、ミコナゾール、テルビナフィン、クロロキン、メフロキン、キニーネ、天然テルペノイド、ヒッポカエスクリン、バリントゲノール−C21−アンゲレート、14−デヒロドアグロスチスタチン、アグロスケリン、アガロスチスタチン、17−ヒドロキシアグロスチスタチン、オバトジオリド、4,7−オキシシクロアニソメル酸、バッカリノイドB1、B2、B3およびB7、ツベイモシド、ブルセアノールA、BおよびC、ブルセアンチノシドC、ヤダンジオシドNおよびP、イソデオキシエレファントピン、トメンファントピンAおよびB、コロナリンA、B、CおよびD、ウルソール酸、ヒプタチン酸A、ゼオリン、イソイリドゲルマナール、メイテンホリオール、エフサンチンA、エクシサニンAおよびB、ロンギカウリンB、スクルポネアチンC、カメバウニン、ロイカメニンAおよびB、13,18−デヒドロ−6−α−セネシオイロキシチャパリン、タクサマイリンAおよびB、レジェニロール、トリプトライド、シマリン、アポシマリン、アリストロキア酸、アノプテリン、ヒドロキシアノプテリン、アネモニン、プロトアネモニン、ベルベリン、塩化ケルブリン、シクトキシン、シンコクリン、コンブレスタチンAおよびB、クドライソフラボンA、クルクミン、ジヒドロニチジン、塩化ニチジン、12−β−ヒドロキシプレグナジエン−3,20−ジオンビロボール、ギンコール、ギンコール酸、ヘレナリン、インジシン、インジシン−N−オキシド、ラシオカルピン、イノトジオール、グリコシド1a、ジャスチシジンAおよびB、ラレアチン、マロテリン、マロトクロマノール、イソブチリルマロトクロマノール、マーチャンチンA、メイタンシン、リコリジシン、マルゲチン、パンクラチスタチン、リリオデニン、ビスパルセノリジン、オキソウシンスニン、アリストラクタム−AII、ペリプロコシドA、グハラキノシド、デオキシプソロスペルミン、サイコルビン、リシンA、サンギナリン、マヌー小麦酸、メチルソルビフォリン、スファセリアのクロモン、スチゾフィリン、アカゲリン、ジヒロドウサムバレンシン、ヒドロキシウサムバリン、ストリクノペンタミン、ストリクノフィリン、ウサムバリン、ウサムバレンシン、ダフノレチン、ラリシレシノール、メトキシラリシレシノール、シリンガレシノール、ウンベリフェロン、アフロモソン、アセチルビスミオンB、デスアセチルビスミオンA、ビスミオンAおよびB)、放射線治療(例えば、強度変調放射線療法(IMRT)、三次元原体放射線療法(3DCRT)、定位放射線療法(SBRT)、定位放射線手術(SRS)、画像誘導放射線療法(IGRT)、粒子線療法(例えば、陽子線療法)、密封小線源治療、放射性同位元素療法(RIT)(例えば、ヨウ素−131、ルテニウム−177、ストロンチウム−89、およびサマリウム(153Sm)レキシドロナム、ならびに/またはイットリウム−90を用いる))、抗血管新生療法(例えば、カルボキシアミドトリアゾール、TNP−470、CM101、スラミン、SU5416、トロンボスポンジン、VEGFRアンタゴニスト、血管新生抑制ステロイド+ヘパリン、軟骨由来血管新生阻害因子、マトリックスメタロプロテイナーゼ阻害剤、2−メトキシエストラジオール、テコガラン、テトラチオモリブデート、タリドミド、トロンボスポンジン、可溶性VEGFR−1およびNRP−1、アンジオポエチン2、アンジオスタチン(例えば、TSP−1およびTSP−2アンジオスタチン)、エンドスタチン、バソスタチン、カンスタチン、カルレチキュリン、血小板第4因子、TIMPおよびCDAI、Meth−1およびMeth−2、CXCL10プロトロンビン(クリングルドメイン−2)、アンチトロンビンIII断片プロラクチン、VEGI、SPARC、オステオポンチン、マスピン、プロリフェリン関連タンパク質、レスチン)、キナーゼ阻害剤(例えば、イマチニブ、メシル酸イマチニブ、ゲフィチニブ、エルロチニブ、パゾパニブ、アパチニブ)、プロテアソーム阻害剤(例えば、ボルテゾミブ)、PARP阻害剤(例えば、イニパリブ、オラパリブ)、ならびにこれらのうち2つ以上の組み合わせからなる群から選択することができる。
(i)免疫細胞を準備する工程と;
(ii)工程(i)の細胞を:
(a)本発明の、少なくとも1つの化合物またはその医薬的に許容される塩、および場合により、
(b)前記免疫細胞を活性化する1つまたはそれ以上のさらなる刺激剤と接触させる工程と;
(iii)工程(ii)の細胞の生存率の維持にとって好適な条件下で、前記細胞を培養する工程と、を含む方法に関する。
本明細書に記載される化学実体、組成物、および方法について、以下の非限定的実施例でさらに例証する。
本明細書で使用する場合、以下の略語は、以下の意味を有する。ある略語が定義されていない場合、その略語は一般に認められた意味を有する。
市販の試薬および溶媒(HPLCグレード)を、さらに精製せずに使用した。1H NMRスペクトルは、重水素化溶媒で、Bruker DRX 500 MHz分光計、またはBruker DPX 250 MHz分光計、またはBruker Avance分光計300 MHz、またはBruker Avance分光計400 MHzで記録した。ケミカルシフト(δ)は、百万分率単位である。
Generic 3.5 minutesである。
中間体A−03の合成
(2S,3S)−2−{[(tert−ブトキシ)カルボニル]アミノ}−3−ヒドロキシブタン酸(2g、4.79mmol)の無水DCM(100mL)溶液に、Et3N(2.67mL、19.16mmol)、その後HBTU(3.63g、9.68mmol)を添加した。結果として得られた混合物を、室温で16時間撹拌した。溶媒を減圧下で除去し、残留物を、フラッシュカラムクロマトグラフィー(溶離液:ヘプタン、0〜40% EtOAc)で精製して、収率65%およびNMRによる良好な純度(>95%)で、白色の固体として所望の生成物630mgを得た。
NMR: 1H NMR (500 MHz, DMSO-d6) δ 7.79 (d, J = 8.0 Hz, 1H), 4.79 - 4.68 (m, 1H),
4.61 (dd, J = 8.0, 4.3 Hz, 1H), 1.47 (d, J = 6.2 Hz, 3H), 1.40 (s, 9H).
中間体A−01(95%、430mg、2.03mmol)を、無水DMF(14mL)中に溶解させ、エタンチオン酸カリウム(348mg、3.05mmol、1.5当量)を添加し、反応混合物を、窒素下において(ガス出口は水性漂白剤を通して洗浄した)室温で18時間撹拌した。さらなるエタンチオン酸カリウム(347.78mg、3.05mmol、および1.5当量)を添加し、撹拌を18時間継続した。反応混合物を、1NのHCl水溶液(15mL)を用いてクエンチし、混合物を、EtOAcを用いて抽出した(3回×15mL)。合わせた有機抽出物を、水(15mL)およびブライン(15mL)を用いて洗浄し、Na2SO4で脱水した。濾過および減圧下での濃縮により、UV純度97%および定量的収率で、白色の固体として所望の生成物673mgを得て、これを、さらに精製せずに次のステップにおいて使用した。
LCMS: METCR1673 Generic 2 minutes rt=1.12分, M/Z (ES-)= 276 [M-H+], 97% UV
NMR: 1H NMR (500 MHz, DMSO-d6) δ 12.89 (s, 1H), 7.08 (d, J = 8.5 Hz, 1H), 4.22 (dd, J = 8.1, 5.5 Hz, 1H), 3.93 - 3.67 (m, 1H), 2.30 (s, 3H), 1.39 (s, 9H), 1.25
(d, J = 7.0 Hz, 3H)
1MのLiOH・H2O水溶液(12mL)を、中間体A−02(673mg、2.08mmol)のMeOH(27mL)溶液に添加した。結果として得られた混合物を、室温で1.5時間撹拌した。この反応混合物に、NaHCO3飽和水溶液(13mL)を添加し、有機溶媒を減圧下で除去した。水性残留物を、Et2O(10mL)を用いて洗浄した後、1MのHCl水溶液を用いて、pHを最大でpH1まで調整した。結果として得られた、下側の水性層を、EtOAcを用いて抽出した(2回×50mL)。合わせたEtOAc抽出物を、Na2SO4で脱水し、濾過し、減圧下で濃縮して、収率87%で、UV純度80%の黄色の油状物として所望の生成物526mgを得て、これを、さらに精製せずに次のステップにおいて使用した。
LCMS:METCR1673 Generic 2 minutes rt=1.09分,M/Z(ES−)=234[M−H+],80% UV
4−フルオロ−3−ニトロ安息香酸メチル(15g、75.33mmol)を、EtOH300mL中に溶解させた。N−(tert−ブトキシカルボニル)−L−システイン(15.15g、68.48mmol)を一度に添加し、その後NaHCO3(12.6g、150.6mmol)の水(75mL)溶液を添加した。この明るい黄色の懸濁液を、80℃で3時間撹拌した。溶媒を、減圧下で除去した。残留物を、水(100mL)を用いて希釈し、Et2Oを用いて洗浄した(3回×50mL)。水性相を、1MのHClを用いて酸性化し、EtOAcを用いて抽出した(2回×80mL)。合わせた有機相を、ブラインを用いて洗浄し、Na2SO4で脱水し、濾過し、減圧下で濃縮して、収率86.7%で、淡黄色の固体として所望の生成物29.36gを得た。
LCMS: METCR1416 Generic 7 minutes rt = 3.15分, M/Z (ES-)= 399 [M-H+], 81%
NMR: 1H NMR (500 MHz, CDCl3) δ 8.80 (s, 1H), 8.18 (dd, J = 8.5, 1.6 Hz, 2H), 7.62 (d, J = 8.3 Hz, 1H), 5.38 (d, J = 6.9 Hz, 1H), 4.73 - 4.67 (m, 1H), 3.96 (s, 3H), 1.43 (s, 9H).
60/1のEtOH/水(610mL)中に溶解させた中間体I−01(89%、29.4g、65.26mmol、1当量)に、1MのHCl(6.5mL、6.53mmol、0.1当量)を添加した。反応混合物を、50℃で加熱し、その後、この反応混合物に鉄(36.44g、652.6mmol、10当量)を添加した。この反応混合物を、80℃で16時間撹拌し、加熱した。次いで、反応混合物を冷まし、Celite(登録商標)を通して濾過した。Celite(登録商標)を、EtOHを用いて洗浄した(4回×400mL)。濾液を合わせ、400mLに濃縮した。暗色の溶液を再度Celiteを通して濾過し、EtOHを用いてすすいだ(4回×300mL)。濾液を合わせ、減圧下で濃縮して、収率80%で、暗色の固体として所望の生成物24.9gを得た。
LCMS:METCR1673 Generic 2 minutes rt=1.71分,M/Z(ES+)=393[M+Na+],71% UV
無水DMF(500mL)中の中間体I−02(78%、24.9g、52.43mmol、1当量)に、NaHCO3(22.0g、262.16mmol、5当量)、その後PyBOP(30.0g、57.68mmol、1.1当量)を添加した。この反応混合物を、室温で2時間撹拌した。反応混合物を、減圧下で濃縮した。残留物をDCM(500mL)中に懸濁させ、この懸濁液を、1NのNaOH(200mL)を用いて洗浄した。結果として得られたエマルションを、焼結式漏斗を通して濾過し、残留物を、DCMを用いてすすいだ(2回×150mL)。濾液を合わせ、層を分離させた。有機層を、飽和NaHCO3(2回×100mL)、1%クエン酸溶液(100mL)、その後ブライン(100mL)を用いて洗浄し、Na2SO4で脱水した。濾過および減圧下での濃縮により、褐色の油状物として粗生成物を得た。フラッシュカラムクロマトグラフィー(シリカ、溶離液:DCMおよび0〜0.1% MeOH)による精製、その後のEt2Oでのすり混ぜにより、収率48%で、灰白色の固体として所望の化合物9.9gを得た。
LCMS: METCR1673 Generic 2 minutes: rt = 1.91分, M/Z (ES+)= 375 [M+Na+], 91% UV
NMR (500 MHz, CDCl3) δ 1.40 (s, 9H), 3.01 (t, J = 11.38 Hz, 1H), 3.82 (dd, J = 6.27, 10.90 Hz, 1H), 3.93 (s, 3H), 4.42 - 4.52 (m, 1H), 5.58 (d, J = 7.33 Hz, 1H), 7.63 - 7.72 (m, 2H), 7.76 (d, J = 1.56 Hz, 1H), 7.83 (dd, J = 1.61, 8.03 Hz, 1H)
2,4−ジフルオロ−5−ニトロ安息香酸(25.00g、123mmol)を、Me
OH(300mL)中に溶解させた。硫酸(0.7mL、12.3mmol、0.1当量)を滴下添加した。この反応物を、40時間65℃に加熱した。反応混合物を冷却し、減圧下で濃縮した。残留物を、DCM(100mL)中に溶解し、水(50mL)、NaHCO3飽和水溶液(50mL)、およびブライン(50mL)を用いて洗浄した。水性層を、DCMを用いて逆抽出した(2回×50mL)。合わせた有機相を、Na2SO4で脱水し、濾過し、減圧下で濃縮して、明褐色の固体として所望の生成物25.21gを得た。収率:93%、純度99%。
LCMS: METCR1673 Generic 2 minutes rt=1.14分, M/Z (ES+) イオン化せず, 99%;
NMR: 1H NMR (500 MHz, DMSO-d6) δ 8.70 - 8.58 (m, 1H), 7.90 (t, J = 11.0 Hz, 1H), 3.91 (s, 3H).
DCE(700mL)中の、中間体II−01’(99%、24g、110mmol、1.01当量)およびN−(tert−ブトキシカルボニル)−L−システイン(95%、5.500g、24mmol、1当量)の撹拌溶液に、DIPEA(30.55mL、219mmol、2当量)を添加した。反応物を80℃に加熱し、3時間撹拌した。反応混合物を、水(400mL)およびDCM(200mL)に添加し、1NのHClを用いてpH1まで酸性化した。有機層を分離し、ブライン(200mL)を用いて洗浄し、Na2SO4で脱水し、濾過し、減圧下で濃縮して、黄色の泡状物として粗生成物を得て、これを、さらに精製せずに次のステップにおいて使用した。収率45.90g、81%、純度81%。
LCMS: METCR1673 Generic 2 minutes rt=1.28分, M/Z (ES+) 441 [M+Na+], 81% UV
NMR: 1H NMR (500 MHz, クロロホルム-d) δ 11.33 (s, 1H), 8.88 (d, J = 6.6 Hz, 1H), 7.35 (d, J = 11.3 Hz, 1H), 5.44 (d, J = 6.4 Hz, 1H), 4.77 - 4.68 (m, 1H), 3.99 (s, 3H), 3.69 - 3.59 (m, 1H), 3.43 (dt, J = 13.2, 6.7 Hz, 1H), 1.46 (s, 9H).
中間体II−01(81%、45g、87mmol)を、EtOH(600mL)および水(100mL)中に溶解させた。1MのHCl(8.71mL、8.7mmol、0.1当量)を添加し、反応混合物を50℃に加熱した。鉄(34.06g、610mmol)を、高温であり、かつ撹拌されている反応混合物に添加した。加熱を80℃で16時間継続した。反応混合物を室温まで冷却し、Celite(登録商標)を通して濾過した。濾過ケーキを、EtOAcを用いて洗浄し(400mL×2回)、再度Celite(登録商標)を通して濾過し、減圧下で濃縮して、黒色の固体として生成物を得て、これを、さらに精製せずに次のステップにおいて使用した。収率50g、定量的と推定(痕跡量の鉄を含有)、純度85%(LCMSによる)。
LCMS: METCR1673 Generic 2 minutes:, rt = 1.24, M/Z (ES-) = 387 [M-H+], 85% UV
方法A:
中間体II−02(85%、40g、87.54mmol)およびDIPEA(54.69mL、306mmol、3.5当量)を、DMF(600mL)中に溶解させた。0℃に冷却した後、HATU(49.93g、131mmol、1.5当量)を20分かけて少量ずつ添加し、反応物を室温に温まるまで放置して、その後16時間撹拌した。反応混合物を減圧下で濃縮した。残留物を、クロロホルム:IPA(2:1)(600mL)中に溶解させ、濾過した。濾液を、水(200mL)、その後ブライン(200mL)を用いて洗浄した。水性層を、DCMを用いて逆抽出した(2回×100mL)。合わせた有機抽出物を減圧下で濃縮して、暗褐色の油状物(95g)として粗生成物を得て、これを、順相フラッシュクロマトグラフィー(溶離液:EtOAc:ヘプタン)で精製して、黄色の固体として所望の生成物を得た。収率11.2g、28%、純度85%
LCMS: METCR1673 Generic 2 minutes: rt = 1.24分, M/Z (ES-) = 369 [M-H+], 85% UV;
1H NMR (500 MHz, クロロホルム-d) δ 7.71 (d, J = 6.2 Hz, 1H), 7.62 (s, 1H), 7.45
(d, J = 9.6 Hz, 1H), 5.59 (s, 1H), 4.49 (s, 1H), 3.97 (s, 3H), 3.86 - 3.77 (m, 1H), 3.03 (t, J = 11.2 Hz, 1H), 1.43 (s, 9H).
中間体II−02(69%、8g、14mmol)のTHF(100mL)懸濁液に、DIPEA(6.19mL、35.5mmol)およびT3P(登録商標)の50%EtOAc溶液(16.75mL、28mmol)を添加した。反応物を、室温で3時間撹拌し、その後、水(150mL)を用いてクエンチした。この混合物を、EtOAcを用いて抽出した(150mL×2回)。有機抽出物を合わせ、MgSO4で脱水し、溶媒を減圧下で除去した。粗生成物を、フラッシュクロマトグラフィー(溶離液:EtOAc:ヘプタン)で精製して、灰白色の固体として所望の生成物を得た。収率4.16g、67%、純度86%。
LCMS: METCR1410 Generic 2 minutes: rt = 1.1分, M/Z (ES-) = 369 [M-H+], 86% UV;
1H NMR (250 MHz, DMSO-d6) δ 10.11 (s, 1H), 7.70 - 7.54 (m, 2H), 7.31 (d, J = 8.3 Hz, 1H), 4.21 - 4.02 (m, 1H), 3.88 (s, 3H), 3.56 (dd, J = 11.2, 6.4 Hz, 1H), 3.17 (t, J = 11.8 Hz, 1H), 1.34 (s, 9H).
MeOH(100mL)中の、2−クロロ−4−フルオロ−5−ニトロ安息香酸(9.93g、45.23mmol)の撹拌溶液に、硫酸(2.5ml、46.9mmol)を添加した。反応混合物を65℃で4時間撹拌し、分子ふるいを添加し、反応物を65℃でさらに3時間撹拌した。反応混合物を、Celite(登録商標)を通して濾過してふるいを除去した後、減圧下で濃縮した。残留物をDCM(200mL)中に溶解し、水(150mL)を用いて洗浄した。水性部分を、DCMを用いてさらに抽出した(4回×100mL)。合わせた有機相を、NaHCO3飽和水溶液(2回×150mL)、ブライン(150mL)を用いて洗浄し、MgSO4で脱水し、濾過し、減圧下で濃縮して、収率67%および純度99%で、淡黄色の固体として所望の生成物7.12gを得た。
LCMS: METCR1410 Generic 1.7 min rt=1.09分, M/Z (ES+) イオン化せず, 99%;
1H NMR (250 MHz, クロロホルム-d) δ 8.67 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 10.2 Hz, 1H), 3.98 (s, 3H).
DCE(25mL)中の、中間体III−01’(99.5%、2g、8.52mmol)およびN,N−ジエチルエタンアミン(2.46ml、17.65mmol)の撹拌溶液に、N−(tert−ブトキシカルボニル)−L−システイン(1.98g、8.95mmol)を少量ずつ添加した。発熱反応により、内部温度が約30℃に上昇した。反応物を、さらなる1.5時間撹拌した。反応混合物を、DCM(20mL)を用いて希釈し、水(3回×20mL)、1MのHCl水溶液(2回×20mL)、ブライン(20mL)を用いて洗浄し、MgSO4で脱水し、濾過し、減圧下で濃縮して、収率85%および純度90%で、黄色の泡状物として粗生成物3.5gを得て、これを、さらに精製せずに次のステップにおいて使用した。
LCMS: METCR1410 Generic 1.7 min rt=1.17分, M/Z (ES+) 433/435 [M+H+], 94% UV
1H NMR (250 MHz, クロロホルム-d) δ 8.76 (s, 1H), 7.59 (s, 1H), 5.37 (d, J = 7.3
Hz, 1H), 4.73 (s, 1H), 3.96 (s, 3H), 3.70 - 3.55 (m, 1H), 3.49 - 3.32 (m, 1H), 1.44 (s, 9H).
中間体III−01(3.5g、8.05mmol)を、EtOH(100mL)および水(25mL)中に溶解させた。1MのHCl水溶液(0.8mL、0.8mmol)を添加し、反応混合物を50℃に加熱した。鉄(900mg、16.12mmol)を、高温であり、かつ撹拌されている反応混合物に添加した。加熱を80℃で0.5時間継続した。反応混合物を70℃に冷却し、さらなる鉄(500mg、8.95mmol)で処理した後、加熱を80℃で6.5時間継続した。反応混合物を、Celite(登録商標)を通して濾過した。濾過ケーキを、EtOAcを用いて洗浄し(50mL×2回)、減圧下で濃縮して、暗褐色の固体として生成物を得て、これを、さらに精製せずに次のステップにおいて使用した。収率3.49g、定量的と推定(痕跡量の鉄を含有)、純度89%(LCMSによる)。
LCMS: METCR1410 Generic 1.7 min, rt = 1.07, M/Z (ES+) = 304.95 [M-Boc+H+], 348.8
[M-tBu+H+], 89% UV
THF(30mL)中の、中間体III−02(89%、3.49g、7.67mmol)の撹拌溶液に、DIPEA(3.4ml、19.18mmol)およびT3P(登録商標)の50%EtOAc溶液(9.1ml、15.44mmol)を添加した。反応物を室温で1時間撹拌し、その後、減圧下で濃縮した。残留物を、水(30mL)を用いて希釈し、DCMに抽出し(3回×30mL)、ブラインを用いて洗浄し、MgSO4で脱水し、濾過し、減圧下で濃縮した。粗生成物を、フラッシュクロマトグラフィー(溶離液:ヘプタン、0〜100% EtOAc)で精製して、収率79%およびUV純度96%で、クリーム色の固体として所望の生成物2.44gを得た。
LCMS: METCR1410 Generic 1.7 min: rt = 1.12分, M/Z (ES+) = 330.9/332.7 [M-tBu+H+], 97% UV
1H NMR: (500 MHz, クロロホルム-d) δ 7.80 (s, 1H), 7.73 (s, 1H), 7.61 (s, 1H), 5.56 (d, J = 7.6 Hz, 1H), 4.46 (dt, J = 13.4, 7.0 Hz, 1H), 3.94 (s, 3H), 3.80 (dd, J = 10.9, 6.2 Hz, 1H), 3.01 (t, J = 11.4 Hz, 1H), 1.40 (s, 9H).
中間体A−03(526mg、2.01mmol)をMeCN(12mL)中に溶解させ、DIPEA(0.56mL、4mmol)を添加した。結果として得られた混合物を室温で5分間撹拌した後、4−フルオロ−3−ニトロ安息香酸メチル(361mg、1.8mmol)を添加した。結果として得られた混合物を18時間、80℃に加熱した。反応混合物を室温まで冷却した後、2MのHCl水溶液(20mL)に添加した。混合物を、EtOAcを用いて抽出し(2回×15mL)、合わせた有機抽出物を、Na2SO4で脱水し、減圧下で濃縮して、UV純度80%および収率72.5%で、黄色の固体として所望の生成物756mgを得て、これを、さらに精製せずに次のステップにおいて使用した。
LCMS: METCR1673 Generic 2 minutes rt =1.31分, M/Z (ES+) 437 [M+Na+], 80%
NMR: 1H NMR (500 MHz, DMSO-d6) δ 8.57 (d, J = 1.9 Hz, 1H), 8.27 - 8.10 (m, 1H),
7.90 (d, J = 8.6 Hz, 1H), 7.36 (d, J = 9.0 Hz, 1H), 4.33 - 4.20 (m, 1H), 4.06 -
3.98 (m, 1H), 3.91 (s, 3H), 1.43 - 1.32 (m, 12H).
中間体IV−01(80%、1.04g、2.09mmol)を、EtOH(20mL)および水(2mL)の混合物中に溶解させた。1NのHCl(0.2mL)を添加し、反応混合物を50℃に加熱した。鉄(586mg、10.44mmol)を、高温であり、撹拌されている反応混合物に添加した。暗色の反応混合物を、80℃で2.5時間撹拌した。冷却した後、混合物を、Celite(登録商標)を通して濾過し、濾過ケーキを、EtOAc(3回×100mL)、その後mEtOH(1回×50mL)を用いて洗浄した。合わせた濾液を減圧下で濃縮して、UV純度72%(鉄残留物を含有)で、黒色の固体として所望の生成物1.29gを得て、これを、さらに精製せずに次のステップにおいて使用した。
LCMS: METCR1673 Generic 2 minutes: rt = 1.65分, M/Z (ES-) 383 [M-H+], 72% UV;
中間体IV−02(72%、1035mg、1.94mmol)およびDIPEA(0.338mL、1.94mmol)を、DMF(20mL)中に溶解させた。0℃に冷却した後、HATU(811mg、2.13mmol)を少量ずつ添加した。反応物を、室温に温まるまで放置し、18時間撹拌した。混合物を減圧下で濃縮した。残留物を、EtOAc(50mL)と1NのNaOH(50mL)との間で分配した。有機層を、1NのHCl(50mL)およびブライン(50mL)を用いて洗浄した。両方の水性層(酸性および塩基性)を、IPA/クロロホルム混合物(1/1)を用いて、別個に再抽出した。合わせた有機抽出物をNa2SO4で脱水し、濾過し、濾液を減圧下で濃縮した。粗製残留物を、カラムクロマトグラフィー(シリカ、溶離液:ヘプタン、0〜50% EtOAc)で精製して、収率47%で、UV純度97%の黄色の固体として所望の生成物341mgを得た。
LCMS: METCR1673 Generic 2 minutes rt = 1.32分, M/Z (ES-) 365 [M-H+], 97% UV
NMR: 1H NMR (500 MHz, DMSO-d6) δ 10.34 (s, 1H), 7.87 - 7.56 (m, 3H), 6.99 (d, J
= 8.2 Hz, 1H), 4.33 (dd, J = 8.0, 5.3 Hz, 1H), 3.93 (m, 1H), 3.87 (s, 3H), 1.37
- 1.21 (m, 12H)
中間体A−03(466mg、1.78mmol)を1,2−ジクロロエタン(30mL)中に溶解させた。次いで、DIPEA(0.50mL、3.57mmol)を添加した。結果として得られた混合物を室温で5分間撹拌した後、2,4−ジフルオロ−5−ニトロ安息香酸メチル(387mg、1.78mmol)を添加した。結果として得られた混合物を22時間撹拌した後、それを、DCM(40mL)と水(40mL)との間で分配した。1MのHCl水溶液を添加することで、pHをpH=1に調整した。有機層を分離し、MgSO4で脱水し、濾過し、濾液を減圧下で濃縮して、UV純度55%および収率55%で、黄色の油状物767mgを得た。
LCMS: METCR1410 Generic 1.5 minutes, rt=1.16分, M/Z (ES+) 455 [M+Na+] , 55% UV
NMR: 1H NMR (250 MHz, DMSO-d6) δ 13.21 (br. s, 1H), 8.62 (d, J = 7.0 Hz, 1H), 7.76 (d, J = 11.6 Hz, 1H), 7.39 (d, J = 7.8 Hz, 1H), 4.30 (s, 1H), 4.04 (t, J = 6.4 Hz, 1H), 3.93 - 3.89 (m, 3H), 1.38 (d, J = 9.4 Hz, 12H)
中間体V−01(55%、0.76g、0.98mmol)を、EtOH(9mL)および水(2mL)中に溶解させた。1NのHCl(0.1mL)を添加し、反応混合物を50℃に加熱した。鉄(381mg、6.83mmol)を添加し、反応物を2時間、80℃に加熱した。反応混合物を室温に冷めるまで放置し、EtOAcを用いて溶出して(3回×100mL)、Celite(登録商標)を通して濾過した。濾液を減圧下で濃縮して、UV純度55%および収率97%で、暗褐色の油状物0.69gを得て、これを、さらに精製せずに次のステップにおいて使用した。
LCMS: METCR1410 Generic 1.5 minutes rt = 1.10分, M/Z (ES-) 401 [M-H+], 55% UV
中間体V−02(55%、690mg、0.94mmol)およびDIPEA(0.411mL、2.36mmol)を、THF(20mL)中に溶解させた。EtOAc中50%のT3P(登録商標)(1.11mL、1.89mmol)を添加し、反応物を室温で1.5時間撹拌した。この混合物を、水(15mL)を用いてクエンチし、EtOAcを用いて抽出した(15mL×2回)。抽出物を、MgSO4で脱水し、溶媒を減圧下で除去して、粗製油状物を得た。この粗製物を、フラッシュクロマトグラフィー(溶離液:ヘプタン、10%〜100% EtOAc)で精製して、収率74%で、UV純度90%の黄色の固体341mgを得た。
LCMS: METCR1410 Generic 1.5 minutes, rt = 1.26分, M/Z (ES-) 383 [M-H+] , 90% UV;NMR: 1H NMR (250 MHz, DMSO-d6) δ 10.26 (s, 1H), 7.64 - 7.54 (m, 2H), 6.99 (d, J = 8.1 Hz, 1H), 4.34 (dd, J = 8.0, 5.3 Hz, 1H), 4.00 - 3.90 (m, 1H), 3.86 (s, 3H), 1.41 - 1.22 (m, 12H).
MeCN(300ml)中の、2,2−ジフルオロシクロプロパン−1−カルボン酸(50%、36g、147.46mmol)の撹拌溶液に、(1S)−1−(4−メトキシフェニル)エタン−1−アミン(43.55ml、147.46mmol)を添加した。反応物を、濃灰白色の固体の沈殿が起こるまで、室温で4時間撹拌した。酸の所望される(S)エナンチオマーは、(1S)−1−(4−メトキシフェニル)エタン−1−アミンとコングロメレートを形成して溶液から沈殿し、不要な(R)エナンチオマーは溶液中に残り、濾過中に洗い出すことができる(参考文献:国際公開第2014/170197(A1)号)。最初に沈殿したコングロメレート(49g)を、高温のMeCNで再結晶させた(×8回)。結晶性固体を濾過によって単離し、低温のMeCNですすいだ。その後、SCX−2カートリッジ(2×70g、溶離液MeOH)でコングロメレート22.8gを分離し、これらの画分を減圧下で濃縮して、収率47.5%およびNMRで判定した純度100%で、灰白色の固体として所望の生成物8.56gを得た。
NMR: 1H NMR (250 MHz, クロロホルム-d) δ 9.65 (s, 1H), 2.45 (ddd, J = 12.6, 10.7, 7.8 Hz, 1H), 2.09 (dtd, J = 12.1, 7.8, 6.5 Hz, 1H), 1.92 - 1.59 (m, 1H).
tBuOH(100ml)中の、(1S)−2,2−ジフルオロシクロプロパン−1−カルボン酸(8.56g、70.12mmol)の撹拌溶液に、TEA(11.83ml、84.15mmol)、その後ジフェニルリン酸アジド(18.09ml、84.15mmol)を室温で添加した。次いで、反応物を18時間、90℃に加熱した。反応を、薄層クロマトグラフィー(溶離液:ヘプタン、10%EtOAc、発色KMnO4、Rf0.27)でモニタリングした。溶媒を減圧下で除去し、得られた粗製残留物を、カラムクロマトグラフィー(100gのSNAP、溶離液:ヘプタン、0〜10% EtOAc)で精製して、収率60%およびNMRで判定した純度100%で、白色の固体として所望の生成物8.1gを得た。
NMR: 1H NMR (250 MHz, クロロホルム-d) δ 4.82 (s, 1H), 3.14 (s, 1H), 1.85 - 1.62
(m, 1H), 1.46 (s, 1H), 1.34 (td, J = 9.0, 4.1 Hz, 1H).
ジオキサン(5mL)中の、N−[(1R)−2,2−ジフルオロシクロプロピル]カルバミン酸tert−ブチル(8.1g、41.93mmol)の撹拌溶液に、1,4−ジオキサン中4MのHCl溶液(41.93mL)を添加した。反応物を室温で3時間撹拌した。反応の進行を、薄層クロマトグラフィー(溶離液:ヘプタン、10%EtOAc、発色KMnO4、Rfの消失0.27)でモニタリングした。沈殿物を濾過によって単離し、1,4−ジオキサンですすぎ、減圧下で乾燥させて、白色の固体として所望の生成物3.38gを得た。収率62%およびNMRで判定した純度100%。
NMR: 1H NMR (250 MHz, DMSO-d6) δ 9.02 (s, 2H), 3.52 - 3.32 (m, 1H), 2.21 - 2.00
(m, 1H), 1.99 - 1.80 (m, 1H).
条件1:無水DMSO(20Vol)中の、中間体(I〜II、IV〜V)−03の撹拌溶液に、K2CO3(3当量)、R2−CH2−X(1.5当量)(Xはハロまたは適切な脱離基を表す)、およびKI(0.5当量)を添加した。反応混合物を室温で16時間撹拌した。水(50Vol)を混合物に滴下添加し、0℃に冷却することで、沈殿物を形成した。この沈殿物を濾過し、水で洗浄し(2回×50Vol)、その後フラッシュカラムクロマトグラフィーで精製して、所望の中間体VIを得た。
中間体VIを、THF/MeOH/水(10/1/3;10Vol)の混合物中に溶解させた。水酸化リチウム水和物(2当量)を添加し、反応混合物を、16時間または反応の完了まで撹拌した。
HATUを試薬として用いるアミドカップリング
中間体VIIをDMF(3Vol)中に溶解させ、DIPEA(3.5当量)を添加した。0℃に冷却した後、HATU(1.5〜3当量)を反応混合物に添加し、これを0℃で20分間撹拌した。アミンR3NH2(1.2当量)を添加し、反応物を0℃で5分間撹拌し、次いで室温で16時間撹拌した。混合物を減圧下で濃縮し、以下の方法のいずれか、またはこれらを適合させた方法によって残留物を処理して、所望の中間体VIIIを得た:
後処理方法a:
DCMを残留物に添加し、それを水で2回およびブラインで1回洗浄した。有機相を再び合わせ、Na2SO4で脱水し、減圧下で濃縮した。残留物を、カラムクロマトグラフィーで精製した。
後処理方法b:
DCMを残留物に添加し、それを水、1NのHCl、1NのNaOH、およびブラインで1回洗浄した。有機相を再び合わせ、Na2SO4で脱水し、減圧下で濃縮した。残留物を、カラムクロマトグラフィーで精製した。
後処理方法c:
反応混合物を減圧下で濃縮し、残留物をカラムクロマトグラフィーで精製した。
中間体VII(700mg、1.36mmol)のDCM(10Vol)溶液に、TEA(5当量)およびT3P(登録商標)の50%EtOAc溶液(2当量)を添加した。反応混合物を、室温で10分間撹拌した。次いで、アミンR3NH2(0.9当量)を添加した。反応混合物を、室温で8時間撹拌した。反応混合物を、水およびDCMを用いて希釈し、K2CO3飽和溶液を添加した。水性層を、DCMを用いて抽出した。合わせた有機抽出物を、水を用いて洗浄し、硫酸ナトリウムで脱水し、減圧下で濃縮して、粗製中間体VIIIを得て、これをカラムクロマトグラフィーで精製した(必要な場合)。
中間体VIIIをDCM(2Vol)中に溶解させ、反応混合物を0℃に冷却した。m−CPBA(3.5当量)を少量ずつ添加し、反応混合物を、0℃で15〜30分間、および室温で16〜54時間、反応の完了まで撹拌した。反応混合物を、DCMを用いて希釈し、1MのNaOH水溶液(×2回)およびブラインを用いて洗浄した。有機層を硫酸ナトリウムで脱水し、濾過し、濾液を減圧下で濃縮した。残留物を、逆相カラムクロマトグラフィー(Biotage中性pH)で精製して、所望の中間体IXを得た。
中間体VIIIまたは中間体IXを、過剰量のHClのエーテル溶液、例えばジオキサン中4NのHClを用いて処理することで脱保護して、第一級アミンを放出した。室温で2〜12時間撹拌した後、反応混合物を減圧下で濃縮して、塩酸塩として所望の化合物を得た。
遊離塩基方法1:SCX−2カートリッジ
最終化合物のHCl塩を、最小限のMeOH中に溶解させ、溶液をSCX−2カートリッジに充填した。カートリッジをMeOHでフラッシュした(3回×10mL)。次いで、化合物を、7MのNH3のMeOH溶液(3回×10mL)で溶出させた。これらの画分を合わせ、減圧下で濃縮して、最終化合物の遊離塩基を得た。
遊離塩基方法2:KP−NHカラム
最終化合物のHCl塩をDCM(必要な場合、MeOHを伴う)中に溶解させ、Biotage SNAP KP−NH塩基性シリカカートリッジBiotage Isolera(グラジエント DCM中0〜10%のMeOH)から溶出させることで遊離塩基化した。これらの画分を合わせ、減圧下で濃縮して、最終化合物の遊離塩基を得た。
遊離塩基方法3:水性抽出
最終生成物のHCl塩をDCM(5mL)中に懸濁させ、NaHCO3飽和水溶液(1mL)および水(5mL)を添加した。層を分離させ、有機層を、水(5mL)を用いて洗浄し、TELOS疎水性フェーズセパレーターを通し、減圧下で濃縮して、最終化合物の遊離塩基を得た。
LCMS: METCR1440 Generic 1.5 minutes: rt = 1.35分, M/Z (ES+) 517/519 [M+Na+]; 98%
UV
1H NMR (500 MHz, クロロホルム-d) d 8.94 (d, J = 10.7 Hz, 1H), 7.73 (dd, J = 10.5, 6.4 Hz, 1H), 7.61 - 7.55 (m, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.29 (q, J = 8.4 Hz, 4H), 5.31 - 5.19 (m, 1H), 4.89 (d, J = 15.6 Hz, 1H), 4.16 (dt, J = 12.1, 7.6 Hz, 1H), 3.49 (dd, J = 11.2, 7.0 Hz, 2H), 3.13 (t, J = 11.8 Hz, 1H), 2.04 - 1.91 (m, 1H), 1.62 (dd, J = 14.0, 5.5 Hz, 1H), 1.36 (s, 9H).
トラヒドロ−1,5−ベンゾチアゼピン−7−カルボン酸(中間体VII−01)の合成
LCMS: METCR1440 Generic 1.5 minutes: rt 1.23分, M/Z (ES-) 479/481 [M-H+], 95 % UV
1H NMR (500 MHz,クロロホルム-d) d 7.87 (d, J = 6.7 Hz, 1H), 7.58 (d, J = 9.9 Hz,
1H), 7.47 (d, J = 8.2 Hz, 1H), 7.30 (q, J = 8.5 Hz, 4H), 5.18 (d, J = 15.8 Hz, 1H), 4.94 (d, J = 15.7 Hz, 1H), 4.17 (dt, J = 12.2, 7.8 Hz, 1H), 3.49 (dd, J = 11.2, 6.8 Hz, 1H), 3.14 (t, J = 11.7 Hz, 1H), 1.36 (s, 9H).
LCMS: METCR1440 Generic 1.5 minutes: rt = 1.31分, M/Z (ES+) 578/580 [M+Na+], 99%
UV;
1H NMR (500 MHz, DMSO-d6) δ 8.94 (d, J = 10.8 Hz, 1H), 7.73 (dd, J = 10.5, 6.4 Hz, 1H), 7.58 (d, J = 9.2 Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 7.29 (q, J = 8.4 Hz, 4H), 5.34 - 5.15 (m, 1H), 4.89 (d, J = 15.6 Hz, 1H), 4.16 (dt, J = 12.1, 7.8 Hz, 1H), 3.49 (dd, J = 11.2, 6.9 Hz, 2H), 3.13 (t, J = 11.7 Hz, 1H), 2.05 - 1.91 (m, 1H), 1.68 - 1.54 (m, 1H), 1.36 (s, 9H).
LCMS: METCR1440 Generic 1.5 minutes: rt = 1.25分, M/Z (ES+) 610/612 [M+Na+], 99%
UV,
1H NMR (500 MHz, DMSO-d6) δ 9.13 (d, J = 13.6 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.63 (dd, J = 5.4, 3.0 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.34 (d, J = 1.5 Hz, 4H), 5.23 - 5.12 (m, 1H), 4.87 - 4.79 (m, 1H), 4.49 - 4.36 (m, 1H), 4.13 - 4.04 (m, 1H), 3.82 - 3.72 (m, 1H), 3.50 (s, 1H), 2.00 (s, 1H), 1.65 - 1.57 (m, 1H), 1.37 (s, 9H).
LCMS: METCR1416 GENERIC 7 MINUTES : rt = 3.02分, M/Z (ES+) 488/490 [M+H+], 100% UV,
1H NMR (500 MHz, DMSO-d6) δ 9.14 (d, J = 15.1 Hz, 1H), 8.43 (s, 3H), 7.85 (d, J
= 8.4 Hz, 1H), 7.73 (dd, J = 20.2, 5.4 Hz, 1H), 7.42 - 7.36 (m, 4H), 5.25 - 5.14 (m, 1H), 4.99 - 4.86 (m, 1H), 4.47 (q, J = 9.9 Hz, 1H), 4.18 - 4.09 (m, 1H), 4.04 - 3.93 (m, 1H), 3.57 - 3.45 (m, 1H), 2.07 - 1.96 (m, 1H), 1.70 - 1.57 (m, 1H).
上の一般的手順は、反応ステップの順序を変更することで適合させることができる。
無水DCM(20mL)中の中間体VI−13(92%、579mg、0.98mmol)に、m−CPBA(1.1g、4.89mmol、5当量)を添加した。反応混合物を、室温で反応の完了まで撹拌した。反応混合物を、1NのNaOHを用いて洗浄し(2回×15mL)、有機層を硫酸ナトリウムで脱水し、濾過し、濾液を減圧下で濃縮した。残留物を、カラムクロマトグラフィー(シリカ、ヘプタン、5〜50% EtOAc)で精製して、収率71%で、UV純度98%の灰白色の固体として中間体VI−22を0.41g得た。
LCMS: METCR1673 GENERIC 2 MINUTES : rt = 1.50分, M/Z (ES+) 599 [M+Na+], 98% UV
1H NMR (500 MHz, CDCl3) δ 1.41 (s, 9H), 3.51 (dd, J = 11.03, 13.28 Hz, 1H), 3.92 (s, 3H), 4.08 (dd, J = 6.90, 13.35 Hz, 1H), 4.53 (dt, J = 7.13, 10.86 Hz, 1H), 4.59 (d, J = 15.23 Hz, 1H), 5.40 (d, J = 15.23 Hz, 1H), 5.68 (d, J = 7.15 Hz, 1H), 7.20 (d, J = 8.14 Hz, 2H), 7.36 (d, J = 8.61 Hz, 2H), 7.67 (d, J = 5.61 Hz, 1H), 7.83 (d, J = 8.65 Hz, 1H).
8/2/1のTHF/水/MeOH(11mL)中の中間体VI−22(98%、408.6mg、0.70mmol、1当量)に、水酸化リチウム水和物(1:1:1)(58.3mg、1.39mmol、2当量)を添加した。この反応混合物を、室温で反応の完了まで撹拌し、次いで減圧下で濃縮した。残留物を、DCM(5mL)中に溶解させ、1NのHCl(3mL)を用いて洗浄した。水性層を、DCMを用いて抽出した(2回×5mL)。合わせた有機層を、硫酸ナトリウムで脱水し、濾過し、濾液を減圧下で濃縮して、浅黄色の固体として中間体VII−22を得た。収率212mg、38%、UV純度70%。
LCMS: METCR1673 GENERIC 2 MINUTES : rt = 1.50分, M/Z (ES+) 585 [M+Na+], 70% UV
1H NMR (500 MHz, DMSO-d6) δ 1.36 (s, 9H), 3.72 - 3.82 (m, 1H), 4.06 (dd, J = 7.32, 13.20 Hz, 1H), 4.44 (dt, J = 7.64, 11.73 Hz, 1H), 4.77 (d, J = 16.13 Hz, 1H), 5.28 (d, J = 16.16 Hz, 1H), 7.29 (d, J = 8.19 Hz, 2H), 7.43 (d, J = 8.44 Hz, 2H), 7.52 (d, J = 8.09 Hz, 1H), 7.71 - 7.79 (m, 2H)
DCM(1.5mL)中の中間体VII−22(70%、70mg、0.09mmol、1当量)に、DIPEA(54μL、0.31mmol、3.5当量)を添加した。混合物を0℃に冷却した;次いで、HATU(50mg、0.13mmol、1.5当量)を一度に添加した。反応物を0℃で15分間撹拌した;次いで、4,4,4−トリフルオロブタン−1−アミン(13μL、0.13mmol、1.5当量)を添加した。0℃で15分間経過した後、反応物を、室温に温まるまで放置し、反応の完了まで撹拌した。混合物を減圧下で濃縮し、残留物を、分取LC(中性pH方法)で精製して、黄色の固体として中間体IX−08を得た。収率:32mg、53%、UV純度96%。
LCMS: METCR1673 GENERIC 2 MINUTES : rt = 1.49分, M/Z (ES+) 694 [M+Na+], 96% UV
1H NMR (500 MHz, クロロホルム-d) δ 1.40 (s, 9H), 1.92 (dt, J = 7.19, 14.69 Hz, 2H), 2.11 - 2.26 (m, 2H), 3.55 (qd, J = 8.97, 13.63 Hz, 3H), 4.08 (dd, J = 6.71,
13.53 Hz, 1H), 4.53 (dt, J = 7.00, 10.86 Hz, 1H), 4.84 (d, J = 15.25 Hz, 1H), 5.22 (d, J = 15.24 Hz, 1H), 5.70 (d, J = 7.13 Hz, 1H), 6.77 (dt, J = 5.76, 11.56 Hz, 1H), 7.16 (d, J = 8.08 Hz, 2H), 7.37 (d, J = 8.63 Hz, 2H), 7.82 (d, J = 9.87
Hz, 1H), 7.99 (d, J = 6.04 Hz, 1H)
DCM(30mL)中の中間体VII−06(94%、700mg、1.42mmol)の撹拌溶液に、3−クロロベンゼンカルボペルオキソ酸(77%、733mg、3.27mmol)を添加した。反応物を室温で18時間撹拌し、白色の沈殿物を形成した。この沈殿物を濾過によって単離して、白色の固体として表題化合物120mg(17%)を得た。濾液を濃縮し、残留物をMeCN中でスラリー化した。固体を濾取して、表題化合物131mg(18%)を得た。結果として得られた濾液を濃縮して、粗製残留物を得た。この粗製残留物を、逆相カラムクロマトグラフィー(Biotage、60g SNAP Ultra、水中5〜100%のMeCN)で精製することで、表題化合物のさらなる部分(278mg、37%)を得た。合わせた収率は、529mg、72%であった(純度93%)。
LCMS: METCR1410 Generic 1.7 min rt=1.11分, M/Z (ES-) 493/ 495 [M-H+] 93% UV
1H NMR (500 MHz, DMSO-d6) δ 8.08 - 7.98 (m, 2H), 7.80 (s, 1H), 7.53 (d, J = 8.0
Hz, 1H), 7.41 - 7.33 (m, 4H), 5.30 (d, J = 16.2 Hz, 1H), 4.73 (d, J = 16.3 Hz, 1H), 4.39 (dt, J = 11.7, 7.6 Hz, 1H), 4.09 (dd, J = 13.2, 7.3 Hz, 1H), 3.75 (t, J = 12.5 Hz, 1H), 1.36 (s, 9H).
GP3(T3P(登録商標)を試薬として用いるアミドカップリング)に記載される手順に従って、中間体VII−35から、中間体IX−104を製造した。収率=78%
LCMS: METCR1410 Generic 1.7 min rt=1.17分, M/Z (ES+) 615/617 [M+H+] 96% UV
1H NMR (500 MHz, DMSO-d6) δ 9.31 (t, J = 5.7 Hz, 1H), 8.12 (d, J = 2.3 Hz, 1H),
8.01 - 7.94 (m, 2H), 7.84 (s, 1H), 7.63 (dd, J = 8.5, 2.4 Hz, 1H), 7.51 (d, J =
8.0 Hz, 1H), 7.37 - 7.30 (m, 4H), 6.79 (d, J = 8.5 Hz, 1H), 5.19 (d, J = 16.0 Hz, 1H), 4.85 (d, J = 16.0 Hz, 1H), 4.43 - 4.33 (m, 3H), 4.07 (dd, J = 13.1, 7.2 Hz, 1H), 3.83 (s, 3H), 3.76 - 3.69 (m, 1H), 1.35 (s, 9H).
LCMS: METUPLCMS-A-004, rt=1.8分, M/Z (ES+) 499 [M+H+], 522 [M+Na+] 78% UV
NMRデータ:1H NMR (400 MHz, クロロホルム-d) d 7.92 (d, J = 1.7 Hz, 1H), 7.81 (dd,
J = 8.0, 1.6 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.27 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 8.4 Hz, 2H), 5.59 (d, J = 8.3 Hz, 1H), 5.27 (d, J = 15.1 Hz, 1H), 4.91 (d, J = 15.1 Hz, 1H), 4.43 (dd, J = 11.7, 6.7 Hz, 1H), 3.94 (s, 3H), 3.72 (dd, J = 10.8, 6.6 Hz, 1H), 2.94 (t, J = 11.3 Hz, 1H), 1.39 (s, 9H), 1.28 - 1.25 (m, 9H).
LCMS: METCR1278 Generic 3.5 minutes , rt=2.34分, M/Z (ES+) 549 [M+H+], 526 [M+Na+] 90% UV
NMRデータ:1HNMR (500 MHz, DMSO-d6) d 7.95 (s, 1H), 7.84 - 7.74 (m, 2H), 7.49 (d,
J = 8.2 Hz, 1H), 7.40 (d, J = 8.5 Hz, 2H), 7.25 (d, J = 8.2 Hz, 2H), 5.18 (d, J
= 15.9 Hz, 1H), 5.08 (d, J = 16.0 Hz, 1H), 4.15 (dt, J = 12.3, 7.6 Hz, 1H), 3.85 (s, 3H), 3.50 (dd, J = 11.2, 6.8 Hz, 1H), 3.15 (t, J = 11.8 Hz, 1H), 1.35 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.35分, M/Z (ES+) 533.2 [M+Na+], 455.0 [M-tBu+H+] 96% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 7.97 - 7.93 (m, 1H), 7.80 (dd, J = 8.0, 1.5 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 8.1 Hz, 2H), 7.53 - 7.48 (m, 3H), 5.26 (d, J = 16.3 Hz, 1H), 5.14 (d, J = 16.2 Hz, 1H), 4.16 (dt, J = 12.2, 7.5 Hz, 1H), 3.84 (s, 3H), 3.50 (dd, J = 11.2, 6.8 Hz, 1H), 3.15 (t, J = 11.8 Hz, 1H), 1.35 (s, 9H).
LCMS:METUPLCMS−A−004,rt=1.74分,M/Z(ES+)527,83% UV
LCMS: METCR1278 Generic 3.5 minutes, rt=2.32分, M/Z (ES+) 499/501 [M+Na+] 100% UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) δ 7.93 (d, J = 1.7 Hz, 1H), 7.82 (dd, J = 8.0, 1.5 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.20 (s, 4H), 5.55 (d, J = 8.2 Hz, 1H), 5.44 (d, J = 15.1 Hz, 1H), 4.75 (d, J = 15.1 Hz, 1H), 4.41 (dt, J = 14.3, 7.4 Hz, 1H), 3.92 (s, 3H), 3.71 (dd, J = 10.8, 6.6 Hz, 1H), 2.93 (t, J = 11.3 Hz, 1H), 1.39 (s, 9H).
LCMS: METUPLCMS-A-004, rt=1.72分,M/Z (ES+)528 [M+H+] 86% UV
LCMS: MET-LCMS (MUX)-A-008, rt=1.54分, M/Z (ES+) 368 [M+H-boc] 93% UV
NMRデータ:1H NMR (400 MHz, クロロホルム-d) 1.40 (s, 9H), 2.94 (t, J = 11.2 Hz, 1H), 3.72 (dd, J = 10.7, 6.5 Hz, 1H), 3.93 (s, 3H), 4.45 (m, 1H), 4.85 (d, J = 15.5 Hz, 1H), 5.49 (d, J = 15.9 Hz, 2H), 7.41 (d, J = 8.5Hz, 2H), 7.57 - 7.53 (m, 2H), 7.67 (d, J = 8.0 Hz, 1H), 7.84 (dd, J = 8.0, 1.7 Hz, 1H), 7.93 (d, J = 1.7 Hz, 1H).
LCMS: METCR1673 Generic 2 minutes , rt=1.44分, M/Z (ES-) 510 [M-H+] 87% UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) d 8.52 (s, 1H), 7.93 (d, J = 1.7 Hz, 1H), 7.83 - 7.77 (m, 2H), 7.60 (d, J = 8.0 Hz, 1H), 7.51 (d, J = 8.1 Hz, 1H), 5.57 (d, J = 15.4 Hz, 1H), 5.43 (d, J = 8.1 Hz, 1H), 4.71 (d, J = 15.4 Hz, 1H), 4.40 - 4.31 (m, 1H), 3.87 (s, 3H), 3.64 (dd, J = 11.0, 6.6 Hz, 1H), 2.85 (t, J = 11.3 Hz, 1H), 1.33 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.43分, M/Z (ES+) 425 [M+H-boc] 99% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) d 7.95 (s, 1H), 7.86 (d, J = 8.2 Hz, 2H), 7.82 - 7.72 (m, 2H), 7.51 (d, J = 8.3 Hz, 1H), 7.46 (d, J = 8.1 Hz, 2H), 5.24 - 5.09 (m, 2H), 4.16 (dt, J = 12.5, 7.8 Hz, 1H), 3.83 (s, 3H), 3.50 (dd, J = 11.1, 6.8 Hz, 1H), 3.16 (t, J = 11.8 Hz, 1H), 2.64 (s, 3H), 1.35 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.46分, M/Z (ES+) 483 [M+Na+], 84% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) d 7.97 (s, 1H), 7.79 (dd, J = 8.0, 1.6 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 8.3 Hz, 1H), 7.29 (dd, J t= 8.3, 5.6 Hz, 2H), 7.06 (t, J = 8.8 Hz, 2H), 5.21 (d, J = 15.6 Hz, 1H), 4.98 (d, J = 15.6 Hz, 1H), 4.13 (dd, J = 7.4, 4.7 Hz, 1H), 3.86 (s, 3H), 3.48 (dd, J = 11.2, 6.8 Hz, 1H), 3.14 (t, J = 11.8 Hz, 1H), 1.35 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.29分, M/Z (ES+) 510 [M+H+], 79% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) d 9.21 (s, 1H), 8.17 (s, 1H), 7.96 (d, J = 1.5 Hz, 1H), 7.75 (dd, J = 8.0, 1.6 Hz, 1H), 7.70 (dd, J = 8.2, 4.9 Hz, 3H), 7.50 (d, J = 8.3 Hz, 1H), 7.40 (d, J = 8.5 Hz, 2H), 5.24 (d, J = 15.9 Hz, 1H), 5.04 (d, J = 15.9 Hz, 1H), 4.11 (dt, J = 12.4, 7.7 Hz, 1H), 3.81 (s, 3H), 3.46 (dd, J = 11.2, 6.8 Hz, 1H), 3.12 (t, J = 11.8 Hz, 1H), 1.31 (s, 9H).
LCMS: METCR1278 Generic 3.5 minutes, rt=2.39分, M/Z (ES+) 608 [M+Na+MeCN] 88% UVNMRデータ:1H NMR (500 MHz, クロロホルム-d) d 7.82 (d, J = 6.4 Hz, 1H), 7.39 (d, J = 9.6 Hz, 1H), 7.29 (d, J = 8.6 Hz, 2H), 7.10 (d, J = 8.1 Hz, 2H), 5.54 (d, J = 7.7 Hz, 1H), 5.38 - 5.34 (m, 1H), 4.78 (d, J = 15.1 Hz, 1H), 4.42 (dt, J = 11.6, 7.5 Hz, 1H), 3.93 (s, 3H), 3.71 (dd, J = 10.9, 6.5 Hz, 1H), 2.93 (t, J = 11.3 Hz, 1H), 1.40 (s, 9H).
LCMS:METCR1673 Generic 2 minutes, rt=1.43分, M/Z (ES+) 549 [M+Na+], 427 [M+H-boc] 86% UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) d 8.59 (s, 1H), 7.99 (d, J = 1.6 Hz, 1H), 7.92 (d, J = 8.2 Hz, 2H), 7.82 (d, J = 7.9 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.43 (d, J = 8.2 Hz, 2H), 5.55 (d, J = 15.2 Hz, 2H), 4.86 (d, J = 15.2 Hz, 1H), 4.45 (d, J = 11.8 Hz, 1H), 3.92 (s, 3H), 3.73 (dd, J = 10.8, 6.6 Hz, 1H), 2.96 (t, J = 11.3 Hz, 1H), 1.40 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.22分, M/Z (ES+) 508 [M+H+Na+] 90% UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) d 7.94 (d, J = 1.7 Hz, 1H), 7.81 (dd,
J = 8.0, 1.5 Hz, 1H), 7.69 (d, J = 8.3 Hz, 2H), 7.64 (d, J = 8.0 Hz, 1H), 7.37 (d, J = 8.2 Hz, 2H), 6.05 (s, 1H), 5.71 - 5.41 (m, 3H), 4.85 (d, J = 15.3 Hz, 1H), 4.43 (dt, J = 12.7, 6.8 Hz, 1H), 3.92 (s, 3H), 3.72 (dd, J = 10.9, 6.5 Hz, 1H), 2.94 (t, J = 11.3 Hz, 1H), 1.40 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.68分, M/Z (ES+) 513/515 [M+Na+] 93% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) d 7.99 (s, 1H), 7.79 (dd, J = 8.0, 1.7 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.31 (s, 4H), 7.12 (d, J = 8.3 Hz, 1H), 5.31 (d, J = 16.0 Hz, 1H), 4.98 (d, J = 15.9 Hz, 1H), 4.42 - 4.30 (m, 1H), 3.86 (m, 4H), 1.43 - 1.26 (m, 12H).
LCMS: METCR1673 Generic 2 minutes, rt=1.63分, M/Z (ES+) 535/537 [M+Na+] 87% UV
NMRデータ: 1H NMR (500 MHz, CDCl3) d 7.89 (d, J = 6.4 Hz, 1H), 7.43 - 7.36 (m, 2H), 7.05 (dd, J = 8.3, 1.8 Hz, 1H), 6.98 (dd, J = 9.6, 2.0 Hz, 1H), 5.52 (d, J = 7.9 Hz, 1H), 5.37 (d, J = 15.2 Hz, 1H), 4.79 (d, J = 15.2 Hz, 1H), 4.40 (dt, J = 14.1, 7.1 Hz, 1H), 3.95 (s, 3H), 3.68 (dd, J = 10.9, 6.5 Hz, 1H), 2.89 (t, J =
11.3 Hz, 1H), 1.40 (s, 9H).
LCMS:METCR1673 Generic 2 minutes , rt=1.52分, M/Z (ES+) 535/537 [M+Na+] 81% UV
NMRデータ:1H NMR (500 MHz, CDCl3) d 7.83 (d, J = 6.4 Hz, 1H), 7.40 (d, J = 9.5 Hz, 1H), 7.28 - 7.24 (m, 1H), 7.12 (dd, J = 9.6, 1.9 Hz, 1H), 7.01 - 6.93 (m, 1H), 5.52 (d, J = 7.9 Hz, 1H), 5.38 (d, J = 15.3 Hz, 1H), 4.69 (d, J = 15.1 Hz, 1H), 4.49 - 4.34 (m, 1H), 3.94 (s, 3H), 3.71 (dd, J = 11.0, 6.4 Hz, 1H), 2.94 (t, J = 11.3 Hz, 1H), 1.40 (s, 9H).
LCMS:METCR1673 Generic 2 minutes, rt=1.64分, M/Z (ES+) 533/535/537 [M+Na+] 61% UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) d 1.40 (s, 9H), 2.94 (t, J = 11.28 Hz, 1H), 3.71 (dd, J = 6.63, 10.86 Hz, 1H), 3.93 (s, 3H), 4.40 - 4.45 (m, 1H), 4.72 (d, J = 15.3 Hz, 1H), 5.42 (d, J = 15.3 Hz, 1H), 5.52 (d, J = 8.09 Hz, 1H), 7.12 (dt, J = 2.38, 8.23 Hz, 1H), 7.30 (d, J = 8.25 Hz, 1H), 7.42 (d, J = 2.15 Hz, 1H), 7.67 (d, J = 8.01 Hz, 1H), 7.84 (dd, J = 1.66, 7.99 Hz, 1H), 7.93 (d, J = 1.69 Hz, 1H).
LCMS: METCR1673 Generic 2 minutes, rt=1.41分, M/Z (ES+) 512 [M+Na+] 99% UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) δ 8.80 - 7.61 (m, 7H), 7.44 (d, J = 9.5 Hz, 1H), 5.81 (s, 1H), 5.55 - 5.45 (m, 2H), 4.58 - 4.45 (m, 1H), 3.94 (s, 3H), 3.78 (dd, J = 10.8, 6.8 Hz, 1H), 2.98 (t, J = 11.4 Hz, 1H), 1.40 (d, J = 7.0 Hz, 9H).
LCMS: METCR1673 Generic 2 minutes , rt=1.28分, M/Z (ES+) 509 [M+H+] 90% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) d 8.18 (d, J = 6.5 Hz, 1H), 7.67 (d, J = 10.0 Hz, 1H), 7.50 (d, J = 8.2 Hz, 1H), 5.43 (d, J = 15.6 Hz, 1H), 5.18 (d, J = 15.7 Hz, 1H), 4.12 (dt, J = 11.8, 7.3 Hz, 1H), 3.90 (s, 3H), 3.48 (dd, J = 11.4, 6.9 Hz, 1H), 3.10 (t, J = 11.8 Hz, 1H), 2.48 - 2.43 (m, 1H), 1.35 (s, 9H), 1.19 (dd, J = 11.4, 9.3 Hz, 2H), 1.03 - 0.93 (m, 2H).
LCMS: METCR1410 Generic 1.7 min, rt=1.27分, M/Z (ES+) 483 [M+Na+] 95% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.97 (d, J = 1.7 Hz, 1H), 7.83 (dd, J = 8.0, 1.7 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.46 (t, J = 6.9 Hz, 1H), 7.22 - 7.14 (m, 1H), 7.11 - 6.89 (m, 2H), 5.56 (d, J = 8.0 Hz, 1H),5.40 (d, J = 15.3 Hz, 1H), 4.96 (d, J = 15.3 Hz, 1H), 4.40 (s, 1H), 3.92 (s, 3H), 3.70 (dd, J = 10.9, 6.5 Hz, 1H), 2.91 (t, J = 11.3 Hz, 1H), 1.39 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.26分, M/Z (ES+) 495.2 [M+Na+] 96% UV
LCMS: METCR1410 Generic 1.7 min, rt=1.26分, M/Z (ES+) 417.15 [M-tBu+H+], 495.15
[M+Na+], 88% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 7.98 (d, J = 1.3 Hz, 1H), 7.81 - 7.66 (m,
2H), 7.44 (d, J = 8.4 Hz, 1H), 7.16 (d, J = 8.6 Hz, 2H), 6.78 (d, J = 8.6 Hz, 2
H), 5.18 (d, J = 15.4 Hz, 1H), 4.90 (d, J = 15.4 Hz, 1H), 4.22 - 4.07 (m, 1H), 3.85 (s, 3H), 3.68 (s, 3H), 3.47 (dd, J = 11.2, 6.8 Hz, 1H), 3.14 (t, J = 11.8 Hz, 1H), 1.35 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.31分, M/Z (ES+) 423.05 [M-tBu+H+], 96% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.83 (d, J = 6.5 Hz, 1H), 7.37 (d,
J = 9.7 Hz, 1H), 7.22 (dd, J = 8.6, 5.4 Hz, 2H), 6.92 (t, J = 8.6 Hz, 2H), 5.55
(d, J = 7.9 Hz, 1H), 5.39 (d, J = 14.9 Hz, 1H), 4.70 (d, J = 14.9 Hz, 1H), 4.40
(dt, J = 12.7, 6.3 Hz, 1H), 3.94 (s, 3H), 3.70 (dd, J = 10.9, 6.5 Hz, 1H), 2.92
(t, J = 11.3 Hz, 1H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.36分, M/Z (ES+) 505.1 [M+Na+], 427.1 [M-tB
u+H+], 100% UV; NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.92 (d, J = 1.7 Hz, 1H), 7.80 (dd, J = 8.0, 1.6 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.14 (d, J = 8.1 Hz, 2H), 6.92 (d, J = 8.1 Hz, 2H), 5.58 (d, J = 8.1 Hz, 1H), 5.36 (d, J = 15.0 Hz, 1H), 4.79 (d, J = 15.0 Hz, 1H), 4.45 - 4.35 (m, 1H), 3.91 (s, 3H), 3.71 (dd, J = 10.9, 6.7 Hz, 1H), 2.93 (t, J = 11.2 Hz, 1H), 1.81 (ddd, J = 13.5, 8.4, 5.0 Hz, 1H), 1.39 (s, 9H), 0.94 - 0.88 (m, 2H), 0.65 - 0.60 (m, 2H).
LCMS: METCR1673 Generic 2 minutes, rt=1.23分, M/Z (ES+) 430 [M-tBu+H+] 88% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 7.91 (d, J = 6.5 Hz, 1H), 7.75 (d, J = 8.3 Hz, 2H), 7.66 (d, J = 9.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 1H), 7.47 (d, J = 8.2 Hz, 2H), 5.25 (d, J = 16.2 Hz, 1H),5.06 (d, J = 16.2 Hz, 1H), 4.18 (dt, J = 12.4, 7.7 Hz, 1H), 3.86 (s, 3H), 3.51 (dd, J = 11.2, 6.8 Hz, 1H), 3.16 (t, J = 11.8 Hz, 1H), 1.36 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.31分, M/Z (ES+) 513.2 [M+Na+], 435.1 [M-tBu+H+] 91% UV; NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.83 (d, J = 6.5 Hz, 1H), 7.35 (d, J = 9.7 Hz, 1H), 7.19 - 7.11 (m, 2H), 6.83 - 6.69 (m, 2H), 5.58 (d, J = 7.8 Hz, 1H), 5.36 (d, J = 14.8 Hz, 1H), 4.67 (d, J = 14.8 Hz, 1H), 4.39 (dt, J = 11.6, 7.3 Hz, 1H), 3.93 (s, 3H), 3.75 (s, 3H), 3.69 (dd, J = 10.9, 6.5 Hz, 1H), 2.92 (t, J = 11.2 Hz, 1H), 1.40 (s, 9H).
−クロロフェニル)メチル]−8−フルオロ−2−メチル−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボン酸メチル(中間体VI−29)の合成
LCMS: METCR1673 Generic 2 minutes, rt=1.43分, M/Z (ES+) 452.75/454.90 [M-tBu+H+]
82% UV
NMRデータ: 1H NMR (250 MHz, DMSO-d6) d 7.94 (d, J = 6.6 Hz, 1H), 7.61 (d, J = 10.1 Hz, 1H), 7.30 (d, J = 2.2 Hz, 4H), 7.12 (d, J = 8.3 Hz, 1H), 5.31 (d, J = 15.9 Hz, 1H), 4.89 (d, J = 15.7 Hz, 1H), 4.45 - 4.34 (m, 1H), 3.86 (m, 4H), 1.40 - 1.27 (m, 12H).
LCMS: METCR1410 Generic 1.7 min, rt=1.28分, M/Z (ES+) 531 [M+Na+] 97% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.86 (d, J = 1.7 Hz, 1H), 7.75 (dd, J = 8.0, 1.7 Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.22 (s, 2H), 6.91 (d, J = 8.6 Hz, 2H), 6.39 (td, J = 73.9, 7.4 Hz, 1H), 5.48 (d, J = 8.1 Hz, 1H), 5.35 (d, J = 15.1 Hz, 1H), 4.81 - 4.63 (m, 1H), 4.41 (d, J = 46.4 Hz, 1H), 3.86 (d, J = 5.5 Hz, 3H), 3.64 (dd, J = 10.9, 6.6 Hz, 1H), 2.86 (t, J = 11.3 Hz, 1H), 1.32 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.37分, M/Z (ES+) 533.05/535.05 [M+Na+] 100% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.70 (d, J = 12.3 Hz, 2H), 7.21 (d, J = 2.0 Hz, 4H), 5.52 (d, J = 7.6 Hz, 1H), 5.35 (d, J = 15.1 Hz, 1H), 4.73 (d, J = 15.1 Hz, 1H), 4.50 - 4.32 (m, 1H), 3.93 (s, 3H), 3.70 (dd, J = 10.9, 6.5 Hz, 1H), 2.93 (t, J = 11.3 Hz, 1H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.34分, M/Z (ES+) 543.05/544.85 [M+Na+], 96%
UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.93 (d, J = 1.7 Hz, 1H), 7.82 (dd, J = 8.0, 1.7 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.40 - 7.29 (m, 2H), 7.15 (d, J = 8.4 Hz, 2H), 5.54 (d, J = 7.6 Hz, 1H), 5.42 (d, J = 15.1 Hz, 1H), 4.73 (d, J = 15.1 Hz, 1H), 4.49 - 4.31 (m, 1H), 3.92 (s, 3H), 3.70 (dd, J = 10.9, 6.6 Hz, 1H), 2.92 (t, J = 11.3 Hz, 1H), 1.39 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.36分, M/Z (ES+) 580 [M+Na+] 87% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 7.95 (d, J = 6.6 Hz, 1H), 7.63 (d, J = 10.0 Hz, 1H), 7.54 (s, 1H), 7.46 (t, J = 6.9 Hz, 2H), 7.13 (d, J = 8.6 Hz, 1H), 5.24 (d, J = 15.4 Hz, 1H), 4.91 (d, J = 15.4 Hz, 1H), 4.15 (dt, J = 12.2, 7.4 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.49 (dd, J = 11.3, 6.8 Hz, 1H), 3.15 (t, J = 11.7 Hz, 1H), 1.35 (s, 9H).
NMRデータ: 1H NMR (400 MHz, DMSO-d6) δ 7.94 (s, 1H), 7.79 - 7.76 (m, 1H), 7.64 (d, J = 7.9 Hz, 1H), 7.47 (d, J = 8.5 Hz, 1H), 7.32 (d, J = 8.3 Hz, 2H), 7.27 (d, J = 8.4 Hz, 2H), 5.12 - 5.06 (m, 2H), 4.28 - 4.19 (m, 1H), 3.56 - 3.49 (m, 1H), 3.16 (t, J = 11.8 Hz, 1H), 1.41 (s, 9H), 1.29 (s, 9H). [OHは見えない]
LCMS: METCR1278 Generic 3.5 minutes, rt=2.1分, M/Z (ES-) 511.10[ M-H+], 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 7.92 (d, J = 1.6 Hz, 1H), 7.79 (dd, J = 8.0, 1.7 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.53 (d, J = 8.3 Hz, 1H), 7.41 (d, J = 8.6 Hz, 2H), 7.26 (d, J = 8.2 Hz, 2H), 5.16 (d, J = 16.1 Hz, 1H), 5.09 (d, J =
16.1 Hz, 1H), 4.15 (dt, J = 12.3, 7.6 Hz, 1H), 3.53 - 3.45 (m, 1H), 3.21 - 3.04
(m, 1H), 1.42 - 1.28 (m, 9H). [OHは見えない]
LCMS: METCR1410 Generic 1.7 min, rt=1.2分, M/Z (ES+) 441.0 [M-tBu+H+], 519.1 [M+Na+] 96% UV NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 7.92 (d, J = 1.3 Hz, 1H), 7.78 (dd, J = 8.0, 1.6 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 8.2 Hz, 2H), 7.55 - 7.47 (m, 3H), 5.23 (d, J = 16.2 Hz, 1H), 5.16 (d, J = 16.3 Hz, 1H), 4.17 (dt, J = 12.3, 7.6 Hz, 1H), 3.50 (dd, J = 11.2, 6.9 Hz, 1H), 3.15 (t, J = 11.8 Hz, 1H), 1.35 (s, 9H) [OHは見えない]
LCMS: METUPLCMS-A-004, rt=1.49分, M/Z (ES-) 511 [M-H+] 95% UV
LCMS:METCR1278 Generic 3.5 minutes, rt=1.35分, M/Z (ES-) 461/463 [M-H+] 97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 7.93 - 7.90 (m, 1H), 7.76 (dd, J = 8.0, 1.6 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 8.1 Hz, 1H), 7.31 - 7.28 (m,
4H), 5.15 (d, J = 15.9 Hz, 1H), 5.01 (d, J = 15.9 Hz, 1H), 4.14 (dt, J = 12.3, 7.4 Hz, 1H), 3.50 - 3.47 (m, 1H), 3.14 (d, J = 11.8 Hz, 1H), 1.35 (s, 9H). [OHは見えない]
題化合物を得た(NMRによる純度73%)。
NMRデータ: 1H NMR (400 MHz, クロロホルム-d) δ 7.95 (d, J = 1.6 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.16 (d, J = 8.7 Hz, 2H), 6.76 (d, J = 8.8 Hz, 2H), 5.66 (d, J = 8.2 Hz, 1H), 5.39 (d, J = 14.8 Hz, 1H), 4.72 (d,J = 14.7 Hz, 1H), 3.85 - 3.77 (m, 4H), 3.72 (dd, J = 10.9, 6.5 Hz, 2H), 3.12 - 3.06 (m, 4H), 2.95 (t, J = 11.2 Hz, 1H), 1.40 (s, 9H). [OHは見えない]
LCMS: METUPLCMS-A-004, rt=1.28分, M/Z (ES-) 452 [M-H+] 73% UV
NMRデータ: 1H NMR (400 MHz, クロロホルム-d) δ 1.41 (s, 9H), 2.97 (t, J = 11.3 Hz, 1H), 3.82 - 3.70 (m, 1H), 4.61 - 4.46 (m, 1H), 4.86 (d, J = 15.7 Hz, 1H), 5.48 (d, J = 15.6 Hz, 1H), 5.66 (d, J = 8.4 Hz, 1H), 7.42 (d, J = 8.2 Hz, 2H), 7.54 (d, J = 8.2 Hz, 2H), 7.81 - 7.63 (m, 2H), 7.92 (s, 1H). [OHは見えない]
LCMS: METCR1673 Generic 2 minutes, rt=1.3分, M/Z (ES-) 496 [M-H+] 98% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) d 8.67 (s, 1H), 7.98 (d, J = 1.3 Hz, 1H), 7.94 (d, J = 8.5 Hz, 1H), 7.83 - 7.79 (m, 2H), 7.74 (d, J = 8.0 Hz, 1H), 7.50 (d, J = 8.2 Hz, 1H), 5.75 (s, 1H), 5.35 (d, J = 16.2 Hz, 1H), 5.12 (d, J = 16.1 Hz, 1H), 4.14 (dt, J = 12.2, 7.5 Hz, 1H), 3.49 (dd, J = 11.3, 6.8 Hz, 1H), 3.13 (t, J = 11.8 Hz, 1H), 1.34 (s, 9H).
LCMS:METCR1673 Generic 2 minutes, rt=1.29分, M/Z (ES-) 509 [M-H+] 100% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) d 7.92 - 7.86 (m, 3H), 7.79 - 7.71 (m, 2H), 7.49 (dd, J = 17.4, 8.2 Hz, 3H), 5.17 (s, 2H), 4.18 (dt, J = 12.3, 7.7 Hz, 1H), 3.51 (dd, J = 11.2, 6.8 Hz, 2H), 3.16 (t, J = 11.8 Hz, 1H), 2.64 (s, 3H), 1.36 (s, 9H).
LCMS:METCR1673 Generic 2 minutes, rt=1.31分, M/Z (ES-) 445 [M-H+] 100% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) d 7.92 (s, 1H), 7.77 (dd, J = 8.0, 1.6 Hz, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 8.3 Hz, 1H), 7.30 (dd, J = 8.4, 5.7 Hz, 2H), 7.07 (t, J = 8.8 Hz, 2H), 5.17 (d, J = 15.8 Hz, 1H), 5.00 (d, J = 15.7 Hz, 1H), 4.14 (dt, J = 12.2, 7.7 Hz, 1H), 3.48 (dd, J = 11.3, 6.8 Hz, 1H), 3.13 (t, J = 11.7 Hz, 1H), 1.35 (s, 9H). [OHは見えない]
LCMS:METCR1673 Generic 2 minutes, rt=1.18分, M/Z (ES+) 496 [M+H+] 90% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) d 9.24 (s, 1H), 8.20 (s, 1H), 7.94 (s, 1H), 7.80 - 7.66 (m, 4H), 7.47 (dd, J = 16.0, 8.4 Hz, 3H), 5.23 (d, J = 15.9 Hz, 1H),
5.10 (d, J = 15.9 Hz, 1H), 4.27 - 4.03 (m, 1H), 3.49 (dd, J = 11.3, 6.8 Hz, 1H), 3.15 (t, J = 11.7 Hz, 1H), 1.35 (s, 9H). [OHは見えない]
LCMS:METCR1278 Standard 3.5 minutes, rt=2.16分, M/Z (ES-) 529 [M-H+] 100% UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) δ 7.87 (d, J = 6.7 Hz, 1H), 7.60 (d,
J = 9.9 Hz, 1H), 7.52 (d, J = 8.2 Hz, 1H), 7.38 (d, J = 8.7 Hz, 2H), 7.25 (d, J
= 8.1 Hz, 2H), 5.17 (d, J = 15.9 Hz, 1H), 5.00 (d, J = 15.9 Hz, 1H), 4.16 (dt, J = 12.3, 7.6 Hz, 1H), 3.13 (t, J = 11.8 Hz, 2H), 1.35 (s, 9H). [OHは見えない]
LCMS: METCR1673 Generic 2 minutes, rt=1.3分 M/Z (ES-) 511 [M-H-] 77% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) d 13.28 (s, 1H), 9.57 (s, 1H), 8.02 (d, J = 8.2 Hz, 2H), 7.95 (s, 1H), 7.80 - 7.65 (m, 3H), 7.45 (d, J = 8.2 Hz, 2H), 5.22 (d, J = 16.1 Hz, 1H), 5.14 (d, J = 16.1 Hz, 1H), 4.24 - 4.13 (m, 1H), 3.51 (dd, J = 10.4, 5.9 Hz, 2H), 1.35 (d, J = 6.6 Hz, 9H). [OHは見えない]
LCMS: METCR1673 Generic 2 minutes, rt=1.1分, M/Z (ES-) 470 [M-H+] 100% UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) δ 7.86 (d, J = 1.6 Hz, 1H), 7.77 (d,
J = 7.9 Hz, 1H), 7.63 (d, J = 8.3 Hz, 2H), 7.58 (d, J = 8.0 Hz, 1H), 7.31 (d, J
= 8.3 Hz, 2H), 5.34 (d, J = 15.3 Hz, 1H), 4.85 (d, J = 15.3 Hz, 1H), 4.40 - 4.33 (m, 1H), 3.71 - 3.59 (m, 2H), 2.94 - 2.85 (m, 1H), 1.33 (s, 9H). [OHおよびNH2は見えない]
LCMS: METCR1673 Generic 2 minutes, rt=1.49分, M/Z (ES+) 499/501 [M+Na+] 93% UV
NMRデータ:7.94 (d, J = 1.4 Hz, 1H), 7.77 (dd, J = 8.0, 1.6 Hz, 1H), 7.70 (d, J =
7.9 Hz, 1H), 7.31 (s, 4H), 7.10 (d, J = 8.2 Hz, 1H), 5.27 (d, J = 15.8 Hz, 1H),
5.00 (d, J = 16.0 Hz, 1H), 4.46 - 4.34 (m, 1H), 3.93 - 3.80 (m, 1H), 1.39 - 1.22 (m, 12H). [OHは見えない]
LCMS:METCR1673 Generic 2 minutes, rt=1.36分, M/Z (ES-) 497 [M-H+] 100% UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) d 7.89 (d, J = 6.5 Hz, 1H), 7.41 (dd,
J = 8.8, 4.8 Hz, 2H), 7.08 - 7.03 (m, 1H), 6.97 (dd, J = 9.6, 2.0 Hz, 1H), 5.61
(d, J = 8.5 Hz, 1H), 5.37 (d, J = 15.1 Hz, 1H), 4.79 (d, J = 15.1 Hz, 1H), 4.55
- 4.44 (m, 1H), 3.72 (dd, J = 11.0, 6.5 Hz, 1H), 2.91 (t, J = 11.3 Hz, 1H), 1.41 (s, 9H). [OHは見えない]
LCMS: METCR1673 Generic 2 minutes, rt=1.36分, M/Z (ES+) 521/523 [M+Na+] 98% UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) d 7.82 (d, J = 6.6 Hz, 1H), 7.43 (d, J = 9.6 Hz, 1H), 7.26 (t, J = 7.9 Hz, 1H), 7.15 (dd, J = 9.8, 1.8 Hz, 1H), 7.04 - 6.93 (m, 1H), 5.72 (d, J = 8.2 Hz, 1H), 5.36 (d, J = 15.4 Hz, 1H), 4.69 (d, J = 15.4 Hz, 1H), 4.65 - 4.54 (m, 1H), 3.76 (dd, J = 10.9, 6.6 Hz, 1H), 2.97 (t, J
= 11.3 Hz, 1H), 1.42 (s, 9H). [OHは見えない]
LCMS: METCR1673 Generic 2 minutes, rt=1.4分, M/Z (ES+) 519/521/523 [M+Na+] 97% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) d 1.35 (s, 9H), 3.08 (t, J = 11.8 Hz, 1H), 3.45 (dd, J = 6.9, 11.31 Hz, 1H), 4.14 (dt, J = 7.5, 12.2 Hz, 1H), 5.04 (s, 2H), 7.27 (dd, J = 1.6, 8.3 Hz, 1H), 7.44 (d, J = 8.2 Hz, 1H), 7.52 (d, J = 8.3 Hz, 1H), 7.56 (d, J = 7.9 Hz, 1H), 7.57 - 7.61 (m, 1H), 7.72 (d, J = 7.8 Hz, 1H), 7.82 (s, 1H). [OHは見えない]
LCMS: METCR1673 Generic 2 minutes, rt=1.26分, M/Z (ES+) 498[M+H+] 97% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) d 1.34 (s, 9H), 3.18 (t, J = 11.7 Hz, 1H), 3.53 (dd, J = 6.8, 11.2 Hz, 1H), 4.27 (dt, J = 7.9, 12.3 Hz, 1H), 5.21 (d, J = 16.3 Hz, 1H), 5.35 (d, J = 16.3 Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 7.55 - 7.67 (m, 3H), 7.75 (t, J = 7.7 Hz, 1H), 7.95 (dd, J = 8.3, 19.2 Hz, 2H), 8.03 (d, J = 6.7 Hz, 1H), 8.35 (d, J = 8.5 Hz, 1H). [OHは見えない]
LCMS: METCR1981 Hydrophobic 3 min, rt=1.68分, M/Z (ES+) 494.95[M+H+] 90% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) d 8.13 (d, J = 6.6 Hz, 1H), 7.63 (d, J = 9.8
Hz, 1H), 7.49 (d, J = 8.3 Hz, 1H), 5.40 (d, J = 15.6 Hz, 1H), 5.20 (d, J = 15.7
Hz, 1H), 4.34 (s, 1H), 4.12 (dt, J =12.0, 7.8 Hz, 1H), 3.48 (dd, J = 11.3, 6.9 Hz, 1H), 3.14 - 3.04 (m, 1H), 2.50 - 2.42 (m, 1H), 1.35 (s, 9H), 1.22 - 1.12 (m,
2H), 0.94 (s, 2H).
LCMS: METCR1410 Generic 1.7 min, rt=1.14分, M/Z (ES+) 469.1 [M+Na+] 97% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.98 (d, J = 1.5 Hz, 1H), 7.80 (d,
J = 7.8 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.48 (t, J = 6.8 Hz, 1H), 7.25 - 7.12 (m, 1H), 7.05 (t, J = 6.9 Hz, 1H), 7.00 - 6.83 (m, 1H), 5.66 (d, J = 8.2 Hz, 1H), 5.39 (d, J = 15.3 Hz, 1H), 4.97 (d, J = 15.4 Hz, 1H), 4.48 (s, 1H), 3.74 - 3.69 (m, 1H), 2.94 (t, J = 11.3 Hz, 1H), 1.40 (s, 9H), [OHは見えない]
LCMS: METCR1410 Generic 1.7 min, rt=1.13分, M/Z (ES+) 481 [M+Na+] 95% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.93 (d, J = 1.5 Hz, 1H), 7.77 (d,
J = 8.0 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.14 (t, J = 7.9 Hz, 1H), 6.84 (d, J
= 7.4 Hz, 2H), 6.78 - 6.65 (m, 1H), 5.70 (d, J = 8.2 Hz, 1H), 5.43 (d, J = 15.2
Hz, 1H), 4.82 (d, J = 15.2 Hz, 1H), 4.51 (s, 1H), 3.74 (m, 4H), 2.99 (t, J = 11.2 Hz, 1H), 1.41 (s, 9H), [OHは見えない]
LCMS: METCR1410 Generic 1.7 min, rt=1.12分, M/Z (ES+) 481.15 [M+Na+] 83% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.95 (d, J = 1.5 Hz, 1H), 7.76 (d,
J = 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.17 (d, J = 8.7 Hz, 2H), 6.79 - 6.70 (m, 2H), 5.76 (d, J = 8.2 Hz, 1H), 5.44 (d, J = 14.8 Hz, 1H), 4.71 (d, J = 14.9 Hz, 1H), 4.48 (dt, J = 11.6, 7.5 Hz, 1H), 3.73 (m, 4H), 2.96 (t, J = 11.3 Hz, 1H), 1.41 (s, 9H), [OHは見えない]
LCMS: METCR1410 Generic 1.7 min, rt=1.14分, M/Z (ES+) 409.35 [M-tBu+] 96% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.81 (d, J = 6.5 Hz, 1H), 7.40 (d,
J = 9.8 Hz, 1H), 7.21 (dd, J = 8.6, 5.4 Hz, 2H), 6.91 (t, J = 8.7 Hz, 2H), 5.74
(d, J = 8.3 Hz, 1H), 5.43 (d, J = 14.9 Hz, 1H), 4.73 - 4.59 (m, 1H), 4.53 (dt, J = 11.5, 5.9 Hz, 1H), 3.82 - 3.77 (m, 1H), 2.95 (t, J = 11.3 Hz, 1H), 1.42 (s, 9H), [OHは見えない]
LCMS: METCR1410 Generic 1.7 min, rt=1.21分, M/Z (ES+) 491.10 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.94 (d, J = 1.4 Hz, 1H), 7.77 (d,
J = 7.9 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.14 (d, J = 8.1 Hz, 2H), 6.92 (d, J
= 8.2 Hz, 2H), 5.69 (d, J = 8.1 Hz, 1H), 5.40 (d, J = 15.0 Hz, 1H), 4.76 (d, J = 15.0 Hz, 1H), 4.47 (dt, J = 11.4, 7.4 Hz, 1H), 4.01 - 3.90 (m, 1H), 2.95 (t, J
= 11.2 Hz, 2H), 1.83 - 1.77 (m, 1H), 1.40 (s, 9H), 0.93 - 0.86 (m, 2H), 0.65 - 0.59 (m, 2H).
LCMS: METCR1410 Generic 1.7 min, rt=1.1分, M/Z (ES-) 469.70 [M-H+] 88% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 13.65 (s, 1H), 7.84 (d, J = 6.5 Hz, 1H), 7.75 (d, J = 8.2 Hz, 2H), 7.60 (d, J = 9.8 Hz, 1H), 7.51 - 7.46 (m, 3H), 5.22 (d, J = 16.4 Hz, 1H), 5.09 (d, J = 16.3Hz, 1H), 4.19 (dt, J = 12.1, 7.4 Hz, 1H), 3.51 (dd, J = 11.2, 6.7 Hz, 1H), 3.15 (t, J = 11.7 Hz, 1H), 1.36 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.12分, M/Z (ES+) 499.5 [M+Na+] 96% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 7.89 (d, J = 6.7 Hz, 1H), 7.56 (d, J = 9.9 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.15 (d, J = 8.6 Hz, 2H), 6.79 (d, J = 8.6 Hz, 2H), 5.17 (d, J = 15.4 Hz, 1H), 4.84 (d, J = 15.4 Hz, 1H), 4.15 (dt, J = 12.2, 7.5 Hz, 1H), 3.69 (s, 3H), 3.48 (dd, J = 11.2, 6.8 Hz, 1H), 3.14 (t, J = 11.7 Hz, 1H), 1.36 (s, 9H), [OHは見えない]
LCMS: METCR1410 Generic 1.7 min, rt=1.29分, M/Z (ES+) 517/519 [M+Na+] 97% UV
NMRデータ: 1H NMR (250 MHz, DMSO-d6) d 7.87 (d, J = 6.7 Hz, 1H), 7.54 (d, J = 9.9 Hz, 1H), 7.40 - 7.24 (m, 4H), 7.09 (d, J = 7.7 Hz, 1H), 5.27 (d, J = 15.5 Hz, 1H), 4.90 (d, J = 15.7 Hz, 1H), 4.44 - 4.32 (m, 1H), 3.92 - 3.80 (m, 1H), 1.43 - 1.20 (m, 12H), [OHは見えない]
LCMS: METCR1410 Generic 1.7 min, rt=1.1分, M/Z (ES+) 517.45 [M+Na+] 87% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.86 (d, J = 1.3 Hz, 1H), 7.71 (d,
J = 8.0 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.21 (d, J = 8.6 Hz, 2H), 6.91 (d, J
= 8.5 Hz, 2H), 6.37 (t, J = 74.0 Hz, 1H), 5.61 (d, J = 8.3 Hz, 1H), 5.36 (d, J = 15.1 Hz, 1H), 4.71 (d, J = 15.2 Hz, 1H), 4.43 (dt, J = 11.5, 7.6 Hz, 1H), 3.70
- 3.64 (m, 1H), 2.89 (t, J = 11.3 Hz, 1H), 1.34 (s, 9H), [OHは見えない]
LCMS: METCR1410 Generic 1.7 min, rt=1.21分, M/Z (ES+) 440.85/442.90 [M-tBu+], 519/521.05 [M+Na+] 94.3% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 7.58 (s, 2H), 7.45 (d, J = 8.3 Hz, 1H), 7.33 - 7.24 (m, 4H), 5.14 (d, J = 15.9 Hz, 1H), 4.93 (d, J = 15.9 Hz, 1H), 4.14 (dt, J = 12.1, 7.6 Hz, 1H), 3.49 - 3.44 (m, 1H), 3.08 (t, J = 11.8 Hz, 1H), 1.35 (s, 9H), [OHは見えない]
LCMS: METCR1410 Generic 1.7 min, rt=1.23分, M/Z (ES+) 451.0/453.05 [M-tBu+H+], 529.1/531.1 [M+Na+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 7.91 (d, J = 1.4 Hz, 1H), 7.77 (dd, J = 8.0, 1.6 Hz, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 8.3 Hz, 1H), 7.44 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.3 Hz, 2H), 5.14 (d, J = 16.0 Hz, 1H), 5.00 (d, J =
15.9 Hz, 1H), 4.14 (dt, J = 12.3, 7.6 Hz, 1H), 3.48 (dd, J = 11.2, 6.8 Hz, 1H),
3.13 (t, J = 11.8 Hz, 1H), 1.35 (s, 9H), [OHは見えない]
LCMS: METCR1410 Generic 1.7 min, rt=1.21分, M/Z (ES+) 566.90 [M+Na+] 94% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 7.81 (d, J = 6.3 Hz, 1H), 7.54 (s, 1H), 7.51 - 7.40 (m, 3H), 7.13 (d, J = 8.6 Hz, 1H), 5.22 (d, J = 15.6 Hz, 1H), 4.89 (d, J = 15.6 Hz, 1H), 4.15 (dt, J = 12.1, 7.6 Hz, 1H), 3.91 - 3.85 (m, 1H), 3.83 (s, 3H), 3.47 (dd, J = 11.3, 6.8 Hz, 1H), 3.11 (t, J = 11.7 Hz, 1H), 1.35 (s, 9H), [OHは見えない]
LCMS:METCR1673 Generic 2 minutes, rt=1.43分, M/Z (ES+) 526/528 [M+Na+] 100% UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) d 1.25 (dd, J = 5.2, 6.5 Hz, 6H), 1.39 (s, 9H), 2.90 (t, J = 11.3 Hz, 1H), 3.67 (dd, J = 6.6, 11.0 Hz, 1H), 4.23 (dp, J = 6.6, 13.2 Hz, 1H), 4.39 (dt, J = 7.5, 11.4 Hz, 1H), 4.81 (d, J = 15.0 Hz, 1H), 5.31 (d, J = 15.0 Hz, 1H), 5.58 (d, J = 8.0 Hz, 1H), 5.91 (d, J = 7.5 Hz, 1H), 7.17 - 7.24 (m, 4H), 7.46 (dd, J = 1.8, 8.0 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.66 (d, J = 1.5 Hz, 1H)
LCMS: METCR1673 Generic 2 minutes, rt=1.44分, M/Z (ES-) 514/516 [M-H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.63 (t, J = 5.6 Hz, 1H), 7.91 (s, 1H), 7.67 (s, 2H), 7.45 (d, J = 8.3 Hz, 1H), 7.28 (s, 4H), 5.82 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 5.29 (d, J = 15.7 Hz, 1H), 5.11 - 4.99 (m, 2H), 4.91 (d, J = 15.7 Hz, 1H), 4.13 (dt, J = 12.2, 7.6 Hz, 1H), 3.46 (dd, J = 11.3, 6.8 Hz, 1H), 3.11 (t, J = 11.8 Hz, 1H), 2.52 (d, J = 1.9 Hz, 2H), 2.28 (q, J = 7.0 Hz, 2H), 1.34 (s, 9H).
NMRデータ: 1H NMR (400 MHz, DMSO-d6) δ 1.35 - 1.21 (m, 9H), 1.48 - 1.35 (m, 4H), 1.72 - 1.62 (m, 2H), 1.76 (s, 3H), 3.01 (q, J = 6.4 Hz, 2H), 3.10 (t, J = 11.8 Hz, 1H), 3.46 (dd, J = 11.3, 6.9 Hz, 1H), 3.91 (t, J = 6.5 Hz, 2H),4.10 (d, J = 6.9 Hz, 1H), 4.39 (qd, J = 14.7, 5.6 Hz, 2H), 4.97 (d, J = 15.7 Hz, 1H), 5.28 (d, J = 15.8 Hz, 1H), 6.87 (d, J = 8.7 Hz, 2H), 7.22 (dd, J = 8.8, 2.6 Hz, 4H), 7.38 (d, J = 8.7 Hz, 2H), 7.46 (d, J = 8.4 Hz, 1H),7.68 (d, J = 8.0 Hz, 1H), 7.73 (dd, J = 8.0, 1.6 Hz, 1H), 7.79 (s, 1H), 7.96 (d, J = 1.5 Hz, 1H), 9.13 (t, J = 5.9 Hz, 1H).
LCMS: METCR1673 Generic 2 minutes, rt=1.41分, M/Z (ES+) 542/544 [M+Na+] 95% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.54 (d, J = 4.1 Hz, 1H), 7.68 (d, J = 6.4 Hz, 1H), 7.53 (d, J = 9.3 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.34 - 7.23 (m, 4H), 5.26 (d, J = 15.6 Hz, 1H), 4.87 (d, J = 15.5 Hz, 1H), 4.14 (dt, J = 12.2, 7.9 Hz, 2H), 3.15 - 3.06 (m, 1H), 2.76 (s, 1H), 1.35 (s, 9H), 0.75 - 0.65 (m, 2H), 0.54 (d, J = 2.0 Hz, 2H)
LCMS: METCR1673 Generic 2 minutes, rt=1.41分, M/Z (ES-) 518/520 [M-H+] 100% UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) d 8.66 (s, 1H), 7.73 - 7.41 (m, 3H), 7.20 (s, 4H), 5.58 (d, J = 8.2 Hz, 1H), 5.34 (t, J = 14.6 Hz, 1H), 4.79 (dd, J =
15.0, 8.6 Hz, 1H), 4.45 - 4.34 (m, 1H), 4.03 (dt, J = 65.1, 6.7 Hz, 2H), 3.68 (dd, J = 11.0, 6.6 Hz, 1H), 2.98 - 2.85 (m, 1H), 1.73 (h, J = 7.1, 6.5 Hz, 2H), 1.40 (s, 9H), 0.99 (dt, J = 11.7, 7.5 Hz, 3H)
LCMS: METCR1673 Generic 2 minutes, rt=1.47分, M/Z (ES+) 544/546 [M+Na+] 99% UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) d 8.05 (d, J = 7.1 Hz, 1H), 7.34 (d, J = 10.8 Hz, 1H), 7.23 - 7.16 (m, 4H), 6.54 - 6.42 (m, 1H), 5.56 (d, J = 7.7 Hz,
1H), 5.51 (d, J = 15.1 Hz, 1H), 4.64 (d, J = 15.1 Hz, 1H), 4.43 - 4.34 (m, 1H),
4.29 (dt, J = 11.8, 6.5 Hz, 1H), 3.70 (dd, J = 10.9, 6.5 Hz, 1H), 2.92 (t, J = 11.3 Hz, 1H), 1.39 (s, 9H), 1.27 (d, J = 6.6 Hz, 6H)
LCMS: METCR1673 Generic 2 minutes, rt=1.45分, M/Z (ES+) 544/546 [M+Na+] 98% UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) d 1.25 (dd, J = 4.2, 6.5 Hz, 6H), 1.39 (s, 9H), 2.91 (t, J = 11.3 Hz, 1H), 3.68 (dd, J = 6.6, 11.0 Hz, 1H), 4.24 (dp, J = 6.6, 13.2 Hz, 1H), 4.40 (dt, J = 7.5, 11.5 Hz, 1H), 4.77 (d, J = 15.2 Hz, 1H), 5.36 (d, J = 15.2 Hz, 1H), 5.56 (d, J = 8.1 Hz, 1H), 5.94 (d, J = 7.5 Hz, 1H), 6.96 - 7.02 (m, 1H), 7.14 (dd, J = 1.9, 9.8 Hz, 1H), 7.24 (t, J = 7.9 Hz, 1H), 7.46 (dd, J = 1.8, 8.0 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.68 - 7.74 (m, 1H).
LCMS: MET-UPLCMS-A-006, rt=4.08分, M/Z (ES+) 632 [M+H+] 94% UV
NMRデータ: 1H NMR (400 MHz, クロロホルム-d) d 1.39 (s, 9H), 2.91 (t, J = 11.3 Hz, 1H), 3.74 - 3.59 (m, 1H), 3.81 (s, 3H), 4.47 - 4.34 (m, 1H), 4.61 - 4.49 (m, 2H), 4.84(d, J = 15.2 Hz, 1H), 5.37 (d, J = 15.2 Hz, 1H), 6.93 - 6.87 (m, 2H), 7.06 (d, J = 8.0 Hz, 2H), 7.33 -7.23 (m, 6H), 7.47 (dd, J = 8.0, 1.8 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.76 (d, J = 1.7 Hz, 1H).
LCMS:METCR1673 Generic 2 minutes, rt=1.22分, M/Z (ES+)549 [M+Na+], 427 [M+H-boc]
100% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) d 8.56 (t, J = 5.6 Hz, 1H), 7.88 (d, J = 12.0 Hz, 2H), 7.72 (d, J = 8.2 Hz, 2H), 7.66 (s, 2H), 7.45 (d, J = 8.4 Hz, 1H), 7.33 (d, J = 8.2 Hz, 2H), 7.27 (s, 1H), 5.29 (d, J = 15.8 Hz, 1H), 5.01 (d, J = 16.0 Hz, 1H), 4.15 (dt, J = 11.9, 7.8 Hz, 1H), 3.46 (dd, J = 11.3, 6.8 Hz, 1H), 3.24 (dt, J = 13.0, 6.6 Hz, 2H), 3.12 (t, J = 11.8 Hz, 1H), 1.49 (p, J = 7.1 Hz, 2H), 1.34 (s, 9H), 1.31 - 1.25 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H).
LCMS: METCR1673 Generic 2 minutes, rt=1.53分, M/Z (ES+) 554/556 [M+Na+] 100% UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) d 7.66 - 7.58 (m, 2H), 7.49 - 7.43 (m, 1H), 7.22 (s, 4H), 5.74 (t, J = 9.7 Hz, 1H), 5.56 (d, J = 8.0 Hz, 1H), 5.21 (dd, J = 27.0, 15.1 Hz, 1H), 4.98 - 4.86 (m, 1H), 4.41 (s, 1H), 4.10 - 3.97 (m, 1H), 3.70 (dd, J = 10.9, 6.6 Hz, 1H), 2.91 (t, J = 11.3 Hz, 1H), 1.86 - 1.73 (m, 1H), 1.40 (s, 9H), 1.17 (dd, J = 6.7, 1.5 Hz, 3H), 0.99 - 0.90 (m, 6H)
LCMS: METCR1673 Generic 2 minutes, rt=1.44分, M/Z (ES-) 531/533 [M-H+] 95% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.69 (d, J = 1.7 Hz, 1H), 7.64 (d,
J = 8.0 Hz, 1H), 7.48 - 7.41 (m, 1H), 7.21 (s, 4H), 5.55 (d, J = 8.1 Hz, 1H), 5.35 (d, J = 15.2 Hz, 1H), 4.81 (d, J = 15.2 Hz, 1H), 4.41 (dt, J = 11.7, 7.4 Hz, 1H), 3.70 (dd, J = 10.9, 6.6 Hz, 1H), 2.98 - 2.86 (m, 1H), 2.76 (dd, J = 6.8, 1.2 Hz, 2H), 1.81 (tt, J = 13.4, 6.7 Hz, 1H), 1.40 (s, 9H), 0.99 (d, J = 6.7 Hz, 6H). [NH-NHは見えない]
LCMS: METCR1673 Generic 2 minutes, rt=1.5分, M/Z (ES+) 556/558 [M+Na+] 97% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.04 (d, J = 7.1 Hz, 1H), 7.35 (d,
J = 10.9 Hz, 1H), 7.23 - 7.14 (m, 4H), 6.79 (dd, J = 13.3, 7.4 Hz, 1H), 5.56 (d, J = 7.3 Hz, 1H), 5.51 (d, J = 15.1 Hz, 1H), 4.63 (d, J = 15.1 Hz, 1H), 4.61 - 4.50 (m, 1H), 4.43 - 4.33 (m, 1H), 3.70 (dd, J = 10.9, 6.4 Hz, 1H), 2.93 (t, J = 11.2 Hz, 1H), 2.50 - 2.40 (m, 2H), 2.04 - 1.93 (m, 2H), 1.88 - 1.75 (m, 2H), 1.39 (s, 9H)
LCMS: METCR1673 Generic 2 minutes, rt=1.47分, M/Z (ES-) 532/534 [M-H+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.67 (s, 1H), 8.15 (s, 1H), 7.65 (d, J = 6.4 Hz, 1H), 7.51 (d, J = 9.3 Hz, 1H), 7.42 (d, J = 8.3 Hz, 1H), 7.28 (q, J = 8.5 Hz, 3H), 5.24 (d, J = 15.6 Hz, 1H), 4.86 (d, J = 15.6 Hz, 1H), 4.12 (dt, J = 12.1, 7.7 Hz, 1H), 3.47 - 3.45 (m, 1H), 3.12 - 3.07 (m, 1H), 1.39 - 1.26 (m, 12H), 0.76 - 0.69 (m, 2H), 0.63 - 0.58 (m, 2H).
LCMS: METCR1673 Generic 2 minutes, rt=1.32分, M/Z (ES+) 556/558 [M+Na] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d d 7.72 (d, J = 1.8 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.52 (dd, J = 8.0, 1.7 Hz, 1H), 7.21 (s, 4H), 6.47 (t, J = 5.6 Hz, 1H), 5.56 (d, J = 8.2 Hz, 1H), 5.31 (d, J = 15.1 Hz, 1H), 4.85 (d, J = 15.1 Hz, 1H), 4.45 - 4.37 (m, 1H), 3.70 (dd, J = 11.0, 6.6 Hz, 1H), 3.51 - 3.40 (m, 2H), 2.91 (t, J = 11.3 Hz, 1H), 1.89 (s, 1H), 1.40 (s, 9H), 1.29 (s, 6H).
LCMS: METCR1673 Generic 2 minutes, rt=1.46分, M/Z (ES-) 532/534 [M-H+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.53 (s, 1H), 7.73 - 7.37 (m, 3H),
7.20 (s, 4H), 5.56 (d, J = 8.2 Hz, 1H), 5.33 (t, J = 15.8 Hz, 1H), 4.80 (dd, J = 15.0, 7.4 Hz, 1H), 4.46 - 4.34 (m, 1H), 3.85 (dd, J = 61.1, 6.8 Hz, 2H), 3.69 (dd, J = 11.0, 6.6 Hz, 1H), 2.97 - 2.84 (m, 1H), 2.12 - 2.02 (m, 1H), 1.40 (s, 9H), 0.98 (dd, J = 15.8, 6.7 Hz, 6H)
LCMS: METCR1673 Generic 2 minutes, rt=1.43分, M/Z (ES-) 532/534 [M-H+] 94% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 11.08 (s, 1H), 8.13 (s, 1H), 7.79 (s, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.61 (d, J = 7.9 Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 7.30 (s, 3H), 5.19 (d, J = 15.6 Hz, 1H), 4.99 (d, J = 15.6 Hz, 1H), 4.14 (dt, J = 12.3, 7.7 Hz, 1H), 3.47 (dd, J = 11.3, 6.9 Hz, 1H), 3.12 (t, J = 11.8 Hz, 1H), 1.35 (s, 9H), 1.22 (s, 9H).
LCMS: METuPLCAB101 uPLC 7 minutes, rt=4.3分, M/Z (ES+) 558/560 [M+Na+] 100% UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) d 8.06 (d, J = 7.1 Hz, 1H), 7.35 (d, J = 10.9 Hz, 1H), 7.23 - 7.17 (m, 4H), 6.71 - 6.62 (m, 1H), 5.61 - 5.47 (m, 2H),
4.64 (d, J = 15.1 Hz, 1H), 4.39 (dt, J = 13.3, 6.9 Hz, 1H), 3.70 (dd, J = 10.8,
6.5 Hz, 1H), 3.54 - 3.41 (m, 2H), 2.93 (t, J = 11.2 Hz, 1H), 1.61 (dt, J = 15.0, 7.3 Hz, 2H), 1.39 (s, 11H), 0.97 (t, J = 7.4 Hz, 3H).
LCMS: METCR1673 Generic 2 minutes, rt=1.55分, M/Z (ES+) 558/560 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.25 (d, J = 8.2 Hz, 1H), 7.62 (d, J = 6.4 Hz, 1H), 7.54 (d, J = 9.1 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.32 - 7.26 (m, 4H), 5.20 (d, J = 15.7 Hz, 1H), 4.93 (s, 1H), 4.15 (dt, J = 12.1, 7.5 Hz, 1H), 3.86 (dt, J = 14.3, 6.9 Hz, 1H), 3.47 (dd, J = 11.4, 6.9 Hz, 1H), 3.11 (t, J = 11.8 Hz, 1H), 1.50 - 1.43 (m, 2H), 1.35 (s, 9H), 1.11 (d, J = 6.6 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H).
LCMS: METCR1673 Generic 2 minutes, rt=1.58分, M/Z (ES+) 558/560 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.01 (s, 1H), 7.62 (d, J = 6.4 Hz, 1H), 7.51 (d, J = 9.1 Hz, 1H), 7.41 (d, J = 8.3 Hz, 1H), 7.31 - 7.27 (m, 4H), 5.22 (d, J = 15.7 Hz, 1H), 4.90 (d, J = 15.7 Hz, 1H), 4.15 (dt, J = 12.2, 8.1 Hz, 1H), 3.46 (dd, J = 11.4, 6.9 Hz, 1H), 3.10 (t, J = 11.8 Hz, 1H), 1.35 - 1.34 (m, 18H).
LCMS: METCR1673 Generic 2 minutes, rt=1.5分, M/Z (ES+) 560/562 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 1.26 (dd, J = 5.1, 6.5 Hz, 6H), 1.39 (s, 9H), 2.91 (t, J = 11.3 Hz, 1H), 3.68 (dd, J = 6.6, 11.0 Hz, 1H), 4.24 (dp, J = 6.6, 13.1 Hz, 1H), 4.40 (dt, J = 7.5, 11.5 Hz, 1H), 4.75 (d, J = 15.2 Hz, 1H), 5.36 (d, J = 15.2 Hz, 1H), 5.56 (d, J = 8.1 Hz, 1H), 5.94 (d, J = 7.5 Hz, 1H), 7.11 (dd, J = 1.9, 8.3 Hz, 1H), 7.29 (d, J = 8.3 Hz, 1H), 7.42 (d, J = 2.0 Hz, 1H), 7.47 (dd, J = 1.8, 8.0 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.68 - 7.73 (m, 1H).
LCMS: METCR1673 Generic 2 minutes, rt=1.44分, M/Z (ES+) 560/562 [M+Na+] 99% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 9.09 (d, J = 11.6 Hz, 1H), 8.05 (d, J = 6.5 Hz, 1H), 7.37 (d, J = 10.5 Hz, 1H), 7.20 (s, 4H), 5.57 (d, J = 7.7 Hz, 1H), 5.52 (d, J = 15.1 Hz, 1H), 4.65 (d, J = 15.1 Hz, 1H), 4.44 - 4.35 (m, 1H), 4.01 (t, J = 6.7 Hz, 2H), 3.71 (dd, J = 10.9, 6.4 Hz, 1H), 2.94 (t, J = 11.2 Hz, 1H), 1.76 (h, J = 7.2 Hz, 2H), 1.40 (s, 9H), 1.02 (t, J = 7.4 Hz, 3H)
LCMS: METCR1673 Generic 2 minutes, rt=1.32分, M/Z (ES+) 566 [M+Na+] 94% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.67 (t, J = 5.8 Hz, 1H), 7.92 (d, J = 1.4 Hz, 1H), 7.74 - 7.62 (m, 2H), 7.49 (d, J = 8.4 Hz, 1H), 7.29 (dd, J = 8.6, 5.6 Hz, 2H), 7.06 (t, J = 8.9 Hz, 2H), 5.29 (d, J = 15.5 Hz, 1H), 4.92 (d, J = 15.5 Hz, 1H), 4.25 - 4.06 (m, 1H), 3.91 - 3.80 (m, 2H), 3.46 (dd, J = 11.3, 6.9 Hz, 1H), 3.31 - 3.23 (m, 2H), 3.22 - 3.05 (m, 3H), 1.78 (tt, J = 7.6, 4.0 Hz, 1H), 1.58 (d, J = 11.6 Hz, 2H), 1.35 (s, 9H), 1.19 (qd, J = 12.2, 4.5 Hz, 3H).
LCMS: METCR1673 Generic 2 minutes, rt=1.3分, M/Z (ES-) 545 [M-H+] 74% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.93 (s, 1H), 8.37 (s, 1H), 7.78 (d, J = 1.7 Hz, 1H), 7.65 (dd, J = 8.0, 2.9 Hz, 1H), 7.57 - 7.49 (m, 1H), 7.20 (d, J = 2.7 Hz, 4H), 5.56 (d, J = 8.1 Hz, 1H), 5.41 (dd, J = 15.1, 12.2 Hz, 1H), 4.79 - 4.73 (m, 1H), 4.42 (s, 1H), 3.70 (dd, J = 10.9, 6.6 Hz, 1H), 2.92 (q, J = 10.7, 10.2 Hz, 1H), 2.30 (q, J = 7.7 Hz, 2H), 1.79 - 1.71 (m, 2H), 1.39 (s, 9H),
1.01 (t, J = 7.4 Hz, 3H)
LCMS: METCR1673 Generic 2 minutes, rt=1.55分, M/Z (ES-) 546/548 [M-H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.47 (s, 1H), 7.67 (d, J = 6.4 Hz, 1H), 7.52 (d, J = 9.2 Hz, 1H), 7.42 (d, J = 8.4 Hz, 1H), 7.32 - 7.27 (m, 4H), 5.24 (d, J = 15.7 Hz, 1H), 4.89 (d, J = 15.6 Hz, 1H), 4.14 (dt, J = 12.1, 7.7 Hz, 1H), 3.46 (dd, J = 11.3, 6.9 Hz, 1H), 3.11 (t, J = 11.7 Hz, 1H), 2.33 - 2.29 (m, 2H), 2.00 - 1.91 (m, 2H), 1.85 - 1.76 (m, 2H), 1.46 (s, 3H), 1.35 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.58分, M/Z (ES-) 546/548 [M-H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.44 (d, J = 3.9 Hz, 1H), 7.63 (d, J = 6.4 Hz, 1H), 7.54 (d, J = 9.1 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.32 - 7.26 (m, 4H), 5.19 (d, J = 15.7 Hz, 1H), 4.93 (d, J = 15.7 Hz, 1H), 4.16 (dt, J = 12.2, 7.6 Hz, 1H), 3.48 (dd, J = 11.3, 6.9 Hz, 1H), 3.12 (t, J = 11.7 Hz, 1H), 2.55 (dt, J = 8.2, 4.1 Hz, 1H), 1.35 (s, 9H), 1.07 (s, 3H), 0.98 (s, 3H), 0.67 (dd, J = 7.9, 5.2 Hz, 1H), 0.47 (t, J = 4.7 Hz, 1H).
LCMS: METCR1673 Generic 2 minutes, rt=1.49分, M/Z (ES+) 573/575 [M+Na+] 94% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.92 (s, 1H), 7.63 (d, J = 6.3 Hz, 1H), 7.55 (d, J = 9.2 Hz, 1H), 7.46 - 7.42 (m, 1H), 7.32 - 7.27 (m, 4H), 5.22 - 5.10 (m, 2H), 4.92 (d, J = 15.7 Hz, 1H), 4.15 (dt, J = 12.1, 7.7 Hz, 1H), 3.48 (dd, J = 11.4, 6.9 Hz, 1H), 3.11 (t, J = 11.7 Hz, 1H), 2.60 (d, J = 6.4 Hz, 2H), 1.71 (m, 6.7 Hz, 1H), 1.35 (s, 9H), 0.90 (d, J = 6.7 Hz, 6H).
LCMS: METCR1673 Generic 2 minutes, rt=1.3分, M/Z (ES-) 549 [M-H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.22 (s, 1H), 8.58 (t, J = 5.6 Hz, 1H), 8.19 (s, 1H), 7.94 (s, 1H), 7.72 (d, J = 8.5 Hz, 2H), 7.66 (d, J = 8.0 Hz, 2H), 7.45 (t, J = 7.6 Hz, 3H), 5.36 (d, J = 15.8 Hz, 1H), 5.00 (d, J = 15.7 Hz, 1H), 4.15 (dt, J = 12.2, 7.7 Hz, 1H), 3.47 (dd, J = 11.4, 6.8 Hz, 1H), 3.28 - 3.22 (m, 2H), 3.13 (t, J = 11.8 Hz, 1H), 1.50 (m, 2H), 1.35 (s, 9H), 1.32 - 1.28 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H).
LCMS: METCR1673 Generic 2 minutes, rt=1.35分, M/Z (ES+) 574/576 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.96 (s, 1H), 7.96 (d, J = 8.2 Hz, 1H), 7.74 - 7.66 (m, 2H), 7.30 (s, 4H), 7.08 (d, J = 8.0 Hz, 1H), 5.47 - 5.34 (m, 1H), 4.90 (dd, J = 15.7, 3.5 Hz, 1H), 4.41 - 4.33 (m, 1H), 3.87 - 3.78 (m, 1H), 3.46 (s, 1H), 2.06 - 1.93 (m, 1H), 1.67 (s, 1H), 1.39 - 1.25 (m, 12H).
LCMS: METCR1673 Generic 2 minutes, rt=1.36分, M/Z (ES+) 574/576 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.05 (d, J = 7.0 Hz, 1H), 7.37 (d,
J = 10.8 Hz, 1H), 7.20 (s, 4H), 5.56 (s, 1H), 5.50 (d, J = 15.1 Hz, 1H), 4.66 (d, J = 15.1 Hz, 1H), 4.39 (s, 1H), 3.71 (dd, J = 10.8, 6.5 Hz, 1H), 3.58 - 3.43 (m, 2H), 2.93 (t, J = 11.2 Hz, 1H), 1.40 (s, 9H), 1.31 (s, 6H) [2 × NHは見えない]
LCMS: METCR1673 Generic 2 minutes, rt=1.51分, M/Z (ES+) 574/576 [M+Na+] 97% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 9.12 (d, J = 11.8 Hz, 1H), 8.04 (d, J = 6.5 Hz, 1H), 7.36 (d, J = 10.5 Hz, 1H), 7.19 (s, 4H), 5.57 (d, J = 7.8 Hz, 1H), 5.52 (d, J = 15.1 Hz, 1H), 4.63 (d, J = 15.1 Hz, 1H), 4.39 (dt, J = 11.6, 7.1 Hz, 1H), 3.83 (d, J = 6.7 Hz, 2H), 3.70 (dd, J = 10.9, 6.4 Hz, 1H), 2.94 (t, J = 11.2 Hz, 1H), 2.04 (s, 1H), 1.39 (s, 9H), 1.01 (d, J = 6.7 Hz, 6H)
LCMS: MET-UPLCMS-A-006 , rt=4.31分, M/Z (ES+) 653 [M+H+] 99% UV
NMRデータ: 1H NMR (400 MHz, DMSO-d6) d 1.07 (s, 9H), 1.30 (s, 9H), 1.63 (p, J = 6.9 Hz, 2H), 3.13 - 3.03 (m, 3H), 3.28 - 3.18 (m, 2H), 3.45 (dd, J = 11.3, 6.9 Hz, 1H), 4.18 - 4.05 (m, 1H), 4.97 (d, J = 15.8 Hz, 1H), 5.30 (d, J = 15.8 Hz, 1H), 7.22 (d, J = 8.0 Hz, 2H), 7.39 (d, J = 8.7 Hz, 2H), 7.49 (dd, J = 14.6, 7.1 Hz, 2H), 7.72 - 7.64 (m, 2H), 7.93 (s, 1H), 8.64 (t, J = 5.7 Hz, 1H).
NMRデータ: 1H NMR (400 MHz, クロロホルム-d) δ 8.12 (d, J = 7.0 Hz, 1H), 7.40 - 7.28 (m, 8H), 7.08 (d, J = 7.9 Hz, 2H), 7.05 - 6.97 (m, 1H), 5.55 (t, J = 11.5 Hz, 2H), 4.67 (td, J = 14.8, 6.3 Hz, 3H), 4.46 - 4.35 (m, 1H), 3.71 (dd, J =10.8, 6.4 Hz, 1H), 2.94 (t, J = 11.3 Hz, 1H), 1.40 (s, 9H).
LCMS: METCR1416 generic 7minutes, rt=4.89分, M/Z (ES+) 576/578 [M+Na+] 100 % UV
NMRデータ:1H NMR (500 MHz, クロロホルム-d) d 8.09 (d, J = 7.0 Hz, 1H), 7.44 - 7.32 (m, 2H), 7.04 (dd, J = 8.2, 1.6 Hz, 1H), 6.97 (dd, J = 9.6, 2.0 Hz, 1H), 6.73 - 6.59 (m, 1H), 5.54 (d, J = 7.8 Hz, 1H), 5.40 (d, J = 15.3 Hz, 1H), 4.79 (d, J = 15.2 Hz, 1H), 4.43 - 4.34 (m, 1H), 3.68 (dd, J = 11.6, 7.2 Hz, 1H), 3.48 (dq, J = 13.2, 6.5 Hz, 2H), 2.88 (t, J = 11.3 Hz, 1H), 1.62 (p, J = 7.2 Hz, 2H), 1.46 - 1.40 (m, 2H), 1.39 (s, 9H), 0.97 (t, J = 7.4 Hz, 3H).
LCMS: METCR1673 Generic 2 minutes, rt=1.56分, M/Z (ES+) 576/578 [M+Na] 90% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.06 (d, J = 7.0 Hz, 1H), 7.37 (d,
J = 10.8 Hz, 1H), 7.25 - 7.22 (m, 1H), 7.13 (d, J = 9.8 Hz, 1H), 7.02 - 6.96 (m, 1H), 6.72 - 6.63 (m, 1H), 5.54 (d, J = 8.4 Hz, 1H), 5.50 (d, J = 15.3 Hz, 1H), 4.64 (d, J = 15.3 Hz, 1H), 4.46 - 4.34 (m, 1H), 3.78 - 3.63 (m, 1H), 3.54 - 3.38 (m, 2H), 2.94 (t, J = 11.4 Hz, 1H), 1.66 - 1.58 (m, 2H), 1.48 - 1.41 (m, 2H), 1.40 (s, 9H), 0.97 (t, J = 7.3 Hz, 3H).
LCMS: METCR1673 Generic 2 minutes, rt=1.37分, M/Z (ES+) 560/562 [M+H+] 98% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.67 (d, J = 1.8 Hz, 1H), 7.63 (d,
J = 8.0 Hz, 1H), 7.46 (dd, J = 8.0, 1.8 Hz, 1H), 7.21 (s, 4H), 6.07 (t, J = 5.9
Hz, 1H), 5.55 (d, J = 8.1 Hz, 1H), 5.28 (d, J = 15.2 Hz, 1H), 4.86 (d, J = 15.1
Hz, 1H), 4.45 - 4.36 (m, 1H), 4.00 (dd, J = 11.3, 3.2 Hz, 2H), 3.69 (dd, J = 11.0, 6.6 Hz, 1H), 3.46 - 3.27 (m, 4H), 2.91 (t, J = 11.3 Hz, 1H), 1.87 (ddt, J = 11.6, 8.4, 4.2 Hz, 1H), 1.65 (d, J = 12.4 Hz, 2H), 1.40 (s, 11H)
LCMS: METCR1673 Generic 2 minutes, rt=1.4分, M/Z (ES+) 560/562 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.61 (s, 1H), 7.89 (s, 1H), 7.66 (s, 2H),
7.43 (d, J = 8.3 Hz, 1H), 7.27 (s, 4H), 5.27 (d, J = 15.7 Hz, 1H), 4.91 (d, J =
15.6 Hz, 1H), 4.12 (dt, J = 12.3, 8.0 Hz, 1H), 3.76 - 3.69 (m, 3H), 3.26 - 2.92
(m, 4H), 1.76 (d, J = 14.2 Hz, 2H), 1.58 (d, J = 13.5 Hz, 2H), 1.33 (s, 9H), 1.26 (s, 2H).
LCMS: METCR1673 Generic 2 minutes, rt=1.52分, M/Z (ES+) 582/584 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 1.16 - 1.49 (m, 14H), 1.51 - 1.63 (m, 1H), 1.77 (s, 2H), 1.92 - 2.06 (m, 2H), 2.89 (t, J = 11.27 Hz, 1H), 3.52 - 3.76 (m, 1H), 3.84 - 4.15 (m, 1H), 4.28 - 4.47 (m, 1H), 4.63 - 4.88 (m, 1H), 5.31 - 5.45 (m, 1H), 5.51 - 5.80 (m, 1H), 7.13 - 7.23 (m, 4H), 7.42 - 7.95 (m, 3H), 9.73 (s, 1H)
LCMS: METCR1673 Generic 2 minutes, rt=1.48分, M/Z (ES+) 584/586 [M+Na+] 97% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.06 (d, J = 7.0 Hz, 1H), 7.40 (d,
J = 11.0 Hz, 1H), 7.20 (s, 4H), 6.92 (dt, J = 13.3, 6.4 Hz, 1H), 5.63 - 5.44 (m, 2H), 4.65 (d, J = 15.1 Hz, 1H), 4.39 (dt, J = 14.4, 7.2 Hz, 1H), 4.16 (ddt, J = 24.6, 16.9, 8.1 Hz, 2H), 3.71 (dd, J = 10.9, 6.4 Hz, 1H), 2.95 (t, J = 11.2 Hz, 1H), 1.40 (s, 9H).
LCMS: METUPLCMS-A-004, rt=1.46分, M/Z (ES+) 614 [M+H+] 92% UV
NMRデータ: 1H NMR (400 MHz,クロロホルム-d) δ 8.05 (d, J = 7.1 Hz, 1H), 7.38 (d,
J = 10.9 Hz, 1H), 7.31 (d, J = 8.7 Hz, 2H), 7.08 (d, J = 8.0 Hz, 2H), 6.63 - 6.50 (m, 1H), 5.56 (d, J = 8.1 Hz, 1H), 5.51 (d, J = 15.1 Hz, 1H), 4.71 (d, J =15.2 Hz, 1H), 4.37 (d, J = 7.5 Hz, 1H), 4.22 (s, 1H), 4.00 (d, J = 11.7 Hz, 2H), 3.70 (dd, J = 10.8, 6.4 Hz, 1H), 3.54 (ddd, J = 11.7, 9.3, 2.5 Hz, 2H), 2.94 (t, J = 11.2 Hz, 1H), 2.07 - 1.96 (m, 2H), 1.66 - 1.57 (m, 2H),1.40 (s, 9H).
LCMS: METCR1278 Standard 3.5 minute, rt=2.33分, M/Z (ES+) 590 [M+Na+] 96% UV
NMRデータ: 1H NMR (500 MHz, CDCl3) d 1.14 (t, J = 7.4 Hz, 3H), 1.50 - 1.67 (m, 11H), 1.70 - 1.82 (m, 2H), 3.11 (t, J = 11.3 Hz, 1H), 3.57 (p, J = 6.4 Hz, 2H), 3.83 (dd, J = 6.6, 11.0 Hz, 1H), 4.60 (dt, J = 7.7, 11.3 Hz, 1H), 4.95 (d, J = 15.1 Hz, 1H), 5.60 (d, J = 15.1 Hz, 1H), 6.01 (d, J = 8.3 Hz, 1H), 7.06 - 7.16 (m, 1H), 7.25 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.5 Hz, 2H), 7.72 - 7.82 (m, 2H), 7.93 (s, 1H)
LCMS: METCR1673 Generic 2 minutes, rt=1.52分, M/Z (ES+) 592/594 [M + Na+] 88% UVNMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.95 (d, J = 6.5 Hz, 1H), 7.75 (d, J = 6.4 Hz, 1H), 7.57 (d, J = 9.3 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.30 (d, J = 8.5 Hz, 2H), 7.27 (d, J = 8.6 Hz, 2H), 5.27 (d, J = 15.5 Hz, 1H), 4.87 (d, J = 15.6 Hz, 1H), 4.29 - 4.19 (m, 1H), 4.19 - 4.10 (m, 1H), 3.48 (dd, J = 11.3, 6.9 Hz, 1H), 3.12 (t, J = 11.8 Hz, 1H), 3.03 - 2.91 (m, 2H), 2.79 - 2.65 (m, 2H), 1.35 (s, 9H).
LCMS: METCR 1278 Generic 3 minutes, rt=2.26分, M/Z (ES+) 570/572 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.73 (d, J = 1.6 Hz, 1H), 7.62 (d,
J = 8.0 Hz, 1H), 7.48 (dd, J = 8.0, 1.7 Hz, 1H), 7.31 (dd, J = 8.5, 5.4 Hz, 3H), 7.19 (d, J = 3.3 Hz, 5H), 6.32 (s, 1H), 5.55 (d, J = 8.0 Hz, 1H), 5.33 (d, J = 15.1 Hz, 1H), 4.81 (d, J = 15.1 Hz, 1H), 4.59 (dd, J = 8.4, 5.8 Hz, 2H), 3.68 (s, 1H), 2.91 (s, 1H), 1.39 (s, 9H). [NHは見えない]
LCMS: METCR1673 Generic 2 minutes, rt=1.56分, M/Z (ES+) 592/594 [M+Na+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.04 (t, J = 5.8 Hz, 1H), 7.75 (d, J = 6.5 Hz, 1H), 7.58 (d, J = 9.4 Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 7.40 - 7.23 (m, 9H), 5.22 (d, J = 15.7 Hz, 1H), 4.92 (d, J = 15.6 Hz, 1H), 4.55 - 4.39 (m, 2H), 4.17 (dt, J = 12.1, 7.4 Hz, 1H), 3.49 (dd, J = 11.3, 6.9 Hz, 1H), 3.12 (t, J = 11.7 Hz, 1H), 1.41 - 1.25 (m, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.5分, M/Z (ES+) 594/596 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 1.39 (s, 9H), 2.96 (t, J = 11.3 Hz, 1H), 3.70 (dd, J = 6.4, 10.8 Hz, 1H), 4.41 (dt, J = 7.2, 11.7 Hz, 1H), 4.65 (d, J = 15.1 Hz, 1H), 5.48 (d, J = 15.1 Hz, 1H), 5.60 (d, J = 7.8 Hz, 1H), 7.12 - 7.07 (m, 3H), 7.19 (s, 4H), 7.33 (t, J = 8.0 Hz, 2H), 7.41 (d, J = 10.3 Hz, 1H), 8.03 (d, J = 4.9 Hz, 1H), 9.72 (d, J = 9.6 Hz, 1H).
LCMS: METCR1673 Generic 2 minutes, rt=1.61分, M/Z (ES+) 596/598 [M+Na+] 99% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 0.87 - 1.08 (m, 2H), 1.08 - 1.33 (m, 3H), 1.40 (s, 9H), 1.58 - 1.91 (m, 6H), 2.89 (t, J = 11.1 Hz, 1H), 3.53 - 3.71 (m, 1H), 3.71 - 4.00 (m, 2H), 4.27 - 4.48 (m, 1H), 4.55 - 4.87 (m, 1H), 5.30 - 5.50 (m, 1H), 5.50 - 5.83 (m, 1H), 7.06 - 7.24 (m, 4H), 7.38 - 7.81 (m, 3H), 9.71 (s, 1H)
LCMS: METCR1673 Generic 2 minutes, rt=1.55分, M/Z (ES+) 598/600 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.04 (d, J = 7.0 Hz, 1H), 7.37 (d,
J = 10.9 Hz, 1H), 7.20 (s, 4H), 6.96 (s, 1H), 5.68 - 5.44 (m, 2H), 4.65 (d, J =
15.1 Hz, 1H), 4.41 (s, 1H), 3.84 - 3.64 (m, 3H), 2.94 (t, J = 11.3Hz, 1H), 2.49
(ddt, J = 17.0, 10.8, 5.4 Hz, 2H), 1.40 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.54分, M/Z (ES+) 598/600 [M+Na+] 99% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.04 (d, J = 7.0 Hz, 1H), 7.39 (d,
J = 11.0 Hz, 1H), 7.20 (s, 4H), 6.70 (dd, J = 13.4, 9.4 Hz, 1H), 5.64 - 5.39 (m, 2H), 5.12 - 4.77 (m, 1H), 4.65 (d, J = 15.1 Hz, 1H), 4.38 (dt, J= 11.6, 7.2 Hz, 1H), 3.69 (dd, J = 10.9, 6.4 Hz, 1H), 2.95 (t, J = 5.6 Hz, 1H), 1.45 (d, J = 7.0 Hz, 3H), 1.39 (s, 9H)
LCMS: METuPLCAB101 uPLC 7 minute, rt=3.8分, M/Z (ES+) 578/580 [M+H+] 98% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.04 (d, J = 7.1 Hz, 1H), 7.36 (d,
J = 10.9 Hz, 1H), 7.23 - 7.17 (m, 4H), 6.76 (dt, J = 12.7, 5.9 Hz, 1H), 5.61 - 5.47 (m, 2H), 4.65 (d, J = 15.1 Hz, 1H), 4.39 (dt, J = 13.9, 7.1 Hz, 1H), 4.00 (dd, J = 11.4, 3.9 Hz, 2H), 3.70 (dd, J = 10.9, 6.5 Hz, 1H), 3.42 - 3.37 (m, 4H), 2.93 (t, J = 11.3 Hz, 1H), 1.89 (ttt, J = 10.7, 7.1, 3.7 Hz, 1H), 1.71 - 1.63 (m, 2H), 1.44 - 1.33 (m, 11H).
LCMS: METCR1673 Generic 2 minutes, rt=1.78分, M/Z (ES+) 600/602 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.44 (s, 1H), 7.66 (d, J = 6.3 Hz, 1H), 7.54 (d, J = 9.2 Hz, 1H), 7.44 (d, J = 8.3 Hz, 1H), 7.33 - 7.25 (m, 4H), 5.20 (d, J = 15.6 Hz, 1H), 4.91 (d, J = 15.7 Hz, 1H), 4.19 - 4.11 (m, 1H), 3.47 (dd, J = 11.1, 6.9 Hz, 1H), 3.21 (dt, J = 13.6, 7.0 Hz, 2H), 3.11 (t, J = 11.7 Hz, 1H), 1.50 (d, J = 11.2 Hz, 2H), 1.31 (m, 17H), 0.86 (t, J = 6.8 Hz, 3H).
LCMS: METCR1673 Generic 2 minutes, rt=1.6分, M/Z (ES+) 602/604 [M+Na+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.44 (d, J = 7.6 Hz, 1H), 7.93 (s, 1H), 7.74 - 7.65 (m, 2H), 7.45 (d, J = 8.3 Hz, 1H), 7.33 - 7.25 (m, 4H), 5.29 (d, J = 15.6 Hz, 1H), 4.92 (d, J = 15.6 Hz, 1H), 4.12 (dt, J = 12.2, 7.6 Hz, 1H), 3.98 (s, 1H), 3.46 (dd, J = 11.3, 6.8 Hz, 1H), 3.11 (t, J = 11.8 Hz, 1H), 2.03 (d, J = 30.8 Hz, 2H), 1.98 - 1.85 (m, 4H), 1.64 (q, J = 12.3, 11.2 Hz, 2H), 1.35 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.53分, M/Z (ES+) 606/608 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.72 (d, J = 4.0 Hz, 1H), 7.71 (d, J = 6.4 Hz, 1H), 7.57 (d, J = 9.2 Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 7.29 (q, J = 8.5 Hz, 4H), 5.26 (d, J = 14.0 Hz, 1H), 4.89 (d, J = 15.6 Hz, 1H), 4.39 (q, J = 7.5 Hz, 1H), 4.15 (dt, J = 12.1, 8.0 Hz, 1H), 3.48 (dd, J = 11.4, 6.9 Hz, 1H), 3.12 (t, J = 11.8 Hz, 1H), 2.34 - 2.03 (m, 5H), 1.86 - 1.73 (m, 1H), 1.36 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.64分, M/Z (ES+) 584 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.95 (d, J = 7.6 Hz, 1H), 7.96 (s, 0H), 7.75 (t, J = 7.3 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.48 - 7.37 (m, 3H), 7.29 (s, 4H), 7.16 (td, J = 8.9, 2.3 Hz, 2H), 5.28 (dd, J = 15.7, 5.4 Hz, 1H), 5.20 - 5.11 (m, 1H), 4.94 (d, J = 15.7 Hz, 1H), 4.14 (dt, J = 12.2, 7.7 Hz, 1H), 3.46 (dd, J = 11.3, 6.9 Hz, 1H), 3.12 (t, J = 11.8 Hz, 1H), 1.48 (dd, J = 7.0, 2.2 Hz, 3H), 1.35 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.54分, M/Z (ES+)606/608 [M+Na+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.95 (d, J = 7.9 Hz, 1H), 7.95 (d, J = 1.4 Hz, 1H), 7.77 - 7.71 (m, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.48 - 7.38 (m, 3H), 7.29 (s, 4H), 7.15 (t, J = 8.9 Hz, 2H), 5.28 (d, J= 15.6 Hz, 1H), 5.23 - 5.10 (m, 1H), 4.94 (d, J = 15.6 Hz, 1H), 4.20 - 4.06 (m, 1H), 3.46 (dd, J = 11.5, 6.8 Hz, 1H), 3.10 (d, J = 11.7 Hz, 1H), 1.48 (d, J = 7.1 Hz, 3H), 1.35 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.61分, M/Z (ES+) 608/610 [M+Na+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.68 (t, J = 5.5 Hz, 1H), 7.94 (s, 1H), 7.73 - 7.64 (m, 2H), 7.30 (s, 4H), 7.06 (d, J = 8.3 Hz, 1H), 5.40 (d, J = 15.7 Hz, 1H), 4.91 (d, J = 15.7 Hz, 1H), 4.43
- 4.34 (m, 1H), 3.88 - 3.78 (m, 1H), 3.39 - 3.33 (m, 2H), 2.38 - 2.26 (m, 2H), 1.76 (p, J = 7.1 Hz, 2H), 1.38 - 1.27 (m, 12H).
LCMS: METCR1416 Generic 2 minutes, rt=4.91分, M/Z (ES+) 608 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.45 (s, 1H), 7.67 (d, J = 6.4 Hz, 1H), 7.56 (d, J = 9.3 Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 7.40 (d, J = 8.6 Hz, 2H), 7.25 (d, J = 8.2 Hz, 2H), 5.20 (d, J = 15.8 Hz, 1H), 4.98 (d, J =15.9 Hz, 1H), 4.17 (dt, J = 12.0, 7.4 Hz, 1H), 3.49 (dd, J = 11.3, 6.9 Hz, 1H), 3.29 - 3.16 (m, 2H), 3.12 (t, J = 11.7 Hz, 1H), 1.48 (p, J = 7.0 Hz, 2H), 1.40 - 1.21 (m, 11H), 0.89 (t, J = 7.4 Hz, 3H).
LCMS: METuPLCAB101 uPLC 7 minute, rt=4.29分, M/Z (ES+) 588 [M+H+]100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.08 (d, J = 7.1 Hz, 1H), 7.38 - 7.30 (m, 3H), 7.20 (d, J = 1.3 Hz, 4H), 7.08 - 6.95 (m, 3H), 5.60 - 5.50 (m, 2H), 4.70 - 4.57 (m, 3H), 4.39 (dt, J = 11.6, 7.3 Hz, 1H), 3.70 (dd, J = 10.9, 6.5 Hz, 1H), 2.94 (t, J = 11.3 Hz, 1H), 1.40 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.48分, M/Z (ES+) 611/613 [M+Na+] 97% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 1.40 (s, 9H), 2.96 (t, J = 11.3 Hz, 1H), 3.72 (dd, J = 6.4, 10.9 Hz, 1H), 4.41 (dt, J = 7.2, 13.9 Hz, 1H), 4.64 (d, J = 15.1 Hz, 1H), 5.48 (d, J = 15.1 Hz, 1H), 5.58 (d, J = 7.9 Hz, 1H), 6.86 - 6.91 (m, 2H), 6.94 - 7.00 (m, 2H), 7.19 (s, 4H), 7.44 (d, J = 10.6 Hz, 1H), 8.02 (d, J = 6.7 Hz, 1H), 8.41 (d, J = 12.0 Hz, 1H) [NHは見えない].
LCMS: METCR1673 Generic 2 minutes, rt=1.31分, M/Z (ES+) 589 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 10.61 (s, 1H), 8.91 (d, J = 2.3 Hz, 1H), 8.35 (dd, J = 4.7, 1.2 Hz, 1H), 8.18 (d, J = 8.4 Hz, 1H), 8.10 (d, J = 1.5 Hz, 1H), 7.85 (dd, J = 8.0, 1.6 Hz, 1H), 7.78 (d, J = 8.0 Hz,1H), 7.48 (d, J = 8.4 Hz, 1H), 7.43 (dd, J = 8.4, 4.0 Hz, 3H), 7.24 (d, J = 8.2 Hz, 2H), 5.36 (d, J = 15.8 Hz, 1H), 5.02 (d, J = 15.8 Hz, 1H), 4.20 (dt, J = 12.2, 7.7 Hz, 1H), 3.51 (dd, J = 11.3, 6.8 Hz, 1H), 3.19 -3.12 (m, 1H), 1.35 (s, 9H).
LCMS: METuPLCAB101 uPLC 7 minute, rt=4.2分, M/Z (ES+) 590/592 [M+H+] 97% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.04 (d, J = 7.1 Hz, 1H), 7.37 (d,
J = 10.9 Hz, 1H), 7.20 (s, 4H), 6.76 (dt, J = 12.3, 5.9 Hz, 1H), 5.61 - 5.49 (m, 2H), 4.64 (d, J = 15.1 Hz, 1H), 4.39 (dt, J = 13.7, 7.1 Hz, 1H), 3.70 (dd, J = 10.9, 6.5 Hz, 1H), 3.55 (dh, J = 13.4, 6.8 Hz, 2H), 2.94 (t, J = 11.3 Hz, 1H), 2.25 - 2.13 (m, 2H), 1.92 (dt, J = 14.8, 6.9 Hz, 2H), 1.39 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.62分, M/Z (ES-) 594 [M-H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.79 (d, J = 4.1 Hz, 1H), 7.73 (dd, J = 6.4, 2.9 Hz, 1H), 7.55 (d, J = 9.2 Hz, 1H), 7.44 (d, J = 8.2 Hz, 1H), 7.29 (q, J = 8.3 Hz, 7H), 5.27 (d, J = 15.6 Hz, 1H), 4.87 (d, J = 15.6 Hz, 1H), 4.15 (dt, J
= 12.0, 8.1 Hz, 1H), 3.50 - 3.46 (m, 2H), 3.13 (t, J = 11.9 Hz, 1H), 2.11 - 2.07 (m, 1H), 1.35 (s, 9H), 1.19 - 1.11 (m, 2H). [2 × NHは見えない]
LCMS: METCR1416 generic 7min, rt=4.49分, M/Z (ES+) 618/620 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.08 (d, J = 7.1 Hz, 1H), 7.43 - 7.34 (m, 2H), 7.04 (dd, J = 8.2, 1.6 Hz, 1H), 6.97 (dd, J = 9.6, 2.0 Hz, 1H), 6.81 - 6.70 (m, 1H), 5.54 (d, J = 7.8 Hz, 1H), 5.40 (d, J = 15.2 Hz, 1H), 4.79 (d, J = 15.2 Hz, 1H), 4.42 - 4.33 (m, 1H), 4.00 (dd, J = 11.3, 3.9 Hz, 2H), 3.71 - 3.64 (m, 1H), 3.47 - 3.30 (m, 4H), 2.89 (t, J = 11.3 Hz, 1H), 1.95 - 1.84 (m, 1H), 1.71 - 1.64 (m, 2H), 1.42 - 1.36 (m, 11H).
LCMS: METCR1673 Generic 2 minutes, rt=1.42分, M/Z (ES+) 618/620 [M+Na+]100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.05 (d, J = 7.0 Hz, 1H), 7.39 (d,
J = 11.0 Hz, 1H), 7.25 - 7.23 (m, 1H), 7.12 (d, J = 9.8 Hz, 1H), 6.99 (d, J = 6.7 Hz, 1H), 5.54 (d, J = 8.0 Hz, 1H), 5.49 (d, J = 15.3 Hz, 1H), 4.65 (d, J = 15.3 Hz, 1H), 4.00 (dd, J = 11.6, 3.9 Hz, 2H), 3.71 (dd, J = 10.9, 6.5 Hz, 1H), 3.48 - 3.29 (m, 4H), 2.94 (t, J = 11.3 Hz, 1H), 1.96 - 1.83 (m, 1H), 1.67 (d, J = 11.0 Hz, 2H), 1.44 - 1.33 (m, 11H). [2 × NHは見えない]
LCMS: METCR1673 Generic 2 minutes, rt=1.52分, M/Z (ES+) 596/598 [M+H+] 100 % UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.87 (d, J = 8.0 Hz, 1H), 7.94 (d, J = 1.3 Hz, 1H), 7.74 (dd, J = 8.0, 1.5 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.29 (d, J = 7.3 Hz, 6H), 6.89 (d, J = 8.7 Hz, 2H), 5.26 (d, J = 15.6 Hz, 1H), 5.17 - 5.04 (m, 1H), 4.94 (d, J = 15.6 Hz, 1H), 4.13 (dt, J = 12.3, 7.6 Hz, 1H), 3.73 (s, 3H), 3.11 (s, 1H), 1.46 (d, J = 7.0 Hz, 3H), 1.34 (s, 9H), 1.26 (s, 1H). [NHは見えない]
LCMS: METCR1673 Generic 2 minutes, rt=1.61分, M/Z (ES+) 596/598 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.88 (d, J = 8.0 Hz, 2H), 7.94 (s, 1H), 7.78 - 7.71 (m, 1H), 7.68 (d, J = 8.0 Hz, 2H), 7.45 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 Hz, 4H), 6.89 (d, J = 8.7 Hz, 1H), 5.28 (d, J = 15.6 Hz, 1H), 5.12 (q, J = 7.3 Hz, 1H), 4.94 (d, J = 15.6 Hz, 1H), 4.12 (s, 1H), 3.73 (s, 3H), 3.46 (dd, J = 11.3, 6.8 Hz, 1H), 3.11 (t, J = 11.8 Hz, 1H), 1.47 (d, J = 7.0 Hz, 3H), 1.35 (s, 9H).
LCMS: METCR1416 Generic 7 minutes, rt=4.22分, M/Z (ES+) 600/602 [M+Na+] 97% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.09 (d, J = 7.0 Hz, 1H), 7.34 (d,
J = 10.8 Hz, 1H), 7.28 (d, J = 8.6 Hz, 2H, CHCl3より一部不明確), 7.22 - 7.18 (m, 4H), 6.92 - 6.88 (m, 2H), 5.59 - 5.50 (m, 2H), 4.68 - 4.55 (m, 3H), 4.39 (dt, J = 14.4, 7.2 Hz, 1H), 3.81 (s, 3H), 3.70 (dd, J = 10.9, 6.4 Hz, 1H), 2.93 (t, J = 11.3 Hz, 1H), 1.40 (s, 9H).
LCMS: METCR1673 Generic 2 minutes , rt=1.3分, M/Z (ES-) 606 [M-H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.66 (t, J = 5.8 Hz, 1H), 7.94 - 7.82 (m,
3H), 7.68 (s, 2H), 7.52 (d, J = 8.3 Hz, 1H), 7.46 (d, J = 8.3 Hz, 2H), 5.27 (d,
J = 16.0 Hz, 1H), 5.08 (d, J = 15.9 Hz, 1H), 4.23 - 4.09 (m, 1H), 3.82 (dd, J =
11.0, 3.1 Hz, 2H), 3.47 (dd, J = 11.3, 6.8 Hz, 1H), 3.28 - 3.20 (m, 2H), 3.19 -
3.05 (m, 3H), 2.64 (s, 3H), 1.76 (ddd, J = 11.2, 7.4, 4.0 Hz, 1H), 1.56 (d, J =
11.5 Hz, 2H), 1.34 (s, 9H), 1.16 (qd, J = 12.4, 4.6 Hz, 2H).
LCMS: METCR1278 Standard 3.5 minutes, rt=2.15分, M/Z (ES+) 632 [M+Na+] 97% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 1.30 - 1.46 (m, 11H), 1.64 - 1.72 (m, 2H), 1.80 - 1.94 (m, 1H), 2.92 (t, J = 11.3 Hz, 1H), 3.26 - 3.46 (m, 4H), 3.69 (dd, J = 6.6, 10.9 Hz, 1H), 4.00 (dd, J = 3.6, 11.3 Hz, 2H), 4.42 (dt, J = 7.2, 13.8 Hz, 1H), 4.88 (d, J = 15.2 Hz, 1H), 5.34 (d, J = 15.2 Hz, 1H), 5.55 (d, J = 8.0 Hz, 1H), 6.12 (t, J = 5.9 Hz, 1H), 7.08 (d, J = 8.3 Hz, 2H), 7.31 (d, J = 8.5 Hz, 2H), 7.46 (d, J = 7.9 Hz, 1H), 7.64 (d, J = 7.9 Hz, 1H), 7.71 (s, 1H)
LCMS: METCR1673 Generic 2 minutes, rt=1.43分, M/Z (ES+) 642 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.55 (s, 1H), 9.22 (t, J = 5.9 Hz, 1H), 8.01 (d, J = 8.5 Hz, 3H), 7.77 - 7.67 (m, 2H), 7.46 (t, J = 7.1 Hz, 3H), 7.35 (dd, J = 8.4, 5.7 Hz, 2H), 7.14 (t, J = 8.8 Hz, 2H), 5.37 (d, J = 15.8 Hz, 1H), 5.04 (d, J = 15.8 Hz, 1H), 4.46 (q, J = 9.2 Hz, 2H), 4.18 (dt, J = 12.3, 7.8 Hz, 1H), 3.15 (t, J = 11.7 Hz, 2H), 1.36 (s, 9H).
LCMS: METCR1278 Standard 3.5 minute, rt=2.34分, M/Z (ES+) 642 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 1.39 (s, 9H), 2.91 (t, J = 11.3 Hz, 1H), 3.67 (dd, J = 6.6, 11.0 Hz, 1H), 4.40 (dt, J = 7.3, 11.5 Hz, 1H), 4.49 - 4.64 (m, 2H), 4.81 (d, J = 15.2 Hz, 1H), 5.36 (d, J = 15.2 Hz, 1H), 5.57 (d, J = 8.0 Hz, 1H), 6.47 (t, J = 5.00 Hz, 1H), 7.00 - 7.09 (m, 4H), 7.27 - 7.33 (m, 4H), 7.49 (dd, J = 1.7, 8.0 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.72 - 7.77 (m, 1H).
LCMS: METCR1278 Standard 3.5 minute, rt=2.31分, M/Z (ES+) 644 [M+Na+] 96% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 1.40 (s, 9H), 1.90 (p, J = 7.3 Hz,
2H), 2.12 - 2.26 (m, 2H), 2.92 (t, J = 11.3 Hz, 1H), 3.53 (q, J = 6.7 Hz, 2H), 3.70 (dd, J = 6.6, 10.9 Hz, 1H), 4.35 - 4.48 (m, 1H), 4.86 (d, J = 15.2 Hz, 1H),
5.36 (d, J = 15.2 Hz, 1H), 5.55 (d, J = 8.1 Hz, 1H), 6.12 (t, J = 5.8 Hz, 1H), 7.09 (d, J = 8.2 Hz, 2H), 7.31 (d, J = 8.6 Hz, 2H), 7.46 (dd, J = 1.7, 7.9 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 1.4 Hz, 1H)
LCMS: METCR1673 Generic 2 minutes , rt=1.39分, M/Z (ES+) 695/696 [M+H+] 97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.12 (t, J = 5.8 Hz, 1H), 7.97 (s, 1H), 7.79 (s, 1H), 7.76 - 7.70 (m, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 7.29 (s, 4H), 7.23 (d, J = 8.5 Hz, 2H), 6.89 (d, J = 8.6 Hz, 2H), 5.30 (d, J = 15.6 Hz, 1H), 4.92 (d, J = 15.7 Hz, 1H), 4.41 (qd, J = 15.0, 6.1 Hz, 2H), 4.12 (d, J = 7.6 Hz, 1H), 3.93 (t, J = 6.5 Hz, 2H), 3.47 (dd, J = 11.3, 6.8 Hz, 1H), 3.12 (t, J = 11.8 Hz, 1H), 3.03 (q, J =6.5 Hz, 2H), 1.78 (s, 3H), 1.70 (p, J = 6.6 Hz, 2H), 1.47 - 1.30 (m, 13H).
LCMS: METCR1981 Hydrophobic 3 min, rt=2.69分, M/Z (ES+) 726/728 [M+Na+] 92% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.44 (s, 1H), 7.67 (d, J = 6.4 Hz, 1H), 7.55 (d, J = 9.3 Hz, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.35 - 7.24 (m, 4H), 5.21 (d, J = 15.7 Hz, 1H), 4.92 (d, J = 15.7 Hz, 1H), 4.16 (dt, J = 12.1, 7.7 Hz, 1H), 3.48 (dd, J = 11.3, 6.8 Hz, 1H), 3.25 - 3.20 (m, 2H), 3.12 (t, J = 11.8 Hz, 1H), 1.54 - 1.45 (m, 2H), 1.30 (m, 40H), 0.86 (t, J = 6.9 Hz, 3H).
LCMS: METCR1673 Generic 2 minutes, rt=1.52分, M/Z (ES+) 562/564 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.10 (d, J = 7.0 Hz, 1H), 7.49 - 7.34 (m, 2H), 7.05 - 7.01 (m, 2H), 6.51 (dd, J = 12.0, 7.8 Hz, 1H), 5.56 (d, J = 7.8 Hz, 1H), 5.42 (d, J = 15.2 Hz, 1H), 4.81 (d, J = 15.2 Hz, 1H), 4.39 - 4.33 (m, 2H), 3.70 (dd, J = 10.9, 6.5 Hz, 1H), 2.90 (t, J = 11.3 Hz, 1H), 1.41 (s, 9H), 1.30 (d, J = 6.6 Hz, 6H).
LCMS: METCR1673 Generic 2 minutes, rt=1.52分, M/Z (ES+) 594/596 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.70 (d, J = 1.6 Hz, 1H), 7.64 (d,
J = 8.0 Hz, 1H), 7.45 (dd, J = 8.0, 1.6 Hz, 1H), 7.21 (s, 4H), 6.11 (s, 1H), 5.56 (d, J = 7.8 Hz, 1H), 5.36 (d, J = 15.1 Hz, 1H), 4.80 (d, J = 15.1 Hz, 1H), 4.41 (dt, J = 11.4, 7.6 Hz, 1H), 3.69 (dd, J = 10.9, 6.6 Hz, 1H), 3.53 (q, J = 6.7 Hz, 2H), 2.92 (t, J = 11.3 Hz, 1H), 2.27 - 2.09 (m, 2H), 1.96 - 1.84 (m, 2H), 1.40 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.62分, M/Z (ES-) 583/585 [M-H+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 9.19 (s, 1H), 7.92 (s, 1H), 7.78 -
7.64 (m, 2H), 7.23 (s, 4H), 6.84 (s, 1H), 5.61 (d, J = 8.1 Hz, 1H), 5.49 (d, J = 15.2 Hz, 1H), 4.79 (d, J = 15.2 Hz, 1H), 4.52 - 4.41 (m, 1H), 3.76 (dd, J = 10.9, 6.5 Hz, 1H), 2.98 (t, J = 11.3 Hz, 1H), 1.42 (s, 9H), 1.40 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.43分, M/Z (ES+) 627 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.61 (s, 1H), 7.94 - 7.87 (m, 2H),
7.67 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.50 (dd, J = 8.0, 1.8 Hz, 1H), 7.35 (dd, J = 8.6, 5.3 Hz, 2H), 7.11 - 7.05 (m, 2H), 6.39 (t, J = 5.5 Hz, 1H), 5.66 (d, J = 15.3 Hz, 1H), 5.52 (d, J = 8.2 Hz, 1H), 4.78 (d, J = 15.4 Hz, 1H), 4.69 - 4.58 (m, 2H), 4.44 (dt, J = 11.5, 7.5 Hz, 1H), 3.71 (dd, J = 11.0, 6.7 Hz, 1H), 2.92 (t, J = 11.3 Hz, 1H), 1.42 (s, 9H).
LCMS: METUPLCMS-A-004, rt=1.47分, M/Z (ES+) 509 [M+H+] 57% UV
LCMS: METUPLCMS-A-004, rt=1.67分, M/Z (ES+) 518/520 [M+H+] 99% UV
NMRデータ: 1H NMR (400 MHz,クロロホルム-d) δ 7.69 (d, J = 1.8 Hz, 1H), 7.62 (d,
J = 8.0 Hz, 1H), 7.46 (dd, J = 8.0, 1.8 Hz, 1H), 7.22 (d, J = 9.3 Hz, 4H), 6.00
(s, 1H), 5.57 (d, J = 8.1 Hz, 1H), 5.32 (t, J = 9.9 Hz, 1H), 4.82 (d, J = 15.1 Hz, 1H), 4.41 (dt, J = 11.7, 7.3 Hz, 1H), 3.69 (dd, J = 11.0, 6.6 Hz, 1H), 3.52 - 3.34 (m, 2H), 2.91 (t, J = 11.3 Hz, 1H), 1.66 - 1.49 (m, 3H), 1.46 - 1.41 (m, 1H), 1.40 (s, 9H), 0.97 (t, J = 7.3 Hz, 3H).
LCMS: METUPLCMS-A-004, rt=1.76分, M/Z (ES+) 526 [M+H+] 92% UV
NMRデータ: 1H NMR (400 MHz,クロロホルム-d) δ 7.62 (dd, J = 6.1, 5.0 Hz, 2H), 7.50 (dd, J = 7.9, 1.7 Hz, 1H), 7.29 (d, J = 8.5 Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 5.74 (d, J = 7.7 Hz, 1H), 5.59 (d, J = 8.0 Hz, 1H), 5.06 (s, 2H), 4.42 (dt, J = 11.2, 7.4 Hz, 1H), 4.31 - 4.17 (m, 1H), 3.70 (dd, J = 11.0, 6.6 Hz, 1H), 2.92 (t, J = 11.3 Hz, 1H), , 1.40 (s, 9H), 1.27 (s, 9H), 1.24 (d, J = 3.1 Hz, 3H), 1.23 (d, J = 3.1 Hz, 3H).
LCMS METCR1673 Generic 2 minutes, rt=1.52分, M/Z (ES-) 534/536 [M-H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.54 (s, 1H), 7.69 (d, J = 6.5 Hz, 1H), 7.55 (d, J = 9.4 Hz, 1H), 7.44 (d, J = 8.3 Hz, 1H),7.35 - 7.25 (m, 4H), 5.21 (d,
J = 15.7 Hz, 1H), 4.91 (d, J = 15.7 Hz, 1H), 4.16 (dt, J = 12.1,7.2 Hz, 1H), 3.48 (dd, J = 11.3, 6.9 Hz, 1H), 3.17 - 3.12 (m, 3H), 1.35 (s, 9H), 1.05 - 0.95 (m, 1H),0.51 - 0.37 (m, 2H), 0.22 (q, J = 4.9, 4.4 Hz, 2H).
LCMS: METUPLCMS-A-004, rt=1.85分, M/Z (ES+) 540 [M+H+] 99% UV
LCMS: METUPLCMS-A-004., rt=1.7分, M/Z (ES+) 568 [M+H+] 97% UV
NMRデータ: 1H NMR (300 MHz, クロロホルム-d) δ 0.98 (t, J = 7.3 Hz, 3H), 1.41 (s, 9H), 1.69 - 1.54 (m, 3H), 2.93 (t, J = 11.3 Hz, 1H), 3.45 (dd, J = 12.9, 7.0 Hz, 2H), 3.71 (dd, J = 11.0, 6.6 Hz, 1H), 4.44 (dt, J = 11.3, 7.2 Hz, 1H), 4.86 (d, J = 15.2 Hz, 1H), 5.43 (d, J = 15.2 Hz, 1H), 5.59 (d, J = 8.1 Hz, 1H), 6.09 (s, 1H), 7.08 (d, J = 7.9 Hz, 1H), 7.28 - 7.16 (m, 3H), 7.49 (dd, J = 8.0, 1.8 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 1.6 Hz, 1H). [NHは見えない]
LCMS: METUPLCMS-A-004, rt=1.47分, M/Z (ES+) 569 [M+H+] 95% UV
LCMS: METUPLCMS-A-004, rt=1.55分, M/Z (ES+) 572 [M+H+] 92% UV
NMRデータ: 1H NMR (400 MHz, クロロホルム-d) δ 8.06 (d, J = 7.1 Hz, 1H), 7.37 - 7.29 (m, 3H), 7.07 (d, J = 8.0 Hz, 2H), 6.56 - 6.43 (m, 1H), 5.61 - 5.47 (m, 2H), 4.69 (d, J = 15.1 Hz, 1H), 4.44 - 4.24 (m, 2H), 3.70 (dd, J =11.0, 6.5 Hz, 1H), 2.96 - 2.90 (m, 1H), 1.39 (s, 9H), 1.28 (d, J = 6.6 Hz, 6H).
LCMS:METCR1416, generic 7 minutes, rt=3.32分, M/Z (ES+) 484/486 [M+H-boc] 97% UVNMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.98 (d, J = 7.9 Hz, 1H), 8.00 (s, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.41 (dd, J = 8.7, 5.6 Hz, 2H), 7.31 (q, J = 8.6 Hz, 4H), 7.15 (t, J = 8.9 Hz, 2H), 5.37 (d, J = 15.4 Hz, 1H), 5.15 (t, J = 7.3 Hz, 1H), 4.97 (d, J = 15.4 Hz, 1H), 3.99 - 3.89 (m, 1H), 3.62 - 3.56 (m, 1H), 3.18 (t, J = 11.7 Hz, 1H), 1.48 (d, J = 7.0 Hz, 3H), 1.40 (s, 9H). [NHは見えない]
LCMS: METUPLCMS-A-004, rt=1.53分, M/Z (ES+) 596 [M+H+] 80% UV
NMRデータ: 1H NMR (400 MHz, クロロホルム-d) δ 7.70 (d, J = 1.6 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.47 (dd, J = 8.0, 1.8 Hz, 1H), 7.32 (d, J = 8.7 Hz, 2H), 7.09 (d, J = 7.9 Hz, 2H), 5.87 (d, J = 7.9 Hz, 1H), 5.54 (d, J = 8.3 Hz, 1H), 5.42 - 5.27 (m, 2H), 4.88 (d, J = 15.2 Hz, 1H), 4.39 (d, J = 8.1 Hz, 1H), 4.18 (dd, J = 7.8, 3.7 Hz, 1H), 4.01 (d, J = 12.0 Hz, 3H), 3.69 (dd, J = 11.0, 6.7 Hz, 1H), 3.57 - 3.49 (m, 2H), 2.92 (t, J = 11.3 Hz, 1H), 1.99 (d, J = 12.6 Hz, 2H), 1.40 (s, 9H). [NHは見えない]
LCMS: MET-UPLCMS-A-006, rt=4.14分, M/Z (ES+) 602 [M+H+] 92% UV
NMRデータ: 1H NMR (400 MHz, クロロホルム-d) δ 1.39 (s, 9H), 2.91 (t, J = 11.3 Hz, 1H), 3.69 (dd, J = 11.0, 6.6 Hz, 1H), 4.47 - 4.38 (m, 1H), 4.69 - 4.57 (m, 2H), 4.84 (d, J= 15.2 Hz, 1H), 5.38 (d, J = 15.2 Hz, 1H), 5.55 (d, J = 8.1 Hz, 1H), 6.30 (s, 1H), 7.06 (d, J = 8.0 Hz, 2H), 7.41 - 7.28 (m, 7H), 7.49 (dd, J = 8.0, 1.8 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 1.7 Hz, 1H).
LCMS: METCR1673 Generic 2 minutes, rt=1.43分, M/Z (ES+) 629 [M+Na] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 8.59 (s, 1H), 7.90 - 7.83 (m, 2H), 7.66 (d, J = 8.0 Hz, 1H), 7.58 (d, J = 8.1 Hz, 1H), 7.47 (dd, J = 8.0, 1.8 Hz, 1H), 6.23 (t, J = 5.5 Hz, 1H), 5.64 (d, J = 15.4 Hz, 1H), 5.52 (d, J = 8.2 Hz, 1H), 4.76 (d, J = 15.4 Hz, 1H), 4.42 (dt, J = 11.6, 7.5 Hz, 1H), 3.69 (dd, J = 11.0, 6.6 Hz, 1H), 3.55 (q, J = 6.7 Hz, 2H), 2.90 (t, J = 11.3 Hz, 1H), 2.27 - 2.15 (m, 2H), 1.92 (p, J = 7.2 Hz, 2H), 1.40 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.43分, M/Z (ES+) 553 [M+H+] 100% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) δ0.95 (t, J = 7.2 Hz, 3H), 1.26 - 1.49 (m, 11H), 1.60 (dt, J = 7.2, 14.5 Hz, 2H), 2.97 (t, J = 11.2 Hz, 1H), 3.45 (q, J = 6.8 Hz, 2H), 3.76 (dd, J = 6.5, 10.7 Hz, 1H), 4.40 - 4.59 (m, 1H), 5.26 - 5.49 (m, 2H), 5.49 - 5.63 (m, 1H), 6.75 (s, 1H), 7.37 (d, J = 10.6 Hz, 1H), 7.54 (t, J = 7.6 Hz, 1H), 7.64 - 7.78 (m, 2H), 7.80 (d, J = 7.8 Hz, 1H), 8.10 (d, J = 8.2 Hz, 1H), 8.19 (d, J = 8.5 Hz, 1H), 8.32 (d, J = 7.0 Hz, 1H).
LCMS: METCR1673 Generic 2 minutes, rt=1.36分, M/Z (ES+) 602 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ8.16 (d, J = 6.9 Hz, 1H), 7.39 (d,
J = 10.6 Hz, 1H), 6.81 - 6.68 (m, 1H), 5.58 - 5.45 (m, 2H), 5.13 (d, J = 15.2 Hz, 1H), 4.45 - 4.33 (m, 1H), 3.69 (dd, J = 10.9, 6.6 Hz, 1H), 3.63 - 3.51 (m, 2H), 2.86 (t, J = 11.2 Hz, 1H), 2.39 - 2.30 (m, 1H), 2.27 - 2.14 (m, 2H), 1.97 - 1.86 (m, 2H), 1.39 (s, 9H), 1.25 - 1.17 (m, 2H), 1.13 - 1.06 (m, 2H).
LCMS: METCR1410 Generic 1.7 min, rt=1.28分, M/Z (ES+) 641.90 [M+Na+] 97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.94 (d, J = 8.1 Hz, 1H), 7.76 (dd, J = 12.5, 6.4 Hz, 1H), 7.59 (dd, J = 9.3, 2.5 Hz, 1H), 7.55 (s, 1H), 7.45 (t, J = 7.8 Hz, 2H), 7.13 (d, J = 8.6 Hz, 1H), 5.30 (dd, J = 15.5, 9.4Hz, 1H), 4.88 (d, J = 15.5 Hz, 1H), 4.15 (dt, J = 12.1, 7.8 Hz, 1H), 3.83 (s, 3H), 3.49 (dd, J = 11.3, 7.0 Hz, 2H), 3.13 (t, J = 11.8 Hz, 1H), 2.05 - 1.94 (m, 1H), 1.63 (dd, J = 9.3, 5.2 Hz, 1H), 1.35 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.42分, M/Z (ES+) 625.95/627.90 [M+Na+] 83% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.02 (d, J = 7.0 Hz, 1H), 7.35 (d, J = 10.9 Hz, 1H), 7.23 - 7.16 (m, 4H), 6.77 (dt, J = 12.3, 5.8 Hz, 1H), 5.60 (d, J = 6.3 Hz, 1H), 5.56 (d, J = 15.2 Hz, 1H), 4.62 (d, J = 15.2 Hz,1H), 4.49 (t, J = 6.8 Hz, 1H), 3.98 (p, J = 6.6 Hz, 1H), 3.55 (dp, J = 13.8, 6.9 Hz, 2H), 2.25 - 2.13 (m, 2H), 1.91 (dt, J = 14.8, 7.0 Hz, 2H), 1.39 (s, 9H), 1.32 (d, J = 6.8 Hz, 3H).
LCMS: METCR1410 Generic 1.7 min, rt=1.27分, M/Z (ES+) 642 [M+Na+] 99% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.85 (d, J = 8.0 Hz, 2H), 7.66 (s,
1H), 7.54 (d, J = 8.0 Hz, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.31 (d, J = 8.0 Hz, 2H), 6.49 (s, 1H), 5.56 (s, 1H), 5.38 (d, J = 15.2 Hz, 1H), 4.79 (d,J = 15.2 Hz, 1H), 4.35 (dt, J = 14.0, 7.6 Hz, 1H), 3.61 (dd, J = 10.3, 7.0 Hz, 1H), 3.41 (d, J = 5.9 Hz, 2H), 2.55 (s, 3H), 2.18 - 2.02 (m, 2H), 1.80 (p, J = 7.2 Hz, 2H), 1.33 (s, 9H). [NHは見えない]
LCMS: METCR1410 Generic 1.7 min, rt=1.25分, M/Z (ES+) 559.90/561.90 [M+Na+], 482.35/483.95 [M-tBu+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.51 (s, 1H), 7.70 (d, J = 6.5 Hz, 1H), 7.56 (d, J = 9.4 Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 7.37 - 7.24 (m, 4H), 5.21 (d, J = 15.6 Hz, 1H), 4.91 (d, J = 15.7 Hz, 1H), 4.16 (dt, J = 12.2, 7.6 Hz, 1H), 3.52 - 3.37 (m, 5H), 3.27 (s, 3H), 3.12 (t, J = 11.7 Hz, 1H), 1.36 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.21分, M/Z (ES+) 608 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.92 (dd, J = 8.3, 1.6 Hz, 2H), 7.72 (dd, J = 6.8, 1.5 Hz, 1H), 7.62 (dd, J = 8.0, 2.3 Hz, 1H), 7.51 - 7.42 (m, 1H), 7.38 (d, J = 7.6 Hz, 2H), 6.47 - 6.34 (m, 1H), 5.66 - 5.57 (m, 1H), 5.45 (dd, J = 15.2, 2.4 Hz, 1H), 4.88 (dd, J = 15.2, 6.1 Hz, 1H), 4.42 (dt, J = 11.5, 7.5 Hz, 1H), 3.68 (ddd, J = 10.3, 6.5, 2.9 Hz, 1H), 3.48 (d, J = 5.0 Hz, 1H), 2.94 (t, J = 11.3 Hz, 1H), 2.62 (s, 3H), 1.89 (ddd, J = 12.9, 6.5, 3.3 Hz, 1H), 1.39 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.18分, M/Z (ES+) 490.95 [M-tBu+H+] 96% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.94 (d, J = 11.2 Hz, 1H), 7.77 - 7.68 (m, 3H), 7.61 (d, J = 9.2 Hz, 1H), 7.48 (d, J = 7.9 Hz, 3H), 5.29 (dd, J = 16.1, 7.3 Hz, 1H), 5.03 (d, J = 16.2 Hz, 1H), 4.18 (dt, J = 12.1, 7.5 Hz, 1H), 3.51 (dd, J = 11.2, 6.8 Hz, 2H), 3.14 (t, J = 11.7 Hz, 1H), 2.06 - 1.90 (m, 1H), 1.70 - 1.55 (m, 1H), 1.35 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.23分, M/Z (ES+) 524.95 [M-tBu+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.59 (t, J = 5.5 Hz, 1H), 7.74 (d, J = 8.3 Hz, 2H), 7.71 (d, J = 6.4 Hz, 1H), 7.59 (d, J = 9.3 Hz, 1H), 7.48 (d, J = 8.2 Hz, 3H), 5.28 (d, J = 16.3 Hz, 1H), 5.04 (d, J = 16.3 Hz, 1H), 4.18 (dt, J = 12.3, 7.8 Hz, 1H), 3.50 (dd, J = 11.3, 6.9 Hz, 1H), 3.38 - 3.33 (m, 2H), 3.14 (t, J = 11.7 Hz, 1H), 2.36 - 2.24 (m, 2H), 1.73 (dt, J = 14.8, 7.0 Hz, 2H), 1.36 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.34分, M/Z (ES+) 620.10/622.10 [M+Na+] 100%
UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.48 (d, J = 7.5 Hz, 1H), 7.68 (d, J = 6.4 Hz, 1H), 7.56 (d, J = 9.2 Hz, 1H), 7.44 (d, J = 8.3 Hz, 1H), 7.34 - 7.25 (m, 4H), 5.24 (d, J = 15.7 Hz, 1H), 4.90(d, J = 15.6 Hz, 1H), 4.16 (dt, J = 12.2, 8.1 Hz, 1H), 3.96 (s, 1H), 3.48 (dd, J = 11.4, 6.9 Hz, 1H), 3.12 (t, J = 11.8 Hz, 1H), 2.10 - 1.83 (m, 6H), 1.61 (s, 2H), 1.36 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.34分, M/Z (ES+) 610/612 [M+Na+] 86% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.82 (t, J = 4.1 Hz, 1H), 7.77 (dd, J = 6.4, 2.5 Hz, 1H), 7.57 (d, J = 9.4 Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 7.32 - 7.26 (m, 4H), 5.33 - 5.27 (m, 1H), 4.85 (d, J = 15.6 Hz, 1H), 4.15 (dt, J = 12.1, 7.8 Hz, 1H), 3.53 - 3.45 (m, 1H), 3.24 - 3.17 (m, 1H), 3.12 (t, J = 11.7 Hz, 1H), 2.15 - 2.01 (m, 1H), 1.36 (s, 9H), 1.31 - 1.28 (m, 1H), 0.89 - 0.86 (m, 1H).
LCMS: METCR1410 Generic 1.7 min, rt=1.29分, M/Z (ES+) 518.45 [M-tBu+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.04 (d, J = 7.1 Hz, 1H), 7.36 (d,
J = 10.9 Hz, 1H), 7.23 (dd, J = 8.6, 5.4 Hz, 2H), 6.91 (t, J = 8.7 Hz, 2H), 6.82 - 6.70 (m, 1H), 5.58 (d, J = 8.0 Hz, 1H), 5.50 (d, J = 14.9 Hz, 1H), 4.65 (d, J = 15.0 Hz, 1H), 4.38 (ddd, J = 19.4, 12.9, 6.8 Hz, 1H), 3.70 (dd, J = 10.8, 6.5 Hz, 1H), 3.56 (dp, J = 14.0, 6.8 Hz, 2H), 2.93 (t, J = 11.2 Hz, 1H), 2.27 - 2.14 (m, 2H), 1.92 (dt, J = 14.6, 7.0 Hz, 2H),1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.23分, M/Z (ES+) 484.40 [M-tBu+H+] 98% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.05 (dd, J = 7.0, 4.5 Hz, 1H), 7.37 (d, J = 10.9 Hz, 1H), 7.23 (dd, J = 8.0, 5.5 Hz, 2H), 6.91 (td, J = 8.7, 2.3 Hz, 3H), 5.57 (d, J = 6.4 Hz, 1H), 5.50 (dd, J = 15.0, 7.3 Hz, 1H), 4.66 (dd, J = 15.0, 5.9 Hz, 1H), 4.45 - 4.31 (m, 1H), 3.79 - 3.64 (m, 1H), 3.56 (s, 1H), 2.94 (t, J = 11.2 Hz, 1H), 1.92 (ddd, J = 13.6, 9.7, 7.0 Hz, 1H), 1.48 (dt, J = 14.5, 4.8 Hz, 1H), 1.43 - 1.33 (m, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.29分, M/Z (ES+) 464.45 [M-tBu+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 8.06 (d, J = 7.1 Hz, 1H), 7.34 (d, J = 10.9 Hz, 1H), 7.25 - 7.20 (m, 2H), 6.90 (t, J = 8.7 Hz, 2H), 6.74 - 6.60 (m, 1H), 5.58 (d, J = 7.8 Hz, 1H), 5.51 (d, J = 14.9 Hz, 1H), 4.64 (d, J = 15.0 Hz, 1H), 4.38 (dt, J = 11.6, 7.1 Hz, 1H), 3.69 (dd, J = 10.9, 6.5 Hz, 1H), 3.48 (m, 2H), 2.92 (t, J = 11.2 Hz, 1H), 1.65 - 1.57 (m, 2H), 1.43 (dd, J = 15.1, 7.5 Hz, 2H),1.39 (s, 9H), 0.97 (t, J = 7.4 Hz, 3H).
LCMS: METCR1410 Generic 1.7 min, rt=1.35分, M/Z (ES+) 498.15 [M-tBu+H+] 100% UVNMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 8.10 (d, J = 7.1 Hz, 1H), 7.38 (d, J = 7.4 Hz, 1H), 7.37 - 7.33 (m, 4H), 7.33 - 7.29 (m, 1H), 7.25 - 7.21 (m, 2H), 7.00 (dt, 1H), 6.94 - 6.85 (m, 2H), 5.59 (d, J = 7.8 Hz, 1H), 5.52 (d, J = 15.0 Hz, 1H), 4.74 - 4.66 (m, 2H), 4.66 - 4.61 (m, 1H), 4.39 (dt, J = 11.6, 7.2 Hz, 1H), 3.70 (dd, J = 10.9, 6.5 Hz, 1H), 2.93 (t, J = 11.3 Hz, 1H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.27分, M/Z (ES+) 614.15/616.20 [M+Na+] 99%
UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.47 (s, 1H), 7.68 (d, J = 6.4 Hz, 1H), 7.56 (d, J = 9.3 Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 7.34 - 7.26 (m, 5H), 5.22 (d, J = 15.7 Hz, 1H), 4.92 (d, J = 15.7 Hz, 1H), 4.16 (dt, J = 12.1, 7.7 Hz, 1H), 3.83 (dd, J = 10.3, 4.2 Hz, 3H), 3.48 (dd, J = 11.3, 6.9 Hz, 1H), 3.12 (t, J = 11.8 Hz, 1H), 1.63 - 1.51 (m, 4H), 1.45 (q, J = 7.1 Hz, 2H), 1.36 (s, 9H), 1.16 (m, 3H).
LCMS: METCR1410 Generic 1.7 min, rt=1.26分, M/Z (ES+) 500.10 [M-tBu+H+], 578.15[M+Na+] 99% UV; NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.58 (d, J = 5.2 Hz, 1H), 7.71 (d, J = 6.4 Hz, 1H), 7.56 (d, J = 9.4 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.30 - 7.19 (m, 5H), 5.21 (d, J = 15.7 Hz, 1H), 4.94 (d, J = 15.7 Hz, 1H), 4.18 (dt, J = 12.2, 7.5 Hz, 1H), 3.49 (dd, J = 11.3, 6.9 Hz, 1H), 3.30 (s, 2H), 3.14 (t, J = 11.7 Hz, 1H), 2.33 - 2.25 (m, 2H), 1.76 - 1.69 (m, 2H), 1.36 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.39分, M/Z (ES+) 544.10/546.15 [M-tBu+H+] 96% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 8.15 (d, J = 7.1 Hz, 1H), 7.40 (d,
J = 10.9 Hz, 1H), 7.36 - 7.32 (m, 6H), 7.05 - 6.88 (m, 3H), 5.68 - 5.53 (m, 2H), 4.76 - 4.63 (m, 3H), 4.53 - 4.37 (m, 1H), 3.87 (s, 3H), 3.76 (dd, J = 10.9, 6.7 Hz, 1H), 2.99 (t, J = 11.3 Hz, 1H), 1.46 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.19分, M/Z (ES+) 546.1[M-tBu+H+], 602.5 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.19 (d, J = 6.9 Hz, 1H), 7.37 (d,
J = 10.6 Hz, 1H), 7.35 - 7.29 (m, 2H), 7.07 - 7.01 (m, 2H), 7.02 - 6.94 (m, 1H), 5.59 - 5.44 (m, 2H), 5.12 (d, J = 15.3 Hz, 1H), 4.67 - 4.58 (m, 2H), 4.39 (dt, J = 11.3, 7.3 Hz, 1H), 3.68 (dd, J = 11.0, 6.7 Hz, 1H), 2.86 (t, J = 11.3 Hz, 1H), 2.37 - 2.30 (m, 1H), 1.39 (s, 9H), 1.22 - 1.17 (m, 2H), 1.11 -1.06 (m, 2H).
LCMS: METCR1410 Generic 1.7 min, rt=1.18分, M/Z (ES+) 584 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.04 (d, J = 7.1 Hz, 1H), 7.35 (d,
J = 10.9 Hz, 1H), 7.26 - 7.20 (m, 2H), 6.94 - 6.87 (m, 2H), 6.81 - 6.70 (m, 1H), 5.58 (d, J = 7.8 Hz, 1H), 5.49 (d, J = 15.0 Hz, 1H), 4.65 (d, J = 15.0 Hz, 1H), 4.43 - 4.34 (m, 1H), 4.00 (dd, J = 11.3, 3.9 Hz, 2H), 3.69 (dd, J = 10.9, 6.5 Hz, 1H), 3.47 - 3.30 (m, 4H), 2.93 (t, J = 11.2 Hz, 1H), 1.89 (ttt, J = 10.8, 7.1, 3.8 Hz, 1H), 1.71 - 1.63 (m, 2H), 1.43 - 1.33 (m, 11H).
LCMS: METCR1410 Generic 1.7 min, rt=1.24分, M/Z (ES+) 576 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.02 (d, J = 7.1 Hz, 1H), 7.36 (d,
J = 10.9 Hz, 1H), 7.25 - 7.18 (m, 2H), 6.94 - 6.83 (m, 3H), 5.59 (d, J = 7.9 Hz, 1H), 5.50 (d, J = 15.0 Hz, 1H), 4.64 (d, J = 15.0 Hz, 1H), 4.50 - 4.41 (m, 1H), 4.41 - 4.32 (m, 1H), 3.69 (dd, J = 10.9, 6.4 Hz, 1H), 3.18 - 3.03 (m, 2H), 2.93 (t, J = 11.3 Hz, 1H), 2.66 - 2.53 (m, 2H), 1.39 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.26分, M/Z (ES+) 608.1 [M+Na+], 530.1 [M-tBu+H+] 99% UV; NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.58 (t, J = 5.5 Hz, 1H), 7.74 (d, J = 6.5 Hz, 1H), 7.54 (d, J = 9.3 Hz, 1H), 7.41 (d, J = 8.4 Hz, 1H), 7.16 (d, J = 8.6 Hz, 2H), 6.78 (d, J = 8.6 Hz, 2H), 5.23 (d, J = 15.3 Hz, 1H), 4.79 (d, J = 15.3 Hz, 1H), 4.15 (dt, J = 12.1, 8.1 Hz, 1H), 3.69 (s, 3H), 3.47 (dd, J = 11.3, 6.9 Hz, 1H), 3.12 (t, J = 11.7 Hz, 1H), 2.39 - 2.24 (m, 2H), 1.74 (p, J = 7.0 Hz, 2H), 1.36 (s, 9H), 1.32 - 1.23 (m, 2H).
LCMS: METCR1410 Generic 1.7 min, rt=1.16分, M/Z (ES+) 596.2 [M+Na+], 518.1 [M-tBu+H+] 96% UV; NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.50 (t, J = 5.7 Hz, 1H), 7.66 (d, J = 6.4 Hz, 1H), 7.52 (d, J = 9.2 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.16 (d, J = 8.5 Hz, 2H), 6.78 (d, J = 8.6 Hz, 2H), 5.15 (d, J = 15.3 Hz, 1H), 4.83 (d, J = 15.3 Hz, 1H), 4.14 (dt, J = 12.1, 7.6 Hz, 1H), 3.88 - 3.80 (m, 2H), 3.69 (s, 3H), 3.46 (dd, J = 11.3, 6.9 Hz, 1H), 3.26 (t, J = 10.8 Hz, 2H), 3.16 - 3.07 (m, 3H), 1.80 - 1.68 (m, 1H), 1.57 (d, J = 12.8 Hz, 2H), 1.35 (s, 9H), 1.23 - 1.12 (m, 2H).
LCMS: METCR1410 Generic 1.7 min, rt=1.2分, M/Z (ES+) 574.1 [M+Na+], 496.05 [M-tBu+H+] 93% UV; NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.93 (d, J = 8.8 Hz, 1H), 7.74 (dd, J = 9.7, 6.5 Hz, 1H), 7.56 (dd, J = 9.3, 2.0 Hz, 1H), 7.41 (d, J = 8.4 Hz, 1H), 7.16 (d, J = 7.5 Hz, 2H), 6.78 (d, J = 7.6 Hz, 2H), 5.23 (dd, J = 15.2, 8.7 Hz, 1H), 4.79 (d, J = 15.3 Hz, 1H), 4.14 (dt, J = 12.1, 7.7 Hz, 1H), 3.69 (s, 3H), 3.47 (dd, J = 11.1, 6.9 Hz, 2H), 2.01 - 1.93 (m, 1H), 1.68 - 1.55 (m, 1H), 1.36 (s, 9H), 1.18 (t, J = 7.1 Hz, 1H).
LCMS: METCR1410 Generic 1.7 min, rt=1.26分, M/Z (ES+) 586.15/588.20 [M+Na+] 100%
UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 8.03 (d, J = 7.0 Hz, 1H), 7.36 (d,
J = 10.9 Hz, 1H), 7.20 (s, 4H), 6.58 (s, 1H), 5.49 (d, J = 15.0 Hz, 2H), 4.66 (d, J = 15.1 Hz, 1H), 4.29 (m, 2H), 4.00 (d, J = 11.8 Hz, 2H), 3.70 (dd, J = 10.9, 6.5 Hz, 1H), 3.54 (t, J = 11.6 Hz, 2H), 2.93 (t, J = 11.2 Hz, 1H), 2.02 (d, J = 12.0 Hz, 3H), 1.39 (s, 10H).
LCMS: METCR1410 Generic 1.7 min, rt=1.28分, M/Z (ES+) 496.10/498.20 [M-tBu+H+], 574.15/576.20 [M+Na+] 97% UV; NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.69
(s, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.50 (dd, J = 8.0, 1.7 Hz, 1H), 7.23 (s, 4H), 6.39 (d, J = 6.4 Hz, 1H), 5.62 (d, J = 8.1 Hz, 1H), 5.45 - 4.76 (m, 2H), 4.42 (dt, J = 14.8, 7.3 Hz, 2H), 3.70 (dd, J = 11.0, 6.6 Hz, 1H), 3.21 - 3.03 (m, 2H), 2.94 (t, J = 11.3 Hz, 1H), 2.60 (m, 2H), 1.42 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.32分, M/Z (ES+) 606.15/608.15 [M+Na+] 99%
UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.02 (d, J = 7.1 Hz, 1H), 7.36 (d,
J = 10.9 Hz, 1H), 7.20 (s, 4H), 6.80 (dd, J = 13.1, 7.3 Hz, 1H), 5.56 (d, J = 7.8 Hz, 1H), 5.50 (d, J = 15.1 Hz, 1H), 4.69 - 4.60 (m, 2H), 4.38 (dt, J = 11.6, 7.2 Hz, 1H), 3.69 (dd, J = 10.9, 6.5 Hz, 1H), 2.94 (t, J = 11.3 Hz, 1H), 2.61 (m, 1H), 2.41 - 2.24 (m, 2H), 2.23 - 2.05 (m, 2H), 1.88 - 1.78(m, 1H), 1.39 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.2分, M/Z (ES+) 542.1/ 544.1 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 7.74 (d, J = 1.6 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.50 (dd, J = 8.0, 1.7 Hz, 1H), 7.23 (s, 4H), 6.26 (d, J = 3.5 Hz, 1H), 5.58 (d, J = 7.9 Hz, 1H), 5.36 (d, J = 15.1 Hz, 1H), 4.90 - 4.80 (m, 1H), 4.77 - 4.68 (m, 1H), 4.42 (dt, J = 11.7, 7.3 Hz, 1H), 3.74 - 3.69 (m, 1H), 3.16 - 3.02 (m, 1H), 1.42 (s, 9H), 1.36 - 1.20 (m, 2H), 1.14 - 0.98 (m, 1H).
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.66 (d, J = 9.2 Hz, 2H), 7.55 (dd
, J = 8.0, 1.6 Hz, 1H), 7.50 (t, J = 7.6 Hz, 1H), 7.24 (q, J = 5.9 Hz, 1H), 7.09
(t, J = 7.3 Hz, 1H), 7.02 - 6.90 (m, 1H), 6.30 (d, J = 6.6 Hz,1H), 5.59 (d, J =
8.1 Hz, 1H), 5.33 (d, J = 15.2 Hz, 1H), 5.05 (d, J = 15.2 Hz, 1H), 4.43 (dd, J = 19.5, 7.6 Hz, 2H), 3.71 (dd, J = 10.9, 6.6 Hz, 1H), 3.28 - 3.00 (m, 2H), 2.94 (m, 1H), 2.77 - 2.50 (m, 2H), 1.42 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.21分, M/Z (ES+) 570.15 [M+Na+] 96% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.65 (d, J = 7.9 Hz, 1H), 7.55 (d,
J = 1.7 Hz, 1H), 7.50 (dd, J = 8.0, 1.7 Hz, 1H), 7.17 (t, J = 7.9 Hz, 1H), 6.89
- 6.82 (m, 2H), 6.78 (dd, J = 8.2, 2.3 Hz, 1H), 6.17 (d, J =6.5 Hz, 1H), 5.59 (d, J = 7.9 Hz, 1H), 5.16 - 4.98 (m, 2H), 4.50 - 4.31 (m, 2H), 3.75 (s, 3H), 3.74 - 3.65 (m, 1H), 3.08 (m, 2H), 2.67 - 2.42 (m, 2H), 1.40 (s, 9H), 1.31 - 1.27 (m, 1H).
LCMS: METCR1410 Generic 1.7 min, rt=1.28分, M/Z (ES+) 512.1 [M-tBu+H+], 590.1 [M+Na]+ 93% UV; NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.67 - 7.56 (m, 2H), 7.48 (dd, J = 8.1, 1.5 Hz, 1H), 7.17 (d, J = 8.6 Hz, 2H), 6.75 (d, J = 8.5 Hz, 2H), 6.24 (t, J = 5.6 Hz, 1H), 5.63 (d, J = 8.2 Hz, 1H), 5.22 (d, J = 14.8 Hz, 1H), 4.84 (d, J = 14.8 Hz, 1H), 4.47 - 4.28 (m, 1H), 3.74 (s, 3H), 3.67 (dd, J = 11.0, 6.6 Hz, 1H), 3.49 (q, J = 6.8 Hz, 2H), 2.90 (t, J = 11.2 Hz, 1H), 2.30 - 2.09 (m, 2H), 1.88 (dt, J = 14.5, 7.2 Hz, 2H), 1.39 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.23分, M/Z (ES+) 600.25 [M+Na]+ 98% UV
LCMS: METCR1410 Generic 1.7 min, rt=1.24分, M/Z (ES+) 492.1 [M-tBu+H+] 98% UV;
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.65 - 7.56 (m, 2H), 7.49 (dd, J =
8.0, 1.7 Hz, 1H), 7.31 - 7.14 (m, 7H), 6.90 (d, J = 8.6 Hz, 2H), 6.20 - 6.08 (m, 1H), 5.58 (d, J = 8.0 Hz, 1H), 5.26 - 5.12 (m, 1H), 5.05 - 4.89 (m, 1H), 4.52 (d, J = 5.8 Hz, 2H), 4.49 - 4.32 (m, 1H), 3.82 (s, 3H), 3.69 (dd, J = 10.9, 6.6 Hz, 1H), 2.91 (t, J = 11.2 Hz, 1H), 1.39 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.3分, M/Z (ES+) 526.20 [M-tBu+H+], 604.30 [M+Na+] 89% UV; NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.11 (t, J = 5.7 Hz, 1H), 7.97 (d, J = 1.4 Hz, 1H), 7.73 (dd, J = 8.0, 1.6 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.44 (d, J = 8.3 Hz, 1H), 7.28 (s, 4H), 7.24 (d, J = 8.6 Hz, 2H), 6.89 (d, J = 8.6 Hz, 2H), 5.29 (d, J = 15.6 Hz, 1H), 4.91 (d, J = 15.6 Hz, 1H), 4.41 (ddt, J = 20.6, 14.8, 6.6 Hz, 2H), 4.13 (dt, J = 12.1, 8.0 Hz, 1H), 3.73 (s, 3H), 3.46 (dd, J = 11.3, 6.9 Hz, 1H), 3.11 (t, J = 11.8 Hz, 1H), 1.34 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.24分, M/Z (ES+) 520.15 [M-tBu+H+], 598.20 [M+Na+] 97% UV; NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.43 (d, J = 7.7 Hz, 1H), 7.96 (d, J = 1.4 Hz, 1H), 7.73 - 7.63 (m, 2H), 7.41 (d, J = 8.5 Hz, 1H), 7.16 (d, J = 8.6 Hz, 2H), 6.77 (d, J = 8.7 Hz, 2H), 5.30 (d, J = 15.2 Hz, 1H), 4.81 (d, J= 15.2 Hz, 1H), 4.12 (dt, J = 12.2, 8.2 Hz, 1H), 4.04 - 3.93 (m, 1H), 3.68 (s, 3H), 3.44 (dd, J = 11.3, 6.8 Hz, 1H), 3.11 (t, J = 11.8 Hz, 1H), 2.08 (d, J = 14.2 Hz, 3H), 1.90 (d, J = 12.7 Hz, 3H), 1.66 (t, J = 11.3 Hz, 2H), 1.35 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.27分, M/Z (ES+) 580.10/582.15 [M+Na+] 96% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.85 (t, J = 5.6 Hz, 1H), 7.92 (s, 1H), 7.73 - 7.66 (m, 2H), 7.46 (d, J = 8.3 Hz, 1H), 7.32 - 7.26 (m, 4H), 5.30 (d, J = 15.7 Hz, 1H), 4.91 (d, J = 15.7 Hz, 1H), 4.13 (dt, J = 12.2, 7.5 Hz, 1H), 3.48 (
ddd, J = 15.3, 11.5, 6.3 Hz, 3H), 3.12 (t, J = 11.8 Hz, 1H), 2.57 (dd, J = 11.4,
6.8 Hz, 2H), 1.35 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.17分, M/Z (ES+) 476.05/478.10 [M-tBu+H+], 554.10/556.15 [M+Na+] 94% UV; NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.68 (d, J = 1.7 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.48 (dd, J = 8.0, 1.9 Hz, 1H), 7.21 (s, 4H), 6.24 (d, J = 7.5 Hz, 1H), 5.56 (d, J = 7.9 Hz, 1H), 5.34 (d, J = 15.1 Hz, 1H), 4.81 (d, J = 15.0 Hz, 1H), 4.76 - 4.61 (m, 1H), 4.48 - 4.30 (m, 1H), 4.06 - 3.94 (m, 1H), 3.94 - 3.74 (m, 3H), 3.68 (dd, J = 11.0, 6.6 Hz, 1H), 2.91 (t, J = 11.3 Hz, 1H), 2.46 - 2.27 (m, 1H), 1.98 - 1.80 (m, 1H), 1.39 (s, 9H).
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.68 - 7.49 (m, 2H), 7.39 (d, J = 8.0 Hz, 1H), 7.14 (s, 4H), 6.21 (s, 1H), 5.49 (d, J = 8.1 Hz, 1H), 5.26 (d, J = 15.0 Hz, 1H), 4.76 (d, J = 15.1 Hz, 1H), 4.32 (s, 1H), 3.95 - 3.50 (m, 5H), 3.41
(q, J = 6.2 Hz, 2H), 2.85 (t, J = 11.3 Hz, 1H), 2.53 (s, 1H), 2.05 (m, 1H), 1.61 (td, J = 12.6, 7.5 Hz, 1H), 1.33 (s, 9H).
−ジフルオロシクロプロピル]カルバモイル}−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−3−イル]カルバミン酸tert−ブチル(中間体VIII−132)の合成
LCMS: METCR1410 Generic 1.7 min, rt=1.24分, M/Z (ES+), 482.10 /484.05 [M-tBu+H+], 560.05/562.10 [M+Na+] 86% UV; NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.71 (d, J = 1.7 Hz, 1H), 7.65 (d, J = 7.9 Hz, 1H), 7.48 (dd, J = 8.0, 1.9 Hz, 1H), 7.21 (s, 4H), 6.26 (s, 1H), 5.56 (d, J = 8.1 Hz, 1H), 5.36 (d, J = 15.1 Hz, 1H), 4.82 (d, J = 15.1 Hz, 1H), 4.41 (dt, J = 11.2, 7.6 Hz, 1H), 3.70 (dd, J = 10.9, 6.6 Hz, 1H), 3.58 - 3.49 (m, 1H), 2.93 (t, J = 11.3 Hz, 1H), 1.98 - 1.87 (m, 1H), 1.50 - 1.43 (m, 1H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.26分, M/Z (ES+) 566.2 [M+Na+], 488.1 [M-tBu+H+] 80% UV; NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.64 (d, J = 7.9 Hz, 1H), 7.55 - 7.49 (m, 2H), 7.14 (d, J = 8.1 Hz, 2H), 6.95 (d, J = 8.1 Hz, 2H), 6.16 - 6.09 (m, 1H), 5.58 (d, J = 8.1 Hz, 1H), 5.09 (d, J = 15.0 Hz, 1H), 5.00 (d, J = 14.9 Hz, 1H), 4.43 - 4.36 (m, 1H), 3.69 (dd, J = 10.9, 6.5 Hz, 1H), 3.56 - 3.44 (m, 1H), 1.96 - 1.77 (m, 2H), 1.39 (s, 9H), 0.96 - 0.82 (m, 4H), 0.67 - 0.60 (m, 2H).
LCMS: METCR1410 Generic 1.7 min, rt=1.21分, M/Z (ES+) 592.5 [M+Na+], 514.4 [M-tBu+H+] 79% UV; NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.69 (d, J = 1.6 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.48 (dd, J = 8.0, 1.9 Hz, 1H), 7.27 (d, J = 8.7 Hz, 2H), 6.99 (d, J = 8.6 Hz, 2H), 6.45 (t, J = 73.9 Hz, 1H), 6.23 (s, 1H), 5.55 (d, J = 7.8 Hz, 1H), 5.32 (d, J = 15.2 Hz, 1H), 4.87 (d, J = 15.1 Hz, 1H), 4.45 - 4.34 (m, 1H), 3.70 (dd, J = 10.9, 6.6 Hz, 1H), 3.60 - 3.46 (m, 1H), 2.93 (t, J = 11.3 Hz, 1H), 1.98 - 1.85 (m, 1H), 1.49 - 1.43 (m, 1H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.17分, M/Z (ES+) 478.1 [M-tBu+H+], 556.1 [M+Na+] 91% UV; NMRデータ: 1H NMR (250 MHz, クロロホルム-d) δ 7.69 - 7.53 (m, 2H), 7.50 (dd, J = 8.0, 1.8 Hz, 1H), 7.17 (d, J = 8.6 Hz, 2H), 6.77 (d, J = 8.7 Hz, 2H), 6.22 (s, 1H), 5.59 (d, J = 8.1 Hz, 1H), 5.16 (d, J = 14.7 Hz, 1H), 4.90 (d, J = 14.6 Hz, 1H), 4.47 - 4.28 (m, 1H), 3.75 (s, 3H), 3.68 (dd, J = 11.0, 6.6 Hz, 1H), 3.52 (s, 1H), 2.92 (t, J = 11.3 Hz, 1H), 2.02 - 1.79 (m, 1H), 1.54 - 1.42 (m, 1H), 1.39 (s, 9H).
LCMS: METCR1981 Hydrophobic 3 min, rt=1.51分, M/Z (ES+) 482.1 [M-tBu+H+], 560.15
[M+Na+] 100% UV; NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.64 (d, J = 7.9
Hz, 1H), 7.58 (d, J = 1.8 Hz, 1H), 7.48 (dd, J = 8.0, 1.8 Hz, 1H), 7.30 - 7.21 (m, 5H), 6.09 - 5.94 (m, 1H), 5.59 (d, J = 8.0 Hz, 1H), 5.18 (d, J = 15.1 Hz, 1H), 5.03 (d, J = 15.0 Hz, 1H), 4.42 (dt, J = 11.5, 7.4 Hz, 1H), 3.70 (dd, J = 11.0, 6.6 Hz, 1H), 3.50 (m, 2H), 2.93 (t, J = 11.3 Hz, 1H), 2.22 - 2.09 (m, 2H), 1.87 (dt, J = 14.6, 7.1 Hz, 2H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.61分, M/Z (ES+) 628.10/629.85 [M+Na]+ 97% UV;
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 7.64 (d, J = 5.8 Hz, 2H), 7.24 - 7.16 (m, 4H), 6.47 - 6.33 (m, 1H), 5.54 (d, J = 8.3 Hz, 1H), 5.40 (d, J = 15.1 Hz, 1H), 4.71 (d, J = 15.2 Hz, 1H), 4.45 - 4.35 (m, 1H), 3.69 (dd, J = 10.9, 6.5 Hz, 1H), 3.63 - 3.46 (m, 2H), 2.93 (t, J = 11.3 Hz, 1H), 2.29 - 2.16 (m, 2H), 1.98 - 1.87 (m, 2H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.16分, M/Z (ES+) 614.2 [M+Na+] 99% UV;
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.69 (d, J = 1.7 Hz, 1H), 7.63 (d,
J = 7.9 Hz, 1H), 7.46 (dd, J = 7.9, 1.7 Hz, 1H), 7.28 (d, J = 8.6 Hz, 2H), 6.99
(d, J = 8.5 Hz, 2H), 6.46 (t, J = 73.9 Hz, 1H), 6.08 (t, J = 6.0 Hz, 1H), 5.55 (d, J = 8.4 Hz, 1H), 5.30 (d, J = 15.1 Hz, 1H), 4.88 (d, J = 15.1 Hz, 1H), 4.45 - 4.35 (m, 1H), 4.00 (dd, J = 10.9, 3.7 Hz, 2H), 3.69 (dd, J = 10.9, 6.6 Hz, 1H), 3.45 - 3.30 (m, 4H), 2.91 (t, J = 11.3 Hz, 1H), 1.91 - 1.82 (m, 1H), 1.70 - 1.62 (m, 2H), 1.40 (s, 9H). さらなる2Hはグリースのピークに隠れている。
LCMS: METCR1410 Generic 1.7 min, rt=1.2分, M/Z (ES+) 522.05/524.05 [M-tBu+H+], 600.15/602.20 [M+Na+] 99% UV; NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.82 (t, J = 6.1 Hz, 1H), 7.96 (s, 1H), 7.76 - 7.70 (m, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.29 (s, 4H), 5.28 (d, J = 15.6 Hz, 1H), 4.95(d, J = 15.7 Hz, 1H), 4.14 (dt, J = 12.2, 7.6 Hz, 1H), 3.73 (d, J = 11.5 Hz, 3H), 3.57 (s, 3H), 3.50 - 3.44 (m, 2H), 3.12 (t, J = 11.8 Hz, 1H), 1.73 - 1.66 (m, 3H), 1.35 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.22分, M/Z (ES+) 596.10/598.20 [M+Na+] 100%
UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.30 (d, J = 8.6 Hz, 1H), 7.88 (s, 1H), 7.73 - 7.65 (m, 2H), 7.44 (d, J = 8.4 Hz, 1H), 7.34 - 7.27 (m, 4H), 5.25 (d, J = 15.6 Hz, 1H), 4.97 (d, J = 15.7 Hz, 1H), 4.18 - 4.09 (m, 1H), 3.92 - 3.79 (m, 3H), 3.46 (dd, J = 11.3, 6.8 Hz, 1H), 3.28 - 3.20 (m, 2H), 3.11 (t, J = 11.7 Hz, 1H), 1.67 - 1.54 (m, 3H), 1.35 (s, 9H), 1.21 (td, J = 12.2, 3.9 Hz, 2H), 1.13 (d, J = 6.7 Hz, 3H).
LCMS: METCR1410 Generic 1.7 min, rt=1.21分, M/Z (ES+) 448 [M-tBu+H+], 526 [M+Na+] 98% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.64 (d, J = 7.9 Hz, 1H), 7.57 (d,
J = 1.8 Hz, 1H), 7.50 (dd, J = 8.0, 1.8 Hz, 1H), 7.26 (s, 5H), 6.21 (s, 1H), 5.59 (d, J = 8.0 Hz, 1H), 5.19 (d, J = 15.0 Hz, 1H), 5.01 (d, J = 15.0 Hz, 1H), 4.50 - 4.31 (m, 1H), 3.70 (dd, J = 11.0, 6.6 Hz, 1H), 3.59 - 3.43 (m, 1H), 2.93 (t, J = 11.2 Hz, 1H), 2.02 - 1.78 (m, 1H), 1.51 - 1.42 (m, 1H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.28分, M/Z (ES+) 510.10/512.10 [M-tBu+H+] 93% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.75 (t, J = 5.6 Hz, 1H), 7.91 (s, 1H), 7.68 (s, 2H), 7.45 (d, J = 8.3 Hz, 1H), 7.28 (s, 4H), 5.29 (d, J = 15.5 Hz, 1H), 4.91 (d, J = 15.7 Hz, 1H), 4.13 (dt, J = 12.1, 7.6 Hz, 1H), 3.46 (dd, J = 11.3, 6.7 Hz, 1H), 3.39 (t, J = 5.7 Hz, 2H), 3.11 (t, J = 11.8 Hz, 1H), 2.70 - 2.58 (m, 2H), 2.41 - 2.34 (m, 3H), 1.34 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.28分, M/Z (ES+) 515.95/518.05 [M-tBu+H+], 594/596.05 [M+Na+] 96% UV; NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.59 (s, 2H), 7.17 (s, 4H), 6.93 (s, 1H), 5.61 (d, J = 8.0 Hz, 1H), 5.34 (d, J = 15.1 Hz, 1H), 4.67 (d, J = 15.1 Hz, 1H), 4.34 (dt, J = 11.4, 7.3 Hz, 1H), 3.61 (dd, J = 10.9, 6.5 Hz, 1H), 3.47 (dt, J = 10.1, 6.0 Hz, 1H), 2.90 (t, J = 11.3 Hz, 1H),
1.94 - 1.77 (m, 1H), 1.56 - 1.41 (m, 1H), 1.36 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.3分, M/Z (ES+) 594.2 [M+Na+] 86% UV;
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.97 (s, 1H), 7.92 (s, 1H), 7.74 - 7.67 (m, 2H), 7.61 (d, J = 8.2 Hz, 2H), 7.55 - 7.48 (m, 2H), 7.46 (d, J = 8.3 Hz, 1H), 5.32 (d, J = 16.1 Hz, 1H), 5.05 (d, J = 16.0 Hz, 1H), 4.20 - 4.11 (m, 1H), 3.47 (dd, J = 11.4, 6.9 Hz, 1H), 3.13 (t, J = 11.8 Hz, 1H), 2.04 - 1.92 (m, 1H), 1.70 - 1.52 (m, 2H), 1.34 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.26分, M/Z (ES+) 604.0/605.8 [M+Na+] 88% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.00 - 8.94 (m, 1H), 7.95 (d, J = 12.7 Hz, 1H), 7.71 (s, 2H), 7.48 - 7.39 (m, 3H), 7.27 - 7.19 (m, 2H), 5.36 - 5.22 (m, 1H), 4.95 - 4.82 (m, 1H), 4.18 - 4.08 (m, 1H), 3.50 - 3.43 (m, 2H), 3.12 (t, J = 11.7 Hz, 1H), 2.04 - 1.93 (m, 1H), 1.75 - 1.56 (m, 1H), 1.35 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.29分, M/Z (ES+) 523.2 [M-tBu+H+] 92% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 8.08 (d, J = 7.0 Hz, 1H), 7.54 (d,
J = 8.4 Hz, 2H), 7.45 - 7.28 (m, 5H), 7.11 - 6.94 (m, 3H), 5.60 - 5.48 (m, 2H),
4.77 (d, J = 15.6 Hz, 1H), 4.68 - 4.57 (m, 2H), 4.40 (s, 1H), 3.71 (dd, J = 10.9, 6.5 Hz, 1H), 2.94 (t, J = 11.3 Hz, 1H), 1.40 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.47分, M/Z (ES+) 622 [M+Na+] 100% UV
NMRデータ: 1H NMR (250 MHz, DMSO-d6) δ 8.76 (d, J = 5.3 Hz, 1H), 8.03 - 7.92 (m, 2H), 7.78 (s, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.46 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 5.26 (d, J = 16.1 Hz, 1H), 4.85 (d, J = 16.2Hz, 1H), 4.39 (dt, J = 11.6, 7.7 Hz, 1H), 4.09 (dd, J = 13.2, 7.2 Hz, 1H), 3.74 (t, J = 12.5 Hz, 1H), 3.30 - 3.20 (m, 2H), 1.49 (p, J = 7.2 Hz, 2H), 1.39 - 1.21 (m, 11H), 0.89 (t, J = 7.3 Hz, 3H).
LCMS: METCR1673 Generic 2 minutes, rt=1.46分, M/Z (ES+) 642 [M+Na+] 90% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) δ 8.03 (d, J = 6.1 Hz, 1H), 7.80 (d, J = 9.9 Hz, 1H), 7.35 - 7.26 (m, 6H), 7.06 (t, J = 8.6 Hz, 2H), 5.70 (d, J = 7.1 Hz, 1H), 5.17 (d, J = 15.2 Hz, 1H), 4.84 (d, J = 15.2 Hz, 1H), 4.63 (t, J = 6.1 Hz, 2H), 4.54 (s, 1H), 4.16 - 4.00 (m, 1H), 3.58 - 3.45 (m, 1H), 1.40 (s, 9H). [NHは見えない]
LCMS: METCR1673 Generic 2 minutes, rt=1.45分, M/Z (ES+) 590 [M+Na+] 97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.61 (t, J = 5.5 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.53 (dd, J = 14.6, 6.8 Hz, 2H), 7.38 - 7.32 (m, 4H), 5.22 (d, J = 16.0 Hz, 1H), 4.77 (d, J = 16.0 Hz, 1H), 4.41 (dt, J = 11.6, 7.7 Hz, 1H), 4.12 - 4.04 (m, 1H), 3.83 - 3.70 (m, 1H), 3.26 - 3.17 (m, 2H), 1.51 - 1.42 (m, 2H), 1.36 (s, 9H), 1.29 - 1.25 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H).
LCMS: METCR1673 Generic 2 minutes, rt=1.48分, M/Z (ES+) 644 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.75 (d, J = 5.3 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.64 (d, J = 5.5 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.38 - 7.29 (m, 4H), 5.19 (d, J = 16.0 Hz, 1H), 4.83 (d, J = 15.9 Hz, 1H), 4.41 (dt, J = 11.7, 7.7 Hz, 1H), 4.09 (dd, J = 13.1, 7.4 Hz, 1H), 3.82 - 3.71 (m, 1H), 3.45 - 3.35 (m, 2H), 2.29 (dd, J = 16.2, 11.4 Hz, 2H), 1.79 - 1.64 (m, 2H), 1.37 (s, 9H).
LCMS: METCR1673 Generic 2 minutes , rt=1.38分, M/Z (ES+) 510 [M+H-boc] 98% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 8.01 (d, J = 6.1 Hz, 1H), 7.83 (d, J = 9.9 Hz, 1H), 7.30 (d, J = 2.5 Hz, 4H), 6.77 (dt, J = 11.5, 5.6 Hz, 1H), 5.73 (d, J = 7.1 Hz, 1H), 5.19 (d, J = 15.2 Hz, 1H), 4.85 (d, J = 15.2 Hz, 1H), 4.54 (dt, J = 10.9, 7.0 Hz, 1H), 4.10 (dd, J = 13.9, 6.3 Hz, 1H), 4.02 (dd, J = 11.1, 3.7 Hz, 2H), 3.54 (dd, J = 13.2, 11.1 Hz, 1H), 3.50 - 3.32 (m, 4H), 1.91 (ddt, J = 11.4, 8.0, 4.0 Hz, 1H), 1.72 - 1.63 (m, 2H), 1.61 (s, 2H), 1.48 - 1.35 (m, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.38分, M/Z (ES+) 682 [M+Na+] 97% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 1.40 (s, 11H), 1.64 (dt, J = 7.0,
14.1 Hz, 2H), 1.88 (ttt, J = 3.9, 7.2, 10.9 Hz, 1H), 3.38 (tdq, J = 6.8, 13.3, 20.0 Hz, 4H), 3.52 (dd, J = 11.2, 13.2 Hz, 1H), 4.00 (dd, J = 3.7, 11.2 Hz, 2H),
4.03 - 4.12 (m, 1H), 4.52 (dt, J = 7.0, 10.8 Hz, 1H), 4.84 (d, J = 15.3 Hz, 1H), 5.21 (d, J = 15.3 Hz, 1H), 5.70 (d, J = 7.1 Hz, 1H), 6.76 (dt, J = 5.8, 11.8 Hz, 1H), 7.16 (d, J = 8.1 Hz, 2H), 7.37 (d, J = 8.6 Hz, 2H), 7.82 (d, J = 9.9 Hz, 1H), 8.00 (d, J = 6.0 Hz, 1H).
LCMS: METCR1673 Generic 2 minutes, rt=1.49分, M/Z (ES+) 694 [M+Na+] 96% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 1.40 (s, 9H), 1.92 (dt, J = 7.2, 14.7 Hz, 2H), 2.11 - 2.26 (m, 2H), 3.55 (qd, J = 9.0, 13.6 Hz, 3H), 4.08 (dd, J = 6.7, 13.5 Hz, 1H), 4.53 (dt, J = 7.0, 10.9 Hz, 1H), 4.84 (d, J = 15.3 Hz, 1H),
5.22 (d, J = 15.2 Hz, 1H), 5.70 (d, J = 7.1 Hz, 1H), 6.77 (dt, J = 5.8, 11.6 Hz, 1H), 7.16 (d, J = 8.1 Hz, 2H), 7.37 (d, J = 8.6 Hz, 2H), 7.82 (d, J = 9.9 Hz, 1H), 7.99 (d, J = 6.0 Hz, 1H)
LCMS: METCR1673 Generic 2 minutes, rt=1.47分, M/Z (ES+) 676 [M+Na+] 97% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 1.41 (s, 9H), 3.47 - 3.61 (m, 1H), 4.10 (dd, J = 6.9, 13.3 Hz, 1H), 4.55 (h, J = 8.7, 9.7 Hz, 1H), 4.84 (d, J = 14.9 Hz, 1H), 5.23 (d, J = 15.2 Hz, 1H), 5.72 (d, J = 7.0 Hz, 1H), 7.04 - 7.18 (m, 5H), 7.29 - 7.44 (m, 4H), 7.88 (d, J = 9.36 Hz, 1H), 8.03 (s, 1H), 9.62 (d, J = 9.7 Hz, 1H)
LCMS: METCR1673 Generic 2 minutes, rt=1.43分, M/Z (ES+) 606/608 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 9.11 (d, J = 11.2 Hz, 1H), 8.01 (d, J = 6.1 Hz, 1H), 7.82 (d, J = 9.6 Hz, 1H), 7.30 - 7.27 (m, 4H), 5.70 (s, 1H), 5.16 (d, J = 15.3 Hz, 1H), 4.85 (d, J = 15.2 Hz, 1H), 4.52 (s, 1H), 4.08 (d, J = 6.7 Hz, 1H), 3.83 (d, J = 6.8 Hz, 2H), 3.58 - 3.48 (m, 1H), 2.12 - 1.99 (m, 1H), 1.41 (s, 9H), 1.01 (d, J = 6.7 Hz, 6H).
LCMS: METCR1673 Generic 2 minutes, rt=1.44分, M/Z (ES+) 626/628 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 9.54 (s, 1H), 8.05 (s, 1H), 7.95 - 7.88 (m, 1H), 7.44 - 7.35 (m, 2H), 7.34 - 7.30 (一部不明確 m, 4H), 7.13 (t, J = 7.8 Hz, 3H), 5.74 (d, J = 7.0 Hz, 1H), 5.22 (d, J = 15.2 Hz, 1H), 4.85 (d, J =
15.5 Hz, 1H), 4.65 - 4.52 (m, 1H), 4.13 (dd, J = 13.4, 6.8 Hz, 1H), 3.64 - 3.49
(m, 1H), 1.44 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.40分, M/Z (ES+) 576/578 [M+Na+] 99% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 8.00 (d, J = 6.1 Hz, 1H), 7.79 (d, J = 9.8 Hz, 1H), 7.30 - 7.27 (m, 4H), 6.53 - 6.40 (m, 1H), 5.70 (d, J = 6.8 Hz, 1H), 5.17 (d, J = 15.2 Hz, 1H), 4.83 (d, J = 15.2 Hz, 1H), 4.56 - 4.46 (m, 1H), 4.33 - 4.21 (m, 1H), 4.08 (dd, J = 13.3, 6.9 Hz, 1H), 3.51 (dd, J = 13.3, 11.0 Hz, 1H), 1.40 (s, 9H), 1.28 (dd, J = 6.5, 3.7 Hz, 6H)
LCMS: METCR1673 Generic 2 minutes, rt=1.52分, M/Z (ES+) 640/642 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 7.90 (d, J = 6.0 Hz, 1H), 7.78 (d, J = 9.9 Hz, 1H), 7.23 - 7.16 (m, 4H), 6.73 (dt, J = 11.6, 5.7 Hz, 1H), 5.61 (d, J = 6.9 Hz, 1H), 5.07 (d, J = 15.3 Hz, 1H), 4.74 (d, J = 15.3 Hz, 1H), 4.53 (t, J = 6.8 Hz, 1H), 3.96 (p, J = 6.9 Hz, 1H), 3.48 (qq, J = 13.5, 6.7 Hz, 2H), 2.18 - 2.05 (m, 2H), 1.85 (dt, J = 14.7, 7.2 Hz, 2H), 1.41 (d, J = 7.0 Hz, 3H), 1.33 (s, 9H).
LCMS: METCR1416 Generic 7 minutes, rt=4.23分, M/Z (ES+) 727/729 [M+H+], 627/629 [M+H-Boc] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 9.29 (t, J = 5.8 Hz, 1H), 7.99 (s, 2H), 7.85 (s, 1H), 7.79 (s, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.34 (s, 4H), 7.20 (d, J =
8.6 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 6.21 (d, J = 15.9Hz, 1H), 4.85 (d, J = 16.0 Hz, 1H), 4.37 (s, 3H), 4.08 (dd, J = 13.1, 7.3 Hz, 1H), 3.93 (t, J = 6.5 Hz, 2H), 3.78 - 3.68 (m, 1H), 3.03 (q, J = 6.5 Hz, 2H), 1.78 (s, 3H), 1.70 (p, J = 6.8 Hz, 2H), 1.48 - 1.37 (m, 4H), 1.36 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.45分, M/Z (ES+) 588/590 [M+Na+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.51 (t, J = 5.5 Hz, 1H), 7.54 (d, J = 8.5 Hz, 1H), 7.37 (d, J = 5.4 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.14 (s, 4H), 5.01 (d, J = 16.0 Hz, 1H), 4.58 (d, J = 16.0 Hz, 1H), 4.21 (dt, J = 11.5, 7.7 Hz, 1H), 3.89 (dd, J = 13.3, 7.3 Hz, 1H), 3.60 - 3.51 (m, 1H), 2.93 (qt, J = 13.4, 6.0 Hz, 2H), 1.17 (s, 9H), 0.78 (s, 1H), 0.23 (q, J = 5.6 Hz, 2H), -0.00 (q, J = 4.9 Hz, 2H).
LCMS: METCR1673 Generic 2 minutes, rt=1.36分, M/Z (ES+) 558/560 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 1.24 (d, J = 6.6 Hz, 6H), 1.40 (s, 9H), 3.50 (dd, J = 11.1, 13.2 Hz, 1H), 4.05 (dd, J = 7.0, 13.3 Hz, 1H), 4.22 (dh, J = 6.6, 13.2 Hz, 1H), 4.51 (dt, J = 7.2, 10.9 Hz, 1H), 4.60 (d, J = 15.2 Hz, 1H), 5.39 (d, J = 15.2 Hz, 1H), 5.72 (dd, J = 7.5, 18.3 Hz, 2H), 7.26 - 7.34 (m, 4H), 7.50 (d, J = 1.3 Hz, 1H), 7.75 (dd, J = 1.3, 8.1 Hz, 1H), 8.06 (d, J = 8.1 Hz, 1H)
LCMS: METCR1673 Generic 2 minutes, rt=1.43分, M/Z (ES+) 626/628 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.86 (t, J = 5.6 Hz, 1H), 8.01 - 7.92 (m, 2H), 7.81 (s, 1H), 7.51 (d, J = 8.1 Hz, 1H), 7.37 - 7.30 (m, 4H), 5.20 (d, J = 16.0 Hz, 1H), 4.85 (d, J = 16.0 Hz, 1H), 4.43 - 4.33 (m, 1H), 4.07 (dd, J = 13.2, 7.3 Hz, 1H), 3.77 - 3.70 (m, 1H), 3.43 - 3.34 (m, 2H), 2.36 - 2.23 (m, 2H), 1.81 - 1.63 (m, 2H), 1.36 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.41分, M/Z (ES+) 588/590 [M+Na+] 96% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 8.47 - 7.41 (m, 4H), 7.33 - 7.27 (m, 4H), 5.70 (d, J = 7.0 Hz, 1H), 5.39 (dd, J = 36.7, 15.3 Hz, 1H), 4.66 (d, J = 15.4 Hz, 2H), 4.06 (d, J = 6.9 Hz, 1H), 3.91 (dd, J = 6.9, 1.5 Hz, 1H), 3.76 (s, 1H), 3.57 - 3.43 (m, 1H), 2.12 - 1.93 (m, 1H), 1.41 (s, 9H), 0.97 (dd, J = 16.1, 6.6 Hz, 6H)
LCMS: METCR1673 Generic 2 minutes, rt=1.35分, M/Z (ES+) 574/576 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 8.06 (dd, J = 36.0, 8.1 Hz, 4H), 7.35 - 7.27 (m, 4H), 5.70 (d, J = 7.9 Hz, 1H), 5.39 (d, 15.3 Hz, 1H), 4.65 (d, J
= 15.3 Hz, 2H), 4.08 (dt, J = 14.1, 6.8 Hz, 2H), 3.95 (s, 1H), 3.57 - 3.42 (m, 1H), 1.72 (p, J = 7.1 Hz, 2H), 1.41 (s, 9H), 0.99 (dt, J = 14.9, 7.6 Hz, 3H)
LCMS: METCR1673 Generic 2 minutes, rt=1.46分, M/Z (ES+) 586/588 [M+Na+] 99% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 8.09 (dd, J = 8.1, 1.9 Hz, 1H), 7.78 (t, J = 7.8 Hz, 1H), 7.51 - 7.41 (m, 1H), 7.34 - 7.27 (m, 4H), 5.70 (d, J = 7.2 Hz, 1H), 5.64 (dd, J = 27.2, 8.9 Hz, 1H), 5.46 (dd, J = 15.3, 3.1 Hz, 1H), 4.60 - 4.47 (m, 2H), 4.12 - 3.96 (m, 2H), 3.51 (dd, J = 13.2, 11.0 Hz, 1H), 1.78 (dq, J = 13.1, 6.6 Hz, 1H), 1.41 (s, 9H), 1.16 (d, J = 6.7 Hz, 3H), 0.92 (ddd, J
= 6.2, 4.2, 1.5 Hz, 6H)
LCMS: METCR1981, hydrophobic 3 minutes, rt=2.6分, M/Z (ES+) 758/760 [M+Na+] 97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.62 (t, J = 5.5 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.57 - 7.49 (m, 2H), 7.34 (s, 4H), 5.22 (d, J = 16.1 Hz, 1H), 4.78 (d, J = 16.1 Hz, 1H), 4.42 (dt, J =11.8, 7.8 Hz, 1H), 4.09 (dd, J = 13.3, 7.3 Hz, 1H), 3.81 - 3.70 (m, 1H), 3.25 - 3.19 (m, 2H), 1.52 - 1.42 (m, 2H), 1.32 - 1.17 (m, 35H), 0.88 - 0.83 (m, 3H).
LCMS: METCR1673 Generic 2 minutes, rt=1.35分, M/Z (ES+) 574/576 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.72 (d, J = 4.2 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 5.4 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.39 - 7.30 (m, 4H), 5.17 (d, J = 15.9 Hz, 1H), 4.84 (d, J = 15.9 Hz, 1H),4.39 (dt, J = 11.6, 7.6 Hz, 1H), 4.09 (dd, J = 13.2, 7.4 Hz, 1H), 3.80 - 3.69 (m, 1H), 2.83 (dq, J = 7.3, 3.7 Hz, 1H), 1.37 (s, 9H), 0.72 (d, J = 5.5 Hz, 2H), 0.53 (dd, J = 3.7, 1.9 Hz, 2H).
LCMS: METCR1673 Generic 2 minutes, rt=1.44分, M/Z (ES+) 588/590 [M+Na+] 97% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 8.00 (d, J = 6.1 Hz, 1H), 7.80 (d, J = 9.9 Hz, 1H), 7.30 - 7.26 (m, 4H), 6.84 - 6.72 (m, 1H), 5.70 (d, J = 7.1 Hz, 1H), 5.16 (d, J = 15.2 Hz, 1H), 4.83 (d, J = 15.2 Hz, 1H), 4.60 - 4.46 (m, 2H), 4.08 (dd, J = 13.3, 6.9 Hz, 1H), 3.51 (dd, J = 13.2, 11.0 Hz, 1H), 2.50 - 2.40 (m, 2H), 2.05 - 1.93 (m, 2H), 1.88 - 1.74 (m, 2H), 1.40 (s, 9H)
LCMS: METCR1673 Generic 2 minutes, rt=1.41分, M/Z (ES+) 594/596 [M+Na+] 99% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 8.14 (d, J = 6.0 Hz, 1H), 7.80 (d, J = 9.8 Hz, 1H), 7.41 (t, J = 8.1 Hz, 1H), 7.10 (dd, J = 8.3, 1.7 Hz, 1H), 7.04 (dd, J = 9.7, 2.0 Hz, 1H), 6.56 - 6.44 (m, 1H), 5.66 (d, J = 7.2 Hz, 1H), 5.08 (d, J = 15.2 Hz, 1H), 5.01 (d, J = 15.1 Hz, 1H), 4.49 (dt, J = 10.9, 7.0 Hz, 1H), 4.34 - 4.25 (m, 1H), 4.04 (dd, J = 13.4, 6.9 Hz, 1H), 3.46 (dd, J = 13.3, 11.1 Hz, 1H), 1.40 (s, 9H), 1.30 (dd, J = 6.6, 2.0 Hz, 6H)
LCMS: METCR1673 Generic 2 minutes, rt=1.42分, M/Z (ES+) 592/594 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 8.09 (d, J = 8.1 Hz, 1H), 7.75 (dd, J = 8.1, 1.4 Hz, 1H), 7.60 (d, J = 1.4 Hz, 1H), 7.46 (d, J = 2.1 Hz, 1H), 7.41 (d, J = 8.2 Hz, 1H), 7.18 (dd, J = 8.2, 2.0 Hz, 1H), 5.76 (d, J = 7.5 Hz, 1H), 5.66 (d, J = 7.3 Hz, 1H), 5.31 (d, J = 15.4 Hz, 1H), 4.64 (d, J = 15.4 Hz, 1H), 4.53 (dt, J = 10.9, 7.2 Hz, 1H), 4.25 (dq, J = 13.1, 6.5 Hz, 1H), 4.06 (dd, J = 13.4, 7.0 Hz, 1H), 3.50 (dd, J = 13.3, 11.1 Hz, 1H), 1.41 (s, 9H), 1.26 (d, J = 6.6 Hz, 6H)
LCMS: METCR1673 Generic 2 minutes, rt=1.38分, M/Z (ES+) 576/578 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 8.09 (d, J = 8.1 Hz, 1H), 7.73 (dd, J = 8.1, 1.4 Hz, 1H), 7.62 (d, J = 1.5 Hz, 1H), 7.36 (t, J = 7.8 Hz, 1H), 7.18 (dd, J = 9.6, 2.0 Hz, 1H), 7.10 - 7.03 (m, 1H), 5.77 (d, J = 7.4 Hz, 1H), 5.66 (d, J = 7.4 Hz, 1H), 5.33 (d, J = 15.4 Hz, 1H), 4.65 (d, J = 15.4 Hz, 1H), 4.53 (dt, J = 10.9, 7.2 Hz, 1H), 4.25 (dq, J = 13.2, 6.6 Hz, 1H), 4.06 (dd, J = 13.3, 6.9 Hz, 1H), 3.50 (dd, J = 13.3, 11.1 Hz, 1H), 1.41 (s, 9H), 1.26 (dd, J = 6.6, 0.9 Hz, 6H)
6,5−ベンゾチアゼピン−3−イル]カルバミン酸tert−ブチル(中間体IX−27)の合成
LCMS: METCR1673 Generic 2 minutes, rt=1.45分, M/Z (ES+) 614/616 [M+Na+] 91% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 1.18 - 1.50 (m, 15H), 1.78 (s, 2H), 1.99 (s, 2H), 3.43 - 3.58 (m, 1H), 3.83 - 4.15 (m, 2H), 4.42 - 4.65 (m, 2H), 5.33 - 5.49 (m, 1H), 5.73 (d, J = 7.1 Hz, 1H), 7.26 - 7.33 (m, 4H), 7.37 - 7.62 (m, 1H), 7.63 - 7.93 (m, 1H), 7.93 - 8.08 (m, 1H), 8.83 (s, 1H).
LCMS: METCR1673 Generic 2 minutes, rt=1.53分, M/Z (ES+) 628/630 [M+Na+] 99% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 0.90 - 1.08 (m, 2H), 1.12 - 1.34 (m, 3H), 1.40 (s, 9H), 1.64 - 1.85 (m, 6H), 3.43 - 3.58 (m, 1H), 3.78 (s, 1H), 3.88 - 3.98 (m, 1H), 3.98 - 4.13 (m, 1H), 4.44 - 4.73 (m, 2H), 5.28 - 5.44 (m, 1H), 5.66 - 5.76 (m, 1H), 7.26 - 7.33 (m, 4H), 7.43 - 7.94 (m, 2H), 7.98 - 8.09 (m, 1H), 8.79 (s, 1H)
LCMS: METCR1673 Generic 2 minutes, rt=1.41分, M/Z (ES+) 616/618 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.00 (d, J = 6.0 Hz, 1H), 7.86 (d, J = 9.9 Hz, 1H), 7.27 (d, J = 13.2 Hz, 6H), 6.98 - 6.83 (m, 1H), 5.70 (d, J = 7.1 Hz, 1H), 5.19 (d, J = 15.2 Hz, 1H), 4.83 (d, J = 15.2 Hz, 1H), 4.52 (dt, J = 11.0, 7.0 Hz, 1H), 4.25 - 4.00 (m, 1H), 3.53 (dd, J = 13.3, 11.1 Hz, 1H), 1.40 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.44分, M/Z (ES+) 630/632 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 7.98 (d, J = 6.1 Hz, 1H), 7.82 (d, J = 9.9 Hz, 1H), 7.31 - 7.24 (m, 5H), 7.01 - 6.82 (m, 1H), 5.70 (d, J = 7.2 Hz, 1H), 5.19 (d, J = 15.2 Hz, 1H), 4.82 (d, J = 15.2 Hz, 1H), 4.66 - 4.41 (m, 1H), 4.09 (dd, J = 13.5, 6.9 Hz, 1H), 3.75 (p, J = 5.9 Hz, 1H), 3.52 (dd, J = 13.4, 11.1 Hz, 1H), 2.54 - 2.38 (m, 2H), 1.40 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.46分, M/Z (ES+) 630/632 [M+Na+] 100% UV
LCMS: METCR1673 Generic 2 minutes, rt=1.47分, M/Z (ES+) 590/592 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.41 (d, J = 8.2 Hz, 1H), 7.72 (d, J = 8.3 Hz, 1H), 7.54 - 7.48 (m, 2H), 7.33 (s, 4H), 5.23 (d, J = 15.9 Hz, 1H), 4.77 (d, J = 15.9 Hz, 1H), 4.40 (dt, J = 11.7, 7.7 Hz, 1H), 4.09 (dd, J = 13.3, 7.3 Hz, 1H), 3.84 (dt, J = 14.0, 7.3 Hz, 1H), 3.79 - 3.73 (m, 1H), 1.45 (ddd, J = 20.9, 14.3, 7.0 Hz, 2H), 1.37 (s, 9H), 1.10 (d, J = 6.6 Hz, 3H), 0.82 (t, J = 7.4 Hz, 3H).
LCMS: METCR1673 Generic 2 minutes, rt=1.49分, M/Z (ES+) 590/592 [M+Na+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.19 (s, 1H), 7.70 (d, J = 8.2 Hz, 1H), 7.50 (dd, J = 11.7, 6.8 Hz, 2H), 7.36 - 7.31 (m, 4H), 5.21 (d, J = 15.9 Hz, 1H),
4.79 (d, J = 15.9 Hz, 1H), 4.38 (dt, J = 11.7, 7.7 Hz, 1H), 4.09 (dd, J = 13.3,
7.3 Hz, 1H), 3.80 - 3.68 (m, 1H), 1.36 (s, 9H), 1.33 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.38分, M/Z (ES+) 588/590 [M+Na+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 11.23 (s, 1H), 7.98 (d, J = 8.2 Hz, 1H),
7.87 (d, J = 8.2 Hz, 1H), 7.65 (s, 1H), 7.52 (d, J = 8.1 Hz, 1H), 7.39 - 7.31 (m, 4H), 5.30 (d, J = 16.3 Hz, 1H), 4.73 (d, J = 16.2 Hz, 1H), 4.39 (dt, J = 11.6, 7.6 Hz, 1H), 4.11 - 4.08 (m, 1H), 3.80 - 3.71 (m, 1H), 1.37 (s, 9H), 1.19 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.38分, M/Z (ES+) 570/572 [M+Na+] 91% UV
LCMS: METCR1673 Generic 2 minutes, rt=1.52分, M/Z (ES+) 650/652 [M+Na+]100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.97 (s, 1H), 7.74 (d, J = 8.3 Hz, 1H), 7.65 (d, J = 5.3 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.40 - 7.31 (m, 4H), 7.28 (t, J = 7.4 Hz, 2H), 7.17 (dd, J = 16.6, 7.6 Hz, 3H), 5.16 (d, J = 15.9 Hz, 1H), 4.85 (d, J = 15.5 Hz, 1H), 4.43 - 4.35 (m, 1H), 4.09 (dd, J = 12.8, 8.2 Hz, 1H), 3.75 (t, J = 12.5 Hz, 1H), 3.06 - 2.99 (m, 1H), 1.36 (s, 9H), 1.31 - 1.21 (m, 3H).
LCMS: METCR1673 Generic 2 minutes, rt=1.41分, M/Z (ES+) 588/590 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.84 (s, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 5.5 Hz, 1H), 7.50 (d, J = 8.1 Hz, 1H), 7.36 - 7.29 (m, 4H), 5.17 (d, J = 15.8 Hz, 1H), 4.81 (d, J = 15.9 Hz, 1H), 4.37 (dt, J = 11.7, 7.7 Hz, 1H), 4.07 (dd, J = 13.3, 7.3 Hz, 1H), 3.77 - 3.69 (m, 1H), 1.41 - 1.27 (m, 12H), 0.74 - 0.67 (m, 2H), 0.64 - 0.59 (m, 2H).
LCMS: METCR1673 Generic 2 minutes, rt=1.51分, M/Z (ES+) 602/604 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.65 (s, 1H), 7.71 (d, J = 8.3 Hz, 1H), 7.55 (d, J = 5.5 Hz, 1H), 7.51 (d, J = 8.1 Hz, 1H), 7.34 (s, 4H), 5.19 (d, J = 15.9 Hz, 1H), 4.81 (d, J = 15.9 Hz, 1H), 4.38 (dt, J = 11.7, 7.7 Hz, 1H), 4.08 (dd, J = 13.3, 7.3 Hz, 1H), 3.80 - 3.68 (m, 1H), 2.35 - 2.24 (m, 2H), 1.96 (dt, J = 12.2, 6.2 Hz, 2H), 1.80 (ddd, J = 15.4, 9.6, 6.5 Hz, 2H), 1.44 (s, 3H), 1.36 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.49分, M/Z (ES+) 602/604 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.60 (d, J = 4.1 Hz, 1H), 7.73 (d, J = 8.3 Hz, 1H), 7.51 (dd, J = 10.5, 6.7 Hz, 2H), 7.33 (s, 4H), 5.24 (d, J = 15.9 Hz, 1H), 4.77 (d, J = 15.9 Hz, 1H), 4.40 (dt, J = 11.7, 7.8 Hz, 1H), 4.12 - 4.09 (m, 1H), 3.81 - 3.73 (m, 1H), 2.55 (dt, J = 8.3, 4.3 Hz, 1H), 1.37 (s, 9H), 1.06 (s, 3H), 0.93 (s, 3H), 0.68 (dd, J = 7.9, 5.3 Hz, 1H), 0.43 (t, J = 4.7 Hz, 1H).
LCMS: METCR1673 Generic 2 minutes, rt=1.45分, M/Z (ES+) 624/626 [M+Na+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 9.14 (d, J = 6.5 Hz, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.66 (d, J = 5.5 Hz, 1H), 7.52 (d, J = 8.1 Hz, 1H), 7.33 (s, 4H), 5.17 (d, J = 15.9 Hz, 1H), 4.85 (d, J = 15.9 Hz, 1H), 4.40 (dt, J = 11.8, 7.7 Hz, 1H), 4.28 - 4.19 (m, 1H), 4.10 (dd, J = 13.3, 7.3 Hz, 1H), 3.80 - 3.71 (m, 1H), 3.06 - 2.91 (m, 2H), 2.76 - 2.61 (m, 2H), 1.37 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.49分, M/Z (ES+) 624/626 [M+Na+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 9.20 (t, J = 5.9 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.62 (d, J = 5.5 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.40 - 7.20 (m, 9H), 5.21 (d, J = 16.0 Hz, 1H), 4.79 (d, J = 16.0 Hz, 1H), 4.52 - 4.38 (m, 3H), 4.09 (dd, J = 12.9, 7.0 Hz, 1H), 3.80 - 3.71 (m, 1H), 1.36 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.72分, M/Z (ES+) 632/634 [M+Na+] 95% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.62 (t, J = 5.4 Hz, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.59 - 7.50 (m, 2H), 7.40 - 7.32 (m, 4H), 5.21 (d, J = 16.1 Hz, 1H), 4.79 (d, J = 16.0 Hz, 1H), 4.42 (dt, J = 11.6, 7.5 Hz, 1H), 4.15 - 4.04 (m, 1H), 3.84 - 3.72 (m, 1H), 3.21 (dq, J = 12.8, 6.3, 5.8 Hz, 2H), 1.52 - 1.43 (m, 2H), 1.40 - 1.19 (m, 17H), 0.87 (t, J = 7.0 Hz, 3H).
LCMS: METCR1673 Generic 2 minutes, rt=1.31分, M/Z (ES+) 638/640 [M+Na+] 96% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J = 6.9 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.61 (d, J = 5.3 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.34 (s, 4H), 5.19 (d, J = 15.9 Hz, 1H), 4.83 (d, J =16.0 Hz, 1H), 4.39 (dq, J = 15.3, 7.8 Hz, 2H), 4.10 (dd, J = 13.2, 7.3 Hz, 1H), 3.82 - 3.71 (m, 1H), 2.31 - 2.18 (m, 1H), 2.18 - 2.03 (m, 4H), 1.77 (dd, J = 20.2, 7.2 Hz, 1H), 1.37 (s, 9H).
LCMS: METCR1673 Generic 2 minutes, rt=1.27分, M/Z (ES+) 606/608 [M+Na+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 9.16 (s, 1H), 8.08 (d, J = 8.1 Hz, 1H), 8.03 - 7.96 (m, 1H), 7.83 (d, J = 11.1 Hz, 1H), 7.42 - 7.31 (m, 4H), 7.25 (s, 1H), 5.23 - 5.12 (m, 1H), 4.88 (t, J =16.4 Hz, 1H), 4.63 (s, 1H), 4.09 - 3.94 (m, 1H), 3.48 (s, 1H), 2.01 (s, 1H), 1.67 (d, J = 6.2 Hz, 1H), 1.46 - 1.29 (m, 12H)
LCMS: METCR1416 Generic 7 minutes, rt=1.41分, M/Z (ES+) 556/558 [M+Na+]100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.69 (t, J = 5.6 Hz, 1H), 8.03 (dd, J = 8.1, 1.2 Hz, 1H), 8.01 - 7.97 (m, 1H), 7.71 (d, J = 8.1 Hz, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.34 (d, J = 8.4 Hz, 2H), 7.22 (d, J = 8.4 Hz, 2H), 5.32 (d, J = 15.2 Hz, 1H), 4.82 (d, J = 15.2 Hz, 1H), 4.14 (dt, J = 10.7, 8.2 Hz, 1H), 3.98 (t, J = 11.1 Hz, 1H), 3.30 - 3.22 (m, 3H), 1.54 (p, J = 7.1 Hz, 2H), 1.35 (s, 11H), 0.92 (t, J = 7.4 Hz, 3H).
中間体IX−01(125mg)を、25mg/mLになるようにEtOH中に溶解させ、次いでSFCで精製した。各注入量は、0.75mL(19mg)であった。使用したカラムは、YMC AMY−C(20mm×250mm、5μm)であった。溶離剤は、
MeOH/CO2 15%であった。流量は、波長225nmで、50mL/分であった。
その後、湿式画分(wet fractions)は、回転蒸発装置、ならびに40℃および5mbarの真空オーブンを用いて無水状態になるまで留去して、重量を一定にした。
最終的な分析は、YMC AMY−C(4.6mm×250mm、5μm)を用いてSFCで行った。溶離剤は、MeOH/CO2 10%であった。流量は、4mL/分であった。
異性体_1(中間体IX 46):量:48.3mg
保持時間=5.21分、キラル純度:99.8%、エナンチオマー余剰率:100%
異性体_2(中間体IX 47):量:47.3mg
保持時間=5.24分、キラル純度:99.1%、エナンチオマー余剰率:99.4%
LCMS: METCR1416 Generic 7 min, rt=4.42分, M/Z (ES+) 673.90 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) 9.14 (d, J = 11.3 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.70 (dd, J = 7.3, 5.6 Hz, 1H), 7.60 (s, 1H), 7.51 (t, J = 7.4 Hz, 2H), 7.15 (d, J = 8.6 Hz, 1H), 5.15 (d, J = 15.5 Hz, 1H), 4.91 (dd, J = 15.5, 12.7 Hz, 1H), 4.39 (dtd, J = 11.7, 7.7, 4.1 Hz, 1H), 4.08 (ddd, J = 13.3, 7.4, 3.3 Hz, 1H), 3.85 (d, J = 1.1 Hz, 3H), 3.81 - 3.73 (m, 1H), 3.51 (s, 1H), 2.04 - 1.96 (m, 1H), 1.60 (d, J = 5.3 Hz, 1H), 1.37(s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.34分, M/Z (ES+) 657.95/659.90 [M+Na+] 100%
UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.90 (d, J = 6.0 Hz, 1H), 7.78 (d,
J = 9.9 Hz, 1H), 7.23 - 7.16 (m, 4H), 6.73 (dt, J = 11.6, 5.7 Hz, 1H), 5.61 (d,
J = 6.9 Hz, 1H), 5.07 (d, J = 15.3 Hz, 1H), 4.74 (d, J = 15.3 Hz, 1H), 4.53 (t,
J = 6.8 Hz, 1H), 3.96 (p, J = 6.9 Hz, 1H), 3.48 (m, 2H), 2.18 - 2.05 (m, 2H), 1.85 (dt, J = 14.7, 7.2 Hz, 2H), 1.41 (d, J = 7.0 Hz, 3H), 1.33 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.22分, M/Z (ES+) 674 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.06 (d, J = 8.1 Hz, 1H), 8.03 (d,
J = 8.3 Hz, 2H), 7.78 - 7.71 (m, 1H), 7.56 - 7.51 (m, 1H), 7.44 (d, J = 8.2 Hz,
2H), 6.10 (t, J = 5.7 Hz, 1H), 5.73 (d, J = 7.3 Hz, 1H), 5.50 (d, J = 15.4 Hz, 1H), 4.66 (d, J = 15.4 Hz, 1H), 4.56 (dt, J = 10.9, 7.1 Hz, 1H), 4.07 (dd, J = 13.3, 7.0 Hz, 1H), 3.52 (dd, J = 13.1, 11.2 Hz, 1H), 3.45 (q, J = 6.8 Hz, 2H), 2.64 (s, 3H), 2.20 - 2.05 (m, 2H), 1.82 (p, J = 7.4 Hz, 2H), 1.40 (s, 9H).
LCMS: METCR1416 generic 7 min, rt=4.23分, M/Z (ES+) 591.95 [M+Na+], 513.95/515.95 [M-tBu+H] 100% UV; NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.71 (s, 1H), 7.74 (d, J = 8.5 Hz, 1H), 7.58 (d, J = 5.5 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.34 (s, 4H), 5.21 (d, J = 16.1 Hz, 1H), 4.79 (d, J = 16.0 Hz, 1H), 4.41 (dt, J = 11.7, 7.7 Hz, 1H), 4.09 (dd, J = 13.3, 7.4 Hz, 1H), 3.84 - 3.67 (m, 1H), 3.50 - 3.37 (m, 4H), 3.25 (s, 3H), 1.37 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.18分, M/Z (ES+) 640 [M+Na+] 78% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.10 - 8.00 (m, 2H), 8.00 - 7.95 (m, 1H), 7.78 - 7.72 (m, 1H), 7.61 - 7.53 (m, 2H), 7.47 - 7.39 (m, 2H), 6.33 (s, 1H), 5.78 (m, 1H), 5.50 (m, 1H), 4.66 (m, 1H), 4.56 (dt, J = 11.0, 7.2 Hz, 1H), 4.05 (dd, J = 13.3, 6.9 Hz, 1H), 3.58 - 3.51 (m, 1H), 3.44 (m, 1H), 2.65 (s, 3H), 1.87 (m, 1H), 1.40 (s, 9H).
中間体IX−53(後で溶出したエナンチオマー):
LCMS: METCR1416 generic 7 min, rt=4.46分, M/Z (ES+) 627.90/630 [M+Na+] 99% UV
NMRデータ: 1H NMR (500 MHz, メタノール-d4) d 8.65 (s, 1H), 7.87 (d, J = 5.5 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.32 - 7.22 (m, 4H), 5.41 (d, J = 14.9 Hz, 1H), 4.74 (d, J = 14.9 Hz, 1H), 4.37 (dd, J = 10.6, 8.4 Hz, 1H), 4.01 (t, J = 11.2 Hz, 1H), 3.51 (q, J = 6.6 Hz, 2H), 3.38 - 3.35 (m, 1H), 2.36 - 2.22 (m, 2H), 1.90 (dt, J = 14.7, 7.0 Hz, 2H), 1.42 (s, 9H). NHはNMRでは見えない
中間体IX−54(先に溶出したエナンチオマー):
LCMS: METCR1416 generic 7 min, rt=4.36分, M/Z (ES+) 627.90/630 [M+Na+] 96% UV
NMRデータ: 1H NMR (500 MHz, メタノール-d4) δ 8.59 (s, 1H), 7.62 (d, J = 8.6 Hz,
1H), 7.58 (d, J = 5.8 Hz, 1H), 7.39 (d, J = 8.3 Hz, 2H), 7.31 (q, J = 7.2, 6.8 Hz, 3H), 5.36 (d, J = 15.8 Hz, 1H), 4.64 (d, J = 15.9 Hz, 1H), 4.61 - 4.55 (m, 1H), 3.93 - 3.83 (m, 1H), 3.44 (q, J = 6.6 Hz, 2H), 3.37 - 3.34 (m, 1H), 2.30 - 2.17 (m, 2H), 1.91 - 1.79 (m, 2H), 1.44 (s, 9H). NHはNMRでは見えない
LCMS: METCR1410 Generic 1.7 min, rt=1.14分, M/Z (ES+) 522.95 [M-tBu+H] 99% UV;
NMRデータ: 1H NMR (250 MHz, DMSO-d6) d 9.19 - 9.07 (m, 1H), 7.78 (d, J = 8.5 Hz,
3H), 7.64 - 7.58 (m, 1H), 7.59 - 7.47 (m, 3H), 5.28 (d, J = 16.3 Hz, 1H), 5.04 - 4.82 (m, 1H), 4.56 - 4.30 (m,1H), 4.22 - 3.96 (m, 1H), 3.90 - 3.68 (m, 1H), 3.57 - 3.40 (m, 1H), 2.10 - 1.90 (m, 1H), 1.73 - 1.52 (m, 1H), 1.42 - 1.26 (m, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.27分, M/Z (ES+) 557 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.76 (t, J = 5.6 Hz, 1H), 7.80 - 7.74 (m, 3H), 7.61 (d, J = 5.5 Hz, 1H), 7.57 - 7.49 (m, 3H), 5.28 (d, J = 16.6 Hz, 1H), 4.91 (d, J = 16.5 Hz, 1H), 4.44 (dt,J = 11.7, 7.7 Hz, 1H), 4.11 (dd, J = 13.2, 7.3 Hz, 1H), 3.83 - 3.71 (m, 1H), 3.30 - 3.26 (m, 2H), 2.34 - 2.19 (m, 2H), 1.71 (dt, J = 14.4, 6.8 Hz, 2H), 1.41 - 1.31 (m, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.26分, M/Z (ES+) 574/576 [M-tBu+H], 652.10/654.20 [M+Na+] 100% UV; NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.65 (d, J = 7.6 Hz, 1H), 7.74 (d, J = 8.3 Hz, 1H), 7.57 (d, J = 5.5 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.34 (s, 4H), 5.21 (d, J = 15.8 Hz, 1H), 4.81 (d, J =15.9 Hz, 1H), 4.40 (dt, J = 11.7, 7.6 Hz, 1H), 4.10 (dd, J = 13.3, 7.3 Hz, 1H), 4.00 - 3.92 (m, 1H), 3.82 - 3.71 (m, 1H), 2.06 - 1.80 (m, 6H), 1.60 (d, J = 9.1 Hz, 2H), 1.37 (s, 9H).
LCMS: MET-uPLC-AB-101, rt=3.93分, M/Z (ES+) 620.1/622.1 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.02 (d, J = 4.0 Hz, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.69 (d, J = 5.3 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.40 - 7.30 (m, 4H), 5.14 (d, J = 15.9 Hz, 1H), 4.87 (dd, J = 16.0, 3.8 Hz, 1H), 4.44 - 4.35 (m, 1H), 4.15 - 4.05 (m, 1H), 3.80 - 3.72 (m, 1H), 3.24 - 3.18 (m, 1H), 2.13 - 2.03 (m, 1H), 1.37 (s, 9H), 1.32 - 1.19 (m, 2H).
LCMS: METCR1410 Generic 1.7 min, rt=1.22分, M/Z (ES+) 550.05 [M-tBu+H] 99% UV;
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.97 (d, J = 6.1 Hz, 1H), 7.81 (d,
J = 10.0 Hz, 1H), 7.37 - 7.23 (m, 2H), 7.08 - 6.91 (m, 2H), 6.77 (dt, J = 11.7,
5.8 Hz, 1H), 5.72 (d, J = 7.1 Hz, 1H), 5.20 (d, J = 15.0 Hz, 1H), 4.81 (d, J = 15.0 Hz, 1H), 4.51 (dt, J = 10.9, 7.0 Hz, 1H), 4.18 - 3.97 (m, 1H), 3.64 - 3.43 (m, 3H), 2.32 - 2.05 (m, 2H), 1.91 (p, J = 7.1 Hz, 2H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.16分, M/Z (ES+) 516.05 [M-tBu+H] 100% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.97 (dd, J = 6.0, 3.4 Hz, 1H), 7.81 (d, J = 9.9 Hz, 1H), 7.38 - 7.26 (m, 2H), 7.00 (t, J = 8.6 Hz, 2H), 6.92 (d, J = 13.0 Hz, 1H), 5.73 (d, J = 7.0 Hz, 1H), 5.21 (d, J = 15.0 Hz, 1H), 4.79 (dd, J = 15.1, 1.6 Hz, 1H), 4.60 - 4.41 (m, 1H), 4.07 (m, 1H), 3.52 (dd, J = 13.2, 11.1 Hz, 2H), 1.93 (m, 1H), 1.49 (dt, J = 9.7, 4.6 Hz, 1H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.27分, M/Z (ES+) 496.05 [M-tBu+H] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.00 (d, J = 6.1 Hz, 1H), 7.79 (d,
J = 9.9 Hz, 1H), 7.34 - 7.28 (m, 2H), 7.03 - 6.96 (m, 2H), 6.67 (dt, J = 11.1, 5.3 Hz, 1H), 5.73 (d, J = 7.1 Hz, 1H), 5.18 (d, J = 15.1 Hz, 1H), 4.81 (d, J = 15.1 Hz, 1H), 4.50 (dt, J = 10.9, 7.0 Hz, 1H), 4.08 (dd, J = 13.3, 6.9 Hz, 1H), 3.55 - 3.41 (m, 3H), 1.64 - 1.57 (m, 2H), 1.45 - 1.37 (m, 11H), 0.96 (t, J = 7.4 Hz, 3H).
LCMS: METCR1410 Generic 1.7 min, rt=1.28分, M/Z (ES+) 530.05 [M-tBu+H] 99% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.02 (d, J = 6.1 Hz, 1H), 7.79 (d,
J = 9.8 Hz, 1H), 7.42 - 7.34 (m, 2H), 7.35 - 7.27 (m, 5H), 7.04 - 6.95 (m, 3H),
5.73 (d, J = 7.1 Hz, 1H), 5.18 (d, J = 15.1 Hz, 1H), 4.83 (d, J = 15.1 Hz, 1H),
4.74 - 4.60 (m, 2H), 4.51 (dt, J = 10.9, 7.0 Hz, 1H), 4.07 (dd, J = 13.4, 6.9 Hz, 1H), 3.51 (dd, J = 13.3, 11.1 Hz, 1H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.21分, M/Z (ES+) 524.10/526.10 [M-Boc+H] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.64 (t, J = 5.5 Hz, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 5.5 Hz, 1H), 7.53 (d, J = 8.1 Hz, 1H), 7.34 (s, 4H), 5.21 (d, J = 16.1 Hz, 1H), 4.80 (d, J = 16.0 Hz, 1H), 4.42 (dt, J = 11.7, 7.7 Hz, 1H), 4.13 - 4.08 (m, 1H), 3.86 - 3.73 (m, 3H), 3.29 - 3.20 (m, 4H), 1.58 (d, J = 13.9 Hz, 2H), 1.53 - 1.47 (m, 1H), 1.43 (q, J = 6.8 Hz, 2H), 1.37 (s,9H), 1.20 - 1.10 (m, 2H).
LCMS: METCR1410 Generic 1.7 min, rt=1.21分, M/Z (ES+) 532.05 [M-tBu+H], 610.15
[M+Na+] 98% UV; NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.73 (t, J = 5.6 Hz, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.56 - 7.50 (m, 2H), 7.35 - 7.24 (m, 5H), 5.29 (d, J = 16.1 Hz, 1H), 4.70 (d, J = 16.0 Hz, 1H), 4.44 (dt, J = 11.7, 7.8 Hz, 1H), 4.11 (dd, J = 8.7, 4.6 Hz, 1H), 3.83 - 3.74 (m, 1H), 3.32 - 3.27 (m, 2H), 2.34 - 2.18 (m, 2H), 1.70 (dt, J = 14.8, 7.0 Hz, 2H), 1.37 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.26分, M/Z (ES+) 654.15/656.20 [M+Na+] 100%
UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.03 (d, J = 6.0 Hz, 1H), 7.78 (d,
J = 9.8 Hz, 1H), 7.31 - 7.23 (m, 6H), 6.94 - 6.87 (m, 3H), 5.71 (d, J = 7.1 Hz,
1H), 5.16 (d, J = 15.2 Hz, 1H), 4.84 (d, J = 15.2 Hz, 1H), 4.64 - 4.54 (m, 2H),
4.51 (dt, J = 10.9, 7.0 Hz, 1H), 4.07 (dd, J = 13.4, 6.9 Hz, 1H), 3.81 (s, 3H),
3.51 (dd, J = 13.3, 11.1 Hz, 1H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.21分, M/Z (ES+) 634.25 [M+H+] 97.9% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 8.40 (d, J = 5.9 Hz, 1H), 7.79 (d,
J = 9.5 Hz, 1H), 7.42 - 7.29 (m, 2H), 7.15 - 6.92 (m, 3H), 5.65 (d, J = 7.0 Hz,
1H), 5.45 (d, J = 15.4 Hz, 1H), 5.02 (d, J = 15.4 Hz, 1H), 4.64 (d, J = 5.5 Hz,
2H), 4.49 (dt, J = 10.9, 7.1 Hz, 1H), 4.09 (dd, J = 14.2, 7.1 Hz, 1H), 3.55 - 3.40 (m, 1H), 2.38 (td, J = 8.2, 4.1 Hz, 1H), 1.39 (s, 9H), 1.25 - 1.18 (m, 2H), 1.18 - 1.11 (m, 2H).
LCMS: METCR1410 Generic 1.7 min, rt=1.12分, M/Z (ES+) 616 [M+Na+] 100% UV;
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.97 (d, J = 6.1 Hz, 1H), 7.80 (d,
J = 9.9 Hz, 1H), 7.36 - 7.27 (m, 2H), 7.04 - 6.95 (m, 2H), 6.82 - 6.66 (m, 1H),
5.72 (d, J = 7.1 Hz, 1H), 5.19 (d, J = 15.0 Hz, 1H), 4.81 (d, J = 15.0 Hz, 1H),
4.58 - 4.42 (m, 1H), 4.17 - 3.93 (m, 3H), 3.58 - 3.45 (m, 1H), 3.45 - 3.26 (m, 4H), 1.98 - 1.78 (m, 1H), 1.72 - 1.61 (m, 2H), 1.47 - 1.33 (m, 11H).
4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−3−イル]カルバミン酸tert−ブチル(中間体IX−68)の合成
LCMS: METCR1410 Generic 1.7 min, rt=1.2分, M/Z (ES+) 608 [M+Na+] 100% UV;
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.96 (d, J = 6.1 Hz, 1H), 7.82 (d,
J = 10.0 Hz, 1H), 7.35 - 7.27 (m, 2H), 7.05 - 6.95 (m, 2H), 6.94 - 6.81 (m, 1H), 5.71 (d, J = 7.1 Hz, 1H), 5.19 (d, J = 15.1 Hz, 1H), 4.82 (d, J = 15.1 Hz, 1H), 4.59 - 4.36 (m, 2H), 4.17 - 4.01 (m, 1H), 3.52 (dd, J = 13.2, 11.1 Hz, 1H), 3.24 - 2.99 (m, 2H), 2.75 - 2.47 (m, 2H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.22分, M/Z (ES+) 640.2 [M+Na+] 99% UV;
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.73 (t, J = 5.6 Hz, 1H), 7.73 (d, J = 8.5 Hz, 1H), 7.61 (d, J = 5.5 Hz, 1H), 7.49 (d, J = 8.2 Hz, 1H), 7.22 (d, J = 8.6 Hz, 2H), 6.81 (d, J = 8.6 Hz, 2H), 5.15 (d, J = 15.5 Hz, 1H), 4.73 (d, J = 15.5 Hz, 1H), 4.38 (dt, J = 11.6, 7.8 Hz, 1H), 4.10 - 4.00 (m, 1H), 3.79 - 3.73 (m, 1H), 3.71 (s, 3H), 2.34 - 2.19 (m, 2H), 1.71 (dt, J = 14.6, 7.0 Hz, 2H), 1.37 (s,
9H). [2Hは水のピークに隠れている]
LCMS: METCR1410 Generic 1.7 min, rt=1.11分, M/Z (ES+) 628.2 [M+Na+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.66 (t, J = 5.7 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.50 (dd, J = 10.5, 6.9 Hz, 2H), 7.23 (d, J = 8.6 Hz, 2H), 6.82 (d, J = 8.6 Hz, 2H), 5.21 (d, J = 15.6 Hz, 1H), 4.64 (d, J = 15.5 Hz, 1H), 4.39 (dt, J = 11.6, 7.8 Hz, 1H), 4.08 (dd, J = 13.2, 7.3 Hz, 1H), 3.87 - 3.80 (m, 2H), 3.80 - 3.73 (m, 1H), 3.72 (s, 3H), 3.25 (t, J = 11.2 Hz, 2H), 3.17 - 3.07 (m, J = 6.4 Hz, 2H), 1.77 - 1.66 (m, 1H), 1.52 (d, J = 13.2 Hz, 2H), 1.37 (s, 9H), 1.22 - 1.11 (m, 2H).
LCMS: METCR1410 Generic 1.7 min, rt=1.16分, M/Z (ES+) 606.2 [M+Na+] 96% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.11 (d, J = 9.6 Hz, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 5.4 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.25 - 7.16 (m, 2H), 6.82 (dd, J = 8.8, 2.4 Hz, 2H), 5.16 (dd, J = 15.5, 2.3 Hz, 1H), 4.72 (dd, J = 15.5, 9.8 Hz, 1H), 4.38 (dtd, J = 11.5, 7.8, 3.7 Hz, 1H), 4.08 (dq, J = 9.6, 3.6 Hz, 1H), 3.79 - 3.73 (m, 1H), 3.72 (s, 3H), 2.05 - 1.93 (m, 1H), 1.65 - 1.54
(m, 1H), 1.37 (s, 9H), 1.30 - 1.22 (m, 1H).
LCMS: METCR1410 Generic 1.7 min, rt=1.15分, M/Z (ES+) 618.20/620.25 [M+Na+] 100%
UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.91 (d, J = 6.1 Hz, 1H), 7.74 (d,
J = 9.9 Hz, 1H), 7.21 (s, 3H), 6.47 (d, J = 11.9 Hz, 1H),5.63 (d, J = 7.1 Hz, 1H), 5.13 (d, J = 15.2 Hz, 1H), 4.73 (d, J = 15.2 Hz, 1H), 4.42(s, 1H), 4.02 - 3.87 (m, 3H), 3.46 (t, J = 10.4 Hz, 3H), 1.92 (s, 2H), 1.57 (d, J = 7.9 Hz, 2H), 1.33 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.22分, M/Z (ES+) 606.20/608.30 [M+Na+] 97% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.09 (d, J = 8.1 Hz, 1H), 7.76 (d,
J = 8.1 Hz, 1H), 7.53 (d, J = 1.3 Hz, 1H), 7.33 - 7.27 (m, 4H), 6.18 (d, J = 6.3 Hz, 1H), 5.69 (d, J = 7.3 Hz, 1H), 5.41 - 4.59 (m, 2H), 4.52 (dt, J = 10.8, 7.1 Hz, 1H), 4.42 (d, J = 2.0 Hz, 1H), 4.06 (dd, J = 13.3, 6.9 Hz, 1H), 3.52 (dd, J = 13.2, 11.1 Hz, 1H), 3.16 - 3.04 (m, 2H), 2.55 (qd, J = 13.0, 6.5 Hz, 2H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.25分, M/Z (ES+) 560.15/ 562.15 [M-tBu+H] 99% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) δ 7.97 (d, J = 6.1 Hz, 1H), 7.81 (d, J = 9.9 Hz, 1H), 7.36 - 7.24 (m, 4H), 6.80 (dd, J = 12.1, 7.1 Hz, 1H), 5.70 (d, J = 6.8 Hz, 1H), 5.19 (d, J = 15.1 Hz, 1H), 4.81 (d, J = 15.2 Hz, 1H), 4.70 - 4.57 (m, 1H), 4.51 (dt, J = 10.6, 6.9 Hz, 1H), 4.08 (dt, J = 11.2, 4.3 Hz, 1H), 3.62 - 3.43 (m, 1H), 2.73 - 2.46 (m, 1H), 2.46 - 2.24 (m, 2H), 2.24 - 2.05 (m, 2H), 1.94 - 1.75 (m, 1H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.15分, M/Z (ES+) 574/576 [M+Na+] 100% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) δ 8.09 (d, J = 8.1 Hz, 1H), 7.77 (dd, J = 8.1, 1.6 Hz, 1H), 7.57 (d, J = 1.5 Hz, 1H), 7.29 (d, J = 2.4 Hz, 4H), 6.13 (s, 1H), 5.70 (d, J = 7.0 Hz, 1H), 5.38 (d, J = 15.2 Hz, 1H), 4.97 - 4.87 (m, 1H), 4.70 - 4.40 (m, 3H), 4.13 - 4.01 (m, 1H), 3.51 (dd, J = 13.3, 11.0 Hz, 1H), 3.03 (dd, J = 8.5, 4.9 Hz, 1H), 1.40 (s, 9H), 1.10 - 0.92 (m, 1H).
LCMS: METCR1410 Generic 1.7 min, rt=1.17分, M/Z (ES+) 590 [M+Na+] 99% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 8.02 (d, J = 8.1 Hz, 1H), 7.74 (d,
J = 8.1 Hz, 1H), 7.55 (s, 1H), 7.43 (t, J = 6.8 Hz, 1H), 7.31 - 7.21 (m, 1H), 7.12 - 6.89 (m, 2H), 6.14 (d, J = 6.5 Hz, 1H), 5.62 (d, J = 6.8 Hz, 1H), 5.29 (d, J = 15.3 Hz, 1H), 4.80 (d, J = 15.1 Hz, 1H), 4.58 - 4.27 (m, 2H), 4.02 (m, 1H), 3.43 (dd, J = 13.2, 10.9 Hz, 1H), 3.20 - 2.90 (m, 2H), 2.64 - 2.31 (m, 2H), 1.33 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.17分, M/Z (ES+) 602 [M+Na+] 98% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 8.03 (d, J = 8.1 Hz, 1H), 7.75 (d,
J = 9.6 Hz, 1H), 7.28 - 7.20 (m, 1Hおよび0.5 H), 6.96 - 6.69 (m, 3H), 5.77 (dd,
J = 59.6, 6.7 Hz, 1Hおよび0.5H), 5.57 - 5.34 (m, 1H), 4.57 - 4.23 (m, 3H), 4.14
- 3.97 (m, 2H), 3.72 (s, 3H), 3.58 - 3.38 (m, 1H), 3.01 (s, 2H), 2.60 - 2.26 (m, 2H), 1.34 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.19分, M/Z (ES+) 622.15 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.05 (d, J = 8.1 Hz, 1H), 7.77 (dd, J = 8.1, 1.2 Hz, 1H), 7.40 (s, 1H), 7.25 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 6.02 (t, J = 5.5 Hz, 1H), 5.75 (d, J = 7.2 Hz, 1H), 5.44 (d, J = 14.9 Hz, 1H), 4.54 - 4.45 (m, 2H), 4.05 (dd, J = 13.3, 6.9 Hz, 1H), 3.78 (s, 3H), 3.56 - 3.44 (m, 3H), 2.22 - 2.10 (m, 2H), 1.86 (dt, J = 14.8, 7.2 Hz, 2H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.19分, M/Z (ES+) 632.2 [M+Na+], 554.1 [M-tBu+H] 100% UV; NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.04 (d, J = 8.1 Hz, 1H), 7.78 (dd, J = 8.1, 1.2 Hz, 1H), 7.52 - 7.46 (m, 1H), 7.25 - 7.20 (m, 4H), 6.94 - 6.87 (m, 2H), 6.82 - 6.76 (m, 2H), 6.14 (t, J = 5.1 Hz, 1H), 5.74 (d, J = 7.2 Hz, 1H), 5.39 (d, J = 14.9 Hz, 1H), 4.58 - 4.42 (m, 4H), 4.04 (dd, J = 13.3, 6.9 Hz, 1H), 3.82 (s, 3H), 3.74 (s, 3H), 3.49 (dd, J = 13.2, 11.1 Hz, 1H), 1.39 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.19分, M/Z (ES+) 602.2 [M+Na+] 96% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 8.07 (d, J = 8.1 Hz, 1H), 7.81 (dd, J = 8.1, 1.5 Hz, 1H), 7.36 - 7.17 (m, 8H), 6.95 - 6.87 (m, 2H), 5.99 - 5.89 (m, 1H), 5.73 (d, J = 6.9 Hz, 1H), 5.57 (d, J = 15.0 Hz, 1H), 4.58 - 4.38 (m, 4H), 4.09 - 4.00 (m, 1H), 3.83 (s, 3H), 3.50 (dd, J = 13.3, 11.0 Hz, 1H), 1.40 (s, 9H).
LCMS: METCR1416 generic 7 min, rt=1.23分, M/Z (ES+) 558.05/560.10 [M-tBu+H] 98% UV
NMRデータ: 1H NMR (250 MHz, DMSO-d6) d 9.28 (t, J = 6.0 Hz, 1H), 7.99 (s, 2H), 7.84 (s, 1H), 7.51 (d, J = 7.9 Hz, 1H), 7.34 (s, 4H), 7.21 (d, J = 8.6 Hz, 2H), 6.89 (d, J = 8.6 Hz, 2H), 5.21 (d, J = 16.2 Hz, 1H), 4.84 (d, J = 15.8 Hz, 1H), 4.40 (d, J = 5.8 Hz, 3H), 4.18 - 3.96 (m, 2H), 3.73 (s, 3H), 1.36 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.2分, M/Z (ES+) 552.15 [M-tBu+H] 630.20 [M+Na+] 96% UV; NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.59 (d, J = 7.6 Hz, 1H), 7.95 (q, J = 9.5, 8.8 Hz, 2H), 7.81 (s, 1H), 7.50 (d, J = 8.2 Hz, 1H), 7.24 (d, J = 8.6 Hz, 2H), 6.82 (d, J = 8.7 Hz, 2H), 5.18 (d, J = 15.4 Hz, 1H), 4.76 (d, J
= 15.6 Hz, 1H), 4.35 (dt, J = 11.8, 7.7 Hz, 1H), 4.10 - 4.01 (m, 1H), 3.98 (s, 1H), 3.77 - 3.74 (m, 1H), 3.72 (s, 3H), 2.05 (s, 3H), 1.96 - 1.84 (m, 3H), 1.63 (d, J = 11.2 Hz, 2H), 1.37 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.22分, M/Z (ES+) 534/536 [M-tBu+H], 612.10/614.10 [M+Na+] 100% UV; NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.03 (t, J = 5.6 Hz, 1H), 8.02 (d, J = 8.2 Hz, 1H), 7.97 - 7.92 (m, 1H), 7.81 (s, 1H), 7.53 (d, J = 8.1 Hz, 1H), 7.40 - 7.31 (m, 4H), 5.21 (d, J = 16.0 Hz, 1H), 4.85 (d, J = 16.1 Hz, 1H), 4.38 (dt, J = 11.8, 7.7 Hz, 1H), 4.14 - 4.04 (m, 1H), 3.80 - 3.69 (m, 1H), 3.54 - 3.48 (m, 2H), 2.59 - 2.53 (m, 2H), 1.37 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.12分, M/Z (ES+) 508.05/510.10 [M-tBu+H], 586.15/588.15 [M+Na+] 95.2% UV; NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 7.75 (d, J = 8.0 Hz, 1H), 7.46 (dd, J = 8.1, 1.4 Hz, 1H), 6.99 (dd, J = 18.7, 9.1 Hz, 5H), 6.00 (s, 1H), 5.42 (d, J = 7.2 Hz, 1H), 5.06 (d, J = 15.2 Hz, 1H), 4.40 - 4.35 (m, 1H), 4.33 (d, J = 15.3 Hz, 1H), 4.22 (dt, J = 10.8, 7.2 Hz, 1H), 3.72 (m, 2H), 3.53 (m, 2H), 3.45 (d, J = 9.7 Hz, 1H), 3.21 (dd, J = 13.2, 11.1 Hz, 1H), 2.06 (m, 1H), 1.57 (m, 1H), 1.09 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.12分, M/Z (ES+) 522.05/524.15 [M-tBu+H], 600..15/602.20 [M+Na+] 84% UV; NMRデータ: 1H NMR (250 MHz, DMSO-d6) d 8.89 (t, J = 6.2 Hz, 1H), 8.04 - 7.90 (m, 2H), 7.75 (d, J = 14.1 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.34 (s, 4H), 5.22 (d, J = 16.2 Hz, 1H), 4.83 (d, J = 15.9 Hz, 1H), 4.49 - 4.28 (m, 1H), 4.19 - 3.97 (m, 2H), 3.89 (d, J = 8.1 Hz, 1H), 3.81 - 3.54 (m, 5H), 3.52 - 3.37 (m, 1H), 1.97 - 1.82 (m, 1H), 1.71 - 1.47 (m, 1H), 1.36 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.18分, M/Z (ES+) 514/516 [M-tBu+H], 592.10/594.15 [M+Na+] 97% UV; NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.10 (d, J = 8.1 Hz, 1H), 7.76 (dd, J = 8.1, 1.4 Hz, 1H), 7.56 (d, J = 1.5 Hz, 1H), 7.33 - 7.29 (m, 2H), 7.29 - 7.26 (m, 2H), 6.20 (s, 1H), 5.69 (d, J = 7.3 Hz, 1H), 5.37 (d, J = 15.3 Hz, 1H), 4.65 (d, J = 15.2 Hz, 1H), 4.52 (dt, J = 10.8, 7.1 Hz, 1H), 4.07 (dd, J = 13.3, 6.9 Hz, 1H), 3.56 - 3.47 (m, 2H), 1.94 (m, 1H), 1.50 - 1.42 (m, 1H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.21分, M/Z (ES+) 598.2 [M+Na+] 97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.14 (s, 1H), 8.04 - 7.98 (m, 1H), 7.97 -
7.92 (m, 1H), 7.80 (s, 1H), 7.50 (d, J = 8.2 Hz, 1H), 7.19 (d, J = 8.0 Hz, 2H),
6.98 (d, J = 8.1 Hz, 2H), 5.21 (d, J = 16.0 Hz, 1H), 4.72 (d, J = 15.8 Hz, 1H),
4.38 (dt, J = 11.7, 7.8 Hz, 1H), 4.07 (dd, J = 12.1, 6.2 Hz, 1H), 3.79 - 3.70 (m, 1H), 3.50 - 3.42 (m, 1H), 2.05 - 1.94 (m, 1H), 1.93 - 1.83 (m, 1H), 1.70 - 1.61 (m, 1H), 1.37 (s, 9H), 0.95 - 0.90 (m, 2H), 0.65 - 0.60 (m, 2H).
LCMS: METCR1410 Generic 1.7 min, rt=1.16分, M/Z (ES+) 624.1 [M+Na+] 98% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.11 (d, J = 8.1 Hz, 1H), 7.77 (dd, J = 8.1, 1.4 Hz, 1H), 7.53 (d, J = 1.5 Hz, 1H), 7.34 (d, J = 8.6 Hz, 2H), 7.09 (d, J = 8.5 Hz, 2H), 6.51 (t, J = 73.7 Hz, 1H), 6.17 - 6.11 (m, 1H), 5.69 (d, J = 7.2 Hz, 1H), 5.41 (d, J = 15.2 Hz, 1H), 4.64 (d, J = 15.2 Hz, 1H), 4.52 (dt, J = 11.0, 7.0 Hz, 1H), 4.07 (dd, J = 13.4, 7.0 Hz, 1H), 3.55 - 3.46 (m, 2H), 1.98 - 1.88 (m, 1H), 1.48 - 1.42 (m, 1H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.14分, M/Z (ES+) 510.1 [M-tBu+H], 588.15 [M+Na+] 98% UV; NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.99 (d, J = 8.1 Hz, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.44 (d, J = 1.4 Hz, 1H), 7.23 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 8.4 Hz, 2H), 6.49 (s, 1H), 5.77 (d, J = 7.2 Hz, 1H), 5.40 (d, J = 14.8 Hz, 1H), 4.56 - 4.39 (m, 2H), 3.99 (dd, J = 13.4, 6.9 Hz, 1H), 3.77 (s, 3H), 3.58 - 3.35 (m, 2H), 1.97 - 1.71 (m, 1H), 1.46 (dd, J = 9.9, 4.7 Hz, 1H), 1.38 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.19分, M/Z (ES+) 514.1 [M-tBu+H , 592.15 [M+Na+] 96% UV; NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.06 (d, J = 8.1 Hz, 1H), 7.82 - 7.69 (m, 1H), 7.38 (d, J = 1.2 Hz, 1H), 7.37 - 7.30 (m, 5H), 6.02 (t, J = 5.4 Hz, 1H), 5.75 (d, J = 7.3 Hz, 1H), 5.57 (d, J = 15.1 Hz, 1H), 4.53 (dt, J = 10.9, 7.1 Hz, 1H), 4.47 (d, J = 15.1 Hz, 1H), 4.06 (dd, J = 13.3, 6.9 Hz, 1H), 3.51 (dd, J = 13.2, 11.1 Hz, 1H), 3.49 - 3.42 (m, 2H), 2.19 - 2.08 (m, 2H), 1.84 (dt, J = 14.6, 7.1 Hz, 2H), 1.40 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.26分, M/Z (ES+) 581.9/584.05 [M-tBu+H], 660.10/612.10 [M+Na+] 100% UV; NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 7.98 (s, 1H), 7.41 (s, 1H), 7.32 - 7.18 (m, 4H), 6.37 (t, J = 5.7 Hz, 1H), 5.68 (d, J = 7.2 Hz, 1H), 5.25 (d, J = 15.3 Hz, 1H), 4.63 (d, J = 15.3 Hz, 1H), 4.50 (dt, J = 10.9, 7.1 Hz, 1H), 4.03 (dd, J = 13.7, 7.1 Hz, 1H), 3.56 - 3.43 (m, 3H), 2.30 - 2.07 (m, 2H), 1.97 - 1.79 (m, 2H), 1.38 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.12分, M/Z (ES+) 524.2 [M-Boc+H+], 646.2 [M+Na+] 99% UV; NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.79 (t, J = 5.6 Hz, 1H), 8.00 - 7.95 (m, 1H), 7.95 - 7.90 (m, 1H), 7.77 (s, 1H), 7.51 (d, J = 8.1 Hz, 1H), 7.37 (d, J = 8.6 Hz, 2H), 7.20 (t, J = 74.2 Hz, 1H), 7.07 (d, J = 8.5 Hz, 2H), 5.23 (d, J = 16.0 Hz, 1H), 4.80 (d, J = 15.9 Hz, 1H), 4.37 (dt, J = 11.7, 7.7 Hz, 1H), 4.11 - 4.04 (m, 1H), 3.86 - 3.80 (m, 2H), 3.78 - 3.70 (m, 1H), 3.24 (t, J = 10.8 Hz, 2H), 3.18 - 3.11 (m, 2H), 1.82 - 1.69 (m, 1H), 1.54 (d, J = 12.3 Hz, 2H), 1.36 (s, 9H), 1.22 - 1.10 (m, 2H).
LCMS: METCR1410 Generic 1.7 min, rt=1.15分, M/Z (ES+) 510.10/512.05 [M-Boc+H+];
632.15/634.20 [M+Na+] 95% UV; NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.97 (t, J
= 6.1 Hz, 1H), 8.02 - 7.94 (m, 2H), 7.80 (s, 1H), 7.52 (d, J = 8.1 Hz, 1H), 7.38 - 7.30 (m, 4H), 5.24 (d, J = 16.0 Hz, 1H), 4.83 (d, J = 16.0 Hz, 1H), 4.38 (dt, J = 11.8, 7.7 Hz, 1H), 4.13 - 4.05 (m, 1H), 3.79 - 3.70 (m, 3H), 3.58 - 3.49 (m, 4H), 1.78 - 1.70 (m, 1H), 1.66 (d, J = 12.2 Hz, 3H), 1.36 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.17分, M/Z (ES+) 506.10/508.10 [M-Boc+H+],
628.15/630.20 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.45 (d, J = 8.7 Hz, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.93 (d, J = 8.2 Hz, 1H), 7.72 (s, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.35 (s, 4H), 5.27 (d, J = 16.0 Hz, 1H), 4.81 (d, J = 16.0 Hz, 1H), 4.38 (dt, J = 11.7, 7.7 Hz, 1H), 4.09 (dt, J = 13.3, 6.2 Hz, 1H), 3.90 - 3.79 (m, 3H), 3.78 - 3.72 (m, 1H), 3.28 - 3.20 (m, 2H), 1.65 - 1.54 (m, 2H), 1.51 (d, J = 13.5 Hz, 1H), 1.37 (s, 9H), 1.24 - 1.13 (m, 2H), 1.11 (d, J = 6.7 Hz, 3H).
LCMS: METCR1410 Generic 1.7 min, rt=1.14分, M/Z (ES+) 558.45 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.10 (d, J = 8.1 Hz, 1H), 7.82 (dd, J = 8.1, 1.4 Hz, 1H), 7.41 - 7.30 (m, 6H), 5.99 (s, 1H), 5.73 (d, J = 7.4 Hz, 1H), 5.61 (d, J = 15.0 Hz, 1H), 4.52 (dt, J = 10.9, 7.1 Hz, 1H), 4.45 (d, J = 15.0 Hz, 1H), 4.07 (dd, J = 13.3, 7.0 Hz, 1H), 3.52 (dd, J = 13.3, 11.1 Hz, 1H), 3.49 - 3.42 (m, 1H), 1.97 - 1.85 (m, 1H), 1.40 (s, 9H), 1.39 - 1.35 (m, 1H).
LCMS: METCR1410 Generic 1.7 min, rt=1.03分, M/Z (ES+) 599.55/ 601.20 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.36 (t, J = 5.6 Hz, 1H), 8.41 (d, J = 2.0 Hz, 1H), 8.03 - 7.95 (m, 2H), 7.85 (s, 1H), 7.58 (dd, J = 8.0, 2.3 Hz, 1H), 7.52 (d, J = 8.1 Hz, 1H), 7.38 - 7.29 (m, 4H), 7.22 (d, J = 7.9 Hz, 1H), 5.20 (d, J = 16.0 Hz, 1H), 4.86 (d, J = 16.0 Hz, 1H), 4.45 (d, J = 5.7 Hz, 2H), 4.38 (dt, J = 11.7, 7.6 Hz, 1H), 4.08 (dd, J = 13.5, 7.6 Hz, 1H), 3.78 - 3.70 (m, 1H), 2.45 (s, 3H), 1.36 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.23分, M/Z (ES+) 620.15/622.20 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.88 (d, J = 7.0 Hz, 1H), 8.04 - 7.92 (m,
2H), 7.81 (s, 1H), 7.52 (d, J = 8.1 Hz, 1H), 7.33 (s, 4H), 5.21 (d, J = 15.9 Hz, 1H), 4.84 (d, J = 15.9 Hz, 1H), 4.44 - 4.31 (m, 2H), 4.07 (dd, J = 13.3, 7.3 Hz, 1H), 3.76 - 3.70 (m, 1H), 2.32 - 2.04 (m, 4H), 1.86 - 1.74 (m, 1H), 1.66 - 1.55 (m, 1H), 1.36 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.22分, M/Z (ES+) 542.05/544.10 [M-tBu+H] , 620.10/622.15 [M+Na+] 100% UV; NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.10 (d, J = 8.1 Hz, 1H), 7.74 (dd, J = 8.1, 1.3 Hz, 1H), 7.53 (d, J = 1.4 Hz, 1H), 7.34 - 7.26 (m, 4H), 6.03 (t, J = 5.5 Hz, 1H), 5.70 (d, J = 7.6 Hz, 1H), 5.38 (d, J = 15.3 Hz, 1H), 4.63 (d, J = 15.2 Hz, 1H), 4.53 (dt, J = 10.8, 7.1 Hz, 1H), 4.06 (dd, J = 13.3, 6.9 Hz, 1H), 3.73 - 3.34 (m, 3H), 2.84 - 2.62 (m, 2H), 2.54 - 2.39 (m, 1H), 2.38 - 2.25 (m, 2H), 1.41 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.16分, M/Z (ES+) 636.10/638.15 [M+Na+] 100%
UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.70 (t, J = 5.5 Hz, 1H), 7.74 (d, J = 8.5 Hz, 1H), 7.59 (d, J = 5.5 Hz, 1H), 7.52 (d, J = 8.1 Hz, 1H), 7.34 (s, 4H), 5.19 (d, J = 16.0 Hz, 1H), 4.80 (d, J =16.1 Hz, 1H), 4.42 (dt, J = 11.6, 7.7 Hz, 1H), 4.09 (dd, J = 13.2, 7.3 Hz, 1H), 3.81 - 3.71 (m, 1H), 3.55 - 3.48 (m, 4H), 3.45 - 3.38 (m, 4H), 3.23 (s, 3H), 1.37 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.19分, M/Z (ES+) 586.05/588.10 [M+Na+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.80 (t, J = 5.5 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.62 (d, J = 5.5 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.34 (s, 4H), 5.19 (d, J = 16.1 Hz, 1H), 4.80 (d, J = 16.0 Hz, 1H), 4.42 (dt, J= 11.5, 7.7 Hz, 1H), 4.09 (dd, J = 13.3, 7.3 Hz, 1H), 3.80 - 3.71 (m, 1H), 3.37 (dd, J = 14.4, 7.2 Hz, 2H), 2.78 (t, J = 2.6 Hz, 1H), 2.41 (td, J = 7.0, 2.6 Hz, 2H), 1.37 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.21分, M/Z (ES+) 600.10/602.10 [M+Na+] 94% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.70 (t, J = 5.3 Hz, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 5.5 Hz, 1H), 7.52 (d, J = 8.1 Hz, 1H), 7.34 (s, 4H), 5.19 (d, J = 16.0 Hz, 1H), 4.83 (d, J = 16.0 Hz, 1H), 4.41 (dt,J = 11.5, 7.7 Hz, 1H), 4.09 (dd, J = 13.2, 7.3 Hz, 1H), 3.81 - 3.72 (m, 1H), 3.30 (s, 2H), 2.80 (t, J = 2.6 Hz, 1H), 2.21 (td, J = 7.2, 2.6 Hz, 2H), 1.68 (p, J = 7.0 Hz, 2H), 1.37 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.22分, M/Z (ES+) 626.05/628.10 [M+Na+] 96% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.06 (s, 1H), 7.51 (s, 1H), 7.33 -
7.28 (m, 2H), 7.26 (s, 2H), 6.53 (s, 1H), 5.68 (d, J = 7.2 Hz, 1H), 5.25 (d, J = 15.3 Hz, 1H), 4.71 (d, J = 15.3 Hz, 1H), 4.53 (dt, J = 10.9, 7.1 Hz, 1H), 4.06
(dd, J = 13.4, 6.9 Hz, 1H), 3.58 - 3.47 (m, 2H), 1.95 (m, 1H), 1.49 (m, 1H), 1.41 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1分, M/Z (ES+) 607.55/609.15 [M+H+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.74 (t, J = 5.6 Hz, 1H), 8.00 (d, J = 8.2 Hz, 1H), 7.94 (d, J = 8.2 Hz, 1H), 7.79 (s, 1H), 7.53 (d, J = 8.1 Hz, 1H), 7.38 - 7.31 (m, 4H), 5.21 (d, J = 16.0 Hz, 1H), 4.85 (d, J = 16.1 Hz, 1H), 4.38 (dt, J = 11.6, 7.6 Hz, 1H), 4.08 (dd, J = 13.2, 7.2 Hz, 1H), 3.78 - 3.69 (m, 1H), 3.57 - 3.52 (m, 4H), 3.41 - 3.36 (m, 2H), 2.45 (t, J = 6.8 Hz, 2H), 2.42 - 2.37 (m, 4H), 1.37 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.18分, M/Z (ES+) 615.55/617.10 [M+H+] 96% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.31 (t, J = 5.7 Hz, 1H), 8.12 (d, J = 2.3 Hz, 1H), 8.01 - 7.94 (m, 2H), 7.84 (s, 1H), 7.63 (dd, J = 8.5, 2.4 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.37 - 7.30 (m, 4H), 6.79 (d, J = 8.5 Hz, 1H), 5.19 (d, J = 16.0 Hz, 1H), 4.85 (d, J = 16.0 Hz, 1H), 4.43 - 4.33 (m, 3H), 4.07 (dd, J = 13.1, 7.2 Hz, 1H), 3.83 (s, 3H), 3.76 - 3.69 (m, 1H), 1.35 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.26分, M/Z (ES+) 678.20/680.20 [M+Na+] 93% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.15 (t, J = 5.9 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.63 (d, J = 5.5 Hz, 1H), 7.52 (d, J = 8.1 Hz, 1H), 7.35 (s, 4H), 7.23 (d, J = 8.6 Hz, 2H), 6.96 (d, J = 8.6Hz, 2H), 5.21 (d, J = 15.9 Hz, 1H), 4.83 - 4.78 (m, 3H), 4.46 - 4.34 (m, 3H), 4.14 - 4.05 (m, 1H), 3.82 - 3.72 (m, 1H), 3.55 (t, J = 2.4 Hz, 1H), 1.37 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.21分, M/Z (ES+) 626.1 [M+Na+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.17 (s, 1H), 8.04 (d, J = 8.2 Hz, 1H), 7.98 (dd, J = 8.2, 1.2 Hz, 1H), 7.80 (s, 1H), 7.66 (d, J = 8.2 Hz, 2H), 7.59 - 7.51 (m, 3H), 5.32 (d, J = 16.4 Hz, 1H), 4.91 (d, J = 16.4 Hz, 1H), 4.42 (dt, J = 11.8, 7.6 Hz, 1H), 4.10 (dd, J = 13.2, 7.4 Hz, 1H), 3.79 - 3.71 (m, 1H), 2.05 - 1.93 (m, 1H), 1.70 - 1.56 (m, 2H), 1.36 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.2分, M/Z (ES+) 558.0/560.0 [M-Boc+H+], 636.0/638.0 [M+Na+] 100% UV; NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.17 (s, 1H), 8.01 (d, J = 8.2 Hz, 1H), 7.98 - 7.92 (m, 1H), 7.82 (d, J = 16.4 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.46 (d, J = 8.2 Hz, 2H), 7.27 (d, J = 8.3 Hz, 2H), 5.18 (dd, J = 16.0, 10.6 Hz, 1H), 4.83 (dd, J = 23.0, 16.0 Hz, 1H), 4.37 (dtd, J = 11.9, 7.6, 4.6 Hz, 1H), 4.12 - 4.05 (m, 1H), 2.05 - 1.93 (m, 1H), 1.75 - 1.55 (m, 2H), 1.36 (s, 9H).
LCMS: METCR1410 Generic 1.7 min, rt=1.23分, M/Z (ES+) 555.05 [M-tBu+H] 99% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.04 (d, J = 6.0 Hz, 1H), 7.83 (d,
J = 9.8 Hz, 1H), 7.64 - 7.60 (m, 2H), 7.45 (d, J = 8.3 Hz, 2H), 7.34 - 7.29 (m,
2H), 7.09 - 7.04 (m, 2H), 7.02 (dd, J = 10.9, 5.0 Hz, 1H), 5.65 (d, J = 7.2 Hz,
1H), 5.23 (d, J = 15.6 Hz, 1H), 4.93 (d, J = 15.6 Hz, 1H), 4.70 - 4.57 (m, 2H),
4.57 - 4.50 (m, 1H), 4.16 - 4.09 (m, 1H), 3.52 (dd, J = 13.3, 11.1 Hz, 1H), 1.41 (s, 9H).
LCMS: METCR1673 Generic 2 minutes: rt=1.30分 M/Z (ES+) 626.95/629 [M+H+] 100 % UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) δ 9.10 (t, J = 5.9 Hz, 1H), 7.44 (d, J = 8.3 Hz, 1H), 7.37 - 7.23 (m, 11H), 5.24 (d, J = 16.0 Hz, 1H), 4.53 (d, J = 16.0 Hz, 1H), 4.39 (dd, J = 14.0, 6.6 Hz, 3H), 4.03 (dd, J = 13.3, 7.1 Hz, 1H), 3.74 - 3.66 (m, 1H), 2.81 (s, 6H), 1.37 (s, 9H).
一般的手順の節の始まりに対する例示的合成として、(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(2,2−ジフルオロシクロプロピル)−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド塩酸塩(実施例1)の合成について記載してきた。
LCMS: MET-UPLCMS-B-007, rt=2.77分, M/Z (ES+) 440 [M+H+] 92% UV
NMRデータ: 1H NMR (400 MHz, DMSO) δ 0.96 - 0.82 (m, 3H), 1.22 (s, 9H), 1.40 - 1.26 (m, 2H), 1.57 - 1.44 (m, 2H), 3.30 - 3.17 (m, 3H), 3.73 - 3.60 (m, 1H), 4.07 - 3.93 (m, 1H), 4.98 (d, J = 15.6 Hz, 1H), 5.37 (d, J = 15.6 Hz, 1H), 7.25 (q, J = 8.5 Hz, 4H), 7.80 - 7.65 (m, 2H), 8.05 (s, 1H), 8.70 (t, J = 5.7 Hz, 1H).
LCMS: MET-UPLCMS-B-007, rt=2.83分, M/Z (ES+) 468 [M+H+] 100% UV
NMRデータ: 1H NMR (400 MHz, DMSO) d 0.90 (t, J = 7.3 Hz, 3H), 1.38 - 1.26 (m, 2H), 1.56 - 1.46 (m, 2H), 3.31 - 3.19 (m, 3H), 3.68 (dd, J = 11.4, 6.9 Hz, 1H), 4.00 (dd, J = 11.7, 6.9 Hz, 1H), 5.07 (d, J = 15.6 Hz, 1H), 5.42 (d, J = 15.6 Hz, 1H), 7.26 (d, J = 8.0 Hz, 2H), 7.43 (d, J = 8.7 Hz, 2H), 7.72 (d, J = 8.0 Hz, 1H), 7.77 (dd, J = 8.0, 1.7 Hz, 1H), 8.07 (d, J = 1.6 Hz, 1H), 8.52 (s, 3H), 8.76 (t, J = 5.7 Hz, 1H).
LCMS: MET-UPLCMS-A-006, rt=2.57分, M/Z (ES+) 426 [M+H+] 99% UV
NMRデータ: 1H NMR (300 MHz, DMSO) δ 1.20 - 1.14 (m, 6H), 1.22 (s, 9H), 3.26 (t,
J = 11.6 Hz, 1H), 3.69 (dd, J = 11.5, 6.8 Hz, 1H), 4.02 - 3.90 (m, 1H), 4.16 - 4.02 (m, 1H), 5.01 (d, J = 15.5 Hz, 1H), 5.36 (d, J = 15.6 Hz, 1H), 7.34 - 7.15 (m, 4H), 7.72 (d, J = 8.0 Hz, 1H), 7.78 (dd, J = 8.0, 1.6 Hz, 1H), 8.06 (d, J = 1.5 Hz, 1H), 8.49 (d, J = 7.7 Hz, 1H), 8.55 (s, 3H).
LCMS: METCR 1416 generic 7 minutes, rt=3.37分, M/Z (ES+) 486 [M+H+] 99% UV
NMRデータ: 1H NMR (300 MHz, DMSO) δ 8.44 (t, J = 5.4 Hz, 1H), 8.31 (s, 3H), 7.76 (d, J = 6.4 Hz, 1H), 7.64 (d, J = 9.3 Hz, 1H), 7.42 (d, J = 8.7 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.32 (d, J = 15.5 Hz, 1H), 5.00 (d, J =15.6 Hz, 1H), 4.04 (dd, J = 11.6, 6.9 Hz, 1H), 3.65 (dd, J = 11.5, 6.9 Hz, 1H), 3.30 - 3.18 (m, 3H), 1.49 (p, J = 7.0 Hz, 2H), 1.32 (h, J = 7.4 Hz, 2H), 0.90 (t, J = 7.4 Hz, 3H).
LCMS: MET-UPLCMS-A-006., rt=3.78分, M/Z (ES+) 502 [M+H+] 95% UV
NMRデータ: 1H NMR (300 MHz, DMSO) δ 3.25 (t, J = 11.6 Hz, 1H), 3.67 (dd, J = 11.4, 6.8 Hz, 1H), 4.03 (dd, J = 11.7, 6.9 Hz, 1H), 4.59 - 4.42 (m, 2H), 5.05 (d, J = 15.5 Hz, 1H), 5.44 (d, J = 15.5 Hz, 1H), 7.29 - 7.22 (m, 3H), 7.37 - 7.30 (m, 4H), 7.43 (d, J = 8.7 Hz, 2H), 7.75 (d, J = 8.0 Hz, 1H), 7.83 (dd, J = 8.1, 1.8 Hz, 1H), 8.14 (d, J= 1.6 Hz, 1H), 8.49 (s, 2H), 9.37 (s, 1H).
LCMS: MET-UPLCMS-A-006, rt=3.73分, M/Z (ES+) 532 [M+H+] 96% UV
NMRデータ: 1H NMR (300 MHz, DMSO) 3.25 (t, J = 11.6 Hz, 1H), 3.67 (dd, J = 11.4,
6.8 Hz, 1H), 3.72 (s, 3H), 4.02 (dd, J = 11.8, 6.9 Hz, 1H), 4.49 - 4.34 (m, 2H), 5.05 (d,J = 15.5 Hz, 1H), 5.44 (d, J = 15.5 Hz, 1H), 6.94 - 6.84 (m, 2H), 7.29 - 7.21 (m, 4H), 7.42 (d, J = 8.7 Hz, 2H), 7.74 (d, J = 8.0 Hz, 1H), 7.81 (dd, J = 8.1, 1.8 Hz, 1H), 8.12 (d, J = 1.6 Hz, 1H), 8.49 (s, 2H), 9.29 (t, J = 5.8 Hz, 1H).
LCMS: MET-UPLCMS-A-006, rt=2.08分, M/Z (ES+) 496 [M+H+] 97% UV
NMRデータ: 1H NMR (400 MHz, DMSO) δ 1.20 (dd, J = 16.6, 9.3 Hz, 1H), 1.60 (dd, J = 19.5, 11.8 Hz, 2H), 1.75 (d, J = 11.9 Hz, 2H), 3.24 (t, J = 11.6 Hz, 1H), 3.38 (dd, J = 13.2, 9.0 Hz, 2H), 3.65 (dd, J = 11.4, 6.8 Hz, 1H), 3.88 (d, J = 9.5 Hz, 2H), 4.00 (dd, J = 7.2, 3.8 Hz, 2H), 5.07 (d, J = 15.5 Hz, 1H), 5.41 (d, J = 15.5 Hz, 1H), 7.27 (d, J = 8.1 Hz, 2H), 7.42 (d, J = 8.6 Hz, 2H), 7.73 (d, J = 8.0 Hz, 1H), 7.80 (dd, J = 8.0, 1.6 Hz, 1H), 8.05 (d, J = 1.5 Hz, 1H), 8.48 (s, 2H), 8.58 (d, J = 7.6 Hz, 1H).
LCMS: MET-UPLCMS-A-006, rt=3.19分, M/Z (ES+) 468 [M+H+] 100% UV
NMRデータ: 1H NMR (300 MHz, DMSO) δ 0.89 (t, J = 7.2 Hz, 3H), 1.39 - 1.26 (m, 2H), 1.58 - 1.43 (m, 2H), 3.31 - 3.19 (m, 3H), 3.72 - 3.61 (m, 1H), 4.10 - 3.95 (m, 1H), 5.07 (d, J = 15.7 Hz, 1H), 5.53 (d, J = 15.7 Hz, 1H),7.20 (d, J = 7.6 Hz, 1H), 7.45 - 7.27 (m, 3H), 7.80 - 7.66 (m, 2H), 8.08 (s, 1H), 8.50 (s, 3H), 8.74 (t, J = 5.0 Hz, 1H).
LCMS: MET-UPLCMS-A-006, rt=2.4分, M/Z (ES+) 418/420 [M+H+] 100% UV
NMRデータ: 1H NMR (400 MHz, DMSO) δ 0.90 (t, J = 7.3 Hz, 3H), 1.39 - 1.26 (m, 2H), 1.57 - 1.45 (m, 2H), 3.31 - 3.15 (m, 3H, 溶媒ピークで隠れている), 3.74 - 3.60 (m, 1H), 4.07 - 3.93 (m, 1H), 5.01 (d, J = 15.4 Hz, 1H), 5.41 (d, J = 15.4 Hz, 1H), 7.31 (s, 4H), 7.71 (d, J = 8.0 Hz, 1H), 7.76 (d, J = 8.3 Hz, 1H), 8.06 (s, 1H), 8.52 (s, 3H), 8.76 (t, J = 5.4 Hz, 1H).
LCMS: MET-UPLCMS-A-006, rt=3.04分, M/Z (ES+) 587 [M+H+] 100% UV
NMRデータ: 1H NMR (400 MHz, DMSO) δ 3.27 - 3.09 (m, 4H), 3.32 (t, J = 11.6 Hz, 1H), 3.75 (dd, J = 11.4, 6.8 Hz, 1H), 3.96 - 3.80 (m, 4H), 4.14 - 4.00 (m, 1H), 4.55 - 4.38 (m, 2H), 5.13 (d, J = 15.5 Hz, 1H), 5.50 (d, J = 15.6 Hz, 1H), 6.61 (s, 1H), 7.16 (bs, 2H), 7.32 (d, J = 8.1 Hz, 4H), 7.49 (d, J = 8.7 Hz, 2H), 7.80
(d, J = 8.0 Hz, 1H), 7.87 (dd, J = 8.0, 1.7 Hz, 1H), 8.21 (d, J = 1.5 Hz, 1H), 8.62 (s, 3H), 9.42 (t, J = 5.4 Hz, 1H).
LCMS: MET-UPLCMS-A-006, rt=2.32分, M/Z (ES+) 553 [M+H+] 100% UV
NMRデータ: 1H NMR (300 MHz, DMSO) 1.16 - 1.03 (m, 9H), 1.72 - 1.55 (m, 2H), 3.15
- 3.03 (m, 2H), 3.32 - 3.18 (m, 3H), 3.65 (dd, J = 11.4, 6.8 Hz, 1H), 4.07 - 3.90 (m, 1H, 溶媒ピークで隠れている), 5.07 (d, J = 15.4 Hz, 1H), 5.46 (d, J = 15.4 Hz, 2H), 7.26 (d, J = 7.9 Hz, 2H), 7.43 (d, J = 8.7 Hz, 2H), 7.60 (t, J = 5.7 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.78 (dd, J = 8.1, 1.5 Hz, 1H), 8.11 (d, J = 1.2 Hz, 1H), 8.45 (s, 3H), 8.82 (t, J =5.6 Hz, 1H).
LCMS: MET-UPLCMS-A-006, rt=1.58分, M/Z (ES-) 513 [M+ギ酸-H], 467 [M-H] 97% UV
NMRデータ: 1H NMR (400 MHz, DMSO) δ 8.69 (t, J = 5.6 Hz, 1H), 8.44 (s, 3H), 8.06 (d, J = 1.6 Hz, 1H), 7.74 (dd, J = 8.0, 1.7 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.13 (d, J = 8.7 Hz, 2H), 6.82 (d, J = 8.4 Hz, 2H), 5.41 (d, J = 15.1Hz, 1H), 4.83 (d, J = 15.1 Hz, 1H), 3.75 - 3.67 (m, 4H), 3.64 (dd, J = 11.4, 6.8 Hz, 1H), 3.34 - 3.18 (m, 3H), 3.11 - 2.97 (m, 4H), 1.59 - 1.45 (m, 2H), 1.33 (dq, J = 14.4, 7.3 Hz, 2H), 0.89 (t, 3H).
LCMS: UPLCMS-1 MET-UPLCMS-A-006, rt=2.13分, M/Z (ES+) 514 [M+H+] 99% UV
NMRデータ: 1H NMR (400 MHz, DMSO) δ 1.59 - 1.46 (m, 2H), 1.81 - 1.71 (m, 2H), 3.25 (t, J = 11.6 Hz, 1H), 3.43 - 3.37 (m, 2H), 3.69 (dd, J = 11.4, 6.9 Hz, 1H), 3.90 - 3.80 (m, 2H), 4.05 - 3.92 (m, 2H), 5.02 (d, J = 15.6 Hz,1H), 5.32 (d, J =
15.6 Hz, 1H), 7.29 (d, J = 7.9 Hz, 2H), 7.42 (d, J = 8.7 Hz, 2H), 7.65 (d, J = 9.2 Hz, 1H), 7.75 (d, J = 6.4 Hz, 1H), 8.49 (d, J = 7.6 Hz, 1H), 8.54 (s, 3H).
LCMS: MET-UPLCMS-A-006, rt=2.31分, M/Z (ES+) 472/474 [M+H+] 97% UV
NMRデータ: 1H NMR (400 MHz, DMSO) δ 1.14 (dd, J = 6.6, 2.9 Hz, 6H), 3.24 (t, J = 11.6 Hz, 1H), 3.66 (dd, J = 11.4, 6.9 Hz, 1H), 4.08 - 3.97 (m, 2H), 5.01 (d, J
= 15.6 Hz, 1H), 5.33 (d, J = 15.5 Hz, 1H), 7.29 (d, J = 7.9 Hz,2H), 7.42 (d, J = 8.7 Hz, 2H), 7.64 (d, J = 9.2 Hz, 1H), 7.74 (d, J = 6.4 Hz, 1H), 8.32 (d, J = 7.6 Hz, 1H), 8.48 (s, 3H).
LCMS: MET-UPLCMS-A-006, rt=2.69分, M/Z (ES+) 520 [M+H+] 98% UV
NMRデータ: 1H NMR (400 MHz, DMSO) δ 3.25 (t, J = 11.6 Hz, 1H), 3.66 (dd, J = 11.4, 6.9 Hz, 1H), 4.07 (dd, J = 11.5, 7.0 Hz, 1H), 4.44 (dd, J = 15.1, 5.8 Hz, 1H), 4.52 (dd, J = 15.2, 6.2 Hz, 1H), 5.00 (d, J = 15.5 Hz, 1H),5.34 (d, J = 15.5 Hz, 1H), 7.38 - 7.23 (m, 7H), 7.41 (d, J = 8.7 Hz, 2H), 7.67 (d, J = 9.4 Hz, 1H), 7.84 (d, J = 6.5 Hz, 1H), 8.44 (s, 3H), 9.05 (t, J = 5.7 Hz, 1H).
LCMS: MET-UPLCMS-A-006, rt=1.92分, M/Z (ES+) 426 [M+H+] 100% UV
NMRデータ: 1H NMR (400 MHz, DMSO) δ 2.80 (d, J = 4.5 Hz, 3H), 3.25 (t, J = 11.6
Hz, 1H), 3.68 (dd, J = 11.4, 6.8 Hz, 1H), 4.09 - 3.92 (m, 1H), 5.05 (d, J = 15.6 Hz, 1H), 5.45 (d, J = 15.6 Hz, 1H), 7.26 (d, J = 7.9 Hz, 2H), 7.42 (d, J = 8.7 Hz, 2H), 7.72 (d, J = 8.0 Hz, 1H), 7.75 (dd, J = 8.0, 1.6 Hz, 1H), 8.09 (d, J = 1.5 Hz, 1H), 8.52 (s, 3H), 8.78 (q, J = 4.3 Hz, 1H).
LCMS: MET-UPLCMS-A-006 , rt=2.31分, M/Z (ES+) 440 [M+H+] 99% UV
NMRデータ: 1H NMR (400 MHz, DMSO) δ 1.13 (t, J = 7.2 Hz, 3H), 3.35 - 3.18 (m, 3H), 3.69 (dd, J = 11.4, 6.8 Hz, 1H), 4.06 - 3.90 (m, 1H), 5.07 (d, J = 15.6 Hz, 1H), 5.44 (d, J = 15.6 Hz, 1H), 7.26 (d, J = 7.9 Hz, 2H), 7.43 (d, J = 8.7 Hz, 2H), 7.72 (d, J = 8.0 Hz, 1H), 7.77 (dd, J = 8.0, 1.7 Hz, 1H), 8.10 (d, J = 1.6 Hz, 1H), 8.57 (s, 3H), 8.83 (t, J = 5.5 Hz, 1H).
LCMS: MET-UPLCMS-A-006, rt=2.71分, M/Z (ES+) 645 [M+H+] 97% UV
NMRデータ: 1H NMR (400 MHz, DMSO) δ 1.48 - 1.33 (m, 4H), 1.73 - 1.64 (m, 2H), 1.77 (s, 3H), 3.02 (dd, J = 12.3, 6.4 Hz, 2H), 3.24 (t, J = 11.6 Hz, 1H), 3.65 (dd, J = 11.3, 6.8 Hz, 1H), 3.92 (t, J = 6.5 Hz, 2H), 4.09 - 4.01 (m,1H), 4.49 - 4.34 (m, 2H), 5.03 (d, J = 15.5 Hz, 1H), 5.44 (d, J = 15.5 Hz, 1H), 6.88 (d, J = 8.7 Hz, 2H), 7.24 (dd, J = 15.7, 8.3 Hz, 4H), 7.41 (d, J = 8.7 Hz, 2H), 7.74 (d,
J = 8.0 Hz, 1H), 7.81 (dd, J = 8.0, 1.7 Hz, 2H),8.10 (d, J = 1.5 Hz, 1H), 8.44 (s, 3H), 9.24 (t, J = 5.8 Hz, 1H).
LCMS: MET-UPLCMS-A-006, rt=2.18分, M/Z (ES+) 420 [M+H+] 89% UV
NMRデータ: 1H NMR (400 MHz, DMSO) δ 3.29 - 3.18 (m, 4H), 3.52 - 3.39 (m, 4H), 3.68 (dd, J = 11.4, 6.8 Hz, 1H), 3.98 (dd, J = 11.7, 6.8 Hz, 1H), 5.00 (d, J = 15.4 Hz, 1H), 5.43 (d, J = 15.5 Hz, 1H), 7.31 (s, 4H), 7.71 (d, J =8.0 Hz, 1H), 7.77 (dd, J = 8.0, 1.8 Hz, 1H), 8.09 (d, J = 1.7 Hz, 1H), 8.55 (s, 3H), 8.88 (t, J = 4.8 Hz, 1H).
LCMS: MET-UPLCMS-A-006 , rt=1.89分, M/Z (ES+) 409 [M+H+] 95% UV
NMRデータ: 1H NMR (400 MHz, DMSO) δ 0.89 (t, J = 7.3 Hz, 3H), 1.38 - 1.25 (m, 2H), 1.56 - 1.42 (m, 2H), 3.30 - 3.16 (m, 3H), 3.69 (dd, J = 11.3, 6.8 Hz, 1H), 4.03 (dd, J = 11.4, 6.7 Hz, 1H), 5.17 (d, J = 16.0 Hz, 1H), 5.43 (d, J = 16.0 Hz, 1H), 7.52 (d, J = 8.0 Hz, 2H), 7.84 - 7.67 (m, 4H), 8.03 (s, 1H), 8.52 (s, 3H), 8.75 (t, J = 5.3 Hz, 1H).
LCMS: METCR1416 generic 7 minutes, rt=3.25分, M/Z (ES+) 472/474 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.82 (d, J = 4.1 Hz, 1H), 8.41 (s, 3H), 8.05 (s, 1H), 7.85 - 7.69 (m, 2H), 7.32 (d, J = 2.3 Hz, 4H), 5.44 (d, J = 15.5 Hz, 1H), 4.98 (d, J = 15.4 Hz, 1H), 4.03 (dd, J = 11.7, 6.9 Hz, 1H), 3.65 (dd, J = 11.5, 6.7 Hz, 1H), 3.31 - 3.18 (m, 2H), 2.43 - 2.25 (m, 3H), 1.76 (dt, J = 14.8, 7.1 Hz, 2H).
LCMS: METCR1416 generic 7 minutes, rt=3分, M/Z (ES+) 460/462 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.74 (t, J = 5.7 Hz, 1H), 8.44 (s, 3H), 8.02 (s, 1H), 7.76 (dd, J = 8.0, 1.7 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.39 - 7.24 (m, 4H), 5.40 (d, J = 15.4 Hz, 1H), 5.00 (d, J = 15.5 Hz, 1H), 4.02 (dd, J = 11.7, 6.9 Hz, 1H), 3.92 - 3.80 (m, 2H), 3.65 (dd, J = 11.5, 6.9 Hz, 1H), 3.30 - 3.11 (m, 5H), 1.79 (ddd, J = 11.3, 7.4, 4.0 Hz, 1H), 1.57 (d, J = 13.1 Hz, 2H), 1.19 (qd, J = 12.0, 4.4 Hz, 2H).
LCMS: METCR1416 generic 7 minutes, rt=3.47分, M/Z (ES+) 485/487 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 11.58 (s, 1H), 8.40 (s, 3H), 8.18 (d, J =
1.8 Hz, 1H), 7.89 (dd, J = 8.1, 1.8 Hz, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.41 - 7.22 (m, 4H), 5.45 (d, J = 15.4 Hz, 1H), 5.00 (d, J = 15.4 Hz, 1H), 4.05 (dd, J = 11.7, 6.8 Hz, 1H), 3.66 (dd, J = 11.4, 6.8 Hz, 1H), 3.29 - 3.22 (m, 2H), 1.33 (s, 9H).
LCMS: METCR1416 generic 7 minutes, rt=2.96分, M/Z (ES+) 489 [M+H+] 100% UV
NMRデータ: (s, 1H), 9.29 (s, 1H), 8.66 (d, J = 8.0 Hz, 1H), 8.55 (s, 4H), 8.45 (s, 1H), 7.98 (d, J = 6.7 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.79 (s, 1H), 7.48 (d, J= 8.5 Hz, 2H), 7.27 (d, J = 8.2 Hz, 2H), 5.50 (d, J = 15.6 Hz, 1H), 5.25 (d, J = 15.5 Hz, 1H), 4.05 (s, 1H), 3.71 (dd, J = 11.3, 6.8 Hz, 1H), 3.34 - 3.26 (m, 1H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.27分, M/Z (ES+) 470/472 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.30 (t, J = 5.9 Hz, 1H), 8.30 (s, 2H), 8.06 (d, J = 1.6 Hz, 1H), 7.78 (dd, J = 8.0, 1.7 Hz, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.34 (dd, J = 8.5, 5.7 Hz, 2H), 7.29 (d, J = 2.4 Hz, 4H), 7.14 (t, J = 8.9 Hz, 2H), 5.40 (d, J = 15.4 Hz, 1H), 4.95 (d, J = 15.4 Hz, 1H), 4.52 - 4.39 (m, 2H), 3.98 (s, 1H), 3.65 - 3.58 (m, 1H), 3.22 (d, J = 11.6 Hz, 1H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.36分, M/Z (ES+) 496/498 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.83 (d, J = 8.0 Hz, 1H), 7.92 (d, J = 1.6 Hz, 1H), 7.74 - 7.61 (m, 2H), 7.29 (d, J = 7.1 Hz, 6H), 6.89 (d, J = 8.7 Hz, 2H), 5.35 (d, J = 15.5 Hz, 1H), 5.11 (p, J = 7.1 Hz, 1H), 4.90 (d, J = 15.5 Hz, 1H), 3.73 (s, 3H), 2.97 (s, 1H), 2.87 (t, J = 13.2 Hz, 1H), 1.45 (d, J = 7.0 Hz, 3H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.04分, M/Z (ES+) 460/462 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.73 (s, 1H), 8.35 (s, 2H), 8.02 (s, 1H),
7.79 - 7.69 (m, 2H), 7.37 - 7.28 (m, 4H), 5.42 (d, J = 15.4 Hz, 1H), 4.98 (d, J
= 15.4 Hz, 1H), 4.01 (dd, J = 11.7, 6.9 Hz, 1H), 3.80 - 3.60 (m, 4H), 3.28 - 3.08 (m, 4H), 1.85 - 1.73 (m, 2H), 1.59 (dd, J = 9.8, 3.7 Hz, 1H), 1.51 - 1.40 (m, 1H), 1.24 (q, J = 9.8 Hz, 1H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.33分, M/Z (ES+) 522 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO) d 1.75 (dt, J = 7.06, 14.74 Hz, 2H), 2.24 - 2.35 (m, 2H), 3.24 (t, J = 11.56 Hz, 1H), 3.34 - 3.43 (m, 2H), 3.63 (dd, J = 6.43, 11.14 Hz, 1H), 4.03 (dd, J = 6.89, 11.55 Hz, 1H), 5.03 (d, J = 15.25 Hz, 1H), 5.43 (d, J = 15.56 Hz, 1H), 7.26 (d, J = 8.34 Hz, 2H), 7.42 (d, J = 8.50 Hz, 2H), 7.71 - 7.79 (m, 2H), 8.04 (s, 1H), 8.36 (s, 3H), 8.80 (s, 1H)
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.09分, M/Z (ES+) 510 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO) d 1.20 (qd, J = 4.28, 12.04 Hz, 2H), 1.54 - 1.61 (m, 2H), 1.80 (ddt, J = 3.88, 7.19, 10.88 Hz, 1H), 3.11 - 3.30 (m, 5H), 3.59 - 3.67 (m, 1H), 3.82 - 3.89 (m, 2H), 4.04 (dd, J = 6.98, 11.61 Hz, 1H), 5.03 (d, J = 13.61 Hz, 1H), 5.42 (d, J = 15.55 Hz, 1H), 7.28 (d, J = 8.39 Hz, 2H), 7.42 (d, J = 8.49 Hz, 2H), 7.74 (d, J = 8.01 Hz, 1H), 7.78 (d, J = 8.10 Hz, 1H), 8.01 (s, 1H), 8.35 (s, 3H), 8.70 (s, 1H)
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.38分, M/Z (ES+) 520 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, d6-DMSO) d 3.25 (t, J = 11.59 Hz, 1H), 3.67 (dd, J =
6.86, 11.35 Hz, 1H), 4.02 (dd, J = 6.88, 11.71 Hz, 1H), 4.47 (qd, J = 5.93, 15.05 Hz, 2H), 5.05 (d, J = 15.56 Hz, 1H), 5.44 (d, J = 15.55 Hz, 1H), 7.12 - 7.19 (m, 2H), 7.26 (d, J = 8.19 Hz, 2H), 7.36 (dd, J = 5.63, 8.59 Hz, 2H), 7.42 (d, J = 8.66 Hz, 2H), 7.74 (d, J = 8.02 Hz, 1H), 7.82 (dd, J = 1.74, 8.05 Hz, 1H), 8.13 (d, J = 1.51 Hz, 1H), 8.46 (s, 3H), 9.37 (t, J = 5.80 Hz, 1H)
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.14分, M/Z (ES+) 520 [M+H+] 97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.57 (s, 1H), 9.30 (t, J = 5.9 Hz, 1H), 8.24 (s, 2H), 8.14 (d, J = 1.6 Hz, 1H), 8.04 (d, J = 8.2 Hz, 2H), 7.81 (dd, J = 8.0, 1.7 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 8.2 Hz, 2H), 7.36 (dd, J = 8.5, 5.6 Hz, 2H), 7.16 (t, J = 8.9 Hz, 2H), 5.53 (d, J = 15.6 Hz, 1H), 5.07 (d, J = 15.5 Hz, 1H), 4.57 - 4.39 (m, 2H), 4.06 (dd, J = 11.8, 6.9 Hz, 1H), 3.66 (dd, J = 11.4, 6.8 Hz, 1H), 3.31 - 3.23 (m, 1H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.26分, M/Z (ES+) 480/482 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.55 (d, J = 7.7 Hz, 1H), 8.44 (s, 3H), 8.05 (d, J = 1.7 Hz, 1H), 7.79 (dd, J = 8.0, 1.7 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.40 - 7.26 (m, 4H), 5.40 (d, J = 15.4 Hz, 1H), 5.01 (d, J = 15.4 Hz, 1H), 3.99 (dd, J = 11.7, 6.9 Hz, 2H), 3.66 (dd, J = 11.4, 6.8 Hz, 1H), 3.24 (t, J = 11.6 Hz, 1H), 1.98 (ddd, J = 64.0, 29.8, 11.0 Hz, 6H), 1.67 (q, J = 11.7, 10.7 Hz, 2H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.35分, M/Z (ES+) 484/486 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.04 (d, J = 7.9 Hz, 1H), 8.23 (s, 3H), 8.05 (dd, J = 9.6, 1.6 Hz, 1H), 7.83 (td, J = 7.0, 6.1, 1.7 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.43 (dd, J = 8.6, 5.6 Hz, 2H), 7.36 - 7.27 (m, 4H), 7.16 (t, J = 8.9 Hz, 2H), 5.39 (dd, J = 15.5, 5.5 Hz, 1H), 5.17 (td, J = 7.3, 3.5 Hz, 1H), 5.01 (d, J = 15.4 Hz, 1H), 3.99 (dd, J = 11.7, 6.8 Hz, 1H), 3.63 (dd, J = 11.4, 6.8 Hz, 1H), 3.23 (t, J = 11.6 Hz, 1H), 1.49 (dd, J = 7.0, 3.2 Hz, 3H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.3分, M/Z (ES+) 496/498 [M+H+] 96% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.82 (d, J = 8.0 Hz, 1H), 7.93 (d, J = 1.7 Hz, 1H), 7.70 (dd, J = 8.0, 1.7 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.33 - 7.26 (m, 6H), 6.89 (d, J = 8.7 Hz, 2H), 5.37 (d, J = 15.5 Hz, 1H), 5.12 (m, 1H), 4.90 (d, J = 15.5 Hz, 1H), 3.73 (s, 3H), 3.41 (q, J = 6.3 Hz, 2H), 3.03 - 2.83 (m, 1H), 1.93 (br, 2H), 1.47 (d, J = 7.0 Hz, 3H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.11分, M/Z (ES+) 507 [M+H+] 93% UV
NMRデータ: 1H NMR (500 MHz, MEtOH-d4) δ 8.79 (s, 1H), 8.67 (s, 1H), 8.07 (s, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.77 (s, 2H), 7.70 (d, J = 8.1 Hz, 1H), 5.70 (d, J = 15.4 Hz, 1H), 5.00 (d, J = 15.3 Hz, 1H), 4.56 (s, 2H), 4.11 (dd, J = 11.6, 6.9 Hz, 1H), 3.75 (dd, J = 11.5, 7.4 Hz, 1H), 3.50 - 3.42 (m, 2H), 3.23 (t, J = 11.5 Hz, 1H), 2.33 - 2.17 (m, 2H), 1.88 (p, J = 7.2 Hz, 2H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.13分, M/Z (ES+) 505 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 9.41 (t, J = 5.8 Hz, 1H), 8.72 (d, J = 1.4 Hz, 1H), 8.49 (s, 3H), 8.15 (d, J = 1.5 Hz, 1H), 7.97 (dd, J = 8.1, 1.6 Hz, 1H), 7.86 - 7.81 (m, 2H), 7.76 (d, J = 8.0 Hz, 1H), 7.36 (dd, J = 8.6, 5.6 Hz, 2H), 7.19 - 7.11 (m, 2H), 5.51 (d, J = 15.8 Hz, 1H), 5.19 (d, J = 15.8 Hz, 1H), 4.47 (qd, J = 15.1, 5.9 Hz, 2H), 4.04 (dd, J = 11.7, 6.9 Hz, 1H), 3.67 (dd, J = 11.4, 6.9 Hz, 1H), 3.24 (t, J = 11.6 Hz, 1H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.32分, M/Z (ES+) 484/486 [M+H+] 97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.98 (d, J = 7.9 Hz, 1H), 8.00 (s, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.41 (dd, J = 8.7, 5.6 Hz, 2H), 7.31 (q, J = 8.6 Hz, 4H), 7.15 (t, J = 8.9 Hz, 2H), 5.37 (d, J = 15.4 Hz, 1H), 5.15 (t, J = 7.3 Hz, 1H), 4.97 (d, J = 15.4 Hz, 1H), 3.99 - 3.89 (m, 1H), 3.62 - 3.56 (m, 1H), 3.18 (t, J = 11.7 Hz, 1H), 1.48 (d, J = 7.0 Hz, 3H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.29分, M/Z (ES+) 488/490 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.12 (t, J = 5.8 Hz, 1H), 8.56 (s, 3H), 7.83 (d, J = 6.4 Hz, 1H), 7.67 (d, J = 9.4 Hz, 1H), 7.38 - 7.29 (m, 6H), 7.18 (t, J = 8.8 Hz, 2H), 5.33 (d, J = 15.5 Hz, 1H), 4.96 (d, J = 15.5 Hz, 1H), 4.45 (qd, J = 15.1, 6.0 Hz, 2H), 4.04 (dd, J = 11.6, 6.9 Hz, 1H), 3.69 (dd, J = 11.4, 6.9 Hz, 1H), 3.26 (t, J = 11.6 Hz, 1H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.21分, M/Z (ES+) 490/492 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.64 (t, J = 5.5 Hz, 1H), 8.52 (s, 3H), 7.81 (d, J = 6.4 Hz, 1H), 7.65 (d, J = 9.3 Hz, 1H), 7.32 (q, J = 8.6 Hz, 4H), 5.34 (d, J = 15.5 Hz, 1H), 4.94 (d, J = 15.5 Hz, 1H), 4.02 (dd, J = 11.7, 6.9 Hz, 1H), 3.68 (dd, J = 11.4, 6.9 Hz, 1H), 3.33 - 3.21 (m, 3H), 2.35 - 2.24 (m, 2H), 1.73 (dt, J = 14.7, 7.0 Hz, 2H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.19分, M/Z (ES+) 436/438 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.60 - 8.47 (m, 4H), 7.75 (d, J = 6.3 Hz,
1H), 7.63 (d, J = 9.3 Hz, 1H), 7.32 (q, J = 8.4 Hz, 4H), 5.31 (d, J = 15.5 Hz, 1H), 4.95 (d, J = 15.5 Hz, 1H), 4.01 (dd, J = 11.6, 6.9 Hz, 1H), 3.68 (dd, J = 11.3, 6.8 Hz, 1H), 3.28 - 3.16 (m, 3H), 1.48 (p, J = 7.2 Hz, 2H), 1.31 (h, J = 7.3 Hz, 2H), 0.89 (t, J = 7.3 Hz, 3H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=2.98分, M/Z (ES+) 478/490 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.62 - 8.54 (m, 4H), 7.73 (d, J = 6.4 Hz,
1H), 7.64 (d, J = 9.2 Hz, 1H), 7.32 (q, J = 8.6 Hz, 4H), 5.29 (d, J = 15.5 Hz, 1H), 4.97 (d, J = 15.5 Hz, 1H), 4.01 (dd, J = 11.5, 7.0 Hz, 1H), 3.85 (dd, J = 11.2, 2.9 Hz, 2H), 3.69 (dd, J = 11.6, 7.0 Hz, 1H), 3.27 - 3.22 (m, 3H), 3.14 (dq, J = 31.8, 6.8 Hz, 2H), 1.80 - 1.69 (m, 1H), 1.56 (d, J = 12.7 Hz, 2H), 1.18 (qd, J = 12.2, 4.4 Hz, 2H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.23分, M/Z (ES+) 500/502 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.03 (t, J = 5.8 Hz, 1H), 8.59 (s, 3H), 7.80 (d, J = 6.4 Hz, 1H), 7.64 (d, J = 9.3 Hz, 1H), 7.32 (q, J = 8.4 Hz, 4H), 7.23 (d, J = 8.4 Hz, 2H), 6.89 (d, J = 8.5 Hz, 2H), 5.30 (d, J = 15.4 Hz, 1H), 4.96 (d, J = 15.5 Hz, 1H), 4.39 (qd, J = 14.9, 5.9 Hz, 2H), 4.01 (dd, J = 11.5, 6.9 Hz, 1H), 3.74 - 3.67 (m, 4H), 3.25 (t, J = 11.6 Hz, 1H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=2.83分, M/Z (ES+) 508 [M+H+] 97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.73 (t, J = 5.8 Hz, 1H), 8.14 (br, 2H), 8.02 (d, J = 1.6 Hz, 1H), 7.89 (d, J = 8.3 Hz, 2H), 7.80 - 7.70 (m, 2H), 7.49 (d, J = 8.3 Hz, 2H), 5.45 (d, J = 15.7 Hz, 1H), 5.10 (d, J = 15.8 Hz, 1H), 4.03 (dd, J = 11.7, 6.9 Hz, 1H), 3.84 (d, J = 7.3 Hz, 2H), 3.63 (dd, J = 11.4, 6.8 Hz, 1H), 3.28 - 3.12 (m, 5H), 2.65 (s, 3H), 1.85 - 1.71 (m, 1H), 1.56 (d, J = 12.7 Hz, 2H), 1.19 (qd, J = 12.2, 4.7 Hz, 2H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=2.86分, M/Z (ES+) 444 [M+H+] 94% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.64 (t, J = 5.8 Hz, 1H), 7.92 (d, J = 1.4 Hz, 1H), 7.78 - 7.56 (m, 2H), 7.31 (dd, J = 8.6, 5.6 Hz, 2H), 7.06 (t, J = 8.9 Hz, 2H), 5.39 (d, J = 15.3 Hz, 1H), 4.88 (d, J = 15.3 Hz, 1H), 3.92 - 3.77 (m, 2H), 3.31 - 3.23 (m, 3H), 3.23 - 3.07 (m, 3H), 2.97 - 2.82 (m, 1H), 1.77 (d, J = 3.6 Hz, 1H), 1.58 (d, J = 11.5 Hz, 2H), 1.39 - 1.31 (m, 1H), 1.19 (qd, J = 12.0, 4.5 Hz, 3H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=2.82分, M/Z (ES+) 451 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.23 (s, 1H), 8.67 (t, J = 5.6 Hz, 1H), 8.43 (s, 3H), 8.20 (s, 1H), 8.05 (s, 1H), 7.84 - 7.64 (m, 4H), 7.46 (d, J = 8.5 Hz, 2H), 5.49 (d, J = 15.6 Hz, 1H), 5.05 (d, J = 15.6 Hz, 1H), 4.05 (s, 1H), 3.65 (dd, J = 11.4, 6.9 Hz, 1H), 3.28 - 3.23 (m, 3H), 1.50 (p, J = 7.0 Hz, 2H), 1.32 (h, J = 7.3 Hz, 2H), 0.89 (t, J = 7.4 Hz, 3H).
LCMS: MET-UHPLC-AB-101, rt=1.44分, M/Z (ES+) 427 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.67 (t, J = 5.6 Hz, 1H), 8.35 (s, 3H), 8.03 (d, J = 1.5 Hz, 1H), 7.90 (s, 1H), 7.81 - 7.64 (m, 4H), 7.37 (d, J = 8.3 Hz, 2H), 7.31 (s, 1H), 5.45 (d, J = 15.7 Hz, 1H), 5.07 (d, J = 15.7 Hz, 1H), 4.04 (dd, J = 11.7, 6.8 Hz, 1H), 3.72 - 3.63 (m, 1H), 3.29 - 3.22 (m, 3H), 1.51 (五重線, J = 7.1 Hz, 2H), 1.32 (h, J = 7.3 Hz, 2H), 0.90 (t, J = 7.4 Hz, 3H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=2.91分, M/Z (ES+) 434/436 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.39 (t, J = 6.2 Hz, 1H), 7.94 (d, J = 1.6 Hz, 1H), 7.70 - 7.61 (m, 2H), 7.29 (s, 4H), 5.38 (d, J = 15.5 Hz, 1H), 4.90 (d, J = 15.5 Hz, 1H), 4.53 (s, 1H), 3.41 (q, J = 6.5 Hz, 2H), 3.28 -3.17 (m, 2H), 2.91 - 2.83 (m, 1H), 2.03 (d, J = 40.0 Hz, 2H), 1.09 (d, J = 3.2 Hz, 6H)
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.45分, M/Z (ES+) 484/486 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) 9.02 (d, J = 7.9 Hz, 1H), 8.31 (s, 3H), 8.05 (d, J = 1.6 Hz, 1H), 7.81 (dd, J = 8.0, 1.7 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.41 (dd, J = 8.6, 5.6 Hz, 2H), 7.35 - 7.26 (m, 4H), 7.15 (t, J = 8.9 Hz, 2H), 5.39 (d, J = 15.4 Hz, 1H), 5.16 (p, J = 7.1 Hz, 1H), 5.00 (d, J = 15.4 Hz, 1H), 3.99 (dd, J = 11.7, 6.8 Hz, 1H), 3.62 (dd, J = 11.4, 6.9 Hz, 1H), 3.22 (t, J = 11.5 Hz, 1H), 1.48 (d, J = 7.1 Hz, 3H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3分, M/Z (ES+) 452/454 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.06 (d, J = 7.0 Hz, 1H), 7.37 (d,
J = 10.7 Hz, 1H), 7.24 - 7.16 (m, 4H), 7.16 - 7.09 (m, 1H), 5.52 (d, J = 15.1 Hz, 1H), 4.63 (d, J = 15.0 Hz, 1H), 3.70 - 3.56 (m, 2H), 3.57 - 3.40 (m, 2H), 3.05 - 2.94 (m, 1H), 1.30 (s, 6H)
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.25分, M/Z (ES+) 486/488 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.82 (t, J = 5.7 Hz, 1H), 8.25 (s, 3H), 8.06 (d, J = 1.6 Hz, 1H), 7.76 (dd, J = 8.0, 1.7 Hz, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.32 (s, 4H), 5.49 (d, J = 15.5 Hz, 1H), 4.99 (d, J = 15.5 Hz, 1H), 4.14 (d, J = 6.1 Hz, 1H), 4.04 (p, J = 6.5 Hz, 1H), 3.41 - 3.35 (m, 2H), 2.36 - 2.26 (m, 2H), 1.76 (dt, J = 14.8, 7.1 Hz, 2H), 1.32 (d, J = 6.6 Hz, 3H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.14分, M/Z (ES+) 489/491 [M+H+] 93% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 3.26 (t, J = 11.58 Hz, 1H), 3.68 (dd, J =
6.86, 11.42 Hz, 1H), 4.08 (dd, J = 6.87, 11.67 Hz, 1H), 5.00 (d, J = 15.42 Hz, 1H), 5.30 (d, J = 15.44 Hz, 1H), 6.76 - 6.82 (m, 2H), 6.99 - 7.06 (m, 2H), 7.29 - 7.39 (m, 4H), 7.69 (d, J = 9.20 Hz, 1H), 7.80 (d, J = 6.32 Hz, 1H), 8.02 (d, J
= 2.78 Hz, 1H), 8.44 (s, 3H), 10.36 (d, J = 2.57 Hz, 1H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=2.87分, M/Z (ES+) 447/449 [M+H+] 82% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 10.49 (s, 1H), 9.93 (s, 1H), 8.31 (s, 3H), 8.06 - 8.00 (m, 1H), 7.80 - 7.73 (m, 2H), 7.35 - 7.27 (m, 4H), 5.49 - 5.39 (m, 1H), 4.99 - 4.89 (m, 1H), 4.05 (dd, J = 11.7, 6.9 Hz, 1H), 3.68 - 3.60 (m, 1H), 3.24 (t, J = 11.6 Hz, 1H), 2.17 (t, J = 7.3 Hz, 2H), 1.58 (h, J = 7.4 Hz, 2H), 0.92 (t, J = 7.4 Hz, 3H)
LCMS: MET-uPLC-AB-101, rt=2.39分, M/Z (ES+) 454/456 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.46 (t, J = 5.4 Hz, 1H), 8.42 - 8.19 (m,
3H), 7.85 (d, J = 6.4 Hz, 1H), 7.63 (d, J = 9.3 Hz, 1H), 7.43 (t, J = 8.2 Hz, 1H), 7.36 (dd, J = 9.8, 2.0 Hz, 1H), 7.22 (dd, J = 8.3, 2.0 Hz, 1H), 5.35 (d, J = 15.3 Hz, 1H), 4.90 (d, J = 15.3 Hz, 1H), 3.98 (dd, J = 11.6, 6.9 Hz, 1H), 3.64 (dd, J = 11.4, 6.9 Hz, 1H), 3.30 - 3.22 (m, 2H), 3.18 (t, J = 11.6 Hz, 1H), 1.50
(p, J = 7.1 Hz, 2H), 1.39 - 1.28 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H).
LCMS: MET-uPLC-AB-101, rt=2.05分, M/Z (ES+) 496/498 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.52 (t, J = 5.7 Hz, 1H), 8.48 - 8.27 (m,
3H), 7.83 (d, J = 6.4 Hz, 1H), 7.63 (d, J = 9.3 Hz, 1H), 7.42 (t, J = 8.2 Hz, 1H), 7.36 (dd, J = 9.8, 2.0 Hz, 1H), 7.21 (dd, J = 8.3, 1.9 Hz, 1H), 5.34 (d, J = 15.3 Hz, 1H), 4.90 (d, J = 15.3 Hz, 1H), 3.99 (dd, J = 11.7, 6.9 Hz, 1H), 3.85 (dd, J = 11.3, 2.6 Hz, 2H), 3.67 - 3.60 (m, 1H), 3.26 (td, J = 11.7, 1.8 Hz, 2H), 3.22 - 3.10 (m, 3H), 1.83 - 1.71 (m, 1H), 1.62 - 1.53 (m, 2H), 1.26 - 1.15 (m, 2H).
LCMS: METCR1600, rt=4.01分, M/Z (ES+) 496/498 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.63 - 8.46 (m, 4H), 7.70 (d, J = 6.4 Hz,
1H), 7.65 (d, J = 9.2 Hz, 1H), 7.51 (t, J = 8.0 Hz, 1H), 7.36 (d, J = 10.4 Hz, 1H), 7.16 (d, J = 8.2 Hz, 1H), 5.25 (d, J = 15.7 Hz, 1H), 5.04 (d, J = 15.7 Hz, 1H), 4.03 (dd, J = 11.7, 6.8 Hz, 1H), 3.89 - 3.81 (m, 2H), 3.75 - 3.64 (m, 1H), 3.30 - 3.21 (m, 3H), 3.21 - 3.07 (m, 2H), 1.81 - 1.66 (m, 1H), 1.56 (d, J = 11.1
Hz, 2H), 1.25 - 1.13 (m, 2H).
LCMS: METCR1278 Generic 3.5 minutes, rt=2.4分, M/Z (ES+) 454/456 [M+H+] 96% UV
NMRデータ: 1H NMR (500 MHz, MEtOH-d4) d 7.74 (d, J = 6.6 Hz, 1H), 7.47 (d, J = 9.8 Hz, 1H), 7.32 (t, J = 7.9 Hz, 1H), 7.25 (dd, J = 10.1, 1.9 Hz, 1H), 7.10 (d, J = 8.2 Hz, 1H), 5.41 (d, J = 15.4 Hz, 1H), 4.81 (d, J = 10.2 Hz, 1H), 3.62 - 3.49 (m, 2H), 3.45 - 3.34 (m, 2H), 3.01 - 2.89 (m, 1H), 1.59 (p, J = 7.2 Hz, 2H), 1.50 - 1.35 (m, 2H), 0.97 (t, J = 7.4 Hz, 3H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.06分, M/Z (ES+) 438/440 [M+H+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 11.62 (s, 1H), 8.42 (s, 3H), 7.79 (d, J =
6.2 Hz, 1H), 7.64 (d, J = 9.1 Hz, 1H), 7.31 (dd, 4H), 5.34 (d, J = 15.4 Hz, 1H), 4.91 (d, J = 15.4 Hz, 1H), 4.08 - 3.99 (m, 1H), 3.84 (t, J = 6.5 Hz, 2H), 3.68 - 3.61 (m, 1H), 3.24 (t, J = 11.5 Hz, 1H), 1.61 (h, J = 7.2 Hz, 2H), 0.93 (t, J = 7.4 Hz, 3H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.21分, M/Z (ES+) 452/453 [M+H+] 97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 11.65 (s, 1H), 8.35 (s, 3H), 7.80 (d, J =
6.2 Hz, 1H), 7.65 (d, J = 9.0 Hz, 1H), 7.34 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 5.35 (d, J = 15.5 Hz, 1H), 4.92 (d, J = 15.3 Hz, 1H), 4.04 (dd, J = 11.2, 7.0 Hz, 1H), 3.67 (dd, J = 17.1, 5.6 Hz, 3H), 3.24 (t, J = 11.5 Hz, 1H), 1.93 (dt, J = 13.4, 6.7 Hz, 1H), 0.94 (d, J = 6.7 Hz, 6H)
LCMS: MET-UHPLC-AB-101, rt=2.28分, M/Z (ES+) 451/452 [M+H+] 94% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 10.15 (s, 1H), 8.44 (s, 3H), 7.74 (d, J =
6.3 Hz, 1H), 7.64 (d, J = 9.2 Hz, 1H), 7.37 - 7.28 (m, 4H), 5.29 (d, J = 15.4 Hz, 1H), 4.96 (d, J = 15.4 Hz, 1H), 4.05 (s, 1H), 3.65 (dd, J =11.4, 6.8 Hz, 1H), 3.24 (s, 1H), 2.66 (d, J = 6.7 Hz, 2H), 1.75 (m, 1H), 0.92 (d, J = 6.7 Hz, 6H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.08分, M/Z (ES+) 404/406 [M+H+] 100% UV
NMRデータ: 1H NMR (250 MHz, DMSO-d6) d 1.19 (d, J = 6.60 Hz, 6H), 3.16 - 3.29 (m, 1H), 3.58 - 3.74 (m, 1H), 4.00 (dd, J = 6.76, 11.58 Hz, 1H), 4.12 (dq, J = 6.60, 13.83 Hz, 1H), 4.99 (d, J = 15.41 Hz, 1H), 5.41 (d, J = 15.39 Hz, 1H), 7.24 - 7.40 (m, 4H), 7.71 (d, J = 8.03 Hz, 1H), 7.79 (dd, J = 1.65, 8.05 Hz, 1H), 8.03 (d, J = 1.53 Hz, 1H), 8.20 - 8.66 (m, 4H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.19分, M/Z (ES+) 434/436 [M+H+] 93% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 11.93 (s, 1H), 8.43 (s, 3H), 7.99 - 7.92 (m, 1H), 7.85 - 7.70 (m, 1H), 7.69 - 7.62 (m, 1H), 7.40 - 7.25 (m, 4H), 5.44 - 5.26 (m, 1H), 5.05 - 4.92 (m, 1H), 4.09 - 3.96 (m, 1H), 3.72 - 3.62 (m, 3H), 3.24 (t, J = 11.6 Hz, 1H), 2.00 - 1.86 (m, 1H), 1.01 - 0.80 (m, 6H)
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.27分, M/Z (ES+) 432/434 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.40 - 8.12 (m, 4H), 7.97 (dd, J = 4.5, 1.7 Hz, 1H), 7.80 - 7.75 (m, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.35 - 7.27 (m, 4H), 5.36 (d, J = 15.3 Hz, 1H), 5.00 (dd, J = 15.5, 7.8 Hz, 1H), 4.01 (dd, J = 11.1, 7.5 Hz, 1H), 3.88 - 3.76 (m, 1H), 3.65 - 3.58 (m, 1H), 3.22 (td, J = 11.6, 3.9 Hz, 1H), 1.76 (h, J = 6.9 Hz, 1H), 1.11 (dd, J = 6.8, 3.3 Hz, 3H), 0.88 (t, J = 7.1 Hz, 6H)
LCMS: MET-UHPLC-AB-101, rt=2.1分, M/Z (ES+) 416/418 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.74 (t, J = 5.6 Hz, 1H), 8.53 - 8.16 (m,
3H), 8.02 (d, J = 1.4 Hz, 1H), 7.77 - 7.66 (m, 2H), 7.34 - 7.28 (m, 4H), 5.82 (ddt, J = 17.0, 10.3, 6.7 Hz, 1H), 5.42 (d, J = 15.5 Hz, 1H), 5.11 - 5.00 (m, 2H), 4.98 (d, J = 15.5 Hz, 1H), 4.01 (dd, J = 11.7, 6.7 Hz, 1H), 3.64 (dd, J = 11.4, 6.8 Hz, 1H), 3.39 - 3.35 (m, 2H), 3.23 (dd, J = 13.1, 10.0 Hz, 1H), 2.29 (q, J = 7.0 Hz, 2H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.11分, M/Z (ES+) 433/435 [M+H+] 92% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 10.96 (s, 2H), 8.44 (s, 3H), 8.08 (s, 1H), 7.81 - 7.71 (m, 2H), 7.35 - 7.26 (m, 4H), 5.43 (d, J = 15.4 Hz, 1H), 5.01 (d, J = 15.5 Hz, 1H), 4.09 - 3.97 (m, 1H), 3.68 - 3.61 (m, 1H), 3.30 - 3.21 (m, 1H), 2.77 (d, J = 6.5 Hz, 2H), 1.89 - 1.78 (m, 1H), 0.98 - 0.91 (m, 6H).
LCMS: METCR1600, rt=3.77分, M/Z (ES+) 434/436 [M+H+] 96% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) 8.76 (t, J = 5.6 Hz, 1H), 8.25 (s, 3H), 8.16 - 8.02 (m, 2H), 7.75 (d, J = 8.1 Hz, 1H), 7.37 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 5.38 (d, J = 15.0Hz, 1H), 4.90 (d, J = 15.0 Hz, 1H), 4.22 - 4.10 (m, 2H), 3.32 - 3.22 (m, 3H), 1.54 (p, J = 7.1 Hz, 2H), 1.45 - 1.24 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.27分, M/Z (ES+) 500 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) 8.87 (t, J = 5.6 Hz, 1H), 8.46 (s, 3H), 8.04 (s, 2H), 7.93 (s, 1H), 7.52 (d, J = 8.7 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 5.27 (d, J = 15.8 Hz, 1H), 4.99 (d, J = 15.8 Hz, 1H), 4.46 (dd, J= 10.9, 7.6 Hz, 1H), 4.13 (dd, J = 13.3, 7.5 Hz, 1H), 3.96 (dd, J = 13.1, 11.2 Hz, 1H), 3.27 (q, J = 6.6 Hz, 2H), 1.50 (p, J = 7.1 Hz, 2H), 1.31 (h, J = 7.3 Hz, 2H), 0.89 (t, J = 7.4 Hz, 3H).
LCMS: MET-uPLC-AB-101: , rt=2.43分, M/Z (ES+) 520/522 [M+H+] 90 % UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.20 (t, J = 6.0 Hz, 1H), 8.45 (s, 2H), 7.84 (d, J = 8.5 Hz, 1H), 7.71 (d, J = 5.5 Hz, 1H), 7.38 (s, 4H), 7.33 (dd, J = 8.6, 5.6 Hz, 2H), 7.17 (t, J = 8.9 Hz, 2H), 5.20 (d, J = 15.7 Hz, 1H), 4.88 (d, J = 15.7 Hz, 1H), 4.52 - 4.37 (m, 3H), 4.11 (dd, J = 13.3, 7.4 Hz, 1H), 4.03 - 3.93 (m, 1H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt= 2.33分, M/Z (ES+) 468/470 [M+H+] 94 % UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.68 - 8.50 (m, 4H), 7.81 (d, J = 8.4 Hz,
1H), 7.63 (d, J = 5.5 Hz, 1H), 7.38 (s, 4H), 5.21 (d, J = 15.7 Hz, 1H), 4.86 (d, J = 15.7 Hz, 1H), 4.48 (dd, J = 10.9, 7.5 Hz, 1H), 4.14 (dd, J = 13.3, 7.5 Hz, 1H), 4.04 - 3.90 (m, 1H), 3.29 - 3.11 (m, 2H), 1.47 (p, J = 7.0 Hz, 2H), 1.35 - 1.24 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H).
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.29分, M/Z (ES+)522/524 [M+H+]99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) 8.76 (t, J = 5.6 Hz, 1H), 8.52 (s, 3H), 7.83 (d, J = 8.4 Hz, 1H), 7.71 (d, J = 5.5 Hz, 1H), 7.42 - 7.32 (m, 4H), 5.18 (d, J = 15.7 Hz, 1H), 4.91 (d, J = 15.7 Hz, 1H), 4.47 (dd, J = 10.9, 7.6 Hz, 1H), 4.13 (dd, J = 13.3, 7.5 Hz, 1H), 3.98 (dd, J = 13.2, 11.0 Hz, 1H), 3.37 (d, J = 6.6 Hz, 2H), 2.35 - 2.22 (m, 2H), 1.72 (dt, J = 14.7, 6.9 Hz, 2H).
LCMS:METCR1673 Generic 2 minutes, rt=1.02分, M/Z (ES+)510/512 [M+H+] 92 % UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) 8.65 (s, 1H), 7.96 (bs, 3H), 7.81 (d, J = 8.7 Hz, 1H), 7.60 (s, 1H), 7.39 (s, 4H), 5.22 (d, J = 14.8 Hz, 1H), 4.84 (d, J = 16.0 Hz, 1H), 4.39 (s, 1H), 4.10 (s, 1H), 3.97 (s, 1H), 3.85 (s, 2H), 3.14 (s, 2H), 1.74 (s, 1H), 1.53 (d, J = 11.7 Hz, 3H), 1.18 (d, J = 9.0 Hz, 3H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.12分, M/Z (ES+) 560 [M+H+], 94% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 1.18 (qd, J = 4.32, 12.21 Hz, 2H), 1.53 (d, J = 12.72 Hz, 2H), 1.66 - 1.80 (m, 1H), 3.14 (dh, J = 6.24, 25.75 Hz, 2H), 3.25 (t, J = 11.57 Hz, 2H), 3.78 - 3.89 (m, 2H), 3.93 - 4.05 (m, 1H), 4.13 (dd, J = 7.47, 13.32 Hz, 1H), 4.48 (dd, J = 7.59, 10.81 Hz, 1H), 4.87 (d, J = 15.84 Hz, 1H), 5.25 (d, J = 15.77 Hz, 1H), 7.32 (d, J = 8.27 Hz, 2H), 7.50 (d, J = 8.61 Hz, 2H), 7.63 (d, J = 5.42 Hz, 1H), 7.83 (d, J = 8.33 Hz, 1H), 8.47 (s, 3H), 8.67 (t, J = 5.83 Hz, 1H).
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.35分, M/Z (ES+) 572 [M+H+]97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 1.72 (dt, J = 7.00, 14.60 Hz, 2H), 2.21 -
2.34 (m, 2H), 3.32 - 3.40 (m, 2H), 3.99 (dd, J = 11.15, 13.06 Hz, 1H), 4.14 (dd, J = 7.51, 13.32 Hz, 1H), 4.47 (dd, J = 7.60, 10.84 Hz, 1H), 4.91 (d, J = 15.77 Hz, 1H), 5.24 (d, J = 15.77 Hz, 1H), 7.31 (d, J = 8.33 Hz, 2H), 7.50 (d, J = 8.60 Hz, 2H), 7.69 (d, J = 5.47 Hz, 1H), 7.84 (d, J = 8.42 Hz, 1H), 8.49 (s, 3H), 8.76 (t, J = 5.66 Hz, 1H).
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.31分, M/Z (ES+) 554 [M+H+]96% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) d 3.97 - 4.07 (m, 1H), 4.16 (dd, J = 7.42, 13.19 Hz, 1H), 4.53 (dd, J = 7.86, 10.51 Hz, 1H), 4.98 (d, J = 15.63 Hz, 1H), 5.25 (d, J = 15.87 Hz, 1H), 7.08 (d, J = 7.91 Hz, 3H), 7.26 - 7.42 (m, 4H), 7.52 (d, J = 8.50 Hz, 2H), 7.88 (d, J = 4.07 Hz, 1H), 7.93 (d, J = 8.27 Hz, 1H), 8.59 (s, 3H), 12.80 (s, 1H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.16分, M/Z (ES+) 484/486 [M+H+]98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 0.93 (d, J = 6.69 Hz, 6H), 1.90 (dp, J = 6.97, 13.67 Hz, 1H), 3.67 (dd, J = 2.94, 6.55 Hz, 2H), 3.99 (t, J = 11.95 Hz, 1H), 4.06 - 4.20 (m, 1H), 4.48 (dd, J = 7.77, 10.75 Hz, 1H), 4.92 (d, J = 15.64 Hz, 1H), 5.17 (d, J = 15.57 Hz, 1H), 7.38 (s, 4H), 7.72 (d, J = 4.81 Hz, 1H), 7.84 (d, J = 8.21 Hz, 1H), 8.62 (s, 3H), 11.83 (s, 1H).
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.21分, M/Z (ES+) 504/506 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) 7.89 (d, J = 8.4 Hz, 1H), 7.83 (d, J = 5.2 Hz, 1H), 7.40 (d, J = 6.6 Hz, 6H), 7.09 (dd, J = 13.1, 7.7 Hz, 3H), 5.21 (d, J =
15.8 Hz, 1H), 4.94 (d, J = 15.8 Hz, 1H), 4.28 (s, 1H), 4.07 (dd, J = 13.2, 7.4 Hz, 1H), 3.96 - 3.84 (m, 1H).
LCMS: MET-uHPLC-AB-101, rt=2.09分, M/Z (ES+) 454/456 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.71 - 8.18 (m, 4H), 7.80 (d, J = 8.2 Hz,
1H), 7.62 (d, J = 5.4 Hz, 1H), 7.38 (s, 4H), 5.20 (d, J = 15.6 Hz, 1H), 4.88 (d, J = 15.6 Hz, 1H), 4.46 - 4.39 (m, 1H), 4.12 (dd, J = 13.2, 7.4 Hz, 1H), 4.07 - 3.93 (m, 2H), 1.14 (dd, J = 8.4, 6.7 Hz, 6H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.2分, M/Z (ES+) 627/629 [M+H+] 95% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) 9.39 (t, J = 5.9 Hz, 1H), 8.60 (s, 3H), 8.10 - 8.01 (m, 2H), 7.99 (s, 1H), 7.81 (s, 1H), 7.44 - 7.33 (m, 4H), 7.21 (d, J = 8.6 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 5.22 (d, J = 15.7 Hz,1H), 5.00 (d, J = 15.7 Hz, 1H), 4.49 (dd, J = 10.9, 7.6 Hz, 1H), 4.42 (d, J = 5.9 Hz, 2H), 4.11 (dd, J = 13.3, 7.5 Hz, 1H), 4.03 - 3.89 (m, 3H), 3.03 (q, J = 6.5 Hz, 2H), 1.78 (s, 3H), 1.69 (p, J = 6.7 Hz, 2H), 1.50 -1.31 (m, 4H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.02分, M/Z (ES+) 436/438 [M+H+], 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 1.17 (dd, J = 1.56, 6.58 Hz, 6H), 3.95 (dd, J = 11.30, 13.11 Hz, 1H), 4.01 - 4.17 (m, 2H), 4.42 (dd, J = 7.48, 11.05 Hz, 1H), 4.95 (d, J = 15.70 Hz, 1H), 5.24 (d, J = 15.70 Hz, 1H), 7.32 - 7.45 (m, 4H), 7.92 (s, 1H), 7.97 - 8.08 (m, 2H), 8.50 (s, 3H), 8.65 (d, J = 7.61 Hz, 1H)
LCMS: MET-uHPLC-AB-101, rt=2.29分, M/Z (ES+) 504/506 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.02 (t, J = 5.6 Hz, 1H), 8.49 (s, 3H), 8.04 (s, 2H), 7.97 (s, 1H), 7.42 - 7.33 (m, 4H), 5.23 (d, J = 15.7 Hz, 1H), 4.99 (d, J = 15.7 Hz, 1H), 4.45 (dd, J = 10.9, 7.6 Hz, 1H), 4.11 (dd, J = 13.3, 7.5 Hz, 1H), 3.96 (dd, J = 13.1, 11.3 Hz, 1H), 3.37 - 3.35 (m, 2H), 2.34 - 2.24 (m, 2H), 1.75 (dt, J = 14.7, 7.1 Hz, 2H).
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.14分, M/Z (ES+) 466/468 [M+H+] 96% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 12.11 (s, 1H), 8.54 (s, 3H), 8.15 - 7.98 (m, 1H), 8.01 - 7.89 (m, 1H), 7.89 - 7.84 (m, 1H), 7.46 - 7.28 (m, 4H), 5.33 - 5.16 (m, 1H), 5.02 - 4.79 (m, 1H), 4.54 - 4.41 (m, 1H), 4.17 - 4.06 (m, 1H), 4.03 - 3.90 (m, 1H), 3.77 - 3.62 (m, 2H), 1.91 (dt, J = 13.4, 6.8 Hz, 1H), 1.00 - 0.78 (m, 6H)
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3分, M/Z (ES+) 452/454 [M+H+] 95% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 12.10 (s, 1H), 8.57 (s, 3H), 8.14 - 7.82 (m, 3H), 7.46 - 7.32 (m, 4H), 5.32 - 5.14 (m, 1H), 5.02 - 4.77 (m, 1H), 4.55 - 4.40 (m, 1H), 4.18 - 4.05 (m, 1H), 4.03 - 3.89 (m, 1H), 3.84 (t, J = 6.5 Hz, 2H), 1.60 (h, J = 7.1 Hz, 2H), 0.99 - 0.82 (m, 3H)
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.23分, M/Z (ES+) 464/466 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.86 - 8.17 (m, 4H), 8.09 - 7.98 (m, 2H),
7.86 (d, J = 20.5 Hz, 1H), 7.45 - 7.35 (m, 4H), 5.28 (dd, J = 15.7, 11.0 Hz, 1H), 4.92 (dd, J = 15.7, 4.5 Hz, 1H), 4.47 (dt, J = 11.0, 7.3 Hz, 1H), 4.16 - 4.07 (m, 1H), 3.97 (dd, J = 13.2, 11.2 Hz, 1H), 3.81 (dt, J = 13.9, 6.8 Hz, 1H), 1.75 (dp, J = 13.6, 6.7 Hz, 1H), 1.11 (d, J = 6.8 Hz, 3H), 0.93 - 0.80 (m, 6H)
LCMS: MET-uHPLC-AB-101, rt=2.11分, M/Z (ES+) 448/450 [M+H+] 94% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.91 (t, J = 5.5 Hz, 1H), 8.55 (s, 3H), 8.02 (q, J = 8.2 Hz, 2H), 7.92 (s, 1H), 7.41 - 7.35 (m, 4H), 5.80 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 5.22 (d, J = 15.8 Hz, 1H), 5.09 - 4.99 (m, 2H), 4.97 (d, J = 15.8 Hz, 1H), 4.47 (dd, J = 10.9, 7.6 Hz, 1H), 4.11 (dd, J = 13.3, 7.5 Hz, 1H), 4.00 - 3.93 (m, 1H), 3.37 - 3.34 (m, 2H), 2.28 (q, J = 6.9 Hz, 2H).
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.02分, M/Z (ES+) 452/454 [M+H+] 100% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) 8.70 (d, J = 4.3 Hz, 1H), 8.39 (s, 3H), 7.79
(d, J = 8.3 Hz, 1H), 7.68 (d, J = 5.5 Hz, 1H), 7.37 (s, 4H), 5.16 (d, J = 15.6 Hz, 1H), 4.91 (d, J = 15.6 Hz, 1H), 4.42 (dd, J = 10.9, 7.6 Hz, 1H), 4.11 (dd, J
= 13.3, 7.5 Hz, 1H), 3.96 (dd, J = 13.2, 11.1 Hz, 1H), 2.83 (tq, J = 7.9, 4.0 Hz, 1H), 0.76 - 0.65 (m, 2H), 0.53 (dd, J = 3.8, 1.9 Hz, 2H).
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.13分, M/Z (ES+) 466/468 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.90 (d, J = 7.6 Hz, 1H), 8.64 (s, 3H), 7.80 (d, J = 8.3 Hz, 1H), 7.66 (d, J = 5.5 Hz, 1H), 7.42 - 7.32 (m, 4H), 5.18 (d, J = 15.7 Hz, 1H), 4.91 (d, J = 15.7 Hz, 1H), 4.44 (dd, J = 11.0, 7.5 Hz, 1H), 4.35 (h, J = 8.0 Hz, 1H), 4.17 (dd, J = 13.3, 7.5 Hz, 1H), 3.99 (dd, J = 13.2, 11.1 Hz, 1H), 2.22 (dtp, J = 15.2, 7.8, 4.0, 3.5 Hz, 2H), 2.00 (p, J = 9.6 Hz, 2H), 1.68 (ddt, J = 14.7, 10.4, 5.8 Hz, 2H)
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.09分, M/Z (ES+) 472/474 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.64 (s, 3H), 8.57 (d, J = 7.6 Hz, 1H), 7.87 (d, J = 5.4 Hz, 1H), 7.79 (d, J = 8.3 Hz, 1H), 7.46 (t, J = 8.2 Hz, 1H), 7.35 (dd, J = 9.8, 2.0 Hz, 1H), 7.22 (dd, J = 8.3, 1.9 Hz, 1H), 5.14 - 4.99 (m, 2H), 4.39 (dd, J = 10.9, 7.5 Hz, 1H), 4.12 (dd, J = 13.4, 7.5 Hz, 1H), 4.05 (dt, J = 13.4, 6.7 Hz, 1H), 3.91 (dd, J = 13.2, 11.1 Hz, 1H), 1.17 (t, J = 6.2 Hz, 6H)
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.13分, M/Z (ES+) 470/472/474 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.66 (d, J = 7.7 Hz, 1H), 8.58 (s, 3H), 8.08 - 8.00 (m, 2H), 7.94 (d, 1H), 7.68 (d, J = 1.9 Hz, 1H), 7.58 (d, J = 8.3 Hz, 1H), 7.33 (dd, J = 8.3, 2.0 Hz, 1H), 5.22 (d, J = 15.8 Hz, 1H), 5.00 (d, J = 15.8 Hz, 1H), 4.45 (dd, J = 11.0, 7.5 Hz, 1H), 4.16 - 4.02 (m, 2H), 3.96 (dd, J = 13.2, 11.2 Hz, 1H), 1.18 (dd, J = 6.6, 2.6 Hz, 6H)
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.05分, M/Z (ES+) 454/456 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.65 (d, J = 7.7 Hz, 1H), 8.58 (s, 3H), 8.09 - 8.00 (m, 2H), 7.90 (d, J = 1.1 Hz, 1H), 7.54 (t, J = 8.0 Hz, 1H), 7.45 (dd, J = 10.4, 1.8 Hz, 1H), 7.23 (dd, J = 8.3, 1.6 Hz, 1H), 5.26 (d, J = 16.0 Hz, 1H), 4.95 (d, J = 16.0 Hz, 1H), 4.46 (dd, J = 11.0, 7.5 Hz, 1H), 4.17 - 4.02 (m, 2H), 3.97 (dd, J = 13.2, 11.2 Hz, 1H), 1.17 (dd, J = 6.6, 2.4 Hz, 6H)
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.28分, M/Z (ES+) 492/494 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 1.14 - 1.56 (m, 6H), 1.71 (s, 2H), 1.86 (s, 2H), 3.85 (s, 1H), 3.96 (t, J = 11.84 Hz, 1H), 4.06 - 4.23 (m, 1H), 4.45 (s, 1H), 4.93 (d, J = 15.42 Hz, 1H), 5.23 (d, J = 15.64 Hz, 1H), 7.21 - 7.51 (m, 4H), 7.84 (s, 1H), 7.98 (m, 2H), 8.47 (s, 3H), 11.89 (s, 1H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.47分, M/Z (ES+) 506/508 [M+H+]100% UV
NMRデータ: 1H NMR (250 MHz, DMSO-d6) d 0.75 - 1.39 (m, 5H), 1.47 - 1.92 (m, 6H),
3.70 (d, J = 5.77 Hz, 2H), 3.83 - 4.04 (m, 1H), 4.13 (dd, J = 7.51, 13.25 Hz, 1H), 4.33 - 4.53 (m, 1H), 4.96 (d, J = 15.65 Hz, 1H), 5.22 (d, J = 15.95 Hz, 1H), 7.39 (s, 4H), 7.78 - 8.12 (m, 3H), 8.44 (s, 3H), 12.12 (s, 1H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.14分, M/Z (ES+) 494/496 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 9.36 (t, J = 6.3 Hz, 1H), 8.68 (s, 3H), 7.86 (d, J = 8.4 Hz, 1H), 7.70 (d, J = 5.5 Hz, 1H), 7.55 - 7.22 (m, 4H), 5.21 (d, J = 15.7 Hz, 1H), 4.89 (d, J = 15.7 Hz, 1H), 4.49 (dd, J = 10.9, 7.5 Hz, 1H), 4.26 - 3.92 (m, 4H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.11分, M/Z (ES+) 508/510 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.89 (t, J = 5.5 Hz, 1H), 8.73 (s, 3H), 7.84 (d, J = 8.5 Hz, 1H), 7.69 (d, J = 5.5 Hz, 1H), 7.51 - 7.13 (m, 4H), 5.21 (d, J = 15.7 Hz, 1H), 4.86 (d, J = 15.7 Hz, 1H), 4.49 (dd, J = 10.9, 7.5 Hz, 1H), 4.18 (dd, J = 13.3, 7.5 Hz, 1H), 4.01 (dd, J = 13.2, 11.1 Hz, 1H), 3.54 - 3.46 (m, 2H), 2.58 - 2.51 (m, 2H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.27分, M/Z (ES+) 508/510 [M+H+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 9.27 (d, J = 8.8 Hz, 1H), 8.68 (s, 3H), 7.86 (d, J = 8.2 Hz, 1H), 7.59 (d, J = 5.4 Hz, 1H), 7.39 (q, J = 8.6 Hz, 4H), 5.24 (d, J = 15.6 Hz, 1H), 4.93 - 4.68 (m, 2H), 4.45 (dd, J = 10.9, 7.5 Hz, 1H), 4.18 (dd, J = 13.3, 7.5 Hz, 1H), 4.01 (dd, J = 13.2, 11.2 Hz, 1H), 1.33 (d, J = 7.0 Hz, 3H).
LCMS: MET-uHPLC-AB-101, rt=2.27分, M/Z (ES+) 468/470 [M+H+] 97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.49 (s, 3H), 8.39 (d, J = 8.2 Hz, 1H), 7.81 (d, J = 8.2 Hz, 1H), 7.55 (d, J = 5.4 Hz, 1H), 7.40 - 7.37 (m, 4H), 5.25 (d, J = 15.6 Hz, 1H), 4.83 (d, J = 15.7 Hz, 1H), 4.45 (dd, J = 10.9, 7.6 Hz, 1H), 4.14 (dd, J = 13.3, 7.4 Hz, 1H), 4.04 - 3.95 (m, 1H), 3.85 (dt, J = 14.1, 7.6 Hz, 1H), 1.51 - 1.40 (m, 2H), 1.11 (d, J = 6.6 Hz, 3H), 0.81 (t, J = 7.4 Hz, 3H).
LCMS: MET-uHPLC-AB-101, rt=2.38分, M/Z (ES+) 468/470 [M+H+] 94% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.53 (s, 3H), 8.15 (s, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.54 (d, J = 5.4 Hz, 1H), 7.39 (s, 4H), 5.22 (d, J = 15.6 Hz, 1H), 4.85 (d, J = 15.6 Hz, 1H), 4.42 (dd, J = 10.8, 7.6 Hz, 1H), 4.13 (dd, J = 13.3, 7.4 Hz, 1H), 4.02 - 3.95 (m, 1H), 1.34 (s, 9H).
LCMS: MET-uHPLC-AB-101, rt=2.07分, M/Z (ES+) 467/469 [M+H+] 97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 11.32 (s, 1H), 8.51 (s, 3H), 8.04 (d, J =
8.1 Hz, 1H), 7.96 (d, J = 8.3 Hz, 1H), 7.79 (s, 1H), 7.40 (q, J = 8.6 Hz, 4H), 5.28 (d, J = 15.7 Hz, 1H), 4.88 (d, J = 15.7 Hz, 1H), 4.54 - 4.41 (m, 1H), 4.12 (dd, J = 13.3, 7.4 Hz, 1H), 4.02 - 3.92 (m, 1H), 1.21 (s, 9H).
LCMS: MET-uHPLC-AB-101, rt=2.66分, M/Z (ES+)528/530 [M+H+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.00 (s, 1H), 8.65 (s, 3H), 7.83 (d, J = 8.3 Hz, 1H), 7.73 (d, J = 3.9 Hz, 1H), 7.38 (s, 4H), 7.28 (t, J = 7.5 Hz, 2H), 7.21 - 7.12 (m, 3H), 5.18 (d, J = 15.7 Hz, 1H), 4.94 (dd, J = 15.6, 4.7 Hz, 1H), 4.51 - 4.44 (m, 1H), 4.15 (dd, J = 12.0, 7.6 Hz, 1H), 4.03 - 3.95 (m, 1H), 3.04 (dt, J = 7.8, 3.9 Hz, 1H), 2.07 (td, J = 6.3, 3.1 Hz, 1H), 1.28 (ddq, J = 28.7, 12.0, 5.3 Hz, 2H).
LCMS: MET-uHPLC-AB-101, rt=2.13分, M/Z (ES+) 466/468 [M+H+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.85 (s, 1H), 8.57 (s, 3H), 7.78 (d, J = 8.3 Hz, 1H), 7.62 (d, J = 5.5 Hz, 1H), 7.38 (s, 4H), 5.17 (d, J = 15.6 Hz, 1H), 4.90 (d, J = 15.6 Hz, 1H), 4.42 (dd, J = 10.9, 7.5 Hz, 1H), 4.14 (dd, J = 13.3, 7.5 Hz, 1H), 3.97 (dd, J = 13.2, 11.1 Hz, 1H), 1.35 (s, 3H), 0.74 - 0.67 (m, 2H), 0.67 - 0.61 (m, 2H).
LCMS: MET-uHPLC-AB-101, rt=2.36分, M/Z (ES+) 480/482 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.63 (s, 1H), 8.59 - 7.82 (m, 2H), 7.78 (d, J = 8.2 Hz, 1H), 7.61 (d, J = 5.4 Hz, 1H), 7.38 (s, 4H), 5.20 (d, J = 15.7 Hz, 1H), 4.89 (d, J = 15.6 Hz, 1H), 4.42 - 4.35 (m, 1H), 4.10 (dd, J = 13.4, 7.4 Hz, 1H), 3.99 - 3.91 (m, 1H), 2.35 - 2.24 (m, 2H), 2.02 - 1.94 (m, 2H), 1.87 - 1.76 (m, 2H), 1.45 (s, 3H).
LCMS: MET-uHPLC-AB-101, rt=2.35分, M/Z (ES+) 480/482 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.58 (d, J = 3.9 Hz, 1H), 8.41 (s, 3H), 7.81 (d, J = 8.2 Hz, 1H), 7.53 (d, J = 5.4 Hz, 1H), 7.40 - 7.35 (m, 4H), 5.25 (d, J = 15.6 Hz, 1H), 4.82 (d, J = 15.6 Hz, 1H), 4.46 (dd, J = 10.8, 7.6 Hz, 1H), 4.13 (dd, J = 13.3, 7.4 Hz, 1H), 3.99 (dd, J = 13.1, 11.2 Hz, 1H), 2.55 (dt, J = 8.2, 4.2 Hz, 1H), 1.06 (s, 3H), 0.92 (s, 3H), 0.69 (dd, J = 7.9, 5.2 Hz, 1H), 0.45 (t, J = 4.8 Hz, 1H).
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.11分, M/Z (ES+) 502/504 [M+H+] 96% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.17 (d, J = 6.5 Hz, 1H), 8.49 (s, 3H), 7.85 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 5.5 Hz, 1H), 7.38 (s, 4H), 5.18 (d, J = 15.6 Hz, 1H), 4.94 (d, J = 15.7 Hz, 1H), 4.46 (dd, J = 10.9, 7.6 Hz, 1H), 4.31 - 4.19 (m, 1H), 4.14 (dd, J = 13.3, 7.5 Hz, 1H), 3.98 (dd, J = 13.2, 11.1 Hz, 1H), 3.06 - 2.92 (m, 2H), 2.77 - 2.65 (m, 2H).
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.28分, M/Z (ES+) 502/504 [M+H+] 95% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) 9.20 (t, J = 6.0 Hz, 1H), 7.91 (s, 3H), 7.83 (d, J = 8.5 Hz, 1H), 7.71 (d, J = 5.5 Hz, 1H), 7.43 - 7.32 (m, 6H), 7.32 - 7.22 (m, 3H), 5.21 (d, J = 15.7 Hz, 1H), 4.88 (d, J = 15.7 Hz, 1H), 4.48 (qd, J = 15.2, 6.0 Hz, 2H), 4.42 - 4.36 (m, 1H), 4.11 (dd, J = 13.3, 7.4 Hz, 1H), 4.00 - 3.85 (m, 1H).
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.62分, M/Z (ES+) 510/512 [M+H+] 95% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) 8.62 (t, J = 5.6 Hz, 4H), 7.82 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 5.5 Hz, 1H), 7.39 (t, J = 2.6 Hz, 4H), 5.21 (d, J = 15.8 Hz, 1H), 4.87 (d, J = 15.7 Hz, 1H), 4.48 (dd, J = 10.9, 7.6 Hz,1H), 4.16 (dd, J = 13.3, 7.5 Hz, 1H), 3.99 (dd, J = 13.2, 11.1 Hz, 1H), 3.24 (dq, J = 18.8, 7.1, 6.6 Hz, 2H), 1.53 - 1.44 (m, 2H), 1.27 (t, J = 11.3 Hz, 8H), 0.87 (t, J = 7.0 Hz, 3H).
LCMS: METCR1416 GENERIC 7 MINUTES , rt=3.18分, M/Z (ES+) 516/518 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) 8.89 (d, J = 7.0 Hz, 1H), 8.33 (s, 3H), 7.83 (d, J = 8.3 Hz, 1H), 7.68 (d, J = 5.4 Hz, 1H), 7.42 - 7.32 (m, 4H), 5.19 (d, J = 15.7 Hz, 1H), 4.91 (d, J = 15.6 Hz, 1H), 4.48 - 4.32 (m, 2H), 4.12 (dd, J = 13.0, 7.2 Hz, 1H), 4.01 - 3.93 (m, 1H), 2.31 - 2.20 (m, 1H), 2.20 - 2.03 (m, 4H), 1.84 - 1.71 (m, 1H).
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.05分, M/Z (ES+) 488/490 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.15 (s, 1H), 8.44 (s, 3H), 7.85 (d, J = 8.4 Hz, 1H), 7.71 (d, J = 5.4 Hz, 1H), 7.38 (s, 4H), 5.20 (d, J = 15.6 Hz, 1H), 4.92 (d, J = 15.6 Hz, 1H), 4.53 - 4.40 (m, 1H), 4.07- 4.20 (m, 1H), 3.99 (t, J =
12.0 Hz, 1H), 3.50 (dd, J = 9.8, 6.2 Hz, 1H), 2.07 - 1.94 (m, 1H), 1.64 (d, J =
5.3 Hz, 1H).
代わりに、実施例106は、中間体VII−01から、(1R)−2,2−ジフルオロシクロプロパン−1−アミン塩酸塩を使用して、GP7およびGP5に従い合成した。
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.05分, M/Z (ES+) 488/490 [M+H+] 100% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) d 9.15 (s, 1H), 8.44 (s, 3H), 7.85 (d, J = 8.4 Hz, 1H), 7.71 (d, J = 5.4 Hz, 1H), 7.38 (s, 4H), 5.20 (d, J = 15.6 Hz, 1H), 4.92 (d, J = 15.6 Hz, 1H), 4.53 - 4.40 (m, 1H), 4.07- 4.20 (m, 1H), 3.99 (t, J = 12.0 Hz, 1H), 3.50 (dd, J = 9.8, 6.2 Hz, 1H), 2.07 - 1.94 (m, 1H), 1.64 (d, J = 5.3 Hz, 1H).
LCMS:METCR1416 GENERIC 7 MINUTES, rt=3.09分, M/Z (ES+) 484/486 [M+H+] 96% UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) 9.32 (d, J = 16.5 Hz, 1H), 8.58 (s, 3H), 8.12 (dd, J = 8.2, 1.5 Hz, 1H), 8.07 (ddd, J = 8.2, 4.1, 1.4 Hz, 1H), 8.04 - 7.94 (m, 1H), 7.39 (d, J = 4.6 Hz, 4H), 5.28 - 5.18 (m, 1H), 5.09 - 4.94 (m, 1H), 4.64 (dd, J = 9.9, 6.9 Hz, 1H), 4.16 - 4.06 (m, 1H), 3.49 (dd, J = 15.2, 4.8 Hz, 1H), 2.09 - 1.96 (m, 1H), 1.80 - 1.69 (m, 1H), 1.47 - 1.37 (m, 3H).
LCMS:METCR1416 GENERIC 7 MINUTES, rt=5.52分, M/Z (ES+) 636/638 [M+H+] 94% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) 8.60 (t, J = 5.6 Hz, 1H), 8.23 (s, 3H), 7.81 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 5.5 Hz, 1H), 7.39 (s, 4H), 5.21 (d, J = 15.7 Hz, 1H), 4.87 (d, J = 15.7 Hz, 1H), 4.49 - 4.35 (m, 1H), 4.11 (dd, J = 13.3, 7.5 Hz, 1H), 3.95 (d, J = 13.0 Hz, 1H), 3.23 (dt, J = 16.4, 7.0 Hz, 2H), 1.54 - 1.41 (m, 2H), 1.25 (s, 26H), 0.92 - 0.79 (m, 3H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.23分, M/Z (ES+) 466/468 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.75 - 8.43 (m, 3H), 7.81 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 5.5 Hz, 1H), 7.41-7.34 (m, 4H), 5.20 (d, J = 15.7 Hz, 1H), 4.86 (d, J = 15.7 Hz, 1H), 4.49-4.43 (m, 1H), 4.18-4.11 (m, 1H), 4.02-3.95 (m, 1H), 3.21 - 3.08 (m, 2H), 1.02-0.95 (m, 1H), 0.45 - 0.40 (m, 2H), 0.21 - 0.17 (m, 2H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.27分, M/Z (ES+) 518/520 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 9.00 (t, J = 5.6 Hz, 1H), 8.47 (s, 3H), 8.10 (d, J = 8.2 Hz, 1H), 8.05 (dd, J = 8.2, 1.4 Hz, 1H), 7.95 (d, J = 1.2 Hz, 1H), 7.42 - 7.34 (m, 4H), 5.21 (d, J = 15.8 Hz, 1H), 5.00 (d, J = 15.7 Hz, 1H), 4.60 (d, J = 6.7 Hz, 1H), 4.11 (p, J = 6.9 Hz, 1H), 3.37 2H m, 水のピークに隠れている), 2.36 - 2.24 (m, 2H), 1.75 (dt, J = 14.7, 7.1 Hz, 2H), 1.42 (d, J = 7.0 Hz,3H).
LCMS: METCR1416 GENERIC 7 MINUTES, rt=3.2分, M/Z (ES+) 453 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ0.84 (t, J = 7.32 Hz, 3H), 1.28 (dt, J = 7.29, 14.80 Hz, 2H), 1.44 (p, J = 7.03 Hz, 2H), 3.21 (dp, J = 6.46, 13.47 Hz, 2H), 3.29 (t, J = 11.56 Hz, 1H), 3.73 (dd, J = 6.91, 11.38 Hz, 1H), 4.05 - 4.18 (m, 1H), 5.30 (d, J = 12.79 Hz, 1H), 5.41 (d, J = 16.21 Hz, 1H), 7.62 (t, J = 7.45 Hz, 1H), 7.65 - 7.74 (m, 2H), 7.78 (t, J = 7.59 Hz, 1H), 7.98 (dd, J = 8.25, 14.13 Hz, 2H), 8.02 - 8.08 (m, 1H), 8.37 - 8.47 (m, 2H), 8.54 (s, 3H)
LCMS: METCR1416 GENERIC 7 MINUTES, rt=2.92分, M/Z (ES+) 502 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ9.13 (t, J = 5.8 Hz, 1H), 8.58 (s, 3H), 8.05 (d, J = 6.5 Hz, 1H), 7.69 (d, J = 9.4 Hz, 1H), 7.39 (dd, J = 8.6, 5.6 Hz, 2H), 7.22 - 7.15 (m, 2H), 5.49 (d, J = 15.7 Hz, 1H), 5.31 (d, J = 15.7 Hz, 1H), 4.55 - 4.40 (m, 2H), 4.02 (dd, J = 11.5, 7.0 Hz, 1H), 3.68 (dd, J = 11.5, 6.9 Hz, 1H), 3.21 (t, J = 11.6 Hz, 1H), 2.49 - 2.44 (m, 1H), 1.24 - 1.15 (m, 2H), 1.03 - 0.91 (m, 2H).
封管内で、エタノール(2mL)中の中間体IX−04(97%、40.0mg、0.068mmol)の撹拌溶液に、THF中2MのN−メチルメタンアミン(170.76μL、0.342mmol)を添加した。反応物を16時間、80℃に加熱した。反応混合物を減圧下で濃縮し、DCM(5mL)中に溶解させ、水(5mL)を用いて洗浄し、Na2SO4で脱水し、濾過し、減圧下で濃縮した。残留物を、逆相カラムクロマトグラフィー(Biotage、アセトニトリル:水)で精製して、収率53%で、白色の固体として表題化合物を得た。
LCMS: METCR1673 Generic 2 minutes: rt=1.48分 M/Z (ES+) 593.15 [M+H+] 98 % UV
NMRデータ:1H NMR (500 MHz, DMSO-d6) δ 8.52 (t, J = 5.7 Hz, 1H), 7.43 (d, J = 8.3 Hz, 1H), 7.34 (s, 4H), 7.27 (s, 1H), 7.15 (s, 1H), 5.24 (d, J = 16.0 Hz, 1H), 4.48 (d, J = 15.9 Hz, 1H), 4.37 (dt, J = 11.6, 7.6 Hz, 1H), 4.02 (dd, J = 13.3, 7.3 Hz, 1H), 3.74 - 3.65 (m, 1H), 3.17 (q, J = 6.7 Hz, 2H), 2.84 (s, 6H), 1.42 (dt, J = 14.5, 6.9 Hz, 2H), 1.36 (s, 9H), 1.25 - 1.22 (m, 2H), 0.86 (t, J = 7.4 Hz, 3H).
一般的手順GP5に従って表題化合物を合成して、収率89%で、黄色の固体として表題化合物を得た。
LCMS: METCR-uPLC-AB101 rt=2.32分 M/Z (ES+) 493 [M+H+] 99 % UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.64 (s, 3H), 8.46 (t, J = 5.7 Hz, 1H), 7.40 (s, 4H), 7.26 (s, 1H), 7.18 (s, 1H), 5.24 (d, J = 15.7 Hz, 1H), 4.55 (d, J = 15.7 Hz, 1H), 4.36 (s, 1H), 4.12 (dd, J = 13.3, 7.4 Hz, 1H), 3.91 (dd, J = 13.2, 11.1 Hz, 1H), 3.18 (qt, J = 13.1, 6.7 Hz, 2H), 2.87 (s, 6H), 1.48 - 1.37 (m, 2H), 1.25 (m, 2H), 0.87 (t, J = 7.3 Hz, 3H).
LCMS: METCR-uPLC-AB101 rt=2.92分 M/Z (ES+) 685/687 [M+H+] 99 % UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.88 (t, J = 6.1 Hz, 1H), 7.72 (d, J = 6.5 Hz, 1H), 7.52 (d, J = 9.5 Hz, 1H), 7.38 - 7.18 (m, 6H), 6.90 (d, J = 8.6 Hz, 2H), 6.72 (s, 1H), 5.25 (d, J = 15.4 Hz, 1H), 4.89 (d, J =15.5 Hz, 1H), 4.47 - 4.29 (m, 2H), 3.74 (s, 3H), 3.48 (dd, J = 11.2, 6.6 Hz, 1H), 3.28 - 3.22 (m, 1H), 2.94 - 2.82 (m, 3H), 2.41 (d, J = 9.8 Hz, 1H), 2.21 (s, 1H), 2.11 (s, 1H), 1.36 (s, 9H), 1.34 - 1.25 (m, 4H), 1.24 - 1.14 (m, 2H).
封管内で、エタノール(2mL)中の中間体IX−41(100%、36.0mg、0.06mmol)の撹拌溶液に、THF中2MのN−メチルメタンアミン(0.15mL、0.3mmol)を添加した。反応物を16時間、80℃に加熱した。反応混合物を減圧下で濃縮し、DCM(5mL)中に溶解させ、水およびブライン(5mL)を用いて洗浄し、Na2SO4で脱水し、濾過し、減圧下で濃縮して、収率100%で、白色の固体として表題化合物を得た。
LCMS: METCR1673 Generic 2 minutes: rt=1.30分 M/Z (ES+) 627/629 [M+H+] 100 % UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 9.10 (t, J = 5.9 Hz, 1H), 7.44 (d, J = 8.3 Hz, 1H), 7.37 - 7.23 (m, 11H), 5.24 (d, J = 16.0 Hz, 1H), 4.53 (d, J = 16.0 Hz, 1H), 4.39 (dd, J = 14.0, 6.6 Hz, 3H), 4.03 (dd, J = 13.3, 7.1 Hz, 1H), 3.74 - 3.66 (m, 1H), 2.81 (s, 6H), 1.37 (s, 9H).
一般的手順GP5に従って表題化合物を合成して、収率98%で、灰白色の固体として表題化合物を得た。
LCMS: METCR1416 Generic 7 minutes, rt=3.31分, M/Z (ES+)526.95/529.05 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.03 (t, J = 6.0 Hz, 1H), 8.35 (s, 3H), 7.43 - 7.36 (m, 4H), 7.34 - 7.29 (m, 2H), 7.28 - 7.22 (m, 5H), 5.21 (d, J = 15.7 Hz, 1H), 4.58 (d, J = 15.7 Hz, 1H), 4.47 - 4.28 (m, 3H), 4.08 (dd, J = 13.4, 7.4
Hz, 1H), 3.92 - 3.83 (m, 1H), 2.82 (s, 6H).
LCMS: METCR1416 Generic 7 minutes, rt=3.28分, M/Z (ES+) 551.95 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.17 (d, J = 14.6 Hz, 1H), 8.43 (s, 3H), 7.96 - 7.76 (m, 2H), 7.64 (s, 1H), 7.55 (d, J = 8.6 Hz, 1H), 7.15 (d, J = 8.7 Hz, 1H), 5.18 - 5.06 (m, 2H), 4.47 -4.39 (m, 1H), 4.11 (dd, J = 13.2, 7.4 Hz, 1H), 4.02 - 3.94 (m, 1H), 3.85 (d, J = 1.2 Hz, 3H), 3.51 (s, 1H), 2.08 - 1.96 (m, 1H), 1.70 - 1.60 (m, 1H).
LCMS: METCR1416 Generic 7 minutes, rt=2.51分, M/Z (ES+) 536/538 [M+H+] 96% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.72 (s, 4H), 7.88 (d, J = 8.5 Hz, 1H), 7.70 (d, J = 5.5 Hz, 1H), 7.43 - 7.33 (m, 4H), 5.19 (d, J = 15.7 Hz, 1H), 4.92 (d, J = 15.7 Hz, 1H), 4.63 (d, J = 6.8 Hz, 1H), 4.21 (m, 1H), 3.36 (d, J = 7.4 Hz, 2H), 2.35 - 2.23 (m, 2H), 1.73 (dt, J = 14.7, 7.0 Hz, 2H), 1.43 (d, J = 7.0 Hz, 3H).
LCMS: METCR1416 Generic 7 minutes, rt=2.13分, M/Z (ES+) 552 [M+H] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.02 (d, J = 5.3 Hz, 1H), 8.62 (s, 3H), 8.06 (s, 2H), 7.97 (s, 1H), 7.94 (d, J = 8.3 Hz, 2H), 7.58 (d, J = 8.2 Hz, 2H), 5.35 (d, J = 16.0 Hz, 1H), 5.01 (d, J = 16.0 Hz, 1H), 4.51 (dd, J = 11.0, 7.6 Hz, 1H), 4.15 (dd, J = 13.2, 7.4 Hz, 1H), 4.04 - 3.95 (m, 1H), 3.35 (d, J = 6.9 Hz, 2H), 2.66 (s, 3H), 2.29 (m, 2H), 1.74 (dt, J = 14.7, 7.1 Hz, 2H).
LCMS: MET-UHPLC-AB-101, rt=1.9分, M/Z (ES+) 470/472 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.67 (d, J = 5.1 Hz, 1H), 8.43 (s, 3H), 7.82 (d, J = 8.5 Hz, 1H), 7.68 (d, J = 5.5 Hz, 1H), 7.39 (s, 4H), 5.20 (d, J = 15.7 Hz, 1H), 4.88 (d, J = 15.7 Hz, 1H),4.46 (dd, J = 10.9, 7.5 Hz, 1H), 4.13 (dd, J = 13.3, 7.5 Hz, 1H), 3.98 (dd, J = 13.2, 11.0 Hz, 1H), 3.48 - 3.37 (m, 4H), 3.26 (s, 3H).
LCMS: METCR1416 Generic 7 minutes, rt=2.96分, M/Z (ES+) 518 [M+H+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.38 (br. s, 1H), 8.61 (s, 3H), 8.10 - 7.96 (m, 3H), 7.93 (t, J = 6.4 Hz, 2H), 7.57 (d, J = 7.3 Hz, 2H), 5.36 (d, J = 15.6 Hz, 1H), 5.06 - 5.00 (m, 1H), 4.51 (q, J = 10.9 Hz, 1H), 4.21 - 4.05 (m, 1H), 4.00 (d, J = 11.0 Hz, 1H), 3.46 (s, 1H), 2.66 (s, 3H), 1.99 (s, 1H), 1.75 (s, 1H).
LCMS: METCR1416 Generic 7 minutes, rt=3.09分, M/Z (ES+) 506.05 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.72 (t, J = 5.6 Hz, 1H), 8.28 (s, 3H), 7.90 (d, J = 5.4 Hz, 1H), 7.47 (d, J = 8.5 Hz, 1H), 7.38 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 5.33 (d, J =15.0 Hz, 1H), 4.87 (d, J = 15.1 Hz, 1H), 4.20 (s, 2H), 3.40 (dd, J = 13.2, 6.4 Hz, 3H), 2.40 - 2.26 (m, 2H), 1.76 (dt, J = 14.5, 7.0 Hz, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=3.03分, M/Z (ES+) 506 [M+H+] 96% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.72 (t, J = 5.6 Hz, 1H), 8.28 (s, 3H), 7.90 (d, J = 5.4 Hz, 1H), 7.47 (d, J = 8.5 Hz, 1H), 7.38 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 5.33 (d, J =15.0 Hz, 1H), 4.87 (d, J = 15.1 Hz, 1H), 4.20 (s, 2H), 3.40 (dd, J = 13.2, 6.4 Hz, 3H), 2.40 - 2.26 (m, 2H), 1.76 (dt, J = 14.5, 7.0 Hz, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=2.83分, M/Z (ES+) 479 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.12 (d, J = 14.5 Hz, 1H), 8.56 (s, 3H), 7.89 - 7.86 (m, 1H), 7.83 (dd, J = 8.4, 3.2 Hz, 2H), 7.70 (dd, J = 23.2, 5.4 Hz,
1H), 7.58 (dd, J = 8.4, 2.3 Hz, 2H),5.33 - 5.22 (m, 1H), 5.05 - 4.94 (m, 1H), 4.54 (q, J = 9.9, 9.5 Hz, 1H), 4.19 - 4.10 (m, 1H), 4.00 (dd, J = 13.3, 11.0 Hz, 1H), 3.55 - 3.45 (m, 1H), 2.08 - 1.94 (m, 1H), 1.71 - 1.55 (m, 1H).
LCMS: METCR1416 Generic 7 minutes, rt=3.02分, M/Z (ES+) 513.45 [M+H+]100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) a 8.75 (t, J = 5.6 Hz, 1H), 8.45 (s, 3H), 7.86 (d, J = 8.4 Hz, 1H), 7.82 (d, J = 8.3 Hz, 2H), 7.68 (d, J = 5.5 Hz, 1H), 7.58 (d, J = 8.3 Hz, 2H), 5.28 (d, J =16.2 Hz, 1H), 4.98 (d, J = 16.3 Hz, 1H), 4.57 - 4.45 (m, 1H), 4.14 (dd, J = 13.3, 7.6 Hz, 1H), 4.03 - 3.93 (m, 1H), 3.32 - 3.29 (m, 2H), 2.36 - 2.19 (m, 2H), 1.72 (dt, J = 14.6, 7.0 Hz, 2H).
LCMS: MET-UHPLC-AB-101, rt=2.46分, M/Z (ES+) 530.1/532.1 [M+H+]100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.63 (d, J = 7.5 Hz, 1H), 8.40 (s, 3H), 7.83 (d, J = 8.2 Hz, 1H), 7.63 (d, J = 5.4 Hz, 1H), 7.39 (s, 4H), 5.21 (d, J = 15.6 Hz, 1H), 4.88 (d, J = 15.6 Hz, 1H), 4.47 - 4.40 (m, 1H), 4.17 - 4.09 (m, 1H), 4.02 - 3.93 (m, 2H), 2.10 - 1.82 (m, 6H), 1.67 - 1.53 (m, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=3.26分, M/Z (ES+) 520/522 [M+H+]100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.03 (s, 1H), 8.49 - 8.07 (m, 3H), 7.84 (d, J = 8.4 Hz, 1H), 7.78 (t, J = 5.6 Hz, 1H), 7.38 (s, 4H), 5.20 - 5.13 (m, 1H), 5.05 - 4.90 (m, 1H), 4.47 - 4.40 (m, 1H), 4.12 (ddd, J = 13.1, 7.5, 2.8 Hz, 1H), 4.03 - 3.90 (m, 1H), 3.26 - 3.20 (m, 1H), 2.16 - 2.03 (m, 1H), 1.34 - 1.18 (m, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=3.18分, M/Z (ES+) 469/471 [M+H+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.99 (d, J = 6.5 Hz, 1H), 8.37 (s, 3H), 7.84 (d, J = 6.4 Hz, 1H), 7.66 (d, J = 9.3 Hz, 1H), 7.37 - 7.28 (m, 4H), 5.37 (d, J = 15.4 Hz, 1H), 4.94 (d, J = 15.4 Hz, 1H), 4.31 - 4.19 (m, 1H), 4.02 (dd, J = 11.6, 6.9 Hz, 1H), 3.67 (dd, J = 11.5, 6.9 Hz, 1H), 3.25 (t, J = 11.6 Hz, 1H), 3.04 - 2.92 (m, 2H), 2.80 - 2.66 (m, 2H).
LCMS: MET-UHPLC-AB-101, rt=2.29分, M/Z (ES+) 506.1 [M+H+] 97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.75 (t, J = 5.4 Hz, 1H), 8.57 (s, 3H), 7.83 (d, J = 8.4 Hz, 1H), 7.70 (d, J = 5.5 Hz, 1H), 7.39 (dd, J = 8.6, 5.6 Hz, 2H), 7.13 (t, J = 8.9 Hz, 2H), 5.19 (d, J = 15.5 Hz, 1H), 4.90 (d, J = 15.5 Hz, 1H), 4.47 (dd, J = 10.9, 7.6 Hz, 1H), 4.13 (dd, J = 13.3, 7.5 Hz, 1H), 3.99 (dd, J = 13.2, 11.1 Hz, 1H), 3.40 - 3.23 (m, 2H), 2.34 - 2.21 (m, 2H), 1.72 (dt, J = 14.6, 6.9 Hz, 2H).
LCMS: MET-UHPLC-AB-101, rt=1.98 & 2.01分, M/Z (ES+) 472.1 [M+H+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.14 (d, J = 14.9 Hz, 1H), 8.60 (s, 3H), 7.84 (d, J = 8.3 Hz, 1H), 7.71 (dd, J = 22.9, 5.5 Hz, 1H), 7.39 (dd, J = 8.3, 5.7 Hz, 2H), 7.18 - 7.10 (m, 2H), 5.19 (dd, J = 15.4, 10.4 Hz, 1H), 4.91 (dd, J = 15.5, 9.3 Hz, 1H), 4.47 (dt, J = 10.8, 7.7 Hz, 1H), 4.18 - 4.09 (m, 1H), 3.99 (dd, J = 13.2, 11.1 Hz, 1H), 3.48 (dd, J = 14.8, 5.0 Hz, 1H), 2.06 - 1.94 (m, 1H), 1.69 - 1.58 (m, 1H).
LCMS: : MET-UHPLC-AB-101, rt=2.24分, M/Z (ES+) 420.1 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.51 (s, 3H), 8.47 (t, J = 5.6 Hz, 1H), 7.76 (d, J = 6.4 Hz, 1H), 7.62 (d, J = 9.3 Hz, 1H), 7.31 (dd, J = 8.6, 5.6 Hz, 2H), 7.10 (t, J = 8.9 Hz, 2H), 5.31 (d, J = 15.3 Hz, 1H), 4.93 (d, J = 15.3 Hz, 1H), 4.01 (dd, J = 11.7, 6.9 Hz, 1H), 3.67 (dd, J = 11.4, 6.9 Hz, 1H), 3.29 - 3.19 (m, 3H), 1.48 (m, 2H), 1.31 (h, J = 7.3 Hz, 2H), 0.89 (t, J = 7.4 Hz, 3H).
LCMS: : MET-UHPLC-AB-101, rt=2.31分, M/Z (ES+) 454.1 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.04 (t, J = 5.8 Hz, 1H), 8.34 (s, 3H), 7.83 (d, J = 6.5 Hz, 1H), 7.65 (d, J = 9.4 Hz, 1H), 7.31 (m, 7H), 7.10 (t, J = 8.9 Hz, 2H), 5.33 (d, J = 15.3 Hz, 1H), 4.93 (d, J = 15.3 Hz, 1H), 4.56 - 4.41 (m, 2H), 4.04 (dd, J = 11.7, 6.9 Hz, 1H), 3.63 (dd, J = 11.4, 6.8 Hz, 1H), 3.23 (t, J = 11.6 Hz, 1H).
LCMS: : MET-UHPLC-AB-101, rt=2.17分, M/Z (ES+) 452.1 [M+H+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.61 (t, J = 5.4 Hz, 1H), 8.50 (s, 3H), 7.81 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 5.5 Hz, 1H), 7.39 (dd, J = 8.5, 5.6 Hz, 2H), 7.15 (t, J = 8.9 Hz, 2H), 5.20 (d, J = 15.6 Hz, 1H), 4.86 (d, J = 15.5 Hz, 1H), 4.47 (dd, J = 10.8, 7.7 Hz, 1H), 4.14 - 4.07 (m, 1H), 4.02 - 3.93 (m, 1H), 3.27 - 3.19 (m, 2H), 1.46 (p, J = 7.0 Hz, 2H), 1.29 (h, J = 7.3 Hz, 2H), 0.88 (t, J = 7.4 Hz, 3H).
LCMS: MET-UHPLC-AB-101, rt=2.23分, M/Z (ES+) 486.1 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.22 (t, J = 5.9 Hz, 1H), 8.61 (s, 3H), 7.84 (d, J = 8.4 Hz, 1H), 7.71 (d, J = 5.5 Hz, 1H), 7.40 (dd, J = 8.5, 5.6 Hz, 2H), 7.37 - 7.32 (m, 2H), 7.30 - 7.25 (m, 3H), 7.14 (t, J = 8.8 Hz, 2H), 5.20 (d, J = 15.5 Hz, 1H), 4.88 (d, J = 15.5 Hz, 1H), 4.53 - 4.41 (m, 3H), 4.14 (dd, J = 13.2, 7.5 Hz, 1H), 4.04 - 3.95 (m, 1H).
LCMS: : MET-UHPLC-AB-101, rt=2.14分, M/Z (ES+) 524/526 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.64 (t, J = 5.6 Hz, 1H), 8.55 (s, 3H), 7.83 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 5.5 Hz, 1H), 7.39 (s, 4H), 5.21 (d, J = 15.8 Hz, 1H), 4.88 (d, J = 15.8 Hz, 1H), 4.48 (dd, J = 10.9, 7.6 Hz, 1H), 4.18 - 4.11 (m, 1H), 3.99 (dd, J = 13.2, 11.1 Hz, 1H), 3.83 (dd, J = 11.3, 3.0 Hz, 2H), 3.30 - 3.20 (m, 4H), 1.58 (d, J = 14.4 Hz, 2H), 1.55 - 1.47 (m, 1H), 1.44 (q, J = 6.6 Hz, 2H), 1.21 - 1.10 (m, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=2.18分, M/Z (ES+) 488.12 [M+H+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.71 (t, J = 5.8 Hz, 1H), 8.37 (s, 3H), 7.83 (d, J = 8.5 Hz, 1H), 7.62 (d, J = 5.5 Hz, 1H), 7.46 - 7.25 (m, 5H), 5.27 (d, J = 15.7 Hz, 1H), 4.79 (d, J = 15.7 Hz, 1H), 4.53 - 4.38 (m, 1H), 4.11 (dd, J = 13.3, 7.5 Hz, 1H), 4.05 - 3.89 (m, 1H), 3.28 (d, 一部不明確, J = 7.3 Hz, 2H), 2.33 - 2.16 (m, 2H), 1.71 (dt, J = 14.6, 6.9 Hz, 2H).
LCMS: : MET-UHPLC-AB-101, rt=2.4分, M/Z (ES+) 532.15/534.10 [M+H+] 99% UV
NMRデータ: 1H NMR (250 MHz, DMSO-d6) d 9.13 (t, J = 5.9 Hz, 1H), 8.56 (s, 3H), 7.83 (d, J = 8.5 Hz, 1H), 7.69 (d, J = 5.6 Hz, 1H), 7.38 (s, 4H), 7.21 (d, J = 8.7 Hz, 2H), 6.98 - 6.80 (m, 2H), 5.20 (d, J = 15.7 Hz, 1H), 4.87 (d, J = 15.7 Hz, 1H), 4.48 (dd, J = 10.9, 7.4 Hz, 1H), 4.44 - 4.30 (m, 2H), 4.14 (dd, J = 13.2, 7.4 Hz, 1H), 4.05 - 3.91(m, 1H), 3.74 (s, 3H).
LCMS: : MET-UHPLC-AB-101, rt=2.01分, M/Z (ES+) 534.1 [M+H+] 96% UV
NMRデータ: 1H NMR (500 MHz, メタノール-d4) d 8.20 (d, J = 5.5 Hz, 1H), 7.90 (d, J = 8.6 Hz, 1H), 7.45 - 7.38 (m, 2H), 7.12 - 7.06 (m, 2H), 5.47 (d, J = 15.9 Hz,
1H), 5.26 (d, J = 15.9 Hz, 1H), 4.64 - 4.53 (m, 2H), 4.49 (dd, J = 10.9, 7.6 Hz, 1H), 4.13 (dd, J = 13.3, 7.6 Hz, 1H), 3.88 (dd, J = 13.3, 11.0 Hz, 1H), 2.46 (tt, J = 8.3, 4.9 Hz, 1H), 1.31 - 1.26 (m, 2H), 1.10 - 1.04 (m, 2H). NHアミドおよびNH2・HClはNMRでは見えない
LCMS: MET-UHPLC-AB-101, rt=1.84分, M/Z (ES+) 494.1 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.65 (t, J = 5.8 Hz, 1H), 8.46 (s, 3H), 7.81 (d, J = 8.3 Hz, 1H), 7.60 (d, J = 5.5 Hz, 1H), 7.39 (dd, J = 8.6, 5.5 Hz, 2H), 7.15 (t, J = 8.9 Hz, 2H), 5.22 (d, J = 15.5 Hz, 1H), 4.84 (d, J = 15.6 Hz, 1H), 4.46 (dd, J = 10.7, 7.7 Hz, 1H), 4.11 (dd, J = 13.3, 7.4 Hz, 1H), 3.98 (dd, J = 13.2, 11.1 Hz, 1H), 3.85 (dd, J = 11.0, 2.9 Hz, 2H), 3.25 (t, J = 11.0 Hz, 2H), 3.20 - 3.08 (m, 2H), 1.80 - 1.66 (m, 1H), 1.52 (d, J = 12.3 Hz, 2H), 1.17 (qd, J = 12.1, 4.5 Hz, 2H).
LCMS: MET-UHPLC-AB-101, rt=2.11分, M/Z (ES+) 486.0 [M+H+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.20 (d, J = 6.5 Hz, 1H), 8.68 (s, 3H), 7.84 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 5.5 Hz, 1H), 7.39 (dd, J = 8.7, 5.5 Hz, 2H), 7.17 - 7.09 (m, 2H), 5.17 (d, J = 15.4 Hz, 1H), 4.94 (d, J = 15.5 Hz, 1H), 4.46 (dd, J = 10.9, 7.5 Hz, 1H), 4.24 (dt, J = 14.8, 6.8 Hz, 1H), 4.16 (dd, J = 13.3, 7.5 Hz, 1H), 3.99 (dd, J = 13.2, 11.0 Hz, 1H), 3.05 - 2.92 (m, 2H), 2.75 - 2.65 (m, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=3.18分, M/Z (ES+) 518.25 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.65 (t, J = 5.6 Hz, 1H), 7.71 (d, J = 8.6 Hz, 1H), 7.57 (d, J = 5.6 Hz, 1H), 7.26 (d, J = 8.7 Hz, 2H), 6.86 - 6.82 (m, 2H), 5.17 - 5.07 (m, 1H), 4.76 - 4.68 (m, 1H), 3.89 (dd, J = 12.1, 5.8 Hz, 1H), 3.71 (s, 3H), 3.71 - 3.57 (m, 2H), 2.33 - 2.19 (m, 2H), 2.00 (s, 2H), 1.71 (dt, J = 14.6, 6.9 Hz, 2H). [2Hは水のピークで隠れている]
LCMS: METCR1416 Generic 7 minutes, rt=2.85分, M/Z (ES+) 506.3 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.57 (t, J = 5.8 Hz, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.48 (d, J = 5.6 Hz, 1H), 7.26 (d, J = 8.7 Hz, 2H), 6.87 - 6.82 (m, 2H), 5.22 - 5.11 (m, 1H), 4.67 - 4.58 (m, 1H), 3.89 (dd, J = 12.2, 5.8 Hz, 1H), 3.86 - 3.81 (m, 2H), 3.72 (s, 3H), 3.71 - 3.58 (m, 2H), 3.25 (td, J = 11.7, 1.8 Hz, 2H), 3.17 - 3.07 (m, 2H), 2.03 (s, 2H), 1.78 - 1.66 (m, 1H), 1.52 (d, J = 12.9 Hz, 2H), 1.18 (td, J = 12.9, 12.4, 4.3 Hz, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=3.03分, M/Z (ES+) 484.2 [M+H+] 97% UV
NMRデータ: 1H NMR (250 MHz, DMSO-d6) d 9.06 - 8.95 (m, 1H), 7.72 (d, J = 8.6 Hz,
1H), 7.56 (dd, J = 5.5, 4.3 Hz, 1H), 7.25 (dd, J = 8.6, 1.3 Hz, 2H), 6.84 (dd, J = 8.7, 1.7 Hz, 2H), 5.18 - 5.07 (m, 1H), 4.76 - 4.65 (m, 1H), 3.98 - 3.80 (m, 1H), 3.72 (s, 3H), 3.72 - 3.58 (m, 2H), 3.57 - 3.40 (m, 1H), 2.10 - 1.88 (m, 3H), 1.69 - 1.50 (m, 1H).
LCMS: METCR1416 Generic 7 minutes, rt=2.94分, M/Z (ES+) 496.1/ 498.2 [M+H+] 100%
UV
NMRデータ: 1H NMR (250 MHz, DMSO-d6) d 8.55 (d, J = 7.7 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 7.37 (s, 4H), 5.19 (d, J = 15.6 Hz, 1H), 4.78 (d, J = 15.6 Hz, 1H), 4.11 - 3.82 (m, 4H), 3.80 - 3.59 (m,2H), 3.41 (d, J = 11.4 Hz, 2H), 2.02 (s, 2H), 1.74 (s, 2H), 1.59 - 1.40 (m, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=2.21分, M/Z (ES+) 484.1/486.1 [M+H+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.11 (d, J = 6.4 Hz, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.95 (d, J = 7.9 Hz, 1H), 7.82 (s, 1H), 7.37 (s, 4H), 5.22 - 4.81 (m, 2H), 4.31 - 4.19 (m, 1H), 3.89 (dd, J = 12.6, 6.2 Hz, 1H), 3.69 (s, 1H), 3.66 - 3.57 (m, 1H), 2.97 (td, J = 13.3, 6.7 Hz, 2H), 2.74 (s, 2H), 2.00 (s, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=3.22分, M/Z (ES+) 516.20/518.2 [M+H+] 100%
UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.79 (d, J = 7.0 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 5.5 Hz, 1H), 7.36 (s, 4H), 5.15 (d, J = 15.6 Hz, 1H), 4.81 (d, J = 15.7 Hz, 1H), 4.36 (q, J = 7.5 Hz, 1H), 3.90 (dd, J = 12.2, 5.9 Hz, 1H), 3.75 - 3.60 (m, 2H), 2.30 - 2.18 (m, 1H), 2.19 - 1.90 (m, 6H), 1.75 (dt, J = 12.1, 7.7 Hz, 1H).
LCMS: METCR1416 Generic 7 minutes, rt=2.93分, M/Z (ES+) 452.05/454.05 [M+H+]; 474/476 [M+Na+] 96% UV
NMRデータ: 1H NMR (250 MHz, DMSO-d6) d 8.87 (d, J = 3.5 Hz, 1H), 8.06 - 7.87 (m,
2H), 7.83 (s, 1H), 7.37 (s, 4H), 5.19 (d, J = 15.8 Hz, 1H), 4.98 - 4.79 (m, 1H), 4.76 - 4.56 (m, 1H), 3.98 - 3.83 (m, 1H), 3.79 - 3.53 (m,2H), 2.80 (d, J = 8.4 Hz, 1H), 1.99 (s, 2H), 1.26 - 1.03 (m, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=2.93分, M/Z (ES+) 468.4 [M+H+], 490.05 [M+Na+] 99% UV; NMRデータ: 1H NMR (250 MHz, DMSO-d6) d 9.12 (d, J = 6.3 Hz, 1H), 8.08 - 7.93 (m, 2H), 7.90 (s, 1H), 7.45 (t, J = 7.7 Hz, 1H), 7.30 (t, J = 5.9 Hz, 1H), 7.21 - 7.01 (m, 2H), 5.17 (d, J = 16.0 Hz, 1H), 4.90 (d, J = 15.2 Hz,1H), 4.25 (s, 1H), 3.96 - 3.79 (m, 1H), 3.75 - 3.54 (m, 2H), 2.96 (s, 2H), 2.78 (s, 2H), 1.97 (s, 2H)
LCMS: METCR1416 Generic 7 minutes 215および254nm, rt=2.98分, M/Z (ES+) 480.5 [M+H+]; 502.1 [M+Na+] 98% UV
NMRデータ: 1H NMR (250 MHz, DMSO-d6) d 9.09 (d, J = 6.6 Hz, 1H), 8.08 - 7.91 (m,
2H), 7.82 (s, 1H), 7.22 (t, J = 7.9 Hz, 1H), 6.93 (d, J = 7.6 Hz, 2H), 6.88 - 6.74 (m, 1H), 5.20 (d, J = 15.7 Hz, 1H), 4.80 (d, J = 15.6 Hz,1H), 4.24 (s, 1H), 4.02 - 3.85 (m, 1H), 3.71 (s, 4H), 3.58 (s, 1H), 3.12 - 2.89 (m, 2H), 2.85 - 2.66 (m, 2H), 2.07 (s, 2H).
LCMS: MET-UHPLC-AB-101, rt=2.1分, M/Z (ES+) 500.2 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.80 (t, J = 5.6 Hz, 1H), 7.95 (d, J = 8.1 Hz, 1H), 7.90 (d, J = 8.9 Hz, 1H), 7.83 (s, 1H), 7.26 (d, J = 8.6 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 5.11 (d, J = 15.4 Hz, 1H), 4.82 (d, J = 15.3 Hz, 1H), 3.87 (dd, J = 12.4, 6.1 Hz, 1H), 3.71 (s, 3H), 3.70 - 3.58 (m, 2H), 3.38 - 3.33 (m, 2H), 2.35 - 2.24 (m, 2H), 2.07 (s, 2H), 1.74 (dt, J = 14.8, 7.0 Hz, 2H).
LCMS: MET-UHPLC-AB-101, rt=2.11分, M/Z (ES+) 510.2 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.22 (t, J = 6.0 Hz, 1H), 7.98 - 7.89 (m,
2H), 7.86 (s, 1H), 7.26 (d, J = 8.6 Hz, 2H), 7.22 (d, J = 8.6 Hz, 2H), 6.89 (d,
J = 8.7 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 5.11 (d, J = 15.4 Hz, 1H), 4.83 (d, J = 15.3 Hz, 1H), 4.40 (d, J = 5.8 Hz, 2H), 3.86 (dd, J = 12.6, 6.1 Hz, 1H), 3.73 (s, 3H), 3.71 (s, 3H), 3.69 - 3.64 (m, 1H), 3.64 - 3.57 (m, 1H), 2.00 (s, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=3.04分, M/Z (ES+) 480.5 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.06 (d, J = 8.1 Hz, 1H), 7.78 (dd, J = 8.1, 1.5 Hz, 1H), 7.36 - 7.11 (m, 8H), 6.94 - 6.86 (m, 2H), 6.01 - 5.90 (m, 1H), 5.57 (d, J = 15.0 Hz, 1H), 4.54 - 4.41 (m, 3H), 3.83 (s, 3H), 3.77 (dd, J = 12.9, 6.7 Hz, 1H), 3.70 (dd, J = 9.9, 7.3 Hz, 1H), 3.48 (dd, J = 12.9, 11.0 Hz, 1H). (NH2は見えない)
LCMS: METCR1416 Generic 7 minutes, rt=3.27分, M/Z (ES+) 514.10 /516.10 [M+H+] 97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.23 (t, J = 5.8 Hz, 1H), 7.97 (s, 2H), 7.85 (s, 1H), 7.42 - 7.32 (m, 4H), 7.22 (d, J = 8.6 Hz, 2H), 6.95 - 6.84 (m, 2H), 5.16 (d, J = 15.7 Hz, 1H), 4.89 (d, J = 15.7 Hz, 1H), 4.40 (d, J = 5.9 Hz, 2H), 3.88 (dd, J = 12.8, 6.6 Hz, 1H), 3.83 - 3.61 (m, 4H), 3.65 - 3.55 (m, 1H), 1.98 (s, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=3.08分, M/Z (ES+) 508.50 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.54 (d, J = 7.6 Hz, 1H), 7.98 - 7.88 (m,
2H), 7.78 (d, J = 1.2 Hz, 1H), 7.27 (d, J = 8.7 Hz, 2H), 6.85 (d, J = 8.7 Hz, 2H), 5.17 (d, J = 15.3 Hz, 1H), 4.75 (d, J = 15.2 Hz, 1H), 4.01 - 3.92 (m, 1H), 3.89 - 3.83 (m, 1H), 3.72 (s, 3H), 3.71 - 3.58 (m, 2H), 2.12 - 1.83 (m, 8H), 1.68 - 1.57 (m, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=3.21分, M/Z (ES+) 490.10/492.10 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.98 (t, J = 5.6 Hz, 1H), 7.99 (d, J = 8.1 Hz, 1H), 7.91 (d, J = 8.1 Hz, 1H), 7.81 (s, 1H), 7.36 (s, 4H), 5.17 (d, J = 15.8 Hz, 1H), 4.88 (d, J = 15.8 Hz, 1H), 3.89 (dd, J = 12.9, 6.5 Hz, 1H), 3.74 - 3.68 (m, 1H), 3.66 - 3.59 (m, 1H), 3.50 (q, J = 6.4 Hz, 2H), 2.60 - 2.53 (m, 2H), 2.15 - 1.88 (m, 2H).
LCMS: MET-UHPLC-AB-101, rt=1.86分, M/Z (ES+) 464.1/466.1 [M+H+] 97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.82 (d, J = 6.6 Hz, 1H), 7.95 (s, 2H), 7.81 (s, 1H), 7.36 (s, 4H), 5.18 (d, J = 15.7 Hz, 1H), 4.86 (d, J = 15.7 Hz, 1H), 4.49 - 4.39 (m, 1H), 3.91 - 3.80 (m,3H), 3.75 - 3.65 (m, 2H), 3.65 - 3.55 (m, 2H), 2.21 - 2.10 (m, 1H), 1.99 (s, 2H), 1.92 - 1.82 (m, 1H).
LCMS: MET-UHPLC-AB-101, rt=1.9分, M/Z (ES+) 478.1/480.1 [M+H+] 94% UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) d 8.12 (dd, J = 8.1, 1.1 Hz, 1H), 7.75 (ddd, J = 8.1, 4.1, 1.6 Hz, 1H), 7.58 (dd, J = 3.6, 1.5 Hz, 1H), 7.32 (s, 4H), 6.25 (s, 1H), 5.44 - 4.66 (m, 2H), 3.93 (dtd, J = 13.7, 8.5, 5.2Hz, 1H), 3.85 - 3.71 (m, 4H), 3.65 (dt, J = 9.3, 5.0 Hz, 1H), 3.50 (m, 3H), 2.60 (dt, J = 11.6, 6.5 Hz, 1H), 2.17 - 2.08 (m, 1H), 1.71 - 1.63 (m, 1H).
LCMS: METCR1416 Generic 7 minutes, rt=3.03分, M/Z (ES+) 470.1/472.10 [M+H+] 98%
UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.12 (s, 1H), 7.99 (d, J = 8.1 Hz, 1H), 7.93 (d, J = 8.2 Hz, 1H), 7.81 (s, 1H), 7.36 (s, 4H), 5.17 (d, J = 15.7 Hz, 1H), 4.86 (d, J = 15.8 Hz, 1H), 3.88 (dd, J = 12.9, 6.5 Hz, 1H), 3.71 (dd, J = 11.0, 6.6 Hz, 1H), 3.67 - 3.56 (m, 1H), 3.50 - 3.42 (m, 1H), 2.17 - 1.91 (m, 3H), 1.70
- 1.60 (m, 1H).
LCMS: METCR1416 Generic 7 minutes, rt=2.22分, M/Z (ES+) 476.1 [M+H+] 97% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.09 (s, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.91 (d, J = 8.1 Hz, 1H), 7.80 (s, 1H), 7.21 (d, J = 8.1 Hz, 2H), 6.99 (d, J = 8.2 Hz, 2H), 5.17 (d, J = 15.6 Hz, 1H), 4.73 (d, J = 15.6 Hz, 1H), 3.87 (dd, J = 12.8, 6.4 Hz, 1H), 3.70 (dd, J = 11.0, 6.5 Hz, 1H), 3.66 - 3.56 (m, 1H), 3.51 - 3.40 (m, 1H), 2.22 - 1.91 (m, 3H), 1.92 - 1.82 (m, 1H), 1.70 - 1.61 (m, 1H), 0.95 - 0.88 (m, 2H), 0.65 - 0.60 (m, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=3.01分, M/Z (ES+) 502.5 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.12 (s, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.93 (d, J = 8.2 Hz, 1H), 7.84 (s, 1H), 7.40 (d, J = 8.6 Hz, 2H), 7.21 (t, J = 74.2 Hz, 1H), 7.11 (d, J = 8.6 Hz, 2H), 5.19 (d, J = 15.7 Hz, 1H), 4.85 (d, J = 15.7 Hz, 1H), 3.89 (dd, J = 12.8, 6.5 Hz, 1H), 3.72 (dd, J = 11.2, 6.3 Hz, 1H), 3.67 - 3.58 (m, 1H), 3.51 - 3.43 (m, 1H), 2.11 - 1.89 (m, 3H), 1.71 - 1.59 (m, 1H).
LCMS: MET-UHPLC-AB-101, rt=1.84分, M/Z (ES+) 466.1 [M+H+] 95% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.09 (s, 1H), 7.97 (d, J = 8.1 Hz, 1H), 7.90 (d, J = 8.3 Hz, 1H), 7.82 (d, J = 1.1 Hz, 1H), 7.26 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 5.13 (d, J = 15.3 Hz, 1H), 4.78 (d, J = 15.3 Hz, 1H), 3.86 (dd, J = 12.6, 6.2 Hz, 1H), 3.72 (s, 3H), 3.71 - 3.65 (m, 1H), 3.65 - 3.58 (m, 1H), 3.50 - 3.43 (m, 1H), 2.20 - 1.94 (m, 3H), 1.70 - 1.61 (m, 1H).
LCMS: METCR1416 Generic 7 minutes, rt=3分, M/Z (ES+) 470.50 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.79 (t, J = 5.6 Hz, 1H), 7.97 (d, J = 8.1 Hz, 1H), 7.91 (d, J = 9.0 Hz, 1H), 7.78 (s, 1H), 7.35 (d, J = 7.2 Hz, 2H), 7.30 (t, J = 7.4 Hz, 2H), 7.24 (t, J = 7.2 Hz, 1H), 5.23 (d, J = 15.7 Hz, 1H), 4.79 (d, J = 15.7 Hz, 1H), 3.88 (dd, J = 12.9, 6.5 Hz, 1H), 3.71 (dd, J = 11.1, 6.3 Hz, 1H), 3.67 - 3.59 (m, 1H), 3.37 - 3.32 (m, 2H), 2.34 - 2.22 (m, 2H), 2.05 (s, 2H), 1.72 (dt, J = 14.7, 7.1 Hz, 2H).
LCMS: MET-UHPLC-AB-101, rt=1.05分, M/Z (ES+) 538.05/540.05 [M+H+] 96% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.68 (t, J = 5.7 Hz, 1H), 7.85 (s, 1H), 7.55 (s, 1H), 7.39 - 7.31 (m, 4H), 5.12 (d, J = 15.6 Hz, 1H), 4.93 (d, J = 15.6 Hz, 1H), 3.94 (dd, J = 12.6, 6.3 Hz, 1H), 3.76 - 3.69 (m, 1H), 3.69 - 3.63 (m, 1H), 3.30 - 3.24 (m, 2H), 2.35 - 2.06 (m, 4H), 1.71 (dt, J = 14.6, 6.9 Hz, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=2.87分, M/Z (ES+) 524.2 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.75 (t, J = 5.7 Hz, 1H), 7.97 (d, J = 8.1 Hz, 1H), 7.92 (d, J = 8.2 Hz, 1H), 7.80 (s, 1H), 7.41 (d, J = 8.6 Hz, 2H), 7.21 (t, J = 74.2 Hz, 1H), 7.10 (d, J = 8.5 Hz, 2H), 5.19 (d, J = 15.7 Hz, 1H), 4.85 (d, J = 15.7 Hz, 1H), 3.92 - 3.80 (m, 3H), 3.74 - 3.67 (m, 1H), 3.66 - 3.59 (m, 1H), 3.29-3.21 (m, 2H), 3.15 (見かけt, J = 6.3 Hz, 2H), 2.15 - 1.88 (m, 2H), 1.81 - 1.70 (br. m, 1H), 1.59 - 1.49 (m, 2H), 1.18 (見かけqd, J = 12.3, 4.4 Hz, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=2.86分, M/Z (ES+) 510.50/512 [M+H+] 99% UVNMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.92 (t, J = 6.1 Hz, 1H), 8.00 - 7.93 (m, 2H), 7.81 (s, 1H), 7.40 - 7.33 (m, 4H), 5.20 (d, J = 15.7 Hz, 1H), 4.87 (d, J = 15.6 Hz, 1H), 3.89 (dd, J = 12.8, 6.5 Hz, 1H), 3.77 - 3.68 (m, 3H), 3.66 - 3.60 (m, 1H), 3.54 (dd, J = 21.1, 6.4 Hz, 4H), 2.23 - 1.87 (m, 2H), 1.79 - 1.70 (m, 1H), 1.70 - 1.64 (m, 3H).
LCMS: METCR1416 Generic 7 minutes, rt=2.9分, M/Z (ES+) 507.05/509.20 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.41 (d, J = 8.6 Hz, 1H), 7.96 (d, J = 8.1 Hz, 1H), 7.91 (d, J = 8.1 Hz, 1H), 7.72 (d, J = 1.3 Hz, 1H), 7.42 - 7.33 (m, 4H), 5.23 (d, J = 15.7 Hz, 1H), 4.83 (d, J = 15.8 Hz, 1H), 3.92 - 3.77 (m, 4H), 3.75 - 3.69 (m, 1H), 3.66 - 3.58 (m, 1H), 3.29 - 3.18 (m, 2H), 2.00 (s, 2H), 1.66 - 1.48 (m, 3H), 1.26 - 1.14 (m, 2H), 1.12 (d, J = 6.7 Hz, 3H).
LCMS: METCR1416 Generic 7 minutes, rt=2.75分, M/Z (ES+) 436.45 [M+H+] 95.6% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.09 (s, 1H), 7.99 (d, J = 8.1 Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.79 (s, 1H), 7.39 - 7.22 (m, 5H), 5.24 (d, J = 15.7 Hz, 1H), 4.77 (d, J = 15.7 Hz, 1H), 3.88 (dd, J = 12.9, 6.5 Hz, 1H),3.73 (dd, J = 11.0, 6.6 Hz, 1H), 3.63 (dd, J = 12.8, 11.2 Hz, 1H), 3.45 (d, J = 9.2 Hz, 1H), 2.19 - 1.92 (m, 3H), 1.64 (m, 1H).
LCMS: METCR1416 Generic 7 minutes, rt=2.38分, M/Z (ES+) 499.10/501.20 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.31 (t, J = 5.8 Hz, 1H), 8.40 (d, J = 1.8 Hz, 1H), 7.99 - 7.89 (m, 2H), 7.85 (s, 1H), 7.57 (dd, J = 7.9, 2.3 Hz, 1H), 7.39 - 7.29 (m, 4H), 7.21 (d, J = 8.0 Hz, 1H), 5.15 (d, J = 15.8 Hz, 1H), 4.89 (d, J = 15.8 Hz, 1H), 4.45 (d, J = 5.8 Hz, 2H), 3.87 (dd, J = 12.7, 6.3 Hz, 1H), 3.77 - 3.65 (m, 1H), 3.65 - 3.55 (m, 1H), 2.44 (s, 3H), 1.99 (br. s, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=3.11分, M/Z (ES+) 498.50/ 500.10 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.82 (d, J = 7.0 Hz, 1H), 8.01 - 7.90 (m,
2H), 7.79 (s, 1H), 7.36 (s, 4H), 5.18 (d, J = 15.7 Hz, 1H), 4.84 (d, J = 15.7 Hz, 1H), 4.39 (h, J = 7.6 Hz, 1H), 3.87 (dd, J = 12.6, 6.2 Hz, 1H), 3.73 - 3.66 (m, 1H), 3.66 - 3.53 (m, 1H), 2.58 - 2.43 (m, 1H), 2.33 - 2.20 (m, 1H), 2.20 - 2.04 (m, 3H), 1.99 (s, 2H), 1.85 - 1.74 (m, 1H).
LCMS: MET-UHPLC-AB-101, rt=2.16分, M/Z (ES+) 511.1 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.12 (t, J = 5.9 Hz, 1H), 7.81 - 7.77 (m,
2H), 7.74 (d, J = 8.6 Hz, 1H), 7.60 (d, J = 5.5 Hz, 1H), 7.54 (d, J = 8.3 Hz, 2H), 7.35 - 7.27 (m, 2H), 7.22 - 7.13 (m, 2H), 5.23 (d, J = 16.3 Hz, 1H), 4.88 (d, J = 16.2 Hz, 1H), 4.49 - 4.36 (m, 2H), 3.91 (dd, J = 13.0, 6.7 Hz, 1H), 3.81 - 3.72 (m, 1H), 3.65 (dd, J = 12.9, 11.1 Hz, 1H), 2.00 (s, 2H).
LCMS: MET-UHPLC-AB-101, rt=2.31分, M/Z (ES+) 498.1/500.1 [M+H+] 100% UV
NMRデータ: 1H NMR (250 MHz, クロロホルム-d) d 8.09 (d, J = 8.1 Hz, 1H), 7.71 (dd, J = 8.2, 1.4 Hz, 1H), 7.53 (s, 1H), 7.29 (s, 4H), 6.13 - 6.00 (m, 1H), 5.37 (d, J = 15.2 Hz, 1H), 4.69 (d, J = 15.1 Hz, 1H), 3.93 - 3.64 (m, 2H), 3.64 - 3.42 (m, 3H), 2.87 - 2.60 (m, 2H), 2.55 - 2.17 (m, 3H) [NH2は見えない]
LCMS: METCR1416 Generic 7 minutes, rt=2.87分, M/Z (ES+) 515/517.25 [M+H+]; 536.10/538.05 [M+Na+] 99% UV; NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.61 (t, J = 5.4
Hz, 1H), 7.72 (d, J = 8.6 Hz, 1H), 7.59 (d, J = 5.5 Hz, 1H), 7.37 (s, 4H), 5.15
(d, J = 15.8 Hz, 1H), 4.80 (d, J = 15.8 Hz, 1H), 3.90 (dd, J =12.9, 6.5 Hz, 1H), 3.77 - 3.70 (m, 1H), 3.69 - 3.61 (m, 1H), 3.55 - 3.48 (m, 4H), 3.45 - 3.38 (m, 4H), 3.24 (s, 3H), 2.02 (s, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=2.97分, M/Z (ES+) 464.05/466.05 [M+H+] 96%
UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.71 (t, J = 5.5 Hz, 1H), 7.73 (d, J = 8.6 Hz, 1H), 7.62 (d, J = 5.6 Hz, 1H), 7.37 (s, 4H), 5.15 (d, J = 15.8 Hz, 1H), 4.80 (d, J = 15.8 Hz, 1H), 3.90 (dd, J =12.9, 6.5 Hz, 1H), 3.73 (dd, J = 10.9, 6.6 Hz, 1H), 3.68 - 3.61 (m, 1H), 3.37 (dt, J = 13.7, 7.1 Hz, 2H), 2.80 (t, J = 2.6 Hz, 1H), 2.41 (td, J = 7.0, 2.6 Hz, 2H), 2.12 - 1.97 (m, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=3.04分, M/Z (ES+) 477/479 [M+H+] 95% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.61 (t, J = 5.5 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.60 (d, J = 5.5 Hz, 1H), 7.37 (s, 4H), 5.15 (d, J = 15.7 Hz, 1H), 4.82 (d, J = 15.7 Hz, 1H), 3.90 (dd, J =12.7, 6.3 Hz, 1H), 3.76 - 3.70 (m, 1H), 3.68 - 3.60 (m, 1H), 3.32 (s, 2H), 2.80 (t, J = 2.6 Hz, 1H), 2.21 (td, J = 7.1, 2.6 Hz, 2H), 2.01 (s, 2H), 1.68 (t, J = 7.0 Hz, 2H)
LCMS: METCR1416 Generic 7 minutes, rt=3.03分, M/Z (ES+) 504.95/507.05 [M+H+] 97%
UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.07 (s, 1H), 7.86 (s, 1H), 7.56 (s, 1H),
7.35 (s, 4H), 5.12 (d, J = 15.7 Hz, 1H), 4.91 (d, J = 15.6 Hz, 1H), 3.93 (dd, J
= 12.4, 6.0 Hz, 1H), 3.79 - 3.58 (m, 2H), 3.55 - 3.43 (m, 1H), 2.20 - 1.93 (m, 3H), 1.54 (ddt, J = 14.6, 9.0, 5.6 Hz, 1H).
LCMS: MET-UHPLC-AB-101, rt=1.28分, M/Z (ES+) 507.1/509.1 [M+H+] 95% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 8.70 (t, J = 5.7 Hz, 1H), 7.97 (d, J = 8.1 Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.80 (s, 1H), 7.39 - 7.32 (m, 4H), 5.17 (d, J = 15.8 Hz, 1H), 4.88 (d, J = 15.9 Hz, 1H), 3.88 (dd, J = 13.0, 6.6 Hz, 1H), 3.76 - 3.67 (m, 1H), 3.67 - 3.58 (m, 1H), 3.58 - 3.50 (m, 4H), 3.41 - 3.36 (m, 2H), 2.45 (t, J = 6.8 Hz, 2H), 2.42 - 2.38 (m, 4H), 2.00 (br. s, 2H).
LCMS: MET-UHPLC-AB-101, rt=2.16分, M/Z (ES+) 515.1/517.1 [M+H+] 98% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.28 (t, J = 5.8 Hz, 1H), 8.13 (d, J = 2.3 Hz, 1H), 8.01 - 7.91 (m, 2H), 7.86 (s, 1H), 7.64 (dd, J = 8.5, 2.5 Hz, 1H), 7.40 - 7.30 (m, 4H), 6.80 (d, J = 8.5 Hz, 1H), 5.16 (d, J = 15.7 Hz, 1H), 4.90 (d, J = 15.7 Hz, 1H), 4.42 (d, J = 5.7 Hz, 2H), 3.88 (dd, J = 13.3, 7.0 Hz, 1H), 3.84 (s, 3H), 3.73 - 3.66 (m, 1H), 3.66 - 3.56 (m, 1H), 1.96 (s, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=3.27分, M/Z (ES+) 556.50/558.10 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.06 (t, J = 5.7 Hz, 1H), 7.73 (d, J = 8.6 Hz, 1H), 7.62 (d, J = 5.5 Hz, 1H), 7.37 (s, 4H), 7.23 (d, J = 8.6 Hz, 2H), 6.96 (d, J = 8.7 Hz, 2H), 5.17 (d, J =15.7 Hz, 1H), 4.84 - 4.74 (m, 3H), 4.49 - 4.31 (m, 2H), 3.91 (dd, J = 12.8, 6.4 Hz, 1H), 3.77 - 3.69 (m, 1H), 3.68 - 3.62 (m, 1H), 3.55 (t, J = 2.4 Hz, 1H), 2.00 (s, 2H).
LCMS: METCR1416 Generic 7 minutes, rt=3.07分, M/Z (ES+) 504.5 [M+H+] 99% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.11 (s, 1H), 8.01 (d, J = 8.1 Hz, 1H), 7.95 (d, J = 8.2 Hz, 1H), 7.82 (s, 1H), 7.68 (d, J = 8.2 Hz, 2H), 7.58 (d, J = 8.1 Hz, 2H), 5.28 (d, J = 16.1 Hz, 1H), 4.93 (d, J = 16.1 Hz, 1H), 3.90 (dd, J = 13.0, 6.6 Hz, 1H), 3.74 (dd, J = 11.0, 6.7 Hz, 1H), 3.64 (dd, J = 12.9, 11.1 Hz, 1H), 3.52 - 3.40 (m, 1H), 2.08 - 1.91 (m, 3H), 1.69 - 1.58 (m, 1H).
LCMS: METCR1416 Generic 7 minutes, rt=3.01分, M/Z (ES+) 515.75/517.10 [M+H+] 99%
UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) d 9.12 (s, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.97 - 7.91 (m, 1H), 7.84 (d, J = 11.6 Hz, 1H), 7.50 (dd, J = 8.5, 2.2 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 5.21 - 5.07 (m, 1H), 4.92 - 4.77 (m, 1H), 3.89 (dd, J = 12.6, 5.9 Hz, 1H), 3.78 - 3.67 (m, 1H), 3.67 - 3.58 (m, 1H), 3.52 - 3.41 (m, 1H), 2.25 (br. s, 2H), 2.07 - 1.95 (m, 1H), 1.74 - 1.57 (m, 1H).
一般的手順GP5に従って、中間体IV−06から表題化合物を合成して、定量的収率で、表題化合物を得た。
LCMS: METCR1410 Generic 1.7 minutes, rt=0.94分, M/Z (ES+) 377/379 [M+H+] 98% UV
1H NMR (500 MHz, DMSO-d6) δ 8.59 (s, 3H), 8.00 (d, J = 1.6 Hz, 1H), 7.84 (dd, J
= 8.0, 1.7 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.36 - 7.28 (m, 4H), 5.31 (d, J =
15.6 Hz, 1H), 5.02 (d, J = 15.6 Hz, 1H), 4.02 (dd, J = 11.8, 6.8 Hz, 1H), 3.87 (s, 3H), 3.74 - 3.67 (m, 1H), 3.28 (t, J = 11.7 Hz, 1H).
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボン酸メチル塩酸塩(230mg、0.56mmol)のDCM(6ml)溶液に、DIPEA(290μl、1.67mmol)、次いでクロロギ酸ベンジル(945μl、0.67mmol)を添加した。結果として得られた混合物を、室温で1.5時間撹拌した。反応混合物に、水(20ml)およびDCM(20ml)を添加した。混合物を、フェーズセパレーターを通して分配した(TELOS)。有機層を濃縮して、淡黄色の油状物を得た。残留物を、カラムクロマトグラフィー(シリカ、溶離液:ヘプタン、0〜50% EtOAc)で精製して、純度99%で、白色の固体として所望の表題化合物(0.28g、定量的収率)を得た。
LCMS: METCR1410 Generic 1.7 min, rt=1.31分, M/Z (ES+) 533/535 [M+Na+] 99% UV
1H NMR (500 MHz, クロロホルム-d) δ 7.92 (s, 1H), 7.84 (dd, J = 8.0, 1.7 Hz, 1H)
, 7.66 (d, J = 8.0 Hz, 1H), 7.37 - 7.27 (m, 5H), 7.19 (s, 4H), 5.82 (d, J = 7.7 Hz, 1H), 5.44 (d, J = 15.1 Hz, 1H), 5.04 (s, 2H), 4.72 (d, J = 15.1 Hz, 1H), 4.51 - 4.37 (m, 1H), 3.93 (s, 3H), 3.74 (dd, J = 10.9, 6.6 Hz, 1H), 2.94 (t, J = 11.2 Hz, 1H).
一般的手順GP2に従って、(3R)−3−{[(ベンジルオキシ)カルボニル]アミノ}−5−[(4−クロロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボン酸メチルから表題化合物を合成して、収率94%で、表題化合物を得た(純度94%)。
LCMS: METCR1410 Generic 1.7 min, rt=1.19分, M/Z (ES+) 519/521 [M+Na+] 99% UV
1H NMR (500 MHz, クロロホルム-d) δ 7.94 (d, J = 1.5 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.38 - 7.28 (m, 5H), 7.20 (s, 4H), 5.90 (d, J = 7.9 Hz, 1H), 5.45 (d, J = 15.1 Hz, 1H), 5.06 (s, 2H), 4.74 (d, J = 15.1 Hz, 1H), 4.55 - 4.46 (m, 1H), 3.81 - 3.72 (m, 1H), 2.98 (t, J = 11.3 Hz, 1H).
一般的手順GP3に従って、(3R)−3−{[(ベンジルオキシ)カルボニル]アミノ}−5−[(4−クロロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボン酸から表題化合物を合成して、収率83%で、表題化合物を得た(純度94%)。
LCMS: METCR1410 Generic 1.7 min, rt=1.18分, M/Z (ES+) 592/ 594 [M+H+]および614/616 [M+Na+] 100% UV; 1H NMR (500 MHz, DMSO-d6) δ 8.70 (d, J = 7.0 Hz, 1H), 7.93 (d, J = 9.0 Hz, 2H), 7.68 (s, 2H), 7.37 - 7.21 (m, 9H), 5.33 (d, J = 15.5 Hz, 1H), 4.99 (s, 2H), 4.88 (d, J = 15.5 Hz, 1H), 4.63 (s, 2H), 4.51 (s, 2H), 4.24 - 4.14 (m, 2H), 3.50 (dd, J = 11.1, 6.9 Hz, 1H), 3.11 (t, J = 11.8 Hz, 1H), 2.62 - 2.55 (m, 2H), 2.29 - 2.19 (m, 2H).
一般的手順GP4に従ってN−[(3R)−5−[(4−クロロフェニル)メチル]−7−({2−オキサスピロ[3.3]ヘプタン−6−イル}カルバモイル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−3−イル]カルバミン酸ベンジルから表題化合物を合成して、収率84%で、表題化合物を得た(純度92%)。LCMS: METCR1410 Generic 1.7 min, rt=1.12分, M/Z (ES+) 624/ 626 [M+H+]および646/648 [M+Na+] 100% UV; 1H NMR (500 MHz, DMSO-d6) δ 8.90 (d, J = 7.0 Hz, 1H), 8.03 - 7.92 (m, 3H), 7.81 (s, 1H), 7.33 (t, J = 8.3 Hz, 9H), 5.19 (d, J = 15.9 Hz, 1H), 5.03 (s, 2H), 4.86 (d, J = 15.9 Hz, 1H), 4.63 (s, 2H), 4.51 (s, 2H), 4.47 - 4.39 (m, 1H), 4.23 - 4.09 (m, 2H), 3.77 - 3.67 (m, 1H), 2.59 (dd, J = 11.8, 7.5 Hz, 2H), 2.28 - 2.18 (m, 2H).
EtOH(2ml)およびDCM(2ml)の混合物中の、N−[(3R)−5−[(4−クロロフェニル)メチル]−7−({2−オキサスピロ[3.3]ヘプタン−6−イル}カルバモイル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−3−イル]カルバミン酸ベンジル(55mg、0.08mmol)およびPd/C(10%、8.63mg、0.01mmol)の懸濁液を、水素雰囲気下において室温で3時間撹拌した。反応混合物を、Celite(登録商標)のパッドを通して濾過し、EtOHを用いて洗浄した。濾液を減圧下で濃縮した。残留物を、カラムクロマトグラフィー(シリカ、DCM中0〜10%の(MeOH中7NのNH3))で精製して、表題化合物(86%)および脱ハロゲン化副生成物(14%)の混合物を得た。
LCMS: METCR1416 Generic 7 minutes: rt=2.81分, M/Z (ES+) 490/ 492 [M+H+] UV= 86%
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.84 (d, J = 7.1 Hz, 1H), 7.96 (d, J = 8.1 Hz, 1H), 7.91 (d, J = 7.9 Hz, 1H), 7.78 (s, 1H), 7.35 (s, 4H), 5.17 (d, J = 15.7 Hz, 1H), 4.85 (d, J = 15.7 Hz, 1H), 4.62 (s, 2H), 4.50 (s, 2H), 4.18 (見かけh, J = 8.1 Hz, 1H), 3.87 (dd, J = 12.6, 6.2 Hz, 1H), 3.67 (s, 1H), 3.64 - 3.57 (m, 1H), 2.58 (td, J = 7.5, 4.0 Hz, 2H), 2.22 (ddd, J = 12.9, 8.2, 4.9 Hz, 2H), 1.98 (br. s, 2H).
LCMS: MET-UHPLC-AB-101, rt=2.56分, M/Z (ES+) 550.1/552.1 [M+H+] 100% UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.67 (t, J = 5.4 Hz, 1H), 7.72 (d, J = 8
.6 Hz, 1H), 7.62 (d, J = 5.6 Hz, 1H), 7.40 - 7.27 (m, 4H), 5.19 (d, J = 15.8 Hz,
1H), 4.80 (d, J = 15.8 Hz, 1H), 3.96 (dd, J = 12.5, 6.2 Hz, 1H), 3.74 - 3.57 (m, 2H), 3.35 - 3.31 (m, 2H), 2.48 - 2.42 (m, 1H), 2.34 - 2.15 (m, 4H), 1.72 (dt, J = 14.7, 7.0 Hz, 2H), 0.92 (t, J = 7.0 Hz, 3H).
(3R)−3−アミノ−N−ブチル−1−[(4−クロロフェニル)メチル]−2,5,5−トリオキソ−1H,2H,3H,4H−5λ6−ピリド[3,4−b][1,4]チアゼピン−8−カルボキサミド塩酸塩(実施例183)の合成
氷浴で冷却した1,2−DCE(115mL)中の4−アミノピリジン−2−カルボン酸メチル(3g、19.72mmol)の溶液に、N−ヨードスクシンイミド(4.44g、19.72mmol)を添加した。結果として得られた混合物を、室温に温まるまで放置し、次いで80℃で16時間撹拌した。反応混合物に、さらなるN−ヨードスクシンイミド(1g、0.23当量)を添加し、加熱を5時間継続した。次いで、反応混合物を、DCM(50mL)と水(50mL)との間で分配した。有機相を、水(およびブライン(100mL)を用いて洗浄し、Na2SO4で脱水し、濾過した。濾液を減圧下で濃縮して、収率95%で、赤色の固体として表題化合物を得た。
LCMS: METCR0990: rt=1.12分 M/Z (ES+) 279 [M+H+] 97 % UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.48 (s, 1H), 7.35 (s, 1H), 6.50 (s, 2H), 3.82 (s, 3H).
無水トルエン(30mL)中の、中間体X−01(97%、1500mg、5.23mmol)、Boc−L−システイン(1.16g、5.23mmol)、およびDIPEA(1.87mL、10.47mmol)の混合物を脱気し、窒素雰囲気下に置いた。次いで、(1E,4E)−1,5−ジフェニルペンタ−1,4−ジエン−3−オン−パラジウム(3:2)(120mg、0.131mmol)および(9,9−ジメチル−9H−キサンテン−4,5−ジイル)ビス(ジフェニルホスファン)(151mg、0.262mmol)を添加した。反応混合物を脱気し、窒素雰囲気下に置き、100℃で1.5時間加熱した。反応混合物を室温まで冷却し、DCMを用いて希釈し、Celite(登録商標)を通して濾過した。濾液を減圧下で濃縮し、逆相カラムクロマトグラフィーで精製して、収率98%で、NMRによる純度が66%(DIPEAが主な不純物)の褐色の固体として表題化合物2.88gを得た。
LCMS: MS19 METCR1410 rt=0.75分 M/Z (ES+) 372[M+H+] 96 % UV
NMRデータ: 1H NMR (500 MHz, メタノール-d4) δ 8.35 (s, 1H), 7.43 (s, 1H), 4.19 (s, 1H), 3.93 (s, 3H), 3.30 - 3.26 (m, 1H), 3.20 - 3.12 (m, 1H), 1.40 (s, 9H).
中間体X−02(66%、2.38g、4.23mmol)のTHF(25mL)懸濁液に、DIPEA(1.47mL、1.78mmol)およびT3P(登録商標)(50%EtOAc溶液、5mL、8.46mmol)を添加し、反応物を室温で1時間撹拌した。混合物を、水(15mL)を用いてクエンチし、EtOAcを用いて抽出した(15mL×2回)。合わせた有機抽出物を、ブラインを用いて洗浄し、Na2SO4で脱水し、濾過した。濾液を減圧下で濃縮し、残留物を、フラッシュカラムクロマトグラフィー(シリカ、溶離液:ヘプタン、20〜100% EtOAc)で精製して、NMRによる純度90%、収率41%で、灰白色の固体として表題化合物0.69gを得た。
LCMS: METCR1410 rt=0.94分 M/Z (ES+) 354 [M+H+] 99 % UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 10.62 (s, 1H), 8.72 (s, 1H), 7.72 (s, 1H), 7.45 (d, J = 8.0 Hz, 1H), 4.20 - 4.11 (m, 1H), 3.90 (s, 3H), 3.63 (dd, J = 11.3, 6.4 Hz, 1H), 3.28 (t, J = 11.7 Hz,1H), 1.34 (s, 9H).
DMSO(2mL)中の、中間体X−03(135mg、0.38mmol)、1−(ブロモメチル)−4−クロロベンゼン(117.74mg、0.57mmol)、K2CO3(158.39mg、1.15mmol)、およびKI(31.71mg、0.19mmol)の混合物を、室温で1.5時間撹拌した。反応混合物を氷浴で冷却し、水(5mL)を添加した。結果として得られた沈殿物を濾過で単離し、水(10mL)を用いて洗浄して、純度90%のクリーム色の固体として表題化合物182mgを得た。
LCMS: METCR1673 Generic 2 minutes rt=1.21分M/Z (ES+) 478/480 [M+H+] 90 % UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.78 (s, 1H), 8.04 (s, 1H), 7.67 - 7.59
(m, 1H), 7.35 - 7.28 (m, 4H), 5.19 (q, J = 16.3 Hz, 2H), 4.20 (s, 1H), 3.89 (s, 3H), 3.59 (dd, J = 11.1, 6.7 Hz, 1H), 3.30 - 3.22 (m, 1H), 1.36 (s, 9H).
THF/MeOH/水(10/3/1、20mL)中の、中間体X−04(95%、371mg、0.74mmol)および水酸化リチウム水和物(1:1:1)(61.89mg、1.47mmol)の混合物を、室温で1.5時間撹拌した。反応混合物を、減圧下で濃縮した。残留物を、DCM中に溶解させ、1MのHCl水溶液(20mL)を用いて洗浄した。有機相をNa2SO4で脱水し、濾過した。濾液を減圧下で濃縮して、純度89%および収率84%で、淡黄色の固体として表題化合物を得た。
LCMS: METCR1673 Generic 2 minutes rt=1.24分M/Z (ES+) 464/466 [M+H+] 89 % UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 8.72 (s, 1H), 8.07 (s, 1H), 7.24 - 7.17 (m, 4H), 5.56 (d, J = 15.7 Hz, 1H), 5.51 (s, 1H), 4.81 (d, J = 15.6 Hz, 1H), 4.50 - 4.39 (m, 1H), 3.78 (dd, J = 10.9, 6.3 Hz, 1H), 3.11 (t, J = 11.4 Hz, 1H), 1.40 (s, 9H)
中間体X−05(89%、100mg、0.19mmol)のDMF(2.6mL)溶液に、DIPEA(0.12mL、0.67mmol)を添加した。結果として得られた混合物を氷浴で冷却し、HATU(109.41mg、0.29mmol)を添加した。反応物を0℃で15分間撹拌し、次いで、ブタン−1−アミン(28.44μL、0.29mmol)を添加した。0℃で15分間経過した後、反応物を、室温に温まるまで放置し、1.5時間撹拌した。反応混合物を減圧下で濃縮した。残留物を、カラムクロマトグラフィー(シリカ、溶離液:ヘプタン、12〜100% EtOAc)で精製して、NMRによる純度86%および収率72%で、淡黄色の油状物として表題化合物(84mg)を得た。
LCMS: METCR1673 Generic 2 minutes rt=1.57分M/Z (ES+) 519/521 [M+H+] 99 % UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 8.62 (s, 1H), 8.09 (s, 1H), 7.91 (t, J = 5.9 Hz, 1H), 7.21 (s, 4H), 5.57 - 5.48 (m, 2H), 4.81 (d, J = 15.5 Hz, 1H), 4.45 - 4.37 (m, 1H), 3.74 (dd, J = 10.9, 6.4 Hz, 1H), 3.47 (dh, J = 13.7, 6.8 Hz, 2H), 3.04 (t, J = 11.3 Hz, 1H), 1.62 (p, J = 7.2 Hz, 2H), 1.44 (dd, J = 15.1, 7.5 Hz, 2H), 1.39 (s, 9H), 0.96 (t, J = 7.4 Hz, 3H)
氷浴で冷却したDCM(1.5mL)中の中間体X−06(86%、42mg、0.07mmol)の溶液に、m−CPBA(77%、32.75mg、0.15mmol)を添加した。結果として得られた混合物を、室温に温まるまで放置し、16時間撹拌した。反応混合物を、DCM(5mL)と1MのNaOH水溶液(2mL)との間で分配した。有機相を、1MのNaOH水溶液(2mL)を用いて洗浄し、減圧下で濃縮して、純度100%および収率87%で、白色の固体として表題化合物(34mg)を得た。
LCMS: METCR1673 Generic 2 minutes rt=1.47分M/Z (ES+) 551/553 [M+H+], 100 % UV
NMRデータ: 1H NMR (500 MHz, クロロホルム-d) δ 9.04 (s, 1H), 8.13 (s, 1H), 7.95 (t, J = 6.0 Hz, 1H), 7.27 (s, 4H), 5.64 (d, J = 7.3 Hz, 1H), 5.19 (d, J = 15.5 H
z, 1H), 5.12 (d, J = 15.6 Hz, 1H), 4.58 (dt, J = 11.2, 7.1 Hz, 1H), 4.18 (dd, J = 13.3, 7.0 Hz, 1H), 3.59 (dd, J = 13.1, 11.4 Hz, 1H), 3.54 - 3.42 (m, J = 6.6 Hz, 2H), 1.63 (p, J = 7.2 Hz, 2H), 1.47 - 1.41 (m, 2H), 1.41 (s, 9H), 0.97 (t, J = 7.4 Hz, 3H)
中間体X−07(98%、31mg、0.06mmol)に、ジオキサン中4MのHCl(1mL)およびMeOH(1mL)を添加した。反応混合物を室温で3時間撹拌した。反応混合物を減圧下で濃縮して、定量的収率で、純度96%の褐色の固体として表題化合物(34mg)を得た。
LCMS: METCR1416 GENERIC 7 MINUTES, rt=1.47分M/Z (ES+) 451/453 [M+H+], 98 % UV
NMRデータ: 1H NMR (500 MHz, DMSO-d6) δ 8.91 (t, J = 6.0 Hz, 1H), 8.72 (t, J = 5.7 Hz, 1H), 8.52 (s, 1H), 8.50 (s, 1H), 7.57 (s, 1H), 7.35 (dd, J = 8.3 Hz, 4H), 4.69 - 4.63 (m, 1H), 4.36 - 4.30 (m, 2H), 3.89 - 3.64 (m, 2H), 3.28 - 3.20 (m, 2H), 1.52 - 1.44 (m, 2H), 1.33 - 1.21 (m, 2H), 0.88 (t, J = 7.3 Hz, 3H).
化合物の生物学的活性を判定するために、様々なアッセイでそれらを評価した。
バフィーコートからのPBMCの単離
− バフィーコートの内容物を滅菌したプラスチックボトルに移し、PBSで480mlまで満たし、16×50mlの管に等しく分配した(30ml/管)
− およそ11mlのLymphoprepを下に挿入し、20分間遠心分離した(2200rpm)
− リンパ球を含む中間層をホールピペットで取り出し、細胞を、PBSを用いて2回洗浄し、1本の管にプールして細胞数を判定した(Coulter Diff ACT)
− PBMCをMACSバッファー中に再懸濁させ(MACSバッファー80μl/細胞10^7個)、それぞれのキットを用いてAuto−MACS装置で、製造業者の推奨に従って細胞を単離した
単離したT細胞を、96ウェルの培養プレート当たり細胞1.5*10^5個で、Xvivo培地に蒔き、示される化合物の存在下で、抗CD3/28 mAbを用いてTCRを刺激した。サイトカイン生成について、市販のELISAキット(BDおよびeBioscience)を用いて、製造業者の推奨の通りに、細胞培養上清においてTCR刺激の24時間後または48時間後に判定した。T細胞増殖およびCD25発現(CD25−PC5試薬はBeckman Coulterより購入)を、フローサイトメトリーで判定し(Beckman−Coulter FC500)、Kaluzaソフトウェアを用いて分析した。
単離されたPBMC、NK細胞、またはCD8陽性細胞を、示される場合、腫瘍細胞0.3*10^4個の存在下で、96ウェルの培養プレート当たり細胞1.5*10^5個で、Xvivo培地に蒔いた。サイトカイン分泌について、ELISAで判定し、免疫細胞活性化(Beckman−Coulter Ab CD25−PC5、CD69−PC7を用いた)、細胞生存率および細胞数について、生細胞のための判断基準として7−AADによる除去を用いて、フローサイトメトリー(Beckman−Coulter FC500またはGallios)で判定した。
単離したNK細胞を、96ウェルの培養プレート当たり細胞1.5*10^5個で、Xvivo培地に蒔き、示される場合、50ng/mlのIL−2(アルデスロイキン)を用いて刺激した。サイトカイン分泌について、ELISAで判定し、免疫細胞活性化について、生細胞のための判断基準として7−AADによる除去を用いて、フローサイトメトリー(Beckman−Coulter Ab CD25−PC5、CD69−PC7、およびBeckman−Coulter Galliosにおける取得)で判定した。
単離した単球を、96ウェルの培養プレート当たり細胞1.5*10^5個で、Xvivo培地に蒔き、示される場合、プレコーティングされた抗GD2−Ab(10μg/ml、Apeiron)で刺激した。サイトカイン分泌について、酵素結合イムノソルベントアッセイ(ELISA)で判定した。
− 滅菌した70μmフィルターを通して、PBSを用いて細胞をすすぐことで、脾臓から脾細胞の単細胞懸濁液を調製した
− 15mlの管内で遠心分離することによって細胞を収集し、細胞ペレットをErylyseバッファー1ml中に再懸濁させ、室温で5分間インキュベートし、管をPBSで満たし、細胞を2回洗浄した
− 細胞をカウントし、MACS濃縮またはフローサイトメトリー解析のために、所望のバッファー容量中に再懸濁させた
− 脾細胞を、MACSバッファー中に再懸濁させた(MACSバッファー80μl/細胞10^7個)
− CD4 T細胞を、CD4 T細胞単離キット(Miltenyi)を用いて、製造業者の推奨に従い、LSカラムで単離した
− 細胞を、0.1%のBSAを伴うPBS中に、細胞1×107個/mlで再懸濁させ、CFSE溶液を、最終濃度が2.5μMのCFSEになるように添加した
− 2分毎に振動させながら、37℃で10分間インキュベートした
− 同体積のFCSを添加し、室温で5分間インキュベートした
− 細胞を、RMPI−10%FCS培地を用いて2回洗浄した
− 細胞をカウントし、所望の濃度でPBSまたは培地中に再懸濁させた
− 0日目:PBS中のOT−II細胞(PBS100μl中細胞3*10^6個)を、後眼窩注射によって導入した
− 1日目:野生型マウスにOVAワクチン接種させた(皮下、側腹部、LPS10μg、1匹当たりOVA2μg)
− 2時間後および4時間後に化合物を投与した;経口投与の場合、化合物は懸濁液として使用し(水中0.5%のメチルセルロース)、静脈内投与の場合、化合物はDMSO中に可溶化し、PBSを用いて希釈した
− 2日目:午前中、化合物を2回投与した(2時間の時間間隔を伴った)
− 3日目:マウスを屠殺し、脾細胞を単離した
− T細胞の増殖および表現型を、フローサイトメトリーで判定した
− フローサイトメトリー−染色(すべてのAbはeBioscienceより購入し、製造業者の推奨通りに使用した):B220−eF450、CD4−PE、CD25PerCPCy5.5、CD69−PC7、TCRVa2−APC、CD8−AF700、CD3−eF780;CFSE;7−AAD
− Beckman−Coulter Galliosにおける取得、Kaluzaソフトウェアを用いた分析
− 0日目:野生型マウスの側腹部皮下に、B16−F10−OVA腫瘍細胞100000個を植え付けた
− 7日目:PBS中のOT−I細胞(PBS100μl中細胞3*10^6個)を、後眼窩注射によって導入した
− 2時間後および4時間後に、化合物を懸濁液(水中0.5%のメチルセルロース)として経口投与することで、化合物を投与した
− 10日目:マウスを屠殺し、腫瘍流入領域リンパ節からの免疫細胞および脾細胞を単離した
− T細胞の増殖および表現型を、フローサイトメトリーで判定した
− フローサイトメトリー−染色(すべてのAbはeBioscienceまたはBiolegendより購入し、製造業者の推奨通りに使用した):CD4−eF450、B220−BV510、CD107a−PE、CD69−PC5、PD1−PC7、TCRVa2−APC、CD8−AF700、CD3−eF780;CFSE;7−AAD
− Beckman−Coulter Galliosにおける取得、Kaluzaソフトウェアを用いた分析
− 0日目:野生型マウスの側腹部皮下に、B16−F10−OVA腫瘍細胞100000個を植え付けた
− 7日目および8日目:化合物を懸濁液(水中0.5%のメチルセルロース)として1日に2回(4時間の間隔を置いて)経口投与することで、化合物を投与した
− 9日目〜14日目:化合物を懸濁液(水中0.5%のメチルセルロース)として1日に1回経口投与することで、化合物を投与した
− 15日目:マウスを屠殺し、腫瘍流入領域リンパ節からの免疫細胞および脾細胞を単離した;腫瘍標本を外植し、液体窒素中で瞬間凍結させ、mRNAを、GenElute mammalian total RNA miniprepキット(RTN350−1KT)を用いて、キットで単離した
− T細胞の表現型を、フローサイトメトリーで判定した
− フローサイトメトリー−染色(すべてのAbはeBioscienceまたはBiolegendより購入し、製造業者の推奨通りに使用した):CD4−eF450、B220−BV510、PD1−FITC、CD107a−PE、CD25−PerCPCy5.5、CD69−PC7、NK1.1−APC、CD8−AF700、CD3−eF780;CFSE;7−AAD
− Beckman−Coulter Galliosにおける取得、Kaluzaソフトウェアを用いた分析
− 免疫細胞による腫瘍浸潤について、TaqMan(登録商標)遺伝子発現アッセイを用いて、Agilent Mx3005P QPCRシステム(Stratagene)において、製造業者の推奨に従い、ハウスキーピング較正遺伝子であるEF1aおよび分析物であるCD4、CD8、IL−2、IL−12、IL−23、EOMES、Foxp3、IFN−g、Rorgc、T−bet、TNF−aに関して、定量的RT−PCRで判定した。
本発明の化合物のヒトPBMCにおける免疫調節効果について判定するために、化合物を以下のアッセイ設定で評価した:
活性分類A:IL−2またはIFN−γ pEC50>5.8M
活性分類B IL−2またはIFN−γ pEC50が5.3〜5.8M
活性分類C:IL−2またはIFN−γ pEC50<5.3M、および化合物の非存在下で刺激された細胞と比較した場合、サイトカイン分泌が2倍超の増加
バフィーコートはオーストリア赤十字社から入手し、PBSを用いて3倍に希釈し、50mlの遠心分離管内に、d=1.077g/mで、等張Ficoll分離溶液上に層を形成した。管を、914gで、室温において25分間、ブレーキをオフにして遠心分離した。PBMC層を取り出し、氷冷したPBSで2回洗浄した。CD4 T細胞を、CD4マイクロビーズ(Milteny)およびAutoMACS装置を用いて、製造業者の指示に従って単離した。
活性分類B:化合物濃度3μMにおけるIL−2生成が2〜10ng/mL
活性分類C:化合物濃度3μMにおけるIL−2生成が、化合物の非存在下で刺激された細胞のIL−2生成平均と比較した場合、2倍の増加〜2ng/mL未満
CD69発現の測定については、単離したCD4およびCD8 T細胞を、96ウェルの培養プレート当たり細胞80000個で、Xvivo培地に蒔き、化合物の存在下で、抗CD3/28 mAbを用いてTCRを刺激した。CD69発現を、TCR刺激の24時間後に、フローサイトメトリーで判定し(CD4eF450、CD8APCeF780、およびCD69−PC7試薬はeBioscienceより購入)、Kaluzaソフトウェアを用いて分析した。
活性分類B CD4またはCD8 T細胞におけるCD69+のpEC50が5.3〜5.8M
活性分類C:CD4またはCD8 T細胞におけるCD69+のpEC50<5.3M
単離したCD4 T細胞をCFSEで標識し、抗CD3および抗CD28抗体を用いて刺激した。化合物実施例67は、抗腫瘍および抗病原体免疫応答にとって重要なサイトカイン(IL−2、IFN−γ、TNF−α)の生成を、強力に増進した。また、化合物実施例67は、T細胞増殖および表面活性化マーカーCD25(IL−2受容体の構成要素)の発現も増進した。TCRを刺激した際のT細胞の急速な増大は防御性のT細胞免疫の特徴であるためこれは、インビボでの免疫応答に対する潜在的効果をさらに実証した。
単離したCD8 T細胞をCFSEで標識し、抗CD3および抗CD28抗体を用いて刺激した。化合物実施例67は、その、TCRによって媒介されるCD4 T細胞活性化の関連する側面の増進は別として、CD8 T細胞に関して、サイトカインIL−2、IFN−γ、およびTNF−αの生成、ならびにCD25の発現およびT細胞の増殖を強力に増進した。これらの結果は、化合物実施例67が、TCRの活性化に応答して、CD4およびCD8 T細胞の両方を増進したことを実証するものである。
CD8陽性免疫細胞を、PBMCから単離し、単独で、またはM21黒色腫細胞と共培養で、化合物実施例67と共に、またはこれを伴わずにインキュベートした。腫瘍細胞との接触は、免疫細胞の活性化をもたらして、IL−2およびIFN−γを生成させた。化合物実施例67は、両方のサイトカインの生成を、腫瘍細胞との接触時に特異的に増進した;このような効果は、腫瘍細胞の非存在下では検出されなかった。また、化合物実施例67は、腫瘍細胞との接触により媒介される、腫瘍細胞の殺傷に直接的に関連する、細胞傷害性エフェクターであるグランザイムの放出も増進した。これと一致することには、免疫細胞と腫瘍細胞との共培養物における化合物実施例67の存在は、生存可能な腫瘍細胞を強力に減少させた。一方、CD8 T細胞の数も、CD8 T細胞の非存在下における腫瘍細胞の数も実質的に調節されなかった。
抗腫瘍免疫におけるNK細胞の生理学的機能の1つは、MHC分子の発現が低いため、CD8 T細胞による認識を回避する腫瘍細胞を、認識および破壊することである。MHC分子の下方制御は、多くの場合、感染したウイルスによって活発に媒介されたり、または悪性新生物の発達中に起こったりする。K52白血病細胞株は、非常に少量のMHC分子しか発現しないため、NK細胞の抗腫瘍反応性を調査するためのモデル系として使用されることが多い。
腫瘍細胞株であるM21およびK562は、それぞれ、黒色腫および白血病起源の2つの広く使用される腫瘍株を表す。しかしながら、腫瘍細胞は、免疫機能を抑制するのに異なる機構を採用することが知られているため、腫瘍細胞に対する免疫細胞の活性に及ぼす化合物の効果が、異なる種類の腫瘍に由来する非常に多様な起源の多数の腫瘍細胞に対して普遍化できるかどうかを調査した。
IL−2は、NK細胞の生存、増殖、および活性化にとって重要であり、したがって、T細胞により媒介される適応免疫を、NK細胞により媒介される自然免疫と結びつける因子である。特に、CD8 T細胞は、腫瘍内の抗原遭遇部位において局所的にIL−2を放出することで、NK細胞の抗腫瘍機能を支持および活性化させる。化合物実施例67を、例として選択した。上で既に示したように、化合物は、T細胞により媒介されるIL−2の放出を増進し、腫瘍細胞との接触により媒介されるNK細胞の活性化を増進する。加えて、下のデータは、化合物実施例67が、サイトカインIFN−γおよびTNF−αの放出で判定した場合、IL−2による活性化の際に、NK細胞の応答性も直接的に増進できることを示している。したがって、化合物は、インビボの生理学的状況において、T細胞とNK細胞との相互に関連した抗腫瘍免疫を支持するという特有の潜在能力を有する。
病原体に対する効率的な免疫応答は、一般的に、(T細胞およびNK細胞により媒介されるような)細胞性免疫機能だけでなく、抗体により媒介される体液性免疫にも依存する。病原体または病原体感染細胞に結合した抗体は、特にNK細胞およびミエロイド細胞において発現するFc受容体を介して、免疫細胞の活性化を誘起する。この機構は、がん療法においても活用されている。このがん療法では、がん細胞上に優先的に発現される抗原に対する治療用抗体が患者に投与され、これがひいては免疫細胞を動員および活性化して、がん細胞を直接攻撃させる。GD2抗原は、(神経芽細胞腫および黒色腫の中でも)特定の起源のがん細胞において強力に発現されるため、抗がん療法として臨床的に開発されている。M21黒色腫細胞の場合、GD2は、腫瘍抗原としてアクセス可能であると特徴付けられている、唯一の抗原である。したがって、臨床グレードの品質で利用可能である抗GD2抗体を採用して、化合物が、腫瘍細胞に結合した治療用抗体に対する、Fc受容体によって媒介される免疫細胞の活性化を増進できるかどうか試験した。下のデータは、化合物実施例40が、M21黒色腫細胞に結合した抗GD2抗体に対する免疫細胞の反応性を増進し、結果として、サイトカインの分泌およびNK細胞の活性化の上昇がもたらされたことを示している。したがって、化合物は、腫瘍細胞との接触に対してだけでなく、がん細胞の腫瘍抗原を標的とする抗体に対しても、免疫細胞の反応性を上昇させる。
「腫瘍細胞に結合した治療用抗体による刺激への免疫細胞の反応性の増進」と題される上記の実験の結果から、化合物が、免疫細胞のFcR刺激を増進できることが示される。しかしながら、この中で使用された設定では、Fc受容体刺激の効果から、腫瘍細胞との接触の効果を差し引くことが困難である。したがって、同じ抗GD2−AbによるFcR刺激の効果を、腫瘍細胞を含まないアッセイ設定で試験した。ここでは、抗GD2抗体を細胞培養プレートに対してコーティングすることで、細胞に結合した抗体を模倣した。下のデータは、化合物実施例77を例として示しており、化合物が、FcR刺激によりミエロイド細胞の活性化を直接的に増進し、これが、TNF−α、IL−1、およびIL−6の分泌の増加をもたらしたことを表している。これら2つの実験のデータは、連帯して、化合物が、細胞に結合した抗体によるFcR刺激への免疫細胞の応答性を増進することによって、腫瘍細胞の抗原に対する治療用抗体の抗腫瘍効果を支持できることを実証している。
バフィーコートは地域の病院から入手し、PBSを用いて3倍に希釈し、50mLの遠心分離管内に、d=1.077g/mLで、等張Ficoll分離溶液上に層を形成した。管を、914gで、室温において25分間、ブレーキをオフにして遠心分離した。PBMC層を取り出し、氷冷したPBSで2回洗浄した。ddH2Oを添加することで赤血球を溶解し、細胞をX−Vivo15(Lonza)中に再懸濁させた。
哺乳動物の免疫系は、進化的に保存されているため、マウスおよびヒトの免疫細胞に関して、大部分のシグナル伝達経路は類似している。化合物の医薬開発にとって、主にマウスの機構的モデルおよび疾患モデルを使用することで、インビボのデータを生成することはきわめて重要である。したがって、ヒトT細胞について実証されたように、化合物が、マウスT細胞に対して類似の効果を有するかどうかを調査した。PBMCは、インビトロ実験の場合に、ヒトPBMCで通例行われているようには十分な数を入手することができないため、脾細胞が、マウスにおける容易にアクセス可能な免疫細胞画分として用いられる。脾細胞をBL6マウスの脾臓から単離し、抗CD3および抗CD28抗体で刺激するか、または対照として未刺激のままにした。化合物実施例1および70の両方が、ヒトPBMCの場合のデータと同等に、これもTCRを刺激した免疫細胞について特異的に、サイトカインの生成を強力に増進した;このような効果は、未刺激の細胞では検出されなかった。同様に、CD25の発現も、TCR刺激の存在下において特異的に、CD4およびCD8 T細胞の両方において増進された。
インビボでの抗原特異的なT細胞の活性化および増殖の検出は、技術的に困難である。これは、コグネイト抗原に対して特異的な低頻度T細胞を検出するための研究試薬の開発および検証、ならびにまた血液中または二次リンパ器官における後続の細胞の活性化および/または増殖のための特定の測定手順の確立が必要とされるためである。マウスにおけるポリクローナルT細胞活性化の判定用の代用モデルとして、薬理学的システムを設計および採用した。ここでは、成体B57/BL6マウスに、抗CD3抗体を注射してTCR誘起および末梢T細胞の大きい集団の応答を誘発した。T細胞応答を定量的に判定するために、処置の5時間後に、血清中のIL−2、TNF−α、およびIFN−γの全身的レベル、ならびに脾臓のCD4またはCD8 T細胞における早期活性化マーカーCD69の発現を測定した。
1.8〜14週齢のオスのC57BL/6Nマウスに、マウス1匹当たり0.1μgの抗CD3モノクローナル抗体(BD Bioscience、カタログ番号:553058;ハムスター抗マウスCD3e クローン145−2C11)を、t=0時間において腹腔内注射して、Hirschら、1989年と比較して、より低いレベルのT細胞予備活性化を達成した。
2.化合物実施例1を、t=−1.0時間およびt=1.0時間において、懸濁液(水中0.5%のメチルセルロース)として2回経口投与した。
3.t=4.0時間においてマウスを屠殺し、それらの脾臓および血漿を、それぞれフローサイトメトリーおよびサイトカイン分析のために回収した。
4.末端血漿サンプル中のサイトカイン濃度について、MSDキットを用いて、製造業者の指示に従って判定した。
インビボでの抗原特異的なT細胞の増殖の直接的な検出は、技術的に困難である。これは、コグネイト抗原に対して特異的なT細胞の存在が必要とされ、また、細胞増殖のための特定の測定手順も必要とされるためである。これらの要件は両方とも、オボアルブミン由来のペプチドを抗原として認識するT細胞受容体についてトランスジェニックであるCD4 T細胞の直接導入を活用するOT−II導入モデルで満たされる。導入前に、これらの細胞は、蛍光色素CFSEを用いて標識する。このCFSEは、細胞分裂の度に希釈されるため、細胞増殖の検出を可能とする。CFSE標識T細胞の導入後、マウスに、オボアルブミン抗原およびアジュバントとしてTLRアゴニスト(LPS)をワクチン接種させて、抗原提示細胞(APC)を活性化および成熟させる。その後、これらのAPCは、リンパ器官(特に、リンパ節および脾臓)へと移動し、リンパ器官のT細胞にOVA抗原を提示する。しかしながら、導入されたOT−II細胞のみが、OVA抗原を認識可能であるため、これらの導入されたT細胞のみが活性化される。
T細胞を受容し、次いで、ワクチン接種用の抗原を受容せず、化合物も受容していない群(LPSのみ)、または抗原は受容したが、化合物は受容していない群(LPS&OVA)、または抗原を受容し、10mg/kgの用量の化合物実施例1を経口で受容した群に分けられた。下のデータは、抗原の非存在下では、導入されたOT−II細胞においては最小限のT細胞の増殖しか観察されず、CD69の上方制御は観察されなかったことを示している。対照的に、OT−II細胞に対する抗原が存在する場合、増殖およびCD69の上方制御が、明確に検出可能であった。OT−II細胞の増殖は、化合物実施例1の存在により、非常に有意に(p<0.00001)増進されたが、一方でCD69はさらには上方制御されなかった;これは、T細胞を強力に増殖させると、次の数日間にわたってCD69は下方制御される傾向にあるため、T細胞活性化の動態と合致する。重要なことには、受容者マウス自身のCD4およびCD8 T細胞、ならびにB細胞におけるCD69発現は、化合物の存在によって増進されず、コグネイト抗原が供給されない場合には、化合物単独でT細胞を活性化しないことを示している。したがって、T細胞活性化に対するインビボでの化合物の効果は、インビトロで観察されたものと合致する。また、実験期間中、化合物の毒性の徴候は認められず、免疫細胞機能は細胞特異的な刺激状況において増進されるが、これは望ましくない一般的様式のものではないという、インビトロデータの結論をさらに追認した。
薬物の経口投与は、一般に、外来患者の状況における摂取にとって所望される経路である。しかしながら、がんの進行段階において、腫瘍療法は、入院患者に投与されることが多い。高レベルの薬物が、長期間にわたって安定的に保持される必要がある療法の場合、静脈内投与が選択される。また、過去の治療の副作用が、消化管を損傷している可能性もあることから、静脈内投与も有効な経路であり得るならば有利である。したがって、化合物の静脈内投与が、上記と同様の設定において有効である潜在能力を有するかどうかを調査した。
CD8 T細胞を、M21予備刺激PBMCから単離し、材料および方法の節に記載したように、M21腫瘍細胞を用いて再刺激した。実施例107、抗体無し(Ig無し)、抗PD−1抗体(ニボルマブ)、またはCD8 T細胞に対して直接的な影響を及ぼさない対照抗体(イピリムマブ)を、示される場合に含めた。
インビボでの腫瘍抗原特異的なT細胞の増殖の直接的な検出には、コグネイト腫瘍抗原に対して特異的なT細胞の存在が必要とされる。しかしながら、広く使用されるB16−F10−OVA黒色腫モデルは、数日以内の侵襲性の腫瘍成長を特徴とする。このため、T細胞増殖の特異的測定に使用することができる、腫瘍抗原特異的T細胞の、オボアルブミン抗原に対する抗腫瘍免疫応答の新規発生により大きな集団(robust population)が生じることはない。代替案として、OT−I導入モデルにおいて、オボアルブミン由来のペプチドを抗原として認識するT細胞受容体についてトランスジェニックであるCD8 T細胞の直接導入を活用することができる。導入前に、これらの細胞は、蛍光色素CFSEを用いて標識する。これにより、上記のOT−II導入モデルと同様に、細胞増殖の検出が可能となる。CFSE標識T細胞を、B16−F10−OVA腫瘍を有するマウスに導入した後、これらの細胞の一部が、腫瘍部位で直接、または抗原提示細胞(APC)の状況で、腫瘍抗原オボアルブミンと接触する。これらのAPCは、リンパ器官(特に、リンパ節および脾臓)に存在し、リンパ器官のOT−I T細胞にOVA抗原を提示する。
野生型マウスに、B16−F10−OVA腫瘍細胞を植え付け、方法の節に概説したように、実験環境におけるすべてのマウスが明確に視認できる腫瘍を有した7日目に、ビヒクルのみを受容する群、または10mg/kgまたは30mg/kgの用量の実施例1を経口で受容した群へと無作為に群分けした。加えて、腫瘍を有しない3匹のマウスのセットを含め、ビヒクル対照のみを用いて処置した。15日目にマウスを屠殺し、腫瘍流入領域リンパ節における免疫細胞の活性化状態を、フローサイトメトリーで分析した。
Claims (33)
- 少なくとも1つの医薬的に許容される担体と式(I)の少なくとも1つの化合物またはその医薬的に許容される塩とを含む、医薬組成物。
X1は、S;S(O);またはS(O)2であり;
X2は、N;またはC(R4)であり;
R1は、H;またはメチルであり;
R2は、フェニル;3〜7員ヘテロシクリル;または7〜11員ヘテロビシクリルであり、ここで、R2は、場合により、1つまたはそれ以上の同一であるかまたは異なっているR5で置換されており;
R5は、ハロゲン;CN;C(O)OR6;OR6;C(O)R6;C(O)N(R6R6a);S(O)2N(R6R6a);S(O)N(R6R6a);S(O)2R6;S(O)R6;N(R6)S(O)2N(R6aR6b);SR6;N(R6R6a);OC(O)R6;N(R6)C(O)R6a;N(R6)S(O)2R6a;N(R6)S(O)R6a;N(R6)C(O)OR6a;N(R6)C(O)N(R6aR6b);OC(O)N(R6R6a);該環が少なくとも部分飽和である場合、オキソ(=O);T1;C1-6アルキル;C2-6アルケニル;またはC2
-6アルキニルであり、ここで、C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているハロゲンで置換されており;
R6、R6a、R6bは、独立して、H;C1-6アルキル、C2-6アルケニル;およびC2-6アルキニルからなる群から選択され、ここで、C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているハロゲンで置換されており;
T1は、フェニル;C3-7シクロアルキル;または3〜7員ヘテロシクリルであり、ここで、T1は、場合により、1つまたはそれ以上の同一であるかまたは異なっているR7で置換されており;
R7は、ハロゲン;CN;C(O)OR8;OR8;C(O)R8;C(O)N(R8R8a);S(O)2N(R8R8a);S(O)N(R8R8a);S(O)2R8;S(O)R8;N(R8)S(O)2N(R8aR8b);SR8;N(R8R8a);OC(O)R8;N(R8)C(O)R8a;N(R8)S(O)2R8a;N(R8)S(O)R8a;N(R8)C(O)OR8a;N(R8)C(O)N(R8aR8b);OC(O)N(R8R8a);該環が少なくとも部分飽和である場合、オキソ(=O);C1-6アルキル;C2-6アルケニル;またはC2-6アルキニルであり、ここで、C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているハロゲンで置換されており;
R8、R8a、R8bは、独立して、H;C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルからなる群から選択され、ここで、C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているハロゲンで置換されており;
R3は、R3a;OR3a;NHR3a;またはNHC(O)R3aであり;
R3aは、T2;C1-12アルキル;C2-12アルケニル;またはC2-12アルキニルであり、ここで、C1-12アルキル;C2-12アルケニル;およびC2-12アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているR9で置換されており;
R9は、ハロゲン;CN;C(O)OR10;OR10;C(O)R10;C(O)N(R10R10a);S(O)2N(R10R10a);S(O)N(R10R10a);S(O)2R10;S(O)R10;N(R10)S(O)2N(R10aR10b);SR10;N(R10R10a);OC(O)R10;N(R10)C(O)R10a;N(R10)S(O)2R10a;N(R10)S(O)R10a;N(R10)C(O)N(R10aR10b);N(R10)C(O)OR10a;OC(O)N(R10R10a);T2;C1-12アルキル;C2-12アルケニル;またはC2-12アルキニルであり、ここで、C1-12アルキル;C2-12アルケニル;およびC2-12アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているR11で置換されており;
R10、R10a、R10bは、独立して、H;T2;C1-12アルキル;C2-12アルケニル;およびC2-12アルキニルからなる群から選択され、ここで、C1-12アルキル;C2-12アルケニル;およびC2-12アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているR11で置換されており;
T2は、フェニル;C3-7シクロアルキル;3〜7員ヘテロシクリル;または7〜11員ヘテロビシクリルであり、ここで、T2は、場合により、1つまたはそれ以上の同一であるかまたは異なっているR12で置換されており;
R12は、ハロゲン;CN;C(O)OR13;OR13;C(O)R13;C(O)N(R13R13a);S(O)2N(R13R13a);S(O)N(R13R13a);S(O)2R13;S(O)R13;N(R13)S(O)2N(R13aR13b);SR13;N(R13R13a);OC(O)R13;N(R13)C(O)R13a;N(R13)S(O)2R13a;N(R13)S(O)R13a;N(R13)C(O)OR13a;N(R13)C(O)N(R13aR13b);OC(O)N(R13R13a);該環が少なくとも部分飽和である場合、オキソ(=O);T3;C1-6アルキル;C2-6アルケニル;またはC2-6アルキニルであり、ここで、C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であ
るかまたは異なっているR14で置換されており;
R13、R13a、R13bは、独立して、H;C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルからなる群から選択され、ここで、C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているR14で置換されており;
R11、R14は、独立して、ハロゲン;CN;C(O)OR15;OR15;C(O)R15;C(O)N(R15R15a);S(O)2N(R15R15a);S(O)N(R15R15a);S(O)2R15;S(O)R15;N(R15)S(O)2N(R15aR15b);SR15;N(R15R15a);OC(O)R15;N(R15)C(O)R15a;N(R15)S(O)2R15a;N(R15)S(O)R15a;N(R15)C(O)OR15a;N(R15)C(O)N(R15aR15b);OC(O)N(R15R15a);およびT3からなる群から選択され;
R15、R15a、R15bは、独立して、H;T3;C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルからなる群から選択され、ここで、C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているハロゲンで置換されており;
T3は、フェニル;C3-7シクロアルキル;または3〜7員ヘテロシクリルであり、ここで、T3は、場合により、1つまたはそれ以上の同一であるかまたは異なっているR16で置換されており;
R16は、ハロゲン;CN;C(O)OR17;OR17;C(O)R17;C(O)N(R17R17a);S(O)2N(R17R17a);S(O)N(R17R17a);S(O)2R17;S(O)R17;N(R17)S(O)2N(R17aR17b);SR17;N(R17R17a);OC(O)R17;N(R17)C(O)R17a;N(R17)S(O)2R17a;N(R17)S(O)R17a;N(R17)C(O)OR17a;N(R17)C(O)N(R17aR17b);OC(O)N(R17R17a);該環が少なくとも部分飽和である場合、オキソ(=O);C1-6アルキル;C2-6アルケニル;またはC2-6アルキニルであり、ここで、C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているハロゲンで置換されており;
R17、R17a、R17bは、独立して、H;C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルからなる群から選択され、ここで、C1-6アルキル;C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているハロゲンで置換されており;
R4は、H;F;Cl;またはN(CH3)2であり;
R18は、H;C1-6アルキル;C2-6アルケニル;またはC2-6アルキニルであり;ここで、C1-6アルキル、C2-6アルケニル;およびC2-6アルキニルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているR19で置換されており;
R19は、ハロゲン;CN;C(O)OR20;OR20;C(O)R20;C(O)N(R20R20a);S(O)2N(R20R20a);S(O)N(R20R20a);S(O)2R20;S(O)R20;N(R20)S(O)2N(R20aR20b);SR20;N(R20R20a);NO2;OC(O)R20;N(R20)C(O)R20a;N(R20)SO2R20a;N(R20)S(O)R20a;N(R20)C(O)N(R20aR20b);N(R20)C(O)OR20a;またはOC(O)N(R20R20a)であり;
R20、R20a、R20bは、独立して、H;およびC1-6アルキルからなる群から選択され、ここで、C1-6アルキルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているハロゲンで置換されている)。 - R18はHである、請求項1または2に記載の、医薬組成物。
- X1はS(O)2である、請求項1〜3のいずれか1項に記載の、医薬組成物。
- R1はHである、請求項1〜4のいずれか1項に記載の、医薬組成物。
- X2はC(R4)である、請求項1〜5のいずれか1項に記載の、医薬組成物。
- R4は、H;F;またはN(CH3)2である、請求項1〜6のいずれか1項に記載の、医薬組成物。
- R 4 は、H;またはFである、請求項7に記載の、医薬組成物。
- R2は、フェニル、5〜6員芳香族ヘテロシクリル、または9〜11員芳香族ヘテロビシクリルであり;かつR2は、場合により、1つまたは2つの同一であるかまたは異なっているR5で置換されている、請求項1〜8のいずれか1項に記載の、医薬組成物。
- R 2 は、フェニル、ピリジル、チアジアゾリル、またはキノリニルであり;かつR 2 は、場合により、1つまたは2つの同一であるかまたは異なっているR 5 で置換されている、請求項9に記載の、医薬組成物。
- R 2 は、フェニル、またはピリジルであり;かつR 2 は、場合により、1つまたは2つの同一であるかまたは異なっているR 5 で置換されている、請求項10に記載の、医薬組成物。
- R 2 は、フェニルであり;かつR 2 は、場合により、1つまたは2つの同一であるかまたは異なっているR 5 で置換されている、請求項11記載の、医薬組成物。
- R2は、1つまたは2つの同一であるかまたは異なっているR5で置換されている、請求項1〜12のいずれか1項に記載の、医薬組成物。
- R5は、ハロゲン;CN;OR6;C(O)N(R6R6a);T1;またはC1-6アルキルであり、ここで、C1-6アルキルは、場合により、1つまたはそれ以上の同一であるかまたは異なっているハロゲンで置換されている、請求項1〜13のいずれか1項に記載の、医薬組成物。
- R 5 は、F;Cl;Br;CN;OCH 3 ;OCHF 2 ;OCF 3 ;C(O)NH 2 ;1H−1,2,4−トリアゾール−1−イル;シクロプロピル;5−メチル−1,2,4−オキサジアゾール−3−イル;1,2,3−チアジアゾール−4−イル;モルホリン−4−イル;tert−ブチル;またはCF 3 である、請求項14に記載の、医薬組成物。
- R 5 は、F;Cl;CN;OCF 3 ;C(O)NH 2 ;1H−1,2,4−トリアゾール−1−イル;シクロプロピル;5−メチル−1,2,4−オキサジアゾール−3−イル;1,2,3−チアジアゾール−4−イル;モルホリン−4−イル;tert−ブチル;またはCF 3 である、請求項15に記載の、医薬組成物。
- T1は、シクロプロピル;または3〜7員ヘテロシクリルであり、ここで、T1は、非置換であるか、または非置換C1-6アルキルで置換されている、請求項1〜16のいずれか1項に記載の、医薬組成物。
- R3aは、T2;C1-12アルキル;非置換C2-12アルケニル;または非置換C2-12アルキニルであり、ここで、C1-12アルキルは、場合により、1つ、2つ、または3つの、同一であるかまたは異なっているR9で置換されている、請求項1〜18のいずれか1項に記載の、医薬組成物。
- R 3a は、T 2 ;C 1-12 アルキル;またはC 2-12 アルケニルであり、ここで、C 1-12 アルキルは、場合により、1つ、2つ、または3つの、同一であるかまたは異なっているR 9 で置換されている、請求項19に記載の、医薬組成物。
- R 3a は、T 2 ;CH 2 T 2 ;CH 2 CH 2 T 2 ;C(CH 3 )T 2 ;非置換C 1-12 アルキル;非置換C 2-12 アルケニル;OR 10 で置換されているC 1-12 アルキル;N(R 10 )C(O)R 10a ;C 1-12 アルキル;またはCF 3 である、請求項20に記載の、医薬組成物。
- T2は、フェニル;C3-7シクロアルキル;または3〜7員ヘテロシクリルであり、ここで、T2は、場合により、1つまたはそれ以上の同一であるかまたは異なっているR12で置換されている、請求項1〜21のいずれか1項に記載の、医薬組成物。
- T2は、非置換であるか、または1つもしくは2つの同一であるかもしくは異なっているR12で置換されている、請求項1〜22のいずれか1項に記載の、医薬組成物。
- R12は、ハロゲン;OR13;非置換T3;非置換C1-6アルキルで置換されているT3;または非置換C1-6アルキルである、請求項1〜23のいずれか1項に記載の、医薬組成物。
- 式(I)において、X1、X2、R1、R2、R3、R18は、以下を提供するように選択される、請求項1〜24のいずれか1項に記載の、医薬組成物:
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(2,2−ジフルオロシクロプロピル)−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−5−[(4−tert−ブチルフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−tert−ブチルフェニル)メチル]−4−オキソ−N−(プロパン−2−イル)−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−8−フルオロ−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ベンジル−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−[(4−メトキシフェニル)メチル]−4−オキソ−5−{[4−(トリフルオロメトキシ)−フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(オキサン−4−イル)−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−4−オキソ−5−{[3−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−5−[(4−クロロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;(3R)−3−アミノ−N−{[4−(モルホリン−4−イル)フェニル]メチル}−4−オキソ−5−{[4−(トリフルオロメトキシ)−フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
N−(3−{[(3R)−3−アミノ−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−イル]ホルムアミド}プロピル)−2,2−ジメチルプロパンアミド;
(3R)−3−アミノ−N−ブチル−5−{[4−(モルホリン−4−イル)フェニル]メチル}−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−フルオロ−N−(オキサン−4−イル)−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−フルオロ−4−オキソ−N−(プロパン−2−イル)−5−{[4−(トリフルオロメトキシ)フェニル]−メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ベンジル−8−フルオロ−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−メチル−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−エチル−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−({4−[(5−アセトアミドペンチル)オキシ]フェニル}メチル)−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(2−メトキシエチル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−5−[(4−シアノフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−4−オキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(オキサン−4−イルメチル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(5−tert−ブチル−1,2−オキサゾール−3−イル)−5−[(4−クロロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−4−オキソ−N−(ピリジン−3−イル)−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(4−フルオロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1R)−1−(4−メトキシフェニル)エチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(オキサン−3−イルメチル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−4−オキソ−N−(4,4,4−トリフルオロブチル)−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(オキサン−4−イルメチル)−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−[(4−フルオロフェニル)メチル]−4−オキソ−5−{[4−(トリフルオロメトキシ)フェニル]−メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−[(4−フルオロフェニル)メチル]−4−オキソ−5−{[4−(1,2,3−チアジアゾール−4−イル)フェニル]−メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(4,4−ジフルオロシクロヘキシル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[1−(4−フルオロフェニル)エチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1S)−1−(4−メトキシフェニル)エチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−4−オキソ−N−(4,4,4−トリフルオロブチル)−5−{[6−(トリフルオロメチル)ピリジン−3−イル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−[(4−フルオロフェニル)メチル]−4−オキソ−5−{[6−(トリフルオロメチル)ピリジン−3−イル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1R)−1−(4−フルオロフェニル)エチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−[(4−フルオロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−4−オキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−5−[(4−クロロフェニル)メチル]−8−フルオロ−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(オキサン−4−イルメチル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−[(4−メトキシフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−{[4−(5−メチル−1,2,4−オキサジアゾール−3−イル)フェニル]メチル}−N−(オキサン−4−イルメチル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−フルオロフェニル)メチル]−N−(オキサン−4−イルメチル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−4−オキソ−5−{[4−(1H−1,2,4−トリアゾール−1−イル)フェニル]メチル}−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−5−[(4−カルバモイルフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(2−ヒドロキシ−2−メチルプロピル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1S)−1−(4−フルオロフェニル)エチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(2−ヒドロキシ−2−メチルプロピル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(2R,3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−2−メチル−4−オキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−
1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N'−(4−フルオロフェニル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボヒドラジド;
(3R)−3−アミノ−N'−ブタノイル−5−[(4−クロロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボヒドラジド;
(3R)−3−アミノ−N−ブチル−5−[(4−クロロ−2−フルオロフェニル)メチル]−8−フルオロ−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロ−2−フルオロフェニル)メチル]−8−フルオロ−N−(オキサン−4−イルメチル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロ−3−フルオロフェニル)メチル]−8−フルオロ−N−(オキサン−4−イルメチル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−5−[(4−クロロ−3−フルオロフェニル)メチル]−8−フルオロ−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−4−オキソ−N−プロポキシ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(2−メチルプロポキシ)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N'−(2−メチルプロピル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボヒドラジド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−4−オキソ−N−(プロパン−2−イル)−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(2−メチルプロポキシ)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(3−メチルブタン−2−イル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(ブタ−3−エン−1−イル)−5−[(4−クロロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N'−(2−メチルプロピル)−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボヒドラジド;
(3R)−3−アミノ−N−ブチル−5−[(4−クロロフェニル)メチル]−1,4−ジオキソ−2,3,4,5−テトラヒドロ−1λ4,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−1,1,4−トリオキソ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−[
(4−フルオロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−(4,4,4−トリフルオロ−ブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(オキサン−4−イルメチル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−フルオロ−N−(オキサン−4−イルメチル)−1,1,4−トリオキソ−5−{[4−(トリフルオロメトキシ)−フェニル]メチル}−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−フルオロ−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−5−{[4−(トリフルオロメトキシ)−フェニル]メチル}−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−フルオロ−1,1,4−トリオキソ−N−フェノキシ−5−{[4−(トリフルオロメトキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(2−メチルプロポキシ)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−フェノキシ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−(プロパン−2−イル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−({4−[(5−アセトアミドペンチル)オキシ]フェニル}−メチル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−N−(プロパン−2−イル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(2−メチルプロポキシ)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−N−プロポキシ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(3−メチルブタン−2−イル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(ブタ−3−エン−1−イル)−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−シクロプロピル−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−シクロブチル−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロ−2−フルオロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−(プロパン−2−イル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(3,4−ジクロロフェニル)メチル]−1,1,4−トリオキソ−N−(プロパン−2−イル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロ−3−フルオロフェニル)メチル]−1,1,4−トリオキソ−N−(プロパン−2−イル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(シクロヘキシルオキシ)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(シクロヘキシルメトキシ)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−(2,2,2−トリフルオロ−エチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−(3,3,3−トリフルオロ−プロピル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−[(2S)−1,1,1−トリフルオロプロパン−2−イル]−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(ブタン−2−イル)−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−tert−ブチル−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(tert−ブトキシ)−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−[(1S,2R)−2−フェニルシクロプロピル]−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(1−メチルシクロプロピル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(1−メチルシクロブチル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(2,2−ジメチルシクロプロピル)−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラ
ヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(3,3−ジフルオロシクロブチル)−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ベンジル−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−ヘプチル−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(3,3−ジフルオロシクロペンチル)−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1R)−2,2−ジフルオロシクロプロピル]−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1S)−2,2−ジフルオロシクロプロピル]−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(2R,3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(2,2−ジフルオロシクロプロピル)−2−メチル−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−ヘキサデシル−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(シクロプロピルメチル)−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(2R,3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−2−メチル−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−8−フルオロ−4−オキソ−5−(キノリン−2−イルメチル)−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(5−シクロプロピル−1,3,4−チアジアゾール−2−イル)メチル]−8−フルオロ−N−[(4−フルオロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;(3R)−3−アミノ−N−ブチル−5−[(4−クロロフェニル)メチル]−8−(ジメチルアミノ)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
tert−ブチルN−(5−{[(3R)−5−[(4−クロロフェニル)メチル]−8−フルオロ−7−{[(4−メトキシフェニル)メチル]カルバモイル}−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−3−イル]アミノ}ペンチル)カルバメート;
(3R)−3−アミノ−N−ブチル−1−[(4−クロロフェニル)メチル]−2,5,5−トリオキソ−1H,2H,3H,4H−5λ6−ピリド[3,4−b][1,4]チアゼピン−8−カルボキサミド;
(3R)−3−アミノ−N−ベンジル−5−[(4−クロロフェニル)メチル]−8−(ジメチルアミノ)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(2,2−ジフルオロシクロプロピル)−8−フルオロ−5−{[4−メトキシ−3−(トリフルオロメチル)フェニル]メチル}−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(2R,3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−2−メチル−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−{[4−(5−メチル−1,2,4−オキサジアゾール−3−イル)フェニル]メチル}−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(2−メトキシエチル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(2,2−ジフルオロシクロプロピル)−5−{[4−(5−メチル−1,2,4−オキサジアゾール−3−イル)フェニル]メチル}−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(1S,3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−4−オキソ−7−[(4,4,4−トリフルオロブチル)カルバモイル]−2,3,4,5−テトラヒドロ−1H−1,5−ベンゾチアゼピン−1−イウム−1−オレート;
(1R,3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−4−オキソ−7−[(4,4,4−トリフルオロブチル)カルバモイル]−2,3,4,5−テトラヒドロ−1H−1,5−ベンゾチアゼピン−1−イウム−1−オレート;
(3R)−3−アミノ−5−[(4−シアノフェニル)メチル]−N−(2,2−ジフルオロシクロプロピル)−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−シアノフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(4,4−ジフルオロシクロヘキシル)−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−[2−(トリフルオロメチル)シクロプロピル]−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(3,3−ジフルオロシクロブチル)−8−フルオロ−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−フルオロ−5−[(4−フルオロフェニル)メチル]−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(2,2−ジフルオロシクロプロピル)−8−フルオロ−5−[(4−フルオロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ブチル−8−フルオロ−5−[(4−フルオロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ベンジル−8−フルオロ−5−[(4−フルオロフェニル)メチル]−4−オキソ−2,3,4,5−テトラヒドロ−1,5−ベンゾチアゼピン−7
−カルボキサミド;
(3R)−3−アミノ−N−ブチル−8−フルオロ−5−[(4−フルオロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−ベンジル−8−フルオロ−5−[(4−フルオロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−[2−(オキサン−4−イル)エチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−ベンジル−8−フルオロ−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(5−シクロプロピル−1,3,4−チアジアゾール−2−イル)メチル]−8−フルオロ−N−[(4−フルオロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−フルオロ−5−[(4−フルオロフェニル)メチル]−N−[(オキサン−4−イル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(3,3−ジフルオロシクロブチル)−8−フルオロ−5−[(4−フルオロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−フルオロ−5−[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−フルオロ−5−[(4−メトキシフェニル)メチル]−N−[(オキサン−4−イル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(2,2−ジフルオロシクロプロピル)−8−フルオロ−5−[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−(オキサン−4−イル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−(3,3−ジフルオロシクロブチル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1S)−3,3−ジフルオロシクロペンチル]−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1R,2S)−2−フルオロシクロプロピル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(3,3−ジフルオロシクロブチル)−5−[(2−フルオロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(3,3−ジフルオロシクロブチル)−5−[(3−メトキシフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N,5−ビス[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−ベンジル−N−[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(4,4−ジフルオロシクロヘキシル)−5−[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−N−(3,3,3−トリフルオロプロピル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−N−[(3R)−オキソラン−3−イル]−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−N−[(オキソラン−3−イル)メチル]−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1R)−2,2−ジフルオロシクロプロピル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−シクロプロピルフェニル)メチル]−N−[(1R)−2,2−ジフルオロシクロプロピル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−[(1R)−2,2−ジフルオロシクロプロピル]−5−{[4−(ジフルオロメトキシ)フェニル]メチル}−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−[(1R)−2,2−ジフルオロシクロプロピル]−5−[(4−メトキシフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−ベンジル−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−クロロ−5−[(4−クロロフェニル)メチル]−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−{[4−(ジフルオロメトキシ)フェニル]メチル}−N−[(オキサン−4−イル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(4−フルオロオキサン−4−イル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒド
ロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1R)−1−(オキサン−4−イル)エチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−ベンジル−N−[(1R)−2,2−ジフルオロシクロプロピル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(6−メチルピリジン−3−イル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(1R)−3,3−ジフルオロシクロペンチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−シアノフェニル)メチル]−8−フルオロ−N−[(4−フルオロフェニル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(3,3−ジフルオロシクロブチル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−N−[2−(2−メトキシエトキシ)エチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−(ブタ−3−イン−1−イル)−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−(ペンタ−4−イン−1−イル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−8−クロロ−5−[(4−クロロフェニル)メチル]−N−[(1R)−2,2−ジフルオロシクロプロピル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[2−(モルホリン−4−イル)エチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−[(6−メトキシピリジン−3−イル)メチル]−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−8−フルオロ−1,1,4−トリオキソ−N−{[4−(プロパ−2−イン−1−イルオキシ)フェニル]メチル}−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−N−[(1R)−2,2−ジフルオロシクロプロピル]−1,1,4−トリオキソ−5−{[4−(トリフルオロメチル)フェニル]メチル}−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−ブロモフェニル)メチル]−N−(2,2−ジフルオロシクロプロピル)−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;
(3R)−3−アミノ−5−[(4−クロロフェニル)メチル]−N−{2−オキサスピロ[3.3]ヘプタン−6−イル}−1,1,4−トリオキソ−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド;または
(3R)−5−[(4−クロロフェニル)メチル]−3−(エチルアミノ)−8−フルオロ−1,1,4−トリオキソ−N−(4,4,4−トリフルオロブチル)−2,3,4,5−テトラヒドロ−1λ6,5−ベンゾチアゼピン−7−カルボキサミド - 新生物疾患および/または感染性疾患の治療または予防のための方法において使用するための、請求項1〜25のいずれか1項に記載の、医薬組成物。
- 新生物疾患はがんである、請求項26に記載の使用のための、医薬組成物。
- 医薬組成物は、免疫細胞を活性化する1つまたはそれ以上のさらなる刺激剤と組み合わせて投与される、請求項26または27に記載の使用のための、医薬組成物。
- 活性化免疫細胞を生成するためのインビトロまたはエキソビボ方法であって:
(i)免疫細胞を準備する工程と;
(ii)工程(i)の細胞を:
(a)請求項1〜25のいずれか1項に記載の少なくとも1つの化合物またはその医薬的に許容される塩と接触させる工程と;
(iii)工程(ii)の細胞の生存率の維持にとって好適な条件下で、前記細胞を培養する工程と、を含む前記インビトロまたはエキソビボ方法。 - 工程(ii)で、工程(i)の細胞を(b)前記免疫細胞を活性化する1つまたはそれ以上のさらなる刺激剤とも接触させる、請求項29の方法。
- 以下の化合物またはその医薬的に許容される塩を除く、請求項31に記載の化合物またはその医薬的に許容される塩:
R2は、フェニル;3−クロロフェニル;4−フルオロフェニル;4−メトキシフェニ
ル;3,5−ジメチル−1,2−オキサゾール−4−イル;2−クロロチオフェン−5−イル;ピリジン−4−イル;1,3−ベンゾジオキソール−5−イル;5−フェニル−1,2,4−オキサジアゾール−3−イル;3−(4−tertブチルフェニル)−1,2,4−オキサジアゾール−5−イル;ビフェン−4−イル;または3,4,5−トリメトキシフェニルであり;
R3は、n−ブチル;2−ヒドロキシ−1−ヒドロキシカルボニル−エチル;2−ヒド
ロキシカルボニルエチル;フェニル;またはベンジルである)。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15157175.9 | 2015-03-02 | ||
EP15157175 | 2015-03-02 | ||
PCT/EP2016/054228 WO2016139181A1 (en) | 2015-03-02 | 2016-02-29 | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018508527A JP2018508527A (ja) | 2018-03-29 |
JP6727224B2 true JP6727224B2 (ja) | 2020-07-22 |
Family
ID=52705955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017546189A Active JP6727224B2 (ja) | 2015-03-02 | 2016-02-29 | 新生物疾患および/または感染性疾患の治療にとって有用な二環式テトラヒドロチアゼピン誘導体 |
Country Status (12)
Country | Link |
---|---|
US (1) | US10472341B2 (ja) |
EP (1) | EP3265463B1 (ja) |
JP (1) | JP6727224B2 (ja) |
CN (1) | CN107889487B (ja) |
BR (1) | BR112017018643B1 (ja) |
CA (1) | CA2977588C (ja) |
DK (1) | DK3265463T3 (ja) |
ES (1) | ES2720577T3 (ja) |
HU (1) | HUE041851T2 (ja) |
IL (1) | IL253999B (ja) |
RU (1) | RU2730524C2 (ja) |
WO (1) | WO2016139181A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2563642A (en) * | 2017-06-22 | 2018-12-26 | Curadev Pharma Ltd | Small molecule modulators of human STING |
EP4277897A1 (en) * | 2021-01-12 | 2023-11-22 | Chengdu Anticancer Bioscience, Ltd. | Fused azepine compounds and their use in the treatment of cancer |
CN112876366B (zh) * | 2021-01-21 | 2022-10-04 | 中国科学院昆明植物研究所 | 一种帚状异酯素、其制备方法和应用,以及药物组合物 |
CR20230382A (es) * | 2021-02-12 | 2023-09-06 | Hoffmann La Roche | Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer |
CN113075317A (zh) * | 2021-03-24 | 2021-07-06 | 日照市市场监管检验检测中心 | 一种茶叶中赤霉素含量的检测方法 |
WO2023030295A1 (zh) * | 2021-09-01 | 2023-03-09 | 先声再明医药有限公司 | 泛素特异性蛋白酶1(usp1)抑制剂 |
KR20230100646A (ko) * | 2021-12-24 | 2023-07-05 | 제일약품주식회사 | Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
WO2024033388A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033389A1 (en) * | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033457A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033458A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2030159A1 (en) * | 1989-11-22 | 1991-05-23 | Nahed K. Ahmed | Anti-cancer drug potentiators |
JP2002241368A (ja) | 1997-02-18 | 2002-08-28 | Shionogi & Co Ltd | 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物 |
ES2198613T3 (es) * | 1997-03-14 | 2004-02-01 | Aventis Pharma Deutschland Gmbh | 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos. |
WO2003031376A1 (en) | 2001-10-12 | 2003-04-17 | Aventis Pharmaceuticals Inc. | Solid phase synthesis of substituted 1,5-benzodiazepine-2-one and 1,5-benzothiazepine-2-one |
CN101891706B (zh) * | 2010-04-09 | 2013-05-29 | 复旦大学 | 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途 |
TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
US8962641B2 (en) | 2013-04-17 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof |
-
2016
- 2016-02-29 JP JP2017546189A patent/JP6727224B2/ja active Active
- 2016-02-29 EP EP16707103.4A patent/EP3265463B1/en active Active
- 2016-02-29 ES ES16707103T patent/ES2720577T3/es active Active
- 2016-02-29 CN CN201680025560.XA patent/CN107889487B/zh active Active
- 2016-02-29 US US15/554,354 patent/US10472341B2/en active Active
- 2016-02-29 CA CA2977588A patent/CA2977588C/en active Active
- 2016-02-29 RU RU2017133983A patent/RU2730524C2/ru active
- 2016-02-29 DK DK16707103.4T patent/DK3265463T3/en active
- 2016-02-29 WO PCT/EP2016/054228 patent/WO2016139181A1/en active Application Filing
- 2016-02-29 HU HUE16707103A patent/HUE041851T2/hu unknown
- 2016-02-29 BR BR112017018643-8A patent/BR112017018643B1/pt active IP Right Grant
-
2017
- 2017-08-15 IL IL253999A patent/IL253999B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
RU2730524C2 (ru) | 2020-08-24 |
CN107889487B (zh) | 2021-09-03 |
US20180170888A1 (en) | 2018-06-21 |
HUE041851T2 (hu) | 2019-05-28 |
ES2720577T3 (es) | 2019-07-23 |
CA2977588A1 (en) | 2016-09-09 |
IL253999B (en) | 2020-09-30 |
BR112017018643A2 (pt) | 2018-04-17 |
RU2017133983A3 (ja) | 2019-09-09 |
CN107889487A (zh) | 2018-04-06 |
RU2017133983A (ru) | 2019-04-02 |
BR112017018643B1 (pt) | 2024-02-27 |
JP2018508527A (ja) | 2018-03-29 |
IL253999A0 (en) | 2017-10-31 |
WO2016139181A1 (en) | 2016-09-09 |
DK3265463T3 (en) | 2019-03-18 |
EP3265463A1 (en) | 2018-01-10 |
EP3265463B1 (en) | 2018-12-19 |
CA2977588C (en) | 2023-10-03 |
US10472341B2 (en) | 2019-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6727224B2 (ja) | 新生物疾患および/または感染性疾患の治療にとって有用な二環式テトラヒドロチアゼピン誘導体 | |
US11951133B2 (en) | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | |
JP7062792B2 (ja) | Pd-1/pd-l1阻害剤 | |
CN113423685B (zh) | 整合应激通路的前药调节剂 | |
CA3103286A1 (en) | Pd-1/pd-l1 inhibitors | |
CN112204012A (zh) | 整合应激通路的调节剂 | |
CN112166113A (zh) | 整合应激通路的调节剂 | |
CN114401952A (zh) | 作为整合应激通路的调节剂的被取代的环烷基化合物 | |
CA3084582A1 (en) | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein | |
US20230089255A1 (en) | Combinations of dgk inhibitors and checkpoint antagonists | |
CA3158771A1 (en) | Mcl1 inhibitors | |
US20190359645A1 (en) | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide | |
CA3096424A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
CN116829555A (zh) | 蛋白酪氨酸磷酸酶抑制剂及其使用方法 | |
WO2018165501A1 (en) | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATMENT OF DISEASE | |
EP3762397A1 (en) | Cyclic dinucleotides as anticancer agents | |
EP4389749A1 (en) | Substituted 3,7-dihydro-1h-purine-2,6-diones and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190212 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191107 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200228 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200430 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200512 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200521 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200609 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200630 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6727224 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |